COVID-19 Pick up Report/Research リスト

March 2022
Edson D Moreira Jr, Nicholas Kitchin, Xia Xu et al.

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 VaccineNEW

N Engl J Med. 2022 Mar 23. doi: 10.1056/NEJMoa2200674.
Annika Rössler, Ludwig Knabl, Dorothee von Laer, Janine Kimpel

Neutralization Profile after Recovery from SARS-CoV-2 Omicron InfectionNEW

N Engl J Med. 2022 Mar 23. doi: 10.1056/NEJMc2201607.
Maaike C Swets, Clark D Russell, Ewen M Harrison et al.

SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenovirusesNEW

Lancet. 2022 Mar 25;S0140-6736(22)00383-X. doi: 10.1016/S0140-6736(22)00383-X.
Li Guo, Geng Wang, Yeming Wang et al.

SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort studyNEW

Lancet Microbe. 2022 Mar 23. doi: 10.1016/S2666-5247(22)00036-2.
Michael Fralick, Michael Colacci, Laveena Munshi et al.

Prone positioning of patients with moderate hypoxaemia due to covid-19: multicentre pragmatic randomised trial (COVID-PRONE)NEW

BMJ. 2022 Mar 23;376:e068585. doi: 10.1136/bmj-2021-068585.
Deshayne B Fell, Tavleen Dhinsa, Gillian D Alton et al.

Association of COVID-19 Vaccination in Pregnancy With Adverse Peripartum OutcomesNEW

JAMA. 2022 Mar 24. doi: 10.1001/jama.2022.4255.
Maria C Magnus, Anne K Örtqvist, Elisabeth Dahlqwist et al.

Association of SARS-CoV-2 Vaccination During Pregnancy With Pregnancy OutcomesNEW

JAMA. 2022 Mar 24. doi: 10.1001/jama.2022.3271.
Emily H Adhikari, Lorre MacDonald, Jeffrey A SoRelle et al.

COVID-19 Cases and Disease Severity in Pregnancy and Neonatal Positivity Associated With Delta (B.1.617.2) and Omicron (B.1.1.529) Variant PredominanceNEW

JAMA. 2022 Mar 24. doi: 10.1001/jama.2022.4356.
REMAP-CAP Writing Committee for the REMAP-CAP Investigators

Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical TrialNEW

JAMA. 2022 Mar 22. doi: 10.1001/jama.2022.2910.
Assiamira Ferrara, Monique M Hedderson, Yeyi Zhu et al.

Perinatal Complications in Individuals in California With or Without SARS-CoV-2 Infection During PregnancyNEW

JAMA Intern Med. 2022 Mar 21. doi: 10.1001/jamainternmed.2022.0330.
Timothée Bruel, Jérôme Hadjadj, Piet Maes et al.

Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodiesNEW

Nat Med. 2022 Mar 23. doi: 10.1038/s41591-022-01792-5.
Tongqing Zhou, Lingshu Wang, John Misasi et al.

Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529NEW

Science. 2022 Mar 24;eabn8897. doi: 10.1126/science.abn8897.
Venice Servellita, Abdullah M Syed, Mary Kate Morris et al.

Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variantsNEW

Cell. 2022 Mar 17;S0092-8674(22)00329-4. doi: 10.1016/j.cell.2022.03.019.
Benjamin Rader, Autumn Gertz, A Danielle Iuliano et al.

Use of At-Home COVID-19 Tests ― United States, August 23, 2021–March 12, 2022NEW

MMWR Morb Mortal Wkly Rep. 2022 Mar 25. doi: 10.15585/mmwr.mm7113e1.
Jackie Kleynhans, Stefano Tempia, Nicole Wolter et al.

SARS-CoV-2 Seroprevalence after Third Wave of Infections, South AfricaNEW

Emerg Infect Dis. 2022 Mar 23;28(5). doi: 10.3201/eid2805.220278.
Nicholas Bbosa, Deogratius Ssemwanga, Hamidah Namagembe et al.

Rapid Replacement of SARS-CoV-2 Variants by Delta and Subsequent Arrival of Omicron, Uganda, 2021NEW

Emerg Infect Dis. 2022 Mar 23;28(5). doi: 10.3201/eid2805.220121.
Elizabeth R Jenny-Avital, Ruth A Howe

Severe Multisystem Inflammatory Symptoms in 2 Adults after Short Interval between COVID-19 and Subsequent VaccinationNEW

Emerg Infect Dis. 2022 Mar 23;28(5). doi: 10.3201/eid2805.212316.
Federico Scottoni, Giovanni Giuseppe Giobbe, Elisa Zambaiti et al.

Intussusception and COVID-19 in Infants: Evidence for an Etiopathologic CorrelationNEW

Pediatrics. 2022 Mar 24. doi: 10.1542/peds.2021-054644.
Christopher B Forrest, Evanette K Burrows, Asuncion Mejias et al.

Severity of Acute COVID-19 in Children <18 Years Old March 2020 to December 2021NEW

Pediatrics. 2022 Mar 24;e2021055765. doi: 10.1542/peds.2021-055765.
Margaret K Doll, Stacy M Pettigrew, Julia Ma, Aman Verma

Effects of Confounding Bias in COVID-19 and Influenza Vaccine Effectiveness Test-Negative Designs Due to Correlated Influenza and COVID-19 Vaccination BehaviorsNEW

Clin Infect Dis. 2022 Mar 24;ciac234. doi: 10.1093/cid/ciac234.
Oon Tek Ng, Vanessa Koh, Calvin J Chiew et al.

Impact of SARS-CoV-2 Vaccination and Paediatric Age on Delta Variant Household TransmissionNEW

Clin Infect Dis. 2022 Mar 22;ciac219. doi: 10.1093/cid/ciac219.
Estela Giménez, Eliseo Albert, Joao Zulaica et al.

SARS-CoV-2 adaptive immunity in nursing home residents following a third dose of the Comirnaty® COVID-19 vaccineNEW

Clin Infect Dis. 2022 Mar 21;ciac223. doi: 10.1093/cid/ciac223.
Sumathi Sivapalasingam, David J Lederer, Rafia Bhore et al.

Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19: A Randomized Clinical TrialNEW

Clin Infect Dis. 2022 Feb 26;ciac153. doi: 10.1093/cid/ciac153.
Gereon J Rieke, Kathrin van Bremen, Jenny Bischoff et al.

Induction of NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 after natural infection is more potent than after vaccinationNEW

J Infect Dis. 2022 Mar 22;jiac060. doi: 10.1093/infdis/jiac060.
Chang Yi Wang, Kao-Pin Hwang, Hui-Kai Kuo et al.

A multitope SARS-COV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variantsNEW

J Clin Invest. 2022 Mar 22;e157707. doi: 10.1172/JCI157707.
Gili Regev-Yochay, Tal Gonen, Mayan Gilboa et al.

Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron

N Engl J Med. 2022 Mar 16. doi: 10.1056/NEJMc2202542.
Jingyou Yu, Ai-Ris Y Collier, Marjorie Rowe et al.

Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants

N Engl J Med. 2022 Mar 16. doi: 10.1056/NEJMc2201849.
Linda-Gail Bekker, Nigel Garrett, Ameena Goga et al.

Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study

Lancet. 2022 Mar 19;399(10330):1141-1153. doi: 10.1016/S0140-6736(22)00007-1.
Daniel J Sheward, Changil Kim, Roy A Ehling et al.

Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study

Lancet Infect Dis. 2022 Mar 17;S1473-3099(22)00129-3. doi: 10.1016/S1473-3099(22)00129-3.
Analía Rearte, Juan Manuel Castelli, Ramiro Rearte et al.

Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study

Lancet. 2022 Mar 15;S0140-6736(22)00011-3. doi: 10.1016/S0140-6736(22)00011-3.
Cheryl Cohen, Jackie Kleynhans, Anne von Gottberg et al.

SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-21

Lancet Infect Dis. 2022 Mar 14;S1473-3099(22)00069-X. doi: 10.1016/S1473-3099(22)00069-X.
Ingibjörg Magnúsdóttir, Anikó Lovik, Anna Bára Unnarsdóttir et al.

Acute COVID-19 severity and mental health morbidity trajectories in patient populations of six nations: an observational study

Lancet Public Health. 2022 Mar 11;S2468-2667(22)00042-1. doi: 10.1016/S2468-2667(22)00042-1.
John Allotey, Shaunak Chatterjee, Tania Kew et al.

SARS-CoV-2 positivity in offspring and timing of mother-to-child transmission: living systematic review and meta-analysis

BMJ. 2022 Mar 16;376:e067696. doi: 10.1136/bmj-2021-067696.
Xintong Li, Berta Raventós, Elena Roel et al.

Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis

BMJ. 2022 Mar 16;376:e068373. doi: 10.1136/bmj-2021-068373.
Limor Friedensohn, Dan Levin, Maggie Fadlon-Derai et al.

Myocarditis Following a Third BNT162b2 Vaccination Dose in Military Recruits in Israel

JAMA. 2022 Mar 17. doi: 10.1001/jama.2022.4425.
Anil Gupta, Yaneicy Gonzalez-Rojas, Erick Juarez et al.

Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial

JAMA. 2022 Mar 14. doi: 10.1001/jama.2022.2832.
Hannah G Juncker, Sien J Mulleners, Esmée R M Coenen et al.

Comparing Human Milk Antibody Response After 4 Different Vaccines for COVID-19

JAMA Pediatr. 2022 Mar 14. doi: 10.1001/jamapediatrics.2022.0084.
John Schrom, Carina Marquez, Genay Pilarowski et al.

Comparison of SARS-CoV-2 Reverse Transcriptase Polymerase Chain Reaction and BinaxNOW Rapid Antigen Tests at a Community Site During an Omicron Surge : A Cross-Sectional Study

Ann Intern Med. 2022 Mar 15. doi: 10.7326/M22-0202.
Donia Bouzid, Benoit Visseaux, Christian Kassasseya et al.

Comparison of Patients Infected With Delta Versus Omicron COVID-19 Variants Presenting to Paris Emergency Departments : A Retrospective Cohort Study

Ann Intern Med. 2022 Mar 15. doi: 10.7326/M22-0308.
Victoria Male

SARS-CoV-2 infection and COVID-19 vaccination in pregnancy

Nat Rev Immunol. 2022 Mar 18;1-6. doi: 10.1038/s41577-022-00703-6.
Yannic C Bartsch, Xin Tong, Jaewon Kang et al.

Omicron variant Spike-specific antibody binding and Fc activity is preserved in recipients of mRNA or inactivated COVID-19 vaccines

Sci Transl Med. 2022 Mar 15;eabn9243. doi: 10.1126/scitranslmed.abn9243.
Lauren B Rodda, Peter A Morawski, Kurt B Pruner et al.

Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity

Cell. 2022 Mar 16;S0092-8674(22)00328-2. doi: 10.1016/j.cell.2022.03.018.
Mark W Tenforde, Wesley H Self, Manjusha Gaglani et al.

Effectiveness of mRNA Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death - United States, March 2021-January 2022

MMWR Morb Mortal Wkly Rep. 2022 Mar 25;71(12):459-465. doi: 10.15585/mmwr.mm7112e1.
Christopher A Taylor, Michael Whitaker, Onika Anglin et al.

COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status - COVID-NET, 14 States, July 2021-January 2022

MMWR Morb Mortal Wkly Rep. 2022 Mar 25;71(12):466-473. doi: 10.15585/mmwr.mm7112e2.
Kristin J Marks, Michael Whitaker, Nickolas T Agathis et al.

Hospitalization of Infants and Children Aged 0-4 Years with Laboratory-Confirmed COVID-19 - COVID-NET, 14 States, March 2020-February 2022

MMWR Morb Mortal Wkly Rep. 2022 Mar 18;71(11):429-436. doi: 10.15585/mmwr.mm7111e2.
Megan Wallace, Danielle Moulia, Amy E Blain et al.

The Advisory Committee on Immunization Practices' Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines - United States, February 2022

MMWR Morb Mortal Wkly Rep. 2022 Mar 18;71(11):416-421. doi: 10.15585/mmwr.mm7111a4.
Kenichiro Takahashi, Masahiro Ishikane, Mugen Ujiie et al.

Duration of Infectious Virus Shedding by SARS-CoV-2 Omicron Variant-Infected Vaccinees

Emerg Infect Dis. 2022 Mar 15;28(5). doi: 10.3201/eid2805.220197.
Mohammed Raza, Prosenjit Giri, Subhashis Basu

Surveillance and return to work of healthcare workers following SARS-CoV-2 Omicron variant infection, Sheffield, England, 17 January to 7 February 2022

Euro Surveill. 2022 Mar;27(11). doi: 10.2807/1560-7917.ES.2022.27.11.2200164.
Paula B Blomquist, Jessica Bridgen, Neil Bray et al.

Enhancing epidemiological surveillance of the emergence of the SARS-CoV-2 Omicron variant using spike gene target failure data, England, 15 November to 31 December 2021

Euro Surveill. 2022 Mar;27(11). doi: 10.2807/1560-7917.ES.2022.27.11.2200143.
Sophia Kindzierski, Welmoed van Loon, Stefanie Theuring et al.

SARS-CoV-2 infection among educational staff in Berlin, Germany, June to December 2020

Euro Surveill. 2022 Mar;27(11). doi: 10.2807/1560-7917.ES.2022.27.11.2100524.
Sarah E Messiah, Stacia DeSantis, Luis Leon-Novelo et al.

Durability of SARS-CoV-2 Antibodies From Natural Infection in Children and Adolescents

Pediatrics. 2022 Mar 18. doi: 10.1542/peds.2021-055505.
Leigh Smith, C Paul Morris, Morgan H Jibowu et al.

Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) exposure investigations using genomic sequencing among healthcare workers and patients in a large academic center

Infect Control Hosp Epidemiol. 2022 Mar 2;1-10. doi: 10.1017/ice.2022.37.
P Guisado-Vasco, J Aguareles, M M Carralón González, G Sotres Fernandez, D Carnevali Ruiz

Flipped inflammatory time and the role of antibodies against SARS-CoV-2: optimising tocilizumab against COVID-19

J Infect Dis. 2022 Mar 17;jiac090. doi: 10.1093/infdis/jiac090.
Pyoeng Gyun Choe, Jisu Hong, Jiyoung Park et al.

Persistent Antibody Responses up to 18 Months after Mild SARS-CoV-2 Infection

J Infect Dis. 2022 Mar 17;jiac099. doi: 10.1093/infdis/jiac099.
Laith J Abu-Raddad, Hiam Chemaitelly, Houssein H Ayoub et al.

Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar

N Engl J Med. 2022 Mar 9. doi: 10.1056/NEJMoa2200797.
Rebecca Rockett, Kerri Basile, Susan Maddocks et al.

Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use

N Engl J Med. 2022 Mar 9. doi: 10.1056/NEJMc2120219.
Emi Takashita, Noriko Kinoshita, Seiya Yamayoshi et al.

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2

N Engl J Med. 2022 Mar 9. doi: 10.1056/NEJMc2201933.
Hui-Ling Yen, Thomas H C Sit, Christopher J Brackman et al.

Transmission of SARS-CoV-2 delta variant (AY.127) from pet hamsters to humans, leading to onward human-to-human transmission: a case study

Lancet. 2022 Mar 12;399(10329):1070-1078. doi: 10.1016/S0140-6736(22)00326-9.
James Welker, Juan D Pulido, Andrew T Catanzaro et al.

Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study

Lancet Infect Dis. 2022 Mar 11;S1473-3099(22)00058-5. doi: 10.1016/S1473-3099(22)00058-5.
COVID-19 Excess Mortality Collaborators

Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21

Lancet. 2022 Mar 10;S0140-6736(21)02796-3. doi: 10.1016/S0140-6736(21)02796-3.
Flavia Chiuppesi, John A Zaia, Paul H Frankel et al.

Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial

Lancet Microbe. 2022 Mar 9. doi: 10.1016/S2666-5247(22)00027-1.
Hannah G Rosenblum, Julianne Gee, Ruiling Liu et al.

Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe

Lancet Infect Dis. 2022 Mar 7;S1473-3099(22)00054-8. doi: 10.1016/S1473-3099(22)00054-8.
Adam S Lauring, Mark W Tenforde, James D Chappell et al.

Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study

BMJ. 2022 Mar 9;376:e069761. doi: 10.1136/bmj-2021-069761.
Silje B Jørgensen, Karin Nygård, Oliver Kacelnik, Kjetil Telle

Secondary Attack Rates for Omicron and Delta Variants of SARS-CoV-2 in Norwegian Households

JAMA. 2022 Mar 7;e223780. doi: 10.1001/jama.2022.3780.
Eric J Nelson, Sarah Lindley McKune, Kathleen A Ryan et al.

Antigen vs RT-PCR Tests for Screening Quarantined Students in Florida During the COVID-19 Pandemic SARS-CoV-2 Delta Variant Surge

JAMA Pediatr. 2022 Mar 7;e220080. doi: 10.1001/jamapediatrics.2022.0080.
Mirko Griesel, Carina Wagner, Agata Mikolajewska et al.

Inhaled corticosteroids for the treatment of COVID-19

Cochrane Database Syst Rev. 2022 Mar 9;3(3):CD015125. doi: 10.1002/14651858.CD015125.
Lauren E Wisk, Graham Nichol, Joann G Elmore

Toward Unbiased Evaluation of Postacute Sequelae of SARS-CoV-2 Infection: Challenges and Solutions for the Long Haul Ahead

Ann Intern Med. 2022 Mar 8. doi: 10.7326/M21-4664.
Gwenaëlle Douaud, Soojin Lee, Fidel Alfaro-Almagro et al.

SARS-CoV-2 is associated with changes in brain structure in UK Biobank

Nature. 2022 Mar 7. doi: 10.1038/s41586-022-04569-5.
Ed Pertwee, Clarissa Simas, Heidi J Larson

An epidemic of uncertainty: rumors, conspiracy theories and vaccine hesitancy

Nat Med. 2022 Mar;28(3):456-459. doi: 10.1038/s41591-022-01728-z.
Natalie E Dean, M Elizabeth Halloran

Protecting the herd with vaccination

Science. 2022 Mar 11;375(6585):1088-1089. doi: 10.1126/science.abo2959.
Edward C Holmes

COVID-19-lessons for zoonotic disease

Science. 2022 Mar 11;375(6585):1114-1115. doi: 10.1126/science.abn2222.
Katia Koelle, Michael A Martin, Rustom Antia, Ben Lopman, Natalie E Dean

The changing epidemiology of SARS-CoV-2

Science. 2022 Mar 11;375(6585):1116-1121. doi: 10.1126/science.abm4915.
Ai-Ris Y Collier, Catherine M Brown, Katherine A McMahan et al.

Characterization of immune responses in fully vaccinated individuals following breakthrough infection with the SARS-CoV-2 delta variant

Sci Transl Med. 2022 Mar 8;eabn6150. doi: 10.1126/scitranslmed.abn6150.
Ashley L Fowlkes, Sarang K Yoon, Karen Lutrick et al.

Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022

MMWR Morb Mortal Wkly Rep. 2022 Mar 18;71(11):422-428. doi: 10.15585/mmwr.mm7111e1.
Catherine V Donovan, Charles Rose, Kanna N Lewis et al.

SARS-CoV-2 Incidence in K-12 School Districts with Mask-Required Versus Mask-Optional Policies - Arkansas, August-October 2021

MMWR Morb Mortal Wkly Rep. 2022 Mar 11;71(10):384-389. doi: 10.15585/mmwr.mm7110e1.
Jelle Koopsen, Catharina E van Ewijk, Roisin Bavalia et al.

Epidemiologic and Genomic Analysis of SARS-CoV-2 Delta Variant Superspreading Event in Nightclub, the Netherlands, June 2021

Emerg Infect Dis. 2022 Mar 10;28(5). doi: 10.3201/eid2805.212019.
Eisha Jain, Jeffrey R Donowitz, Elizabeth Aarons, Beth C Marshall, Michael P Miller

Multisystem Inflammatory Syndrome in Children after SARS-CoV-2 Vaccination

Emerg Infect Dis. 2022 Mar 11;28(5). doi: 10.3201/eid2805.212418.
Pinkus Tober-Lau, Henning Gruell, Kanika Vanshylla et al.

Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections

Emerg Infect Dis. 2022 Mar 8;28(5). doi: 10.3201/eid2805.220271.
Alizé Mercier, David A Wilkinson, Camille Lebarbenchon, Patrick Mavingui, Luce Yemadje-Menudier

Spread of SARS-CoV-2 Variants on Réunion Island, France, 2021

Emerg Infect Dis. 2022 Mar 8;28(4). doi: 10.3201/eid2804.212243.
Heather N Grome, Becky Meyer, Erin Read et al.

SARS-CoV-2 Outbreak among Malayan Tigers and Humans, Tennessee, USA, 2020

Emerg Infect Dis. 2022 Mar 12;28(4). doi: 10.3201/eid2804.212219.
Hye Ryeon Lee, Young June Choe, Eun Jung Jang et al.

Time from Exposure to Diagnosis among Quarantined Close Contacts of SARS-CoV-2 Omicron Variant Index Case-Patients, South Korea

Emerg Infect Dis. 2022 Mar 11;28(4). doi: 10.3201/eid2804.220153.
Jannik Fonager, Marc Bennedbæk, Peter Bager et al.

Molecular epidemiology of the SARS-CoV-2 variant Omicron BA.2 sub-lineage in Denmark, 29 November 2021 to 2 January 2022

Euro Surveill. 2022 Mar;27(10). doi: 10.2807/1560-7917.ES.2022.27.10.2200181.
Adrian Lison, Joel Persson, Nicolas Banholzer, Stefan Feuerriegel

Estimating the effect of mobility on SARS-CoV-2 transmission during the first and second wave of the COVID-19 epidemic, Switzerland, March to December 2020

Euro Surveill. 2022 Mar;27(10). doi: 10.2807/1560-7917.ES.2022.27.10.2100374.
Lea Caduff, David Dreifuss, Tobias Schindler et al.

Inferring transmission fitness advantage of SARS-CoV-2 variants of concern from wastewater samples using digital PCR, Switzerland, December 2020 through March 2021

Euro Surveill. 2022 Mar;27(10). doi: 10.2807/1560-7917.ES.2022.27.10.2100806.
Min Kang, Hualei Xin, Jun Yuan et al.

Transmission dynamics and epidemiological characteristics of SARS-CoV-2 Delta variant infections in Guangdong, China, May to June 2021

Euro Surveill. 2022 Mar;27(10). doi: 10.2807/1560-7917.ES.2022.27.10.2100815.
Saahithi Rao, Jillian H Hurst, Congwen Zhao et al.

Asthma and the Risk of SARS-CoV-2 Infection Among Children and Adolescents

Pediatrics. 2022 Mar 11. doi: 10.1542/peds.2021-056164.
Torill A Rotevatn, Petter Elstrøm, Margrethe Greve-Isdahl et al.

School Closure Versus Targeted Control Measures for SARS-CoV-2 Infection

Pediatrics. 2022 Mar 11. doi: 10.1542/peds.2021-055071.
Angelique E Boutzoukas, Kanecia O Zimmerman, Moira Inkelas et al.

School Masking Policies and Secondary SARS-CoV-2 Transmission

Pediatrics. 2022 Mar 9. doi: 10.1542/peds.2022-056687.
Ryan C L Brewster, Chase Parsons, Jess Laird-Gion et al.

COVID-19-Associated Croup in Children

Pediatrics. 2022 Mar 8. doi: 10.1542/peds.2022-056492.
Matthijs L Janssen, Yoram P Klazen, Peter de Man et al.

Airborne SARS-CoV-2 RNA excretion by patients with COVID-19 on different oxygen delivery systems: a prospective observational study

J Hosp Infect. 2022 Mar 11;S0195-6701(22)00075-5. doi: 10.1016/j.jhin.2022.03.001.
L M Kolodziej, S Hordijk, J Koopsen et al.

SARS-CoV-2 transmission risk upon return to work in RNA-positive healthcare workers

J Hosp Infect. 2022 Mar 11;S0195-6701(22)00079-2. doi: 10.1016/j.jhin.2022.02.024.
Josefine Thylefors, Sara Thuresson, Malin Alsved et al.

Detection of SARS-CoV-2 RNA on surfaces in a COVID-19 hospital ward indicates airborne viral spread

J Hosp Infect. 2022 Mar 10;S0195-6701(22)00080-9. doi: 10.1016/j.jhin.2022.02.025.
Hao-Hsin Wu, Chiu-Hsia Su, Li-Jung Chien, Shu-Hui Tseng, Shan-Chwen Chang

Healthcare-associated COVID-19 outbreaks: a nationwide population-based cohort study

J Hosp Infect. 2022 Mar 10;S0195-6701(22)00074-3. doi: 10.1016/j.jhin.2022.02.023.
Michael Edelstein, Karine Wiegler Beiruti, Hila Ben-Amram et al.

Antibody-mediated Immunogenicity against SARS-CoV-2 following priming, boosting and hybrid immunity: insights from 11 months of follow-up of a healthcare worker cohort in Israel, December 2020-October 2021

Clin Infect Dis. 2022 Mar 12;ciac212. doi: 10.1093/cid/ciac212.
Sarah B Doernberg, Marisa Holubar, Vivek Jain et al.

Incidence and prevalence of COVID-19 within a healthcare worker cohort during the first year of the SARS-CoV-2 pandemic

Clin Infect Dis. 2022 Mar 12;ciac210. doi: 10.1093/cid/ciac210.
Kathleen M E Gallagher, Mark B Leick, Rebecca C Larson et al.

Differential T cell immunity to SARS-CoV-2 in mRNA-1273 and BNT162b2 vaccinated individuals

Clin Infect Dis. 2022 Mar 12;ciac201. doi: 10.1093/cid/ciac201.
Nicole Wolter, Stefano Tempia, Anne von Gottberg et al.

Seroprevalence of SARS-CoV-2 after the second wave in South Africa in HIV-infected and uninfected persons: a cross-sectional household survey

Clin Infect Dis. 2022 Mar 10;ciac198. doi: 10.1093/cid/ciac198.
Yaniv Lustig, Ella Mendelson, Michal Mandelboim et al.

Existence of immunological memory response in true sero-negative individuals post COVID-19 molecular diagnosis

Clin Infect Dis. 2022 Mar 10;ciac196. doi: 10.1093/cid/ciac196.
Malin Alsved, David Nygren, Sara Thuresson et al.

SARS-CoV-2 in exhaled aerosol particles from covid-19 cases and its association to household transmission

Clin Infect Dis. 2022 Mar 10;ciac202. doi: 10.1093/cid/ciac202.
Adrianna L Westbrook, Laura C Benedit, Jennifer K Frediani et al.

Predictive value of isolated symptoms for diagnosis of SARS-CoV-2 infection in children tested during peak circulation of the delta variant

Clin Infect Dis. 2022 Mar 10;ciac112. doi: 10.1093/cid/ciac112.
Brittany Rife Magalis, Shannan Rich, Massimiliano S Tagliamonte et al.

SARS-CoV-2 Delta vaccine breakthrough transmissibility in Alachua County, Florida

Clin Infect Dis. 2022 Mar 10;ciac197. doi: 10.1093/cid/ciac197.
Vincent Chi-Chung Cheng, Jonathan Daniel Ip, Allen Wing-Ho Chu et al.

Rapid spread of SARS-CoV-2 Omicron subvariant BA.2 in a single-source community outbreak

Clin Infect Dis. 2022 Mar 10;ciac203. doi: 10.1093/cid/ciac203.
M Elvira Balcells, Nicole Le Corre, Josefina Durán et al.

Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile

Clin Infect Dis. 2022 Mar 7;ciac167. doi: 10.1093/cid/ciac167.
Suvichada Assawakosri, Sitthichai Kanokudom, Nungruthai Suntronwong et al.

Neutralizing Activities against the Omicron Variant after a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination

J Infect Dis. 2022 Mar 10;jiac092. doi: 10.1093/infdis/jiac092.
Priscila M S Castanha, Dylan J Tuttle, Georgios D Kitsios et al.

IgG response to SARS-CoV-2 and seasonal coronaviruses contributes to complement overactivation in severe COVID-19 patients

J Infect Dis. 2022 Mar 10;jiac091. doi: 10.1093/infdis/jiac091.
Brenda Martínez-González, Lucía Vázquez-Sirvent, María E Soria et al.

Vaccine-breakthrough infections with SARS-CoV-2 Alpha mirror mutations in Delta Plus, Iota and Omicron

J Clin Invest. 2022 Mar 8;e157700. doi: 10.1172/JCI157700.
Nick Andrews, Julia Stowe, Freja Kirsebom et al.

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

N Engl J Med. 2022 Mar 2. doi: 10.1056/NEJMoa2119451.
Ainsley Ryan Yan Bin Lee, Shi Yin Wong, Louis Yi Ann Chai et al.

Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis

BMJ. 2022 Mar 2;376:e068632. doi: 10.1136/bmj-2021-068632.
Ronald Lg Flumignan, Vinicius T Civile, Jéssica Dantas de Sá Tinôco et al.

Anticoagulants for people hospitalised with COVID-19

Cochrane Database Syst Rev. 2022 Mar 4;3:CD013739. doi: 10.1002/14651858.CD013739.pub2.
Anjum S Kaka, Roderick MacDonald, Eric J Linskens et al.

Major Update 2: Remdesivir for Adults With COVID-19: A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points

Ann Intern Med. 2022 Mar 1. doi: 10.7326/M21-4784.
Catia Marzolini, Daniel R Kuritzkes, Fiona Marra et al.

Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions

Ann Intern Med. 2022 Mar 1;M22-0281. doi: 10.7326/M22-0281.
Sho Iketani, Lihong Liu, Yicheng Guo et al.

Antibody evasion properties of SARS-CoV-2 Omicron sublineages

Nature. 2022 Mar 3. doi: 10.1038/s41586-022-04594-4.
Laurence Chu, Keith Vrbicky, David Montefiori et al.

Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial

Nat Med. 2022 Mar 3. doi: 10.1038/s41591-022-01739-w.
Anne M Hause, James Baggs, Paige Marquez et al.

Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12-17 Years - United States, December 9, 2021-February 20, 2022

MMWR Morb Mortal Wkly Rep. 2022 Mar 4;71(9):347-351. doi: 10.15585/mmwr.mm7109e2.
Nicola P Klein, Melissa S Stockwell, Maria Demarco et al.

Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022

MMWR Morb Mortal Wkly Rep. 2022 Mar 4;71(9):352-358. doi: 10.15585/mmwr.mm7109e3.
Fredrik Kahn, Carl Bonander, Mahnaz Moghaddassi et al.

Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities - surveillance results from southern Sweden, July 2021 to January 2022

Euro Surveill. 2022 Mar;27(9). doi: 10.2807/1560-7917.ES.2022.27.9.2200121.
Sereina Annik Herzog, Jessie De Bie, Steven Abrams et al.

Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020

Euro Surveill. 2022 Mar;27(9). doi: 10.2807/1560-7917.ES.2022.27.9.2100419.
Frank G Sandmann, Elise Tessier, Joanne Lacy et al.

Long-term health-related quality of life in non-hospitalised COVID-19 cases with confirmed SARS-CoV-2 infection in England: Longitudinal analysis and cross-sectional comparison with controls

Clin Infect Dis. 2022 Mar 5;ciac151. doi: 10.1093/cid/ciac151.
Benjamin D Pollock, Curtis B Storlie, Aaron J Tande, Priya Sampathkumar

Real-world incidence of breakthrough COVID-19 hospitalization after vaccination versus natural infection in a large, local, empaneled primary care population using time-to-event analysis

Clin Infect Dis. 2022 Mar 5;ciac186. doi: 10.1093/cid/ciac186.
Adeel A Butt, Victor B Talisa, Peng Yan et al.

Vaccine Effectiveness of Three vs. Two Doses of SARS-CoV-2 mRNA Vaccines in a High Risk National Population

Clin Infect Dis. 2022 Mar 4;ciac178. doi: 10.1093/cid/ciac178.
Louis D Saravolatz, Shawn Depcinski, Mamta Sharma

Molnupiravir and Nirmatrelvir-Ritonavir: Oral COVID Antiviral Drugs

Clin Infect Dis. 2022 Mar 4;ciac180. doi: 10.1093/cid/ciac180.
Martin Hoenigl, Daniela Abramovitz, Ricardo E Flores Ortega, Natasha K Martin, Nancy Reau

Sustained impact of the COVID-2019 pandemic on HCV treatment initiations in the United States

Clin Infect Dis. 2022 Mar 2;ciac175. doi: 10.1093/cid/ciac175.
David N Fisman, Ashleigh R Tuite

Age-Specific Changes in Virulence Associated with SARS-CoV-2 Variants of Concern

Clin Infect Dis. 2022 Mar 2;ciac174. doi: 10.1093/cid/ciac174.
Esin Kotiloglu-Karaa, Beatrix Kele, Raghavendran Kulasegaran-Shylini et al.

SARS-CoV-2 placental infection is associated with massive perivillous fibrin deposition at the maternal-fetal interface: a preliminary study

Clin Infect Dis. 2022 Mar 2;ciac173. doi: 10.1093/cid/ciac173.
Jasper Fuk-Woo Chan, Gilman Kit-Hang Siu, Shuofeng Yuan et al.

Probable Animal-to-Human Transmission of SARS-CoV-2 Delta Variant AY.127 Causing a Pet Shop-Related COVID-19 Outbreak in Hong Kong

Clin Infect Dis. 2022 Mar 2;ciac171. doi: 10.1093/cid/ciac171.
Benjamin Speich, Frédérique Chammartin, Irene A Abela et al.

Antibody response in immunocompromised patients after the administration of SARS-CoV-2 vaccine BNT162b2 or mRNA-1273: A randomised controlled trial

Clin Infect Dis. 2022 Mar 2;ciac169. doi: 10.1093/cid/ciac169.
Zack Saud, Mark Ponsford, Kirsten Bentley et al.

Mechanically ventilated patients shed high titre live SARS-CoV2 for extended periods from both the upper and lower respiratory tract

Clin Infect Dis. 2022 Mar 1;ciac170. doi: 10.1093/cid/ciac170.
Huong Q McLean, Carlos G Grijalva, Kayla E Hanson et al.

Household Transmission and Clinical Features of SARS-CoV-2 Infections

Pediatrics. 2022 Mar 1;149(3):e2021054178. doi: 10.1542/peds.2021-054178.
February 2022
Alyssa Y Castillo, Allison Zelikoff, Jeannie D Chan, John B Lynch, Chloe Bryson-Cahn

Rapid Molecular SARS-CoV-2 Testing in Hospital Employees with Mild Non-specific Respiratory Symptoms Facilitates Expedient Return to Work

Infect Control Hosp Epidemiol. 2022 Feb 28;1-10. doi: 10.1017/ice.2022.24.
Jun-Won Seo, Da Young Kim, Na Ra Yun et al.

Risk factors for severe acute respiratory syndrome coronavirus 2 RNA environmental contamination in rooms of patients with coronavirus disease 2019

Infect Control Hosp Epidemiol. 2022 Feb 28;1-10. doi: 10.1017/ice.2022.44.
Mindy M Sampson, Kimberly D Reeves, Christopher M Polk, Gregory A Hawkins, Catherine L Passaretti

A case of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) reinfection within ninety days of primary infection in a healthcare worker

Infect Control Hosp Epidemiol. 2022 Feb 22;1-2. doi: 10.1017/ice.2022.42.
Kanika Vanshylla, Pinkus Tober-Lau, Henning Gruell et al.

Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults

Lancet Infect Dis. 2022 Feb 28;S1473-3099(22)00135-9. doi: 10.1016/S1473-3099(22)00135-9.
Bill J Wright, Samuel Tideman, George A Diaz et al.

Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study

Lancet Respir Med. 2022 Feb 25;S2213-2600(22)00042-X. doi: 10.1016/S2213-2600(22)00042-X.
Qin Hong, Wenyu Han, Jiawei Li et al.

Molecular basis of receptor binding and antibody neutralization of Omicron

Nature. 2022 Feb 28. doi: 10.1038/s41586-022-04581-9.
Neil Chandra Murthy, Elizabeth Zell, Hannah E Fast et al.

Disparities in First Dose COVID-19 Vaccination Coverage among Children 5-11 Years of Age, United States

Emerg Infect Dis. 2022 Feb 28;28(5). doi: 10.3201/eid2805.220166.
Lucas D Jones, Ernest R Chan, Jennifer L Cadnum et al.

Investigation of a cluster of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in a hospital administration building

Infect Control Hosp Epidemiol. 2022 Feb 22;1-7. doi: 10.1017/ice.2022.45.
Jessica R Howard-Anderson, Carly Adams, William C Dube et al.

Occupational risk factors for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection among healthcare personnel: A 6-month prospective analysis of the COVID-19 Prevention in Emory Healthcare Personnel (COPE) Study

Infect Control Hosp Epidemiol. 2022 Feb 14;1-8. doi: 10.1017/ice.2021.518.
Sara Thuresson, Carl-Johan Fraenkel, Sviataslau Sasinovich et al.

Airborne SARS-CoV-2 in hospitals - effects of aerosol-generating procedures, HEPA-filtration units, patient viral load and physical distance

Clin Infect Dis. 2022 Feb 28;ciac161. doi: 10.1093/cid/ciac161.
Shabir A Madhi, Gaurav Kwatra, Jonathan E Myers et al.

Population Immunity and Covid-19 Severity with Omicron Variant in South Africa

N Engl J Med. 2022 Feb 23. doi: 10.1056/NEJMoa2119658.
COVID-19 Forecasting Team

Variation in the COVID-19 infection-fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis

Lancet. 2022 Feb 24;S0140-6736(21)02867-1. doi: 10.1016/S0140-6736(21)02867-1.
Anna R Yousaf, Margaret M Cortese, Allan W Taylor et al.

Reported cases of multisystem inflammatory syndrome in children aged 12-20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation

Lancet Child Adolesc Health. 2022 Feb 22;S2352-4642(22)00028-1. doi: 10.1016/S2352-4642(22)00028-1.
Daniel R Feikin, Melissa M Higdon, Laith J Abu-Raddad et al.

Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression

Lancet. 2022 Feb 21;S0140-6736(22)00152-0. doi: 10.1016/S0140-6736(22)00152-0.
Jonathan J Deeks, Anika Singanayagam, Hamish Houston et al.

SARS-CoV-2 antigen lateral flow tests for detecting infectious people: linked data analysis

BMJ. 2022 Feb 23;376:e066871. doi: 10.1136/bmj-2021-066871.
Xue Li, Francisco Tsz Tsun Lai, Gilbert T Chua et al.

Myocarditis Following COVID-19 BNT162b2 Vaccination Among Adolescents in Hong Kong

JAMA Pediatr. 2022 Feb 25. doi: 10.1001/jamapediatrics.2022.0101.
Derek K Chu, Elissa M Abrams, David B K Golden et al.

Risk of Second Allergic Reaction to SARS-CoV-2 Vaccines: A Systematic Review and Meta-analysis

JAMA Intern Med. 2022 Feb 21. doi: 10.1001/jamainternmed.2021.8515.
William Encinosa, Jessica Figueroa, Youssef Elias

Severity of Hospitalizations from SARS-CoV-2 vs Influenza and Respiratory Syncytial Virus Infection in Children Aged 5 to 11 Years in 11 US States

JAMA Pediatr. 2022 Feb 21. doi: 10.1001/jamapediatrics.2021.6566.
Renuka Tipirneni, Monita Karmakar, Megan O'Malley, Hallie C Prescott, Vineet Chopra

Contribution of Individual- and Neighborhood-Level Social, Demographic, and Health Factors to COVID-19 Hospitalization Outcomes

Ann Intern Med. 2022 Feb 22. doi: 10.7326/M21-2615.
Hung Fu Tseng, Bradley K Ackerson, Yi Luo et al.

Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants

Nat Med. 2022 Feb 21. doi: 10.1038/s41591-022-01753-y.
Xuan He, Malika Aid, Abishek Chandrashekar et al.

A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2-specific immune responses in rhesus macaques

Sci Transl Med. 2022 Feb 22;eabm4996. doi: 10.1126/scitranslmed.abm4996.
Julia M Baker, Jasmine Y Nakayama, Michelle O’Hegarty et al.

SARS-CoV-2 B.1.1.529 (Omicron) Variant Transmission Within Households ― Four U.S. Jurisdictions, November 2021–February 2022

MMWR Morb Mortal Wkly Rep. 2022 Feb 25. doi: 10.15585/mmwr.mm7109e1.
Eric D Laing, Carol D Weiss, Emily C Samuels et al.

Durability of Antibody Response and Frequency of SARS-CoV-2 Infection 6 Months after COVID-19 Vaccination in Healthcare Workers

Emerg Infect Dis. 2022 Feb 24;28(4). doi: 10.3201/eid2804.212037.
Isabel Griffin, Kate R Woodworth, Romeo R Galang et al.

Recurrent SARS-CoV-2 RNA Detection after COVID-19 Illness Onset during Pregnancy

Emerg Infect Dis. 2022 Feb 25;28(4). doi: 10.3201/eid2804.212354.
Alex Dulovic, Monika Strengert, Gema Morillas Ramos et al.

Diminishing Immune Responses against Variants of Concern in Dialysis Patients 4 Months after SARS-CoV-2 mRNA Vaccination

Emerg Infect Dis. 2022 Feb 24;28(4). doi: 10.3201/eid2804.211907.
Margarita Pons-Salort, Jacob John, Oliver J Watson et al.

Reassessing Reported Deaths and Estimated Infection Attack Rate during the First 6 Months of the COVID-19 Epidemic, Delhi, India

Emerg Infect Dis. 2022 Feb 25;28(4). doi: 10.3201/eid2804.210879.
Jayna Raghwani, Louis du Plessis, John T McCrone et al.

Genomic Epidemiology of Early SARS-CoV-2 Transmission Dynamics, Gujarat, India

Emerg Infect Dis. 2022 Feb 24;28(4). doi: 10.3201/eid2804.212053.
Janko van Beek, Zsofia Igloi, Timo Boelsums et al.

From more testing to smart testing: data-guided SARS-CoV-2 testing choices, the Netherlands, May to September 2020

Euro Surveill. 2022 Feb;27(8). doi: 10.2807/1560-7917.ES.2022.27.8.2100702.
Pavan V Thakkar, Kanecia O Zimmerman, M Alan Brookhart et al.

COVID-19 Incidence Among 6th-12th Grade Students by Vaccination Status

Pediatrics. 2022 Feb 22. doi: 10.1542/peds.2022-056230.
James R Barnacle, Hamish Houston, Ioannis Baltas et al.

Diagnostic accuracy of the Abbott ID NOW SARS-CoV-2 rapid test for the triage of acute medical admissions

J Hosp Infect. 2022 Feb 22;S0195-6701(22)00060-3. doi: 10.1016/j.jhin.2022.02.010.
Giuseppe Lippi, Riccardo Nocini, Camilla Mattiuzzi, Brandon M Henry

FebriDx for rapid screening of patients with suspected COVID-19 upon hospital admission: systematic literature review and meta-analysis

J Hosp Infect. 2022 Feb 21;S0195-6701(22)00059-7. doi: 10.1016/j.jhin.2022.02.009.
Usha Stiefel, Davinder Bhullar, Trina F Zabarsky et al.

Healthcare personnel frequently have positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen tests 5 days or more after diagnosis of coronavirus disease 2019 (COVID-19)

Infect Control Hosp Epidemiol. 2022 Feb 8;1-2. doi: 10.1017/ice.2022.21.
Sumathi Sivapalasingam, David J Lederer, Rafia Bhore et al.

Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19: A Randomized Clinical Trial

Clin Infect Dis. 2022 Feb 26;ciac153. doi: 10.1093/cid/ciac153.
Peter Katona, Ravina Kullar, Kevin Zhang

Bringing Transmission of SARS-CoV-2 to the Surface: Is there a Role for Fomites?

Clin Infect Dis. 2022 Feb 26;ciac157. doi: 10.1093/cid/ciac157.
George B Sigal, Tanya Novak, Anu Mathew et al.

Measurement of SARS-CoV-2 antigens in plasma of pediatric patients with acute COVID-19 or MIS-C using an ultrasensitive and quantitative immunoassay

Clin Infect Dis. 2022 Feb 25;ciac160. doi: 10.1093/cid/ciac160.
Kevin C Ma, Jaime E Hale, Yonatan H Grad et al.

Trends in SARS-CoV-2 seroprevalence in Massachusetts estimated from newborn screening specimens

Clin Infect Dis. 2022 Feb 25;ciac158. doi: 10.1093/cid/ciac158.
Peter F Wright, Alejandra C Prevost-Reilly, Harini Natarajan et al.

Longitudinal Systemic and Mucosal Immune Responses to SARS-CoV-2 Infection

J Infect Dis. 2022 Feb 21;jiac065. doi: 10.1093/infdis/jiac065.
Eleanor Burnett, Umesh D Parashar, Amber Winn, Jacqueline E Tate

Trends in rotavirus laboratory detections and internet search volume before and after rotavirus vaccine introduction and in the context of the COVID-19 pandemic-- United States 2000-2021

J Infect Dis. 2022 Feb 20;jiac062. doi: 10.1093/infdis/jiac062.
Jennifer Hammond, Heidi Leister-Tebbe, Annie Gardner et al.

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

N Engl J Med. 2022 Feb 16. doi: 10.1056/NEJMoa2118542.
Victoria Hall, Sarah Foulkes, Ferdinando Insalata et al.

Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection

N Engl J Med. 2022 Feb 16. doi: 10.1056/NEJMoa2118691.
Ariel Hammerman, Ruslan Sergienko, Michael Friger et al.

Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19

N Engl J Med. 2022 Feb 16. doi: 10.1056/NEJMoa2119497.
Jeané Cloete, Annelet Kruger, Maureen Masha et al.

Paediatric hospitalisations due to COVID-19 during the first SARS-CoV-2 omicron (B.1.1.529) variant wave in South Africa: a multicentre observational study

Lancet Child Adolesc Health. 2022 Feb 18;S2352-4642(22)00027-X. doi: 10.1016/S2352-4642(22)00027-X.
Erik Duijvelaar, Job R Schippers, Patrick J Smeele et al.

Long-term clinical outcomes of COVID-19 patients treated with imatinib

Lancet Respir Med. 2022 Feb 17;S2213-2600(22)00052-2. doi: 10.1016/S2213-2600(22)00052-2.
William S Hart, Elizabeth Miller, Nick J Andrews et al.

Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis

Lancet Infect Dis. 2022 Feb 14;S1473-3099(22)00001-9. doi: 10.1016/S1473-3099(22)00001-9.
Yan Xie, Evan Xu, Ziyad Al-Aly

Risks of mental health outcomes in people with covid-19: cohort study

BMJ. 2022 Feb 16;376:e068993. doi: 10.1136/bmj-2021-068993.
Steven Chee Loon Lim, Chee Peng Hor, Kim Heng Tay et al.

Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH Randomized Clinical Trial

JAMA Intern Med. 2022 Feb 18. doi: 10.1001/jamainternmed.2022.0189.
Ana Cecilia Ulloa, Sarah A Buchan, Nick Daneman, Kevin A Brown

Estimates of SARS-CoV-2 Omicron Variant Severity in Ontario, Canada

JAMA. 2022 Feb 17. doi: 10.1001/jama.2022.2274.
Amadea Britton, Katherine E Fleming-Dutra, Nong Shang et al.

Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant Predominance

JAMA. 2022 Feb 14;e222068. doi: 10.1001/jama.2022.2068.
Neil Murthy, A Patricia Wodi, Henry Bernstein, Kevin A Ault, Advisory Committee on Immunization Practices

Recommended Adult Immunization Schedule, United States, 2022

Ann Intern Med. 2022 Feb 18. doi: 10.7326/M22-0036.
Sivan Gazit, Roei Shlezinger, Galit Perez et al.

The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine : A Retrospective Cohort Study

Ann Intern Med. 2022 Feb 15. doi: 10.7326/M21-4130.
Sarah Temmam, Khamsing Vongphayloth, Eduard Baquero Salazar et al.

Bat coronaviruses related to SARS-CoV-2 and infectious for human cells

Nature. 2022 Feb 16. doi: 10.1038/s41586-022-04532-4.
Jia Wei, Koen B Pouwels, Nicole Stoesser et al.

Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines

Nat Med. 2022 Feb 14. doi: 10.1038/s41591-022-01721-6.
Keith Sacco, Riccardo Castagnoli, Svetlana Vakkilainen et al.

Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19

Nat Med. 2022 Feb 17. doi: 10.1038/s41591-022-01724-3.
John P Evans, Cong Zeng, Claire Carlin et al.

Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection

Sci Transl Med. 2022 Feb 15;eabn8057. doi: 10.1126/scitranslmed.abn8057.
Sarah E Smith-Jeffcoat, Mary A Pomeroy, Sadia Sleweon et al.

Multistate Outbreak of SARS-CoV-2 B.1.1.529 (Omicron) Variant Infections Among Persons in a Social Network Attending a Convention - New York City, November 18-December 20, 2021

MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):238-242. doi: 10.15585/mmwr.mm7107a3.
Samira Sami, Libby Horter, Diana Valencia et al.

Investigation of SARS-CoV-2 Transmission Associated With a Large Indoor Convention - New York City, November-December 2021

MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):243-248. doi: 10.15585/mmwr.mm7107a4.
Natasha B Halasa, Samantha M Olson, Mary A Staat et al.

Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19-Associated Hospitalization in Infants Aged <6 Months - 17 States, July 2021-January 2022

MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):264-270. doi: 10.15585/mmwr.mm7107e3.
Kristin J Marks, Michael Whitaker, Onika Anglin et al.

Hospitalizations of Children and Adolescents with Laboratory-Confirmed COVID-19 - COVID-NET, 14 States, July 2021-January 2022

MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):271-278. doi: 10.15585/mmwr.mm7107e4.
Tammy E Servies, Eric C Larsen, Rodney C Lindsay et al.

Notes from the Field: Outbreak of COVID-19 Among a Highly Vaccinated Population Aboard a U.S. Navy Ship After a Port Visit - Reykjavik, Iceland, July 2021

MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):279-281. doi: 10.15585/mmwr.mm7107a5.
Souheil Zayet, Vincent Gendrin, Catherine Gay, Philippe Selles, Timothée Klopfenstein

Increased COVID-19 Severity among Pregnant Patients Infected with SARS-CoV-2 Delta Variant, France

Emerg Infect Dis. 2022 Feb 18;28(5). doi: 10.3201/eid2805.212080.
Novy Charel Bobouaka Bonguili, Matthieu Fritz, Hosanna Lenguiya et al.

Early Circulation of SARS-CoV-2, Congo, 2020

Emerg Infect Dis. 2022 Feb 18;28(4). doi: 10.3201/eid2804.212476.
Eun-Young Kim, Young June Choe, Hanul Park et al.

Community Transmission of SARS-CoV-2 Omicron Variant, South Korea, 2021

Emerg Infect Dis. 2022 Feb 16;28(4). doi: 10.3201/eid2804.220006.
Tasnim Hasan, Viet Nhung Nguyen, Hoa Binh Nguyen et al.

Retrospective Cohort Study of Effects of the COVID-19 Pandemic on Tuberculosis Notifications, Vietnam, 2020

Emerg Infect Dis. 2022 Feb 15;28(3). doi: 10.3201/eid2803.211919.
Holly D Mitchell, Tatiana Garcia Vilaplana, Sema Mandal et al.

Effects of COVID-19 Pandemic Response on Service Provision for Sexually Transmitted Infections, HIV, and Viral Hepatitis, England

Emerg Infect Dis. 2022 Feb 15;28(3). doi: 10.3201/eid2803.211998.
Gaetano Marrone, Nathalie Nicolay, Nick Bundle et al.

Risk reduction of severe outcomes in vaccinated COVID-19 cases: an analysis of surveillance data from Estonia, Ireland, Luxembourg and Slovakia, January to November 2021

Euro Surveill. 2022 Feb;27(7). doi: 10.2807/1560-7917.ES.2022.27.7.2200060.
Geert Molenberghs, Christel Faes, Johan Verbeeck et al.

COVID-19 mortality, excess mortality, deaths per million and infection fatality ratio, Belgium, 9 March 2020 to 28 June 2020

Euro Surveill. 2022 Feb;27(7). doi: 10.2807/1560-7917.ES.2022.27.7.2002060.
Ana Requena-Méndez, Aikaterini Mougkou, Pontus Hedberg et al.

SARS-CoV-2 testing in patients with low COVID-19 suspicion at admission to a tertiary care hospital, Stockholm, Sweden, March to September 2020

Euro Surveill. 2022 Feb;27(7). doi: 10.2807/1560-7917.ES.2022.27.7.2100079.
Magda Machado de Miranda Costa, Ana Rubia Guedes, Maria Dolores Santos da Purificação Nogueira et al.

Nationwide surveillance system to evaluate hospital-acquired COVID-19 in Brazilian hospitals

J Hosp Infect. 2022 Feb 14;S0195-6701(22)00044-5. doi: 10.1016/j.jhin.2022.02.004.
Ghady Haidar, Mounzer Agha, Andrew Bilderback et al.

Prospective evaluation of COVID-19 vaccine responses across a broad spectrum of immunocompromising conditions: the COVICS study

Clin Infect Dis. 2022 Feb 18;ciac103. doi: 10.1093/cid/ciac103.
Amihai Rottenstreich, Gila Zarbiv, Esther Oiknine-Djian et al.

The effect of gestational age at BNT162b2 mRNA vaccination on maternal and neonatal SARS-CoV-2 antibody levels

Clin Infect Dis. 2022 Feb 16;ciac135. doi: 10.1093/cid/ciac135.
Christina M Schumacher, Nicole Thornton, Jessica Wagner et al.

Sexually Transmitted Infection Transmission Dynamics During the Coronavirus Disease 2019 (COVID-19) Pandemic Among Urban Gay, Bisexual, and Other Men Who Have Sex With Men

Clin Infect Dis. 2022 Feb 16;ciab1053. doi: 10.1093/cid/ciab1053.
Zhanwei Du, Caifen Liu, Chunyu Wang et al.

Reproduction Numbers of SARS-CoV-2 Variants: A Systematic Review and Meta-analysis

Clin Infect Dis. 2022 Feb 16;ciac137. doi: 10.1093/cid/ciac137.
Tommy Nyberg, Katie Harman, Asad Zaidi et al.

Hospitalisation and mortality risk for COVID-19 cases with SARS-CoV-2 AY.4.2 (VUI-21OCT-01) compared to non-AY.4.2 Delta variant sub-lineages

J Infect Dis. 2022 Feb 20;jiac063. doi: 10.1093/infdis/jiac063.
Keiya Uriu, Paúl Cárdenas, Erika Muñoz et al.

Characterization of the immune resistance of SARS-CoV-2 Mu variant and the robust immunity induced by Mu infection

J Infect Dis. 2022 Feb 18;jiac053. doi: 10.1093/infdis/jiac053.
Meike Meyer, Esra Ruebsteck, Frank Eifinger et al.

Morbidity of Respiratory Syncytial Virus-infections (RSV): RSV compared with SARS-CoV-2 infections in children aged 0 - 4 years in Cologne, Germany

J Infect Dis. 2022 Feb 16;jiac052. doi: 10.1093/infdis/jiac052.
Ji Yun Noh, Jeong-Sun Yang, Soon Young Hwang et al.

Duration of humoral immunity and cross-neutralizing activity against the Alpha, Beta, and Delta variants after wild-type SARS-CoV-2 infection: A prospective cohort study

J Infect Dis. 2022 Feb 16;jiac050. doi: 10.1093/infdis/jiac050.
Jia Zou, Li Li, Peiyi Zheng et al.

Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance

J Clin Invest. 2022 Feb 15;132(4):e154987. doi: 10.1172/JCI154987.
Heba N Altarawneh, Hiam Chemaitelly, Mohammad R Hasan et al.

Protection against the Omicron Variant from Previous SARS-CoV-2 Infection

N Engl J Med. 2022 Feb 9. doi: 10.1056/NEJMc2200133.
Jerald Sadoff, Glenda Gray, An Vandebosch et al.

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

N Engl J Med. 2022 Feb 9. doi: 10.1056/NEJMoa2117608.
Florian B Mayr, Victor B Talisa, Obaid Shaikh, Sachin Yende, Adeel A Butt

Effectiveness of Homologous or Heterologous Covid-19 Boosters in Veterans

N Engl J Med. 2022 Feb 9. doi: 10.1056/NEJMc2200415.
RECOVERY Collaborative Group

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Lancet. 2022 Feb 12;399(10325):665-676. doi: 10.1016/S0140-6736(22)00163-5.
Andrea Alemany, Pere Millat-Martinez, Marc Corbacho-Monné et al.

High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial

Lancet Respir Med. 2022 Feb 9;S2213-2600(21)00545-2. doi: 10.1016/S2213-2600(21)00545-2.
Burc Barin, Ulus Kasap, Ferda Selçuk, Ender Volkan, Özge Uluçkan

Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study

Lancet Microbe. 2022 Feb 9. doi: 10.1016/S2666-5247(21)00305-0.
Jin Young Ahn, Jeongsoo Lee, You Suk Suh et al.

Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults

Lancet Microbe. 2022 Feb 8. doi: 10.1016/S2666-5247(21)00358-X.
Selina Kikkenborg Berg, Susanne Dam Nielsen, Ulrikka Nygaard et al.

Long COVID symptoms in SARS-CoV-2-positive adolescents and matched controls (LongCOVIDKidsDK): a national, cross-sectional study

Lancet Child Adolesc Health. 2022 Feb 7;S2352-4642(22)00004-9. doi: 10.1016/S2352-4642(22)00004-9.
Terence Stephenson, Snehal M Pinto Pereira, Roz Shafran et al.

Physical and mental health 3 months after SARS-CoV-2 infection (long COVID) among adolescents in England (CLoCk): a national matched cohort study

Lancet Child Adolesc Health. 2022 Feb 7;S2352-4642(22)00022-0. doi: 10.1016/S2352-4642(22)00022-0.
Yingying Lu, Yufang Zhu, Miao Cui, Zhengjiang Cheng, Peng Hong

Post-recovery enhancement of anti-variant neutralisation after severe COVID-19

Lancet Microbe. 2022 Feb 7. doi: 10.1016/S2666-5247(22)00032-5.
Massimo Fabiani, Maria Puopolo, Cristina Morciano et al.

Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study

BMJ. 2022 Feb 10;376:e069052. doi: 10.1136/bmj-2021-069052.
Ken Cohen, Sheng Ren, Kevin Heath et al.

Risk of persistent and new clinical sequelae among adults aged 65 years and older during the post-acute phase of SARS-CoV-2 infection: retrospective cohort study

BMJ. 2022 Feb 9;376:e068414. doi: 10.1136/bmj-2021-068414.
Sharon Hui Xuan Tan, Rachael Pung, Lin-Fa Wang et al.

Association of Homologous and Heterologous Vaccine Boosters With COVID-19 Incidence and Severity in Singapore

JAMA. 2022 Feb 11. doi: 10.1001/jama.2022.1922.
Inbal Goldshtein, David M Steinberg, Jacob Kuint et al.

Association of BNT162b2 COVID-19 Vaccination During Pregnancy With Neonatal and Early Infant Outcomes

JAMA Pediatr. 2022 Feb 10. doi: 10.1001/jamapediatrics.2022.0001.
Lydia L Shook, Caroline G Atyeo, Lael M Yonker et al.

Durability of Anti-Spike Antibodies in Infants After Maternal COVID-19 Vaccination or Natural Infection

JAMA. 2022 Feb 7. doi: 10.1001/jama.2022.1206.
Torri D Metz, Rebecca G Clifton, Brenna L Hughes et al.

Association of SARS-CoV-2 Infection With Serious Maternal Morbidity and Mortality From Obstetric Complications

JAMA. 2022 Feb 7. doi: 10.1001/jama.2022.1190.
David C Schultz, Robert M Johnson, Kasirajan Ayyanathan et al.

Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2

Nature. 2022 Feb 7. doi: 10.1038/s41586-022-04482-x.
Rolando Pajon, Yamuna D Paila, Bethany Girard et al.

Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial

Nat Med. 2022 Feb 10. doi: 10.1038/s41591-022-01679-5.
Thiago Cerqueira-Silva, Srinivasa Vittal Katikireddi, Vinicius de Araujo Oliveira et al.

Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil

Nat Med. 2022 Feb 9. doi: 10.1038/s41591-022-01701-w.
Nicole L Welch, Meilin Zhu, Catherine Hua et al.

Multiplexed CRISPR-based microfluidic platform for clinical testing of respiratory viruses and identification of SARS-CoV-2 variants

Nat Med. 2022 Feb 7. doi: 10.1038/s41591-022-01734-1.
Yan Xie, Evan Xu, Benjamin Bowe, Ziyad Al-Aly

Long-term cardiovascular outcomes of COVID-19

Nat Med. 2022 Feb 7. doi: 10.1038/s41591-022-01689-3.
Chengzi I Kaku, Elizabeth R Champney, Johan Normark et al.

Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination

Science. 2022 Feb 10;eabn2688. doi: 10.1126/science.abn2688.
Paul Elliott, Barbara Bodinier, Oliver Eales et al.

Rapid increase in Omicron infections in England during December 2021: REACT-1 study

Science. 2022 Feb 8;eabn8347. doi: 10.1126/science.abn8347.
Wanchao Yin, Youwei Xu, Peiyu Xu et al.

Structures of the Omicron Spike trimer with ACE2 and an anti-Omicron antibody

Science. 2022 Feb 8;eabn8863. doi: 10.1126/science.abn8863.
Sam Afkhami, Michael R D’Agostino, Ali Zhang et al.

Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2

Cell. 2022 Feb 8;S0092-8674(22)00145-3. doi: 10.1016/j.cell.2022.02.005.
Anne M Hause, James Baggs, Paige Marquez et al.

Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults ― United States, September 22, 2021–February 6, 2022

MMWR Morb Mortal Wkly Rep. 2022 Feb 11. doi: 10.15585/mmwr.mm7107e1.
Jill M Ferdinands, Suchitra Rao, Brian E Dixon et al.

Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance ― VISION Network, 10 States, August 2021–January 2022

MMWR Morb Mortal Wkly Rep. 2022 Feb 11. doi: 10.15585/mmwr.mm7107e2.
Anastasia S Lambrou, Philip Shirk, Molly K Steele et al.

Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) Variants - United States, June 2021-January 2022

MMWR Morb Mortal Wkly Rep. 2022 Feb 11;71(6):206-211. doi: 10.15585/mmwr.mm7106a4.
Yusuke Miyazato, Kei Yamamoto, Gen Yamada et al.

Multisystem Inflammatory Syndrome in Adult after First Dose of mRNA Vaccine

Emerg Infect Dis. 2022 Feb 11;28(4). doi: 10.3201/eid2804.212585.
Lívia P Bonifácio, Viviane N F Csizmar, Francisco Barbosa-Júnior et al.

Long-Term Symptoms among COVID-19 Survivors in Prospective Cohort Study, Brazil

Emerg Infect Dis. 2022 Feb 8;28(3). doi: 10.3201/eid2803.212020.
Sarah Reagan-Steiner, Julu Bhatnagar, Roosecelis B Martines et al.

Detection of SARS-CoV-2 in Neonatal Autopsy Tissues and Placenta

Emerg Infect Dis. 2022 Feb 9;28(3). doi: 10.3201/eid2803.211735.
Mars Stone, Eduard Grebe, Hasan Sulaeman et al.

Evaluation of Commercially Available High-Throughput SARS-CoV-2 Serologic Assays for Serosurveillance and Related Applications

Emerg Infect Dis. 2022 Feb 10;28(3). doi: 10.3201/eid2803.211885.
Seonju Yi, Young June Choe, Jia Kim et al.

SARS-CoV-2 Breakthrough Infections after introduction of 4 COVID-19 Vaccines, South Korea, 2021

Emerg Infect Dis. 2022 Feb 8;28(3). doi: 10.3201/eid2803.212210.
Alexis Russell, Collin O'Connor, Erica Lasek-Nesselquist et al.

Spatiotemporal Analyses of 2 Co-Circulating SARS-CoV-2 Variants, New York State, USA

Emerg Infect Dis. 2022 Feb 8;28(3). doi: 10.3201/eid2803.211972.
Faith Ho, Tim K Tsang, Huizhi Gao et al.

Restaurant-Based Measures to Control Community Transmission of COVID-19, Hong Kong

Emerg Infect Dis. 2022 Feb 7;28(3). doi: 10.3201/eid2803.211015.
Jantien A Backer, Dirk Eggink, Stijn P Andeweg et al.

Shorter serial intervals in SARS-CoV-2 cases with Omicron BA.1 variant compared with Delta variant, the Netherlands, 13 to 26 December 2021

Euro Surveill. 2022 Feb;27(6). doi: 10.2807/1560-7917.ES.2022.27.6.2200042.
Brice Mastrovito, Chloé Naimi, Leslie Kouam et al.

Investigation of outbreak cases infected with the SARS-CoV-2 B.1.640 variant in a fully vaccinated elderly population, Normandy, France, November to December 2021

Euro Surveill. 2022 Feb;27(6). doi: 10.2807/1560-7917.ES.2022.27.6.2200078.
Frederik Plesner Lyngse, Carsten Kirkeby, Tariq Halasa et al.

Nationwide study on SARS-CoV-2 transmission within households from lockdown to reopening, Denmark, 27 February 2020 to 1 August 2020

Euro Surveill. 2022 Feb;27(6). doi: 10.2807/1560-7917.ES.2022.27.6.2001800.
Juliette Paireau, Alexandra Mailles, Catherine Eisenhauer et al.

Early chains of transmission of COVID-19 in France, January to March 2020

Euro Surveill. 2022 Feb;27(6). doi: 10.2807/1560-7917.ES.2022.27.6.2001953.
Samuel Alizon, Christian Selinger, Mircea T Sofonea et al.

Epidemiological and clinical insights from SARS-CoV-2 RT-PCR crossing threshold values, France, January to November 2020

Euro Surveill. 2022 Feb;27(6). doi: 10.2807/1560-7917.ES.2022.27.6.2100406.
Elissa M Schecter-Perkins, Shira Doron, Russell Johnston et al.

A Test-to-Stay Modified Quarantine Program for COVID-19 in Schools

Pediatrics. 2022 Feb 8. doi: 10.1542/peds.2021-055727.
Jos M B M van der Vossen, Ahmed Fawzy, Anita Ouwens et al.

Respirator undersupply issues can safely be mitigated by applying UVC disinfection as demonstrated in challenges with Geobacillus stearothermophilus spores and SARS-CoV-2 virus

J Hosp Infect. 2022 Feb 9;S0195-6701(22)00037-8. doi: 10.1016/j.jhin.2022.01.021.
Shotaro Okachi, Takayasu Ito, Hirotoshi Yasui, Noriaki Fukatsu, Kazuhide Sato

Oropharyngeal suctioning and nasogastric tube insertion with a new mask for reduction of droplet dispersion: a proposal for a new preventive strategy during the coronavirus disease pandemic

J Hosp Infect. 2022 Feb 8;S0195-6701(22)00039-1. doi: 10.1016/j.jhin.2022.01.022.
Anna Bershteyn, Angela M Dahl, Tracy Q Dong et al.

Self-Assessed Severity as a Determinant of COVID-19 Symptom Specificity: A Longitudinal Cohort Study

Clin Infect Dis. 2022 Feb 13;ciac129. doi: 10.1093/cid/ciac129.
Marisa A P Donnelly, Meagan R Chuey, Raymond Soto et al.

Household transmission of SARS-CoV-2 Alpha variant - United States, 2021

Clin Infect Dis. 2022 Feb 11;ciac125. doi: 10.1093/cid/ciac125.
Yaron Niv, Noa Eliakim-Raz, Yaron Bar-Lavi et al.

Comparing Covid-19 pandemic waves in hospitalized patients - a retrospective, multicenter, cohort study

Clin Infect Dis. 2022 Feb 10;ciac119. doi: 10.1093/cid/ciac119.
Adeel A Butt, Victor B Talisa, Peng Yan et al.

Real-world Effectiveness of the SARS-CoV-2 mRNA Vaccines in Preventing Confirmed Infection in Patients on Chronic Hemodialysis

Clin Infect Dis. 2022 Feb 9;ciac118. doi: 10.1093/cid/ciac118.
Meghan A Baker, Chanu Rhee, Robert Tucker et al.

Rapid control of hospital-based SARS-CoV-2 Omicron clusters through daily testing and universal use of N95 respirators

Clin Infect Dis. 2022 Feb 7;ciac113. doi: 10.1093/cid/ciac113.
Paul E Drawz, Malini DeSilva, Peter Bodurtha et al.

Effectiveness of BNT162b2 and mRNA-1273 Second Doses and Boosters for SARS-CoV-2 infection and SARS-CoV-2 Related Hospitalizations: A Statewide Report from the Minnesota Electronic Health Record Consortium

Clin Infect Dis. 2022 Feb 7;ciac110. doi: 10.1093/cid/ciac110.
Malcolm Risk, Chen Shen, Salim S Hayek et al.

Comparative Effectiveness of COVID-19 Vaccines against the Delta Variant

Clin Infect Dis. 2022 Feb 7;ciac106. doi: 10.1093/cid/ciac106.
Zheng Li, Brian Lewis, Kevin Berney et al.

Social vulnerability and rurality associated with higher SARS-CoV-2 infection-induced seroprevalence: a nationwide blood donor study, United States, July 2020 - June 2021

Clin Infect Dis. 2022 Feb 7;ciac105. doi: 10.1093/cid/ciac105.
Meagan E Deming, Tracy Q Dong, Vaidehi Agrawal et al.

Detection and kinetics of subgenomic SARS-CoV-2 RNA viral load in longitudinal diagnostic RNA positive samples

J Infect Dis. 2022 Feb 12;jiac048. doi: 10.1093/infdis/jiac048.
Iana H Haralambieva, Jonathon M Monroe, Inna G Ovsyannikova et al.

Distinct Homologous and Variant-Specific Memory B-Cell and Antibody Response Over Time after SARS-CoV-2 mRNA Vaccination

J Infect Dis. 2022 Feb 8;jiac042. doi: 10.1093/infdis/jiac042.
Alessio Mazzoni, Anna Vanni, Michele Spinicci et al.

SARS-CoV-2 infection and vaccination trigger long-lived B and CD4+ T lymphocytes: implications for booster strategies

J Clin Invest. 2022 Feb 9;e157990. doi: 10.1172/JCI157990.
E Wesley Ely, Athimalaipet V Ramanan, Cynthia E Kartman et al.

Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial

Lancet Respir Med. 2022 Feb 3;S2213-2600(22)00006-6. doi: 10.1016/S2213-2600(22)00006-6.
COVID-19 National Preparedness Collaborators

Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021

Lancet. 2022 Feb 1;S0140-6736(22)00172-6. doi: 10.1016/S0140-6736(22)00172-6.
Jennifer L Alejo, Jonathan Mitchell, Amy Chang et al.

Prevalence and Durability of SARS-CoV-2 Antibodies Among Unvaccinated US Adults by History of COVID-19

JAMA. 2022 Feb 3. doi: 10.1001/jama.2022.1393.
Hidechika Akashi, Satoshi Shimada, Toyomitsu Tamura, Eiki Chinda, Norihiro Kokudo

SARS-CoV-2 Infections in Close Contacts of Positive Cases in the Olympic and Paralympic Village at the 2021 Tokyo Olympic and Paralympic Games

JAMA. 2022 Feb 3. doi: 10.1001/jama.2022.0818.
Anders Hviid, Jørgen Vinsløv Hansen, Emilia Myrup Thiesson, Jan Wohlfahrt

Association of AZD1222 and BNT162b2 COVID-19 Vaccination With Thromboembolic and Thrombocytopenic Events in Frontline Personnel : A Retrospective Cohort Study

Ann Intern Med. 2022 Feb 1. doi: 10.7326/M21-2452.
Min Kang, Yao Yi, Yan Li et al.

Effectiveness of Inactivated COVID-19 Vaccines Against Illness Caused by the B.1.617.2 (Delta) Variant During an Outbreak in Guangdong, China : A Cohort Study

Ann Intern Med. 2022 Feb 1. doi: 10.7326/M21-3509.
Kaspar Staub, Radoslaw Panczak, Katarina L Matthes et al.

Historically High Excess Mortality During the COVID-19 Pandemic in Switzerland, Sweden, and Spain

Ann Intern Med. 2022 Feb 1;M21-3824. doi: 10.7326/M21-3824.
Kenrie P Y Hui, John C W Ho, Man-Chun Cheung et al.

SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo

Nature. 2022 Feb 1. doi: 10.1038/s41586-022-04479-6.
Rigel Suzuki, Daichi Yamasoba, Izumi Kimura et al.

Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant

Nature. 2022 Feb 1. doi: 10.1038/s41586-022-04462-1.
Bo Meng, Adam Abdullahi, Isabella A T M Ferreira et al.

Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity

Nature. 2022 Feb 1. doi: 10.1038/s41586-022-04474-x.
Ronald Swanstrom, Raymond F Schinazi

Lethal mutagenesis as an antiviral strategy

Science. 2022 Feb 4;375(6580):497-498. doi: 10.1126/science.abn0048.
Xavier Charmetant, Maxime Espi, Ilies Benotmane et al.

Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients

Sci Transl Med. 2022 Feb 1;eabl6141. doi: 10.1126/scitranslmed.abl6141.
Vivek Naranbhai, Anusha Nathan, Clarety Kaseke et al.

T-cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals

Cell. 2022 Feb 2;S0092-8674(22)00140-4. doi: 10.1016/j.cell.2022.01.029.
Marianna Zazhytska, Albana Kodra, Daisy A Hoagland et al.

Non-cell autonomous disruption of nuclear architecture as a potential cause of COVID-19 induced anosmia

Cell. 2022 Feb 1;S0092-8674(22)00135-0. doi: 10.1016/j.cell.2022.01.024.
Katlyn Lederer, Emily Bettini, Kalpana Parvathaneni et al.

Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals

Cell. 2022 Feb 1;S0092-8674(22)00138-6. doi: 10.1016/j.cell.2022.01.027.
Kristin L Andrejko, Jake M Pry, Jennifer F Myers et al.

Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection - California, February-December 2021

MMWR Morb Mortal Wkly Rep. 2022 Feb 11;71(6):212-216. doi: 10.15585/mmwr.mm7106e1.
Matthew E Modes, Michael P Directo, Michael Melgar et al.

Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022

MMWR Morb Mortal Wkly Rep. 2022 Feb 11;71(6):217-223. doi: 10.15585/mmwr.mm7106e2.
Phoebe Danza, Tae Hee Koo, Meredith Haddix et al.

SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance - Los Angeles County, California, November 7, 2021-January 8, 2022

MMWR Morb Mortal Wkly Rep. 2022 Feb 4;71(5):177-181. doi: 10.15585/mmwr.mm7105e1.
James M Tesoriero, Wendy Patterson, Demetre Daskalakis et al.

Notes from the Field: COVID-19 Vaccination Among Persons Living with Diagnosed HIV Infection - New York, October 2021

MMWR Morb Mortal Wkly Rep. 2022 Feb 4;71(5):182-184. doi: 10.15585/mmwr.mm7105a4.
Adriana Heguy, Dacia Dimartino, Christian Marier et al.

Amplification Artifact in SARS-CoV-2 Omicron Sequences Carrying P681R Mutation, New York, USA

Emerg Infect Dis. 2022 Feb 7;28(4). doi: 10.3201/eid2804.220146.
Kimberly H Nguyen, Jing Huang, Kathrine Mansfield et al.

COVID-19 Vaccination Coverage, Behaviors, and Intentions among Adults with Previous Diagnosis, United States

Emerg Infect Dis. 2022 Feb 3;28(3). doi: 10.3201/eid2803.211561.
Dustin W Currie, Melisa M Shah, Phillip P Salvatore et al.

Relationship of SARS-CoV-2 Antigen and Reverse Transcription PCR Positivity for Viral Cultures

Emerg Infect Dis. 2022 Feb 2;28(3). doi: 10.3201/eid2803.211747.
Alicia del Cura-Bilbao, Héctor López-Mendoza, Armando Chaure-Pardos et al.

Effectiveness of 3 COVID-19 Vaccines in Preventing SARS-CoV-2 Infections, January–May 2021, Aragon, Spain

Emerg Infect Dis. 2022 Feb 2;28(3). doi: 10.3201/eid2803.212027.
Jin Su Song, Jihee Lee, Miyoung Kim et al.

Serial Intervals and Household Transmission of SARS-CoV-2 Omicron Variant, South Korea, 2021

Emerg Infect Dis. 2022 Feb 2;28(3). doi: 10.3201/eid2803.212607.
Barbara Clyne, Karen Jordan, Susan Ahern et al.

Transmission of SARS-CoV-2 by children: a rapid review, 30 December 2019 to 10 August 2020

Euro Surveill. 2022 Feb;27(5). doi: 10.2807/1560-7917.ES.2022.27.5.2001651.
Gabriele Bianco, Matteo Boattini, Alessandro Bondi et al.

Outbreak of ceftazidime-avibactam resistant KPC-producing Klebsiella pneumoniae in a COVID-19 Intensive Care Unit, Italy: urgent need for updating diagnostic protocols of surveillance cultures

J Hosp Infect. 2022 Feb 6;S0195-6701(22)00038-X. doi: 10.1016/j.jhin.2022.02.001.
C S Sin, Tina L Rochelle

Using the theory of planned behaviour to explain hand hygiene among nurses in Hong Kong during COVID-19

J Hosp Infect. 2022 Feb 3;S0195-6701(22)00033-0. doi: 10.1016/j.jhin.2022.01.018.
Susan Meiring, Stefano Tempia, Jinal N Bhiman et al.

Prolonged shedding of SARS-CoV-2 at high viral loads amongst hospitalised immunocompromised persons living with HIV, South Africa

Clin Infect Dis. 2022 Feb 2;ciac077. doi: 10.1093/cid/ciac077.
Deborah Cromer, Arnold Reynaldi, Megan Steain et al.

Relating in vitro neutralisation level and protection in the CVnCoV (CUREVAC) trial

Clin Infect Dis. 2022 Feb 1;ciac075. doi: 10.1093/cid/ciac075.
De Anna J Friedman-Klabanoff, Meagan C Fitzpatrick, Meagan E Deming et al.

Risk of SARS-CoV-2 acquisition is associated with individual exposure but not community-level transmission

J Infect Dis. 2022 Feb 2;jiac029. doi: 10.1093/infdis/jiac029.
Cécile Alanio, Anurag Verma, Divij Mathew et al.

Cytomegalovirus latent infection is associated with an increased risk of COVID-19-related hospitalization

J Infect Dis. 2022 Feb 2;jiac020. doi: 10.1093/infdis/jiac020.
Judith Kannenberg, Henning Trawinski, Reinhard Henschler et al.

Antibody course and memory B-cell response in the first year after SARS-CoV-2 infection

J Infect Dis. 2022 Feb 1;jiac034. doi: 10.1093/infdis/jiac034.
Namhee Kim, Sue Shin, Dohsik Minn et al.

SARS-CoV-2 Infectivity and Antibody Titer Reduction for 6 Months After Second Dose of BNT162b2 mRNA Vaccine in Healthcare Workers: A Prospective Cohort Study

J Infect Dis. 2022 Feb 1;jiac035. doi: 10.1093/infdis/jiac035.
Jia Zou, Li Li, Peiyi Zheng et al.

Ultra-potent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance

J Clin Invest. 2022 Feb 15;132(4):e154987. doi: 10.1172/JCI154987.
January 2022
Christopher T Mansbridge, Alex R Tanner, Kate R Beard et al.

FebriDx host response point-of-care testing improves patient triage for coronavirus disease 2019 (COVID-19) in the emergency department

Infect Control Hosp Epidemiol. 2022 Jan 31;1-8. doi: 10.1017/ice.2021.531.
Laura M Selby, Angela Hewlett, Mark E Rupp, Richard Starlin

Increase in the coronavirus disease 2019 (COVID-19) attack rate of fully vaccinated healthcare workers with high-risk household exposures correlates with the rise of the severe acute respiratory coronavirus virus 2 (SARS-CoV-2) B.1.617.2 (delta) variant

Infect Control Hosp Epidemiol. 2022 Jan 31;1-2. doi: 10.1017/ice.2022.20.
Zachary C Pope, Carla M Weisend, Aditya Shah, Hideki Ebihara, Stacey A Rizza

Inactivation of replication-competent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on common surfaces by disinfectants

Infect Control Hosp Epidemiol. 2022 Jan 26;1-3. doi: 10.1017/ice.2021.527.
Ruvim Izikson, Daniel Brune, Jean-Sébastien Bolduc et al.

Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study

Lancet Respir Med. 2022 Jan 31;S2213-2600(21)00557-9. doi: 10.1016/S2213-2600(21)00557-9.
Steven Woloshin, Barry Dewitt, Tamar Krishnamurti, Baruch Fischhoff

Assessing How Consumers Interpret and Act on Results From At-Home COVID-19 Self-test Kits: A Randomized Clinical Trial

JAMA Intern Med. 2022 Jan 31. doi: 10.1001/jamainternmed.2021.8075.
Jinyan Liu, Abishek Chandrashekar, Daniel Sellers et al.

Vaccines Elicit Highly Conserved Cellular Immunity to SARS-CoV-2 Omicron

Nature. 2022 Jan 31. doi: 10.1038/s41586-022-04465-y.
Roanne Keeton, Marius B Tincho, Amkele Ngomti et al.

T cell responses to SARS-CoV-2 spike cross-recognize Omicron

Nature. 2022 Jan 31. doi: 10.1038/s41586-022-04460-3.
Johanna Erber, Verena Kappler, Bernhard Haller et al.

Infection Control Measures and Prevalence of SARS-CoV-2 IgG among 4,554 University Hospital Employees, Munich, Germany

Emerg Infect Dis. 2022 Jan 31;28(3). doi: 10.3201/eid2803.204436.
Robert L Atmar, Kirsten E Lyke, Meagan E Deming et al.

Homologous and Heterologous Covid-19 Booster Vaccinations

N Engl J Med. 2022 Jan 26. doi: 10.1056/NEJMoa2116414.
Rolando Pajon, Nicole A Doria-Rose, Xiaoying Shen et al.

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

N Engl J Med. 2022 Jan 26. doi: 10.1056/NEJMc2119912.
Laith J Abu-Raddad, Hiam Chemaitelly, Roberto Bertollini, National Study Group for COVID-19 Vaccination

Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar

N Engl J Med. 2022 Jan 26. doi: 10.1056/NEJMc2119432.
Xin Zhao, Dedong Li, Wenjing Ruan et al.

Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant

N Engl J Med. 2022 Jan 26. doi: 10.1056/NEJMc2119426.
Emi Takashita, Noriko Kinoshita, Seiya Yamayoshi et al.

Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant

N Engl J Med. 2022 Jan 26. doi: 10.1056/NEJMc2119407.
ITAC (INSIGHT 013) Study Group

Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial

Lancet. 2022 Jan 27;S0140-6736(22)00101-5. doi: 10.1016/S0140-6736(22)00101-5.
Giovanni Corrao, Matteo Franchi, Danilo Cereda et al.

Persistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since vaccine completion: a retrospective observational analysis in Lombardy, Italy

Lancet Infect Dis. 2022 Jan 27;S1473-3099(21)00813-6. doi: 10.1016/S1473-3099(21)00813-6.
Annika Fendler, Scott T C Shepherd, Lewis Au et al.

Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer

Lancet. 2022 Jan 25;S0140-6736(22)00147-7. doi: 10.1016/S0140-6736(22)00147-7.
Saranya Sridhar, Arnel Joaquin, Matthew I Bonaparte et al.

Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study

Lancet Infect Dis. 2022 Jan 25;S1473-3099(21)00764-7. doi: 10.1016/S1473-3099(21)00764-7.
Martin Hoenigl, Danila Seidel, Agostinho Carvalho et al.

The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries

Lancet Microbe. 2022 Jan 25. doi: 10.1016/S2666-5247(21)00237-8.
Marc Chadeau-Hyam, Haowei Wang, Oliver Eales et al.

SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys

Lancet Respir Med. 2022 Jan 24;S2213-2600(21)00542-7. doi: 10.1016/S2213-2600(21)00542-7.
Gui-Ling Chen, Xiao-Feng Li, Xia-Hong Dai et al.

Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial

Lancet Microbe. 2022 Jan 24. doi: 10.1016/S2666-5247(21)00280-9.
Matthew E Oster, David K Shay, John R Su et al.

Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021

JAMA. 2022 Jan 25;327(4):331-340. doi: 10.1001/jama.2021.24110.
Yi-Chun Chen, Sheng-Nan Lu, Huey-Ling You, Chih-Chi Wang, Ing-Kit Lee

SARS-CoV-2 Antibody Response After ChAdOx1 nCoV-19 Vaccination in Persons With Previous SARS-CoV-1 Infection

JAMA Intern Med. 2022 Jan 24. doi: 10.1001/jamainternmed.2021.7679.
Gavin D Perkins, Chen Ji, Bronwen A Connolly et al.

Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19: The RECOVERY-RS Randomized Clinical Trial

JAMA. 2022 Jan 24. doi: 10.1001/jama.2022.0028.
Hidde Heesakkers, Johannes G van der Hoeven, Stijn Corsten et al.

Clinical Outcomes Among Patients With 1-Year Survival Following Intensive Care Unit Treatment for COVID-19

JAMA. 2022 Jan 24. doi: 10.1001/jama.2022.0040.
Mauricia Davidson, Sonia Menon, Anna Chaimani et al.

Interleukin-1 blocking agents for treating COVID-19

Cochrane Database Syst Rev. 2022 Jan 26;1(1):CD015308. doi: 10.1002/14651858.CD015308.
Francisco Tsz Tsun Lai, Xue Li, Kuan Peng et al.

Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine : A Case-Control Study

Ann Intern Med. 2022 Jan 25. doi: 10.7326/M21-3700.
Mark Helfand, Celia Fiordalisi, Jack Wiedrick et al.

Risk for Reinfection After SARS-CoV-2: A Living, Rapid Review for American College of Physicians Practice Points on the Role of the Antibody Response in Conferring Immunity Following SARS-CoV-2 Infection

Ann Intern Med. 2022 Jan 25. doi: 10.7326/M21-4245.
Kang Wang, Zijing Jia, Linlin Bao et al.

Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants

Nature. 2022 Jan 28. doi: 10.1038/s41586-022-04466-x.
Paul R Wratil, Marcel Stern, Alina Priller et al.

Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern

Nat Med. 2022 Jan 28. doi: 10.1038/s41591-022-01715-4.
Jingxin Li, Lihua Hou, Xiling Guo et al.

Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial

Nat Med. 2022 Jan 27. doi: 10.1038/s41591-021-01677-z.
Samah Hayek, Galit Shaham, Yatir Ben-Shlomo et al.

Indirect protection of children from SARS-CoV-2 infection through parental vaccination

Science. 2022 Jan 27;eabm3087. doi: 10.1126/science.abm3087.
Ottavia Prunas, Joshua L Warren, Forrest W Crawford et al.

Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel

Science. 2022 Jan 27;eabl4292. doi: 10.1126/science.abl4292.
S Momsen Reincke, Meng Yuan, Hans-Christian Kornau et al.

SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies

Science. 2022 Jan 25;eabm5835. doi: 10.1126/science.abm5835.
Matthew McCallum, Nadine Czudnochowski, Laura E Rosen et al.

Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement

Science. 2022 Feb 25;eabn8652. doi: 10.1126/science.abn8652.
Katharina Röltgen, Sandra C A Nielsen, Oscar Silva et al.

Immune imprinting, breadth of variant recognition and germinal center response in human SARS-CoV-2 infection and vaccination

Cell. 2022 Jan 24;S0092-8674(22)00076-9. doi: 10.1016/j.cell.2022.01.018.
Yapeng Su, Dan Yuan, Daniel G Chen et al.

Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae

Cell. 2022 Jan 24;S0092-8674(22)00072-1. doi: 10.1016/j.cell.2022.01.014.
Zhen Cui, Pan Liu, Nan Wang et al.

Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron

Cell. 2022 Jan 24;S0092-8674(22)00077-0. doi: 10.1016/j.cell.2022.01.019.
Mark W Tenforde, Manish M Patel, Manjusha Gaglani et al.

Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults - United States, August-December 2021

MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):118-124. doi: 10.15585/mmwr.mm7104a2.
A Danielle Iuliano, Joan M Brunkard, Tegan K Boehmer et al.

Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022

MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):146-152. doi: 10.15585/mmwr.mm7104e4.
Anna R Giuliano, Shari Pilon-Thomas, Michael J Schell et al.

SARS-CoV-2 Period Seroprevalence and Related Factors, Hillsborough County, Florida, October 2020-March 2021

Emerg Infect Dis. 2022 Jan 26;28(3). doi: 10.3201/eid2803.211495.
Gil C De Santis, Luciana Correa Oliveira, Pedro M M Garibaldi et al.

High-Dose Convalescent Plasma for Treatment of Severe COVID-19

Emerg Infect Dis. 2022 Jan 26;28(3). doi: 10.3201/eid2803.212299.
Lamprini Veneti, Håkon Bøås, Anja Bråthen Kristoffersen et al.

Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022

Euro Surveill. 2022 Jan;27(4). doi: 10.2807/1560-7917.ES.2022.27.4.2200077.
Dirk Eggink, Stijn P Andeweg, Harry Vennema et al.

Increased risk of infection with SARS-CoV-2 Omicron BA.1 compared with Delta in vaccinated and previously infected individuals, the Netherlands, 22 November 2021 to 19 January 2022

Euro Surveill. 2022 Jan;27(4). doi: 10.2807/1560-7917.ES.2022.27.4.2101196.
Scott Jc Pallett, Rachael Jones, Ahmed Abdulaal et al.

Variability in detection of SARS-CoV-2-specific antibody responses following mild infection: a prospective multicentre cross-sectional study, London, United Kingdom, 17 April to 17 July 2020

Euro Surveill. 2022 Jan;27(4). doi: 10.2807/1560-7917.ES.2022.27.4.2002076.
Gemma L Saravanos, Nan Hu, Nusrat Homaira et al.

RSV Epidemiology in Australia Before and During COVID-19

Pediatrics. 2022 Jan 26;e2021053537. doi: 10.1542/peds.2021-053537.
Nir Friedman, Nitai Levy, Or Kaplan et al.

Pediatric Hospitalizations after School Reopening during the SARS-CoV-2 Alpha (B.1.1.7) Variant Spread: A Multicenter Cross-sectional Study in Israel

Clin Infect Dis. 2022 Jan 29;ciac065. doi: 10.1093/cid/ciac065.
Louise K Francois Watkins, Kiren Mitruka, Layne Dorough et al.

Characteristics of Reported Deaths Among Fully Vaccinated Persons with COVID-19 -United States, January-April 2021

Clin Infect Dis. 2022 Jan 29;ciac066. doi: 10.1093/cid/ciac066.
Carol Strahm, Marco Seneghini, Sabine Güsewell et al.

Symptoms compatible with long-COVID in healthcare workers with and without SARS-CoV-2 infection - results of a prospective multicenter cohort

Clin Infect Dis. 2022 Jan 28;ciac054. doi: 10.1093/cid/ciac054.
Elizabeth T Chin, David Leidner, Yifan Zhang et al.

Effectiveness of COVID-19 vaccines among incarcerated people in California state prisons: retrospective cohort study

Clin Infect Dis. 2022 Jan 27;ciab1032. doi: 10.1093/cid/ciab1032.
Aldo Marrone, Riccardo Nevola, Ausilia Sellitto et al.

Remdesivir plus dexamethasone versus dexamethasone alone for the treatment of COVID-19 patients requiring supplemental O2 therapy: a prospective controlled non-randomized study

Clin Infect Dis. 2022 Jan 27;ciac014. doi: 10.1093/cid/ciac014.
Amanda C Perofsky, Stefano Tempia, Jeremy Bingham et al.

The direct and indirect effects of the COVID-19 pandemic on private healthcare utilization in South Africa, March 2020 - September 2021

Clin Infect Dis. 2022 Jan 27;ciac055. doi: 10.1093/cid/ciac055.
Jan Lawrenz, Qinya Xie, Fabian Zech et al.

SARS-CoV-2 Vaccination boosts Neutralizing Activity against Seasonal Human Coronaviruses

Clin Infect Dis. 2022 Jan 25;ciac057. doi: 10.1093/cid/ciac057.
Kanagavel Murugesan, Prasanna Jagannathan, Jonathan Altamirano et al.

Long Term Accuracy of SARS-CoV-2 Interferon-γ Release Assay and its Application in Household Investigation

Clin Infect Dis. 2022 Jan 25;ciac045. doi: 10.1093/cid/ciac045.
Jiong Wang, Dongmei Li, Andrew Cameron et al.

IgG Against Human β-Coronavirus Spike Proteins Correlates with SARS-CoV-2 anti-Spike IgG Responses and COVID-19 Disease Severity

J Infect Dis. 2022 Jan 29;jiac022. doi: 10.1093/infdis/jiac022.
Amanda M Casto, Julia H Rogers, Amy C Link et al.

Phylogenomics of SARS-CoV-2 in Emergency Shelters for People Experiencing Homelessness

J Infect Dis. 2022 Jan 29;jiac021. doi: 10.1093/infdis/jiac021.
Danuta M Skowronski, Solmaz Setayeshgar, Macy Zou et al.

Comparative single-dose mRNA and ChAdOx1 vaccine effectiveness against SARS-CoV-2, including variants of concern: test-negative design, British Columbia, Canada

J Infect Dis. 2022 Jan 27;jiac023. doi: 10.1093/infdis/jiac023.
Yeny Acosta-Ampudia, Diana M Monsalve, Manuel Rojas et al.

Persistent Autoimmune Activation and Proinflammatory State in Post-COVID Syndrome

J Infect Dis. 2022 Jan 25;jiac017. doi: 10.1093/infdis/jiac017.
Kimberly A Kraynyak, Elliott Blackwood, Joseph Agnes et al.

SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial

J Infect Dis. 2022 Jan 25;jiac016. doi: 10.1093/infdis/jiac016.
Roos S G Sablerolles, Wim J R Rietdijk, Abraham Goorhuis et al.

Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming

N Engl J Med. 2022 Jan 19. doi: 10.1056/NEJMoa2116747.
Sue Ann Costa Clemens, Lily Weckx, Ralf Clemens et al.

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

Lancet. 2022 Jan 21;S0140-6736(22)00094-0. doi: 10.1016/S0140-6736(22)00094-0.
Lulu Bravo, Igor Smolenov, Htay Htay Han et al.

Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial

Lancet. 2022 Jan 20;S0140-6736(22)00055-1. doi: 10.1016/S0140-6736(22)00055-1.
Edward J Carr, Mary Wu, Ruth Harvey et al.

Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients

Lancet. 2022 Jan 20;S0140-6736(22)00104-0. doi: 10.1016/S0140-6736(22)00104-0.
Nicole Wolter, Waasila Jassat, Sibongile Walaza et al.

Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study

Lancet. 2022 Jan 19;S0140-6736(22)00017-4. doi: 10.1016/S0140-6736(22)00017-4.
Mary Wu, Emma C Wall, Edward J Carr et al.

Three-dose vaccination elicits neutralising antibodies against omicron

Lancet. 2022 Jan 19;S0140-6736(22)00092-7. doi: 10.1016/S0140-6736(22)00092-7.
Constanze Kuhlmann, Carla Konstanze Mayer, Mathilda Claassen et al.

Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose

Lancet. 2022 Jan 18;S0140-6736(22)00090-3. doi: 10.1016/S0140-6736(22)00090-3.
Karin Magnusson, Katrine Damgaard Skyrud, Pål Suren et al.

Healthcare use in 700 000 children and adolescents for six months after covid-19: before and after register based cohort study

BMJ. 2022 Jan 17;376:e066809. doi: 10.1136/bmj-2021-066809.
Emma K Accorsi, Amadea Britton, Katherine E Fleming-Dutra et al.

Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants

JAMA. 2022 Jan 21. doi: 10.1001/jama.2022.0470.
Lindsey Wang, Pamela B Davis, David C Kaelber, Nora D Volkow, Rong Xu

Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Delta-Predominant Period

JAMA. 2022 Jan 20. doi: 10.1001/jama.2022.0210.
Jean B Nachega, Nadia A Sam-Agudu, Rhoderick N Machekano et al.

Assessment of Clinical Outcomes Among Children and Adolescents Hospitalized With COVID-19 in 6 Sub-Saharan African Countries

JAMA Pediatr. 2022 Jan 19. doi: 10.1001/jamapediatrics.2021.6436.
Jeffrey S Berger, Lucy Z Kornblith, Michelle N Gong et al.

Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial

JAMA. 2022 Jan 18;327(3):227-236. doi: 10.1001/jama.2021.23605.
Shari Krishnaratne, Hannah Littlecott, Kerstin Sell et al.

Measures implemented in the school setting to contain the COVID-19 pandemic: a rapid review

Cochrane Database Syst Rev. 2022 Jan 17;1(1):CD015029. doi: 10.1002/14651858.CD015029.
Isaac See, Allison Lale, Paige Marquez et al.

Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021

Ann Intern Med. 2022 Jan 18. doi: 10.7326/M21-4502.
Huiping Shuai, Jasper Fuk-Woo Chan, Bingjie Hu et al.

Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron

Nature. 2022 Jan 21. doi: 10.1038/s41586-022-04442-5.
Peter J Halfmann, Shun Iida, Kiyoko Iwatsuki-Horimoto et al.

SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters

Nature. 2022 Jan 21. doi: 10.1038/s41586-022-04441-6.
Samuel M S Cheng, Chris Ka Pun Mok, Yonna W Y Leung et al.

Neutralizing antibodies against the SARS-CoV-2 Omicron variant following homologous and heterologous CoronaVac or BNT162b2 vaccination

Nat Med. 2022 Jan 20. doi: 10.1038/s41591-022-01704-7.
Eddy Pérez-Then, Carolina Lucas, Valter Silva Monteiro et al.

Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination

Nat Med. 2022 Jan 20. doi: 10.1038/s41591-022-01705-6.
Laura A VanBlargan, John M Errico, Peter J Halfmann et al.

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

Nat Med. 2022 Jan 19;1-6. doi: 10.1038/s41591-021-01678-y.
Henning Gruell, Kanika Vanshylla, Pinkus Tober-Lau et al.

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant

Nat Med. 2022 Jan 19;1-4. doi: 10.1038/s41591-021-01676-0.
Frank L van de Veerdonk, Evangelos Giamarellos-Bourboulis, Peter Pickkers et al.

A guide to immunotherapy for COVID-19

Nat Med. 2022 Jan 21. doi: 10.1038/s41591-021-01643-9.
Dhiraj Mannar, James W Saville, Xing Zhu et al.

SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex

Science. 2022 Jan 20;eabn7760. doi: 10.1126/science.abn7760.
Alexander Muik, Bonny Gaby Lui, Ann-Kathrin Wallisch et al.

Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera

Science. 2022 Jan 18;eabn7591. doi: 10.1126/science.abn7591.
Saborni Chakraborty, Joseph C Gonzalez, Benjamin L Sievers et al.

Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity

Sci Transl Med. 2022 Jan 18;eabm7853. doi: 10.1126/scitranslmed.abm7853.
Alexandra C Walls, Kaitlin R Sprouse, John E Bowen et al.

SARS-CoV-2 breakthrough infections elicit potent, broad and durable neutralizing antibody responses

Cell. 2022 Jan 19;S0092-8674(22)00069-1. doi: 10.1016/j.cell.2022.01.011.
Petter Brodin

SARS-CoV-2 infections in children: understanding diverse outcomes

Immunity. 2022 Jan 19;S1074-7613(22)00043-7. doi: 10.1016/j.immuni.2022.01.014.
Amelia G Johnson, Avnika B Amin, Akilah R Ali et al.

COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence - 25 U.S. Jurisdictions, April 4-December 25, 2021

MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):132-138. doi: 10.15585/mmwr.mm7104e2.
Mark G Thompson, Karthik Natarajan, Stephanie A Irving et al.

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022

MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(4):139-145. doi: 10.15585/mmwr.mm7104e3.
Sara E Oliver, Megan Wallace, Isaac See et al.

Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices - United States, December 2021

MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(3):90-95. doi: 10.15585/mmwr.mm7103a4.
Amy E Kirby, Rory M Welsh, Zachary A Marsh et al.

Notes from the Field: Early Evidence of the SARS-CoV-2 B.1.1.529 (Omicron) Variant in Community Wastewater - United States, November-December 2021

MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(3):103-105. doi: 10.15585/mmwr.mm7103a5.
Tomás M León, Vajeera Dorabawila, Lauren Nelson et al.

COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021

MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):125-131. doi: 10.15585/mmwr.mm7104e1.
Martin Chi-Wai Chan

Return of Norovirus and Rotavirus Activity in Winter 2020‒21 in City with Strict COVID-19 Control Strategy, Hong Kong, China

Emerg Infect Dis. 2022 Jan 20;28(3). doi: 10.3201/eid2803.212117.
Patrick Wg Mallon, Mary Horgan, Conor G McAloon et al.

Development of a risk assessment profile tool to determine appropriate use of SARS-CoV-2 rapid antigen detection tests for different activities and events in Ireland, since October 2021

Euro Surveill. 2022 Jan;27(3). doi: 10.2807/1560-7917.ES.2022.27.3.2101202.
Valeria Micheli, Fiorenza Bracchitta, Alberto Rizzo et al.

First identification of the new SARS-CoV-2 Omicron variant (B.1.1.529) in Italy

Clin Infect Dis. 2022 Jan 21;ciab1044. doi: 10.1093/cid/ciab1044.
Sarah E Rowan, David W McCormick, Karen A Wendel et al.

Lower Prevalence of SARS-CoV-2 Infection Among People Experiencing Homelessness Tested in Outdoor Encampments Compared with Overnight Shelters - Denver, Colorado, June - July 2020

Clin Infect Dis. 2022 Jan 18;ciac039. doi: 10.1093/cid/ciac039.
Kensuke Shoji, Shinya Tsuzuki, Takayuki Akiyama et al.

Clinical characteristics and outcomes of COVID-19 in pregnant women: a propensity score matched analysis of the data from the COVID-19 Registry Japan

Clin Infect Dis. 2022 Jan 17;ciac028. doi: 10.1093/cid/ciac028.
Jamin Liu, Matthew T Laurie, Luis Rubio et al.

SARS-CoV-2 transmission dynamics and immune responses in a household of vaccinated persons

Clin Infect Dis. 2022 Jan 17;ciac029. doi: 10.1093/cid/ciac029.
Mary Elizabeth Sexton, Jesse J Waggoner, Ludy R Carmola et al.

Rapid detection and characterization of SARS-CoV-2 omicron variant in a returning traveler

Clin Infect Dis. 2022 Jan 17;ciac032. doi: 10.1093/cid/ciac032.
Nadine Kronfli, Camille Dussault, Mathieu Maheu-Giroux et al.

Seroprevalence and risk factors for SARS-CoV-2 among incarcerated adult men in Quebec, Canada (2021)

Clin Infect Dis. 2022 Jan 17;ciac031. doi: 10.1093/cid/ciac031.
Bezawit A Woldemeskel, Arbor G Dykema, Caroline Garliss et al.

CD4+ T-cells from COVID-19 mRNA vaccine recipients recognize a conserved epitope present in diverse coronaviruses

J Clin Invest. 2022 Jan 21;e156083. doi: 10.1172/JCI156083.
Nick Andrews, Elise Tessier, Julia Stowe et al.

Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines

N Engl J Med. 2022 Jan 12. doi: 10.1056/NEJMoa2115481.
Samantha M Olson, Margaret M Newhams, Natasha B Halasa et al.

Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents

N Engl J Med. 2022 Jan 12. doi: 10.1056/NEJMoa2117995.
Dan-Yu Lin, Yu Gu, Bradford Wheeler et al.

Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina

N Engl J Med. 2022 Jan 12. doi: 10.1056/NEJMoa2117128.
Annika Rössler, Lydia Riepler, David Bante, Dorothee von Laer, Janine Kimpel

SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons

N Engl J Med. 2022 Jan 12. doi: 10.1056/NEJMc2119236.
Ting Shi, Jiafeng Pan, Eleftheria Vasileiou et al.

Risk of serious COVID-19 outcomes among adults with asthma in Scotland: a national incident cohort study

Lancet Respir Med. 2022 Jan 13;S2213-2600(21)00543-9. doi: 10.1016/S2213-2600(21)00543-9.
Seilesh Kadambari, Raphael Goldacre, Eva Morris, Michael J Goldacre, Andrew J Pollard

Indirect effects of the covid-19 pandemic on childhood infection in England: population based observational study

BMJ. 2022 Jan 12;376:e067519. doi: 10.1136/bmj-2021-067519.
Meagan P O'Brien, Eduardo Forleo-Neto, Neena Sarkar et al.

Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial

JAMA. 2022 Jan 14. doi: 10.1001/jama.2021.24939.
Avishay Spitzer, Yoel Angel, Or Marudi et al.

Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel

JAMA. 2022 Jan 10. doi: 10.1001/jama.2021.23641.
Sophie Caillard, Olivier Thaunat, Ilies Benotmane, Christophe Masset, Gilles Blancho

Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series

Ann Intern Med. 2022 Jan 11;L21-0598. doi: 10.7326/L21-0598.
Yu Gao, Curtis Cai, Alba Grifoni et al.

Ancestral SARS-CoV-2-specific T cells cross-recognize Omicron

Nat Med. 2022 Jan 14. doi: 10.1038/d41591-022-00017-z.
Nick Andrews, Julia Stowe, Freja Kirsebom et al.

Effectiveness of BNT162b2 COVID-19 booster vaccine against covid-19 related symptoms and hospitalization in England

Nat Med. 2022 Jan 14. doi: 10.1038/d41591-022-00013-3.
Sarah J Stock, Jade Carruthers, Clara Calvert et al.

SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland

Nat Med. 2022 Jan 13. doi: 10.1038/s41591-021-01666-2.
Benjamin L Sievers, Saborni Chakraborty, Yong Xue et al.

Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses

Sci Transl Med. 2022 Jan 13;eabn7842. doi: 10.1126/scitranslmed.abn7842.
Jocelyne Piret, Guy Boivin

Viral Interference between Respiratory Viruses

Emerg Infect Dis. 2022 Jan 13. doi: 10.3201/eid2802.211727.
Shirley Ll Kwok, Samuel Ms Cheng, Jennifer Ns Leung et al.

Waning antibody levels after COVID-19 vaccination with mRNA Comirnaty and inactivated CoronaVac vaccines in blood donors, Hong Kong, April 2020 to October 2021

Euro Surveill. 2022 Jan;27(2). doi: 10.2807/1560-7917.ES.2022.27.2.2101197.
Tetsuya Seikai, Ayato Takada, Akira Hasebe et al.

Gargling with povidone iodine has a short-term inhibitory effect on SARS-Cov-2 in COVID-19 patients

J Hosp Infect. 2022 Jan 15;S0195-6701(22)00006-8. doi: 10.1016/j.jhin.2022.01.001.
Rachel Brown, Amanda M Brown, Sharon Markman et al.

Assessing the confidence, knowledge and learning preferences of healthcare workers regarding personal protective equipment use during the COVID-19 pandemic

Infect Control Hosp Epidemiol. 2022 Jan 6;1-9. doi: 10.1017/ice.2022.1.
Vishal P Shah, Laura E Breeher, Julie M Alleckson et al.

Occupational Exposure to SARS-CoV-2 and Risk of Infection Among Healthcare Personnel

Infect Control Hosp Epidemiol. 2022 Jan 6;1-13. doi: 10.1017/ice.2021.533.
Christopher R Bailie, Yeu-Yang Tseng, Louise Carolan et al.

Trend in sensitivity of SARS-CoV-2 serology one year after mild and asymptomatic COVID-19: unpacking potential bias in seroprevalence studies

Clin Infect Dis. 2022 Jan 13;ciac020. doi: 10.1093/cid/ciac020.
Nabin K Shrestha, Patrick C Burke, Amy S Nowacki, Paul Terpeluk, Steven M Gordon

Necessity of COVID-19 Vaccination in Persons Who Have Already Had COVID-19

Clin Infect Dis. 2022 Jan 13;ciac022. doi: 10.1093/cid/ciac022.
Bobby G Warren, Alicia Nelson, Aaron Barrett et al.

SARS-CoV-2 Environmental contamination in hospital rooms is uncommon using viral culture techniques

Clin Infect Dis. 2022 Jan 12;ciac023. doi: 10.1093/cid/ciac023.
Minhui Guan, Eric Johannesen, Cynthia Y Tang et al.

Intrauterine fetal demise in the third trimester of pregnancy associated with mild infection with the SARS-CoV-2 Delta variant without protection from vaccination

J Infect Dis. 2022 Jan 13;jiac007. doi: 10.1093/infdis/jiac007.
Lydia L Shook, Sara Brigida, James Regan et al.

SARS-CoV-2 placentitis associated with B.1.617.2 (Delta) variant and fetal distress or demise

J Infect Dis. 2022 Jan 13;jiac008. doi: 10.1093/infdis/jiac008.
Taewon Han, Heedo Park, Yungje Jeong et al.

COVID-19 Cluster Linked to Aerosol Transmission of SARS-CoV-2 via Floor Drains

J Infect Dis. 2022 Jan 12;jiab598. doi: 10.1093/infdis/jiab598.
David W Eyre, Donald Taylor, Mark Purver et al.

Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants

N Engl J Med. 2022 Jan 5. doi: 10.1056/NEJMoa2116597.
Paul K Drain

Rapid Diagnostic Testing for SARS-CoV-2

N Engl J Med. 2022 Jan 7. doi: 10.1056/NEJMcp2117115.
INSPIRATION-S Investigators

Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial

BMJ. 2022 Jan 7;376:e068407. doi: 10.1136/bmj-2021-068407.
Joshua S Gans, Avi Goldfarb, Ajay K Agrawal et al.

False-Positive Results in Rapid Antigen Tests for SARS-CoV-2

JAMA. 2022 Jan 7. doi: 10.1001/jama.2021.24355.
Anica C Law, Daniel Peterson, Allan J Walkey, Nicholas A Bosch

Lottery-Based Incentives and COVID-19 Vaccination Rates in the US

JAMA Intern Med. 2022 Jan 4. doi: 10.1001/jamainternmed.2021.7052.
Prabhat Jha, Yashwant Deshmukh, Chinmay Tumbe et al.

COVID mortality in India: National survey data and health facility deaths

Science. 2022 Jan 6;eabm5154. doi: 10.1126/science.abm5154.
Paulina Kaplonek, Stephanie Fischinger, Deniz Cizmeci et al.

mRNA-1273 vaccine-induced antibodies maintain Fc-effector functions across SARS-CoV-2 Variants of Concern

Immunity. 2022 Jan 5;S1074-7613(22)00030-9. doi: 10.1016/j.immuni.2022.01.001.
Pengcheng Han, Linjie Li, Sheng Liu et al.

Receptor binding and complex structures of human ACE2 to spike RBD from Omicron and Delta SARS-CoV-2

Cell. 2022 Jan 5;S0092-8674(22)00001-0. doi: 10.1016/j.cell.2022.01.001.
Wanwisa Dejnirattisai, Jiandong Huo, Daming Zhou et al.

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Cell. 2022 Jan 3;S0092-8674(21)01578-6. doi: 10.1016/j.cell.2021.12.046.
Laura D Zambrano, Margaret M Newhams, Samantha M Olson et al.

Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18 Years ― United States, July–December 2021

MMWR Morb Mortal Wkly Rep. 2022 Jan 7. doi: 10.15585/mmwr.mm7102e1.
Catherine E Barrett, Alain K Koyama, Pablo Alvarez et al.

Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 years ― United States, March 1, 2020–June 28, 2021

MMWR Morb Mortal Wkly Rep. 2022 Jan 7. doi: 10.15585/mmwr.mm7102e2.
Christina Yek, Sarah Warner, Jennifer L Wiltz et al.

Risk Factors for Severe COVID-19 Outcomes Among Persons Aged ≥18 Years Who Completed a Primary COVID-19 Vaccination Series - 465 Health Care Facilities, United States, December 2020-October 2021

MMWR Morb Mortal Wkly Rep. 2022 Jan 7;71(1):19-25. doi: 10.15585/mmwr.mm7101a4.
Heather S Lipkind, Gabriela Vazquez-Benitez, Malini DeSilva et al.

Receipt of COVID-19 Vaccine During Pregnancy and Preterm or Small-for-Gestational-Age at Birth - Eight Integrated Health Care Organizations, United States, December 15, 2020-July 22, 2021

MMWR Morb Mortal Wkly Rep. 2022 Jan 7;71(1):26-30. doi: 10.15585/mmwr.mm7101e1.
Hyejin Lee, Ho Kyung Sung, Dokyoung Lee et al.

Comparison of Complications after Coronavirus Disease and Seasonal Influenza, South Korea

Emerg Infect Dis. 2022 Jan 4. doi: 10.3201/eid2802.211848.
Ae Kyung Park, Il-Hwan Kim, Heui Man Kim et al.

SARS-CoV-2 B.1.619 and B.1.620 Lineages, South Korea, 2021

Emerg Infect Dis. 2022 Jan 4. doi: 10.3201/eid2802.211653.
Marta Grgič Vitek, Irena Klavs, Veronika Učakar et al.

Vaccine effectiveness against severe acute respiratory infections (SARI) COVID-19 hospitalisations estimated from real-world surveillance data, Slovenia, October 2021

Euro Surveill. 2022 Jan;27(1). doi: 10.2807/1560-7917.ES.2022.27.1.2101110.
Georgina Ireland, Heather Whitaker, Shamez N Ladhani et al.

Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021

Euro Surveill. 2022 Jan;27(1). doi: 10.2807/1560-7917.ES.2022.27.1.2101114.
Paolo Bosetti, Cécile Tran Kiem, Alessio Andronico et al.

Impact of booster vaccination on the control of COVID-19 Delta wave in the context of waning immunity: application to France in the winter 2021/22

Euro Surveill. 2022 Jan;27(1). doi: 10.2807/1560-7917.ES.2022.27.1.2101125.
Lloyd A C Chapman, Rosanna C Barnard, Timothy W Russell et al.

Unexposed populations and potential COVID-19 hospitalisations and deaths in European countries as per data up to 21 November 2021

Euro Surveill. 2022 Jan;27(1). doi: 10.2807/1560-7917.ES.2022.27.1.2101038.
Stephanie E Perez, Luis Diego Luna Centeno, Wesley A Cheng et al.

Human Milk SARS-CoV-2 Antibodies up to 6 Months After Vaccination

Pediatrics. 2022 Jan 3;e2021054260. doi: 10.1542/peds.2021-054260.
Ilesh V Jani, Trevor F Peter

Nucleic Acid Point-of-Care Testing to Improve Diagnostic Preparedness

Clin Infect Dis. 2022 Jan 7;ciac013. doi: 10.1093/cid/ciac013.
Line Dam Heftdal, Martin Schultz, Theis Lange et al.

Incidence of positive SARS-CoV-2 PCR after COVID-19 vaccination with up to eight months of follow-up: Real life data from the Capital Region of Denmark

Clin Infect Dis. 2022 Jan 7;ciac012. doi: 10.1093/cid/ciac012.
Hooman Parhizkar, Leslie Dietz, Andreas Olsen-Martinez et al.

Quantifying environmental mitigation of aerosol viral load in a controlled chamber with participants diagnosed with COVID-19

Clin Infect Dis. 2022 Jan 6;ciac006. doi: 10.1093/cid/ciac006.
Xin Li, Jacky Man-Chun Chan, Bosco Lam et al.

COVID-19 mRNA vaccines delay the onset of breakthrough infections with less radiographic abnormalities

Clin Infect Dis. 2022 Jan 4;ciab1062. doi: 10.1093/cid/ciab1062.
Taketomo Maruki, Noriko Iwamoto, Kohei Kanda et al.

Two cases of breakthrough SARS-CoV-2 infections caused by the Omicron variant (B.1.1.529 lineage) in international travelers to Japan

Clin Infect Dis. 2022 Jan 3;ciab1072. doi: 10.1093/cid/ciab1072.
Jonas Henrik Kristensen, Rasmus Bo Hasselbalch, Mia Pries-Heje et al.

Effect of influenza vaccination on risk of COVID-19 - A prospective cohort study of 46,000 health care workers

J Infect Dis. 2022 Jan 5;jiac001. doi: 10.1093/infdis/jiac001.
Matthew T Laurie, Jamin Liu, Sara Sunshine et al.

SARS-CoV-2 variant exposures elicit antibody responses with differential cross-neutralization of established and emerging strains including Delta and Omicron

J Infect Dis. 2022 Jan 3;jiab635. doi: 10.1093/infdis/jiab635.
Katrine K Iversen, Shoaib Afzal, Magnus G Ahlström et al.

Lung function decline in relation to COVID-19 in the general population: a matched cohort study with pre-pandemic assessment of lung function

J Infect Dis. 2022 Jan 3;jiab636. doi: 10.1093/infdis/jiab636.
Joseph Heskin, Scott J C Pallett, Nabeela Mughal et al.

Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management

Lancet. 2022 Jan 1;399(10319):21-22. doi: 10.1016/S0140-6736(21)02657-X.
Srinivasa Vittal Katikireddi, Thiago Cerqueira-Silva, Eleftheria Vasileiou et al.

Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil

Lancet. 2022 Jan 1;399(10319):25-35. doi: 10.1016/S0140-6736(21)02754-9.
Wilfredo F Garcia-Beltran, Kerri J St Denis, Angelique Hoelzemer et al.

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

Cell. 2022 Jan 6;S0092-8674(21)01496-3. doi: 10.1016/j.cell.2021.12.033.
Amitabh B Suthar, Sara Schubert, Julie Garon et al.

Coronavirus Disease Case Definitions, Diagnostic Testing Criteria, and Surveillance in 25 Countries with Highest Reported Case Counts

Emerg Infect Dis. 2022 Jan;28(1):148-156. doi: 10.3201/eid2801.211082.
December 2021
Shirley Collie, Jared Champion, Harry Moultrie, Linda-Gail Bekker, Glenda Gray

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa

N Engl J Med. 2021 Dec 29. doi: 10.1056/NEJMc2119270.
Ital Nemet, Limor Kliker, Yaniv Lustig et al.

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection

N Engl J Med. 2021 Dec 29. doi: 10.1056/NEJMc2119358.
Fabian Schmidt, Frauke Muecksch, Yiska Weisblum et al.

Plasma Neutralization of the SARS-CoV-2 Omicron Variant

N Engl J Med. 2021 Dec 30. doi: 10.1056/NEJMc2119641.
Hannah R Whittaker, Claudia Gulea, Ardita Koteci et al.

GP consultation rates for sequelae after acute covid-19 in patients managed in the community or hospital in the UK: population based study

BMJ. 2021 Dec 29;375:e065834. doi: 10.1136/bmj-2021-065834.
Caroline Maslo, Richard Friedland, Mande Toubkin et al.

Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves

JAMA. 2021 Dec 30. doi: 10.1001/jama.2021.24868.
Jing Sun, Qulu Zheng, Vithal Madhira et al.

Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US

JAMA Intern Med. 2021 Dec 28. doi: 10.1001/jamainternmed.2021.7024.
Philipp Georg, Rosario Astaburuaga-García, Lorenzo Bonaguro et al.

Complement activation induces excessive T cell cytotoxicity in severe COVID-19

Cell. 2021 Dec 27;S0092-8674(21)01562-2. doi: 10.1016/j.cell.2021.12.040.
Anne M Hause, James Baggs, Paige Marquez et al.

COVID-19 Vaccine Safety in Children Aged 5-11 Years - United States, November 3-December 19, 2021

MMWR Morb Mortal Wkly Rep. 2021 Dec 31;70(5152):1755-1760. doi: 10.15585/mmwr.mm705152a1.
Karen Lutrick, Patrick Rivers, Young M Yoo et al.

Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12-17 Years - Arizona, July-December 2021

MMWR Morb Mortal Wkly Rep. 2021 Dec 31;70(5152):1761-1765. doi: 10.15585/mmwr.mm705152a2.
Valentine Wanga, Megan E Gerdes, Dallas S Shi et al.

Characteristics and Clinical Outcomes of Children and Adolescents Aged <18 Years Hospitalized with COVID-19 - Six Hospitals, United States, July-August 2021

MMWR Morb Mortal Wkly Rep. 2021 Dec 31;70(5152):1766-1772. doi: 10.15585/mmwr.mm705152a3.
Lauren Jansen, Bryan Tegomoh, Kate Lange et al.

Investigation of a SARS-CoV-2 B.1.1.529 (Omicron) Variant Cluster - Nebraska, November-December 2021

MMWR Morb Mortal Wkly Rep. 2021 Dec 31;70(5152):1782-1784. doi: 10.15585/mmwr.mm705152e3.
Vanessa C Nicolete, Priscila T Rodrigues, Anderson R J Fernandes et al.

Epidemiology of COVID-19 after Emergence of SARS-CoV-2 Gamma Variant, Brazilian Amazon, 2020-2021

Emerg Infect Dis. 2021 Dec 28;28(3). doi: 10.3201/eid2803.211993.
Andrew Fox-Lewis, Felicity Williamson, Jay Harrower et al.

Airborne Transmission of SARS-CoV-2 Delta Variant within Tightly Monitored Isolation Facility, New Zealand (Aotearoa)

Emerg Infect Dis. 2021 Dec 29;28(3). doi: 10.3201/eid2803.212318.
Matthew J Ziegler, Elizabeth Huang, Selamawit Bekele et al.

Spatial and temporal effects on severe acute respiratory coronavirus virus 2 (SARS-CoV-2) contamination of the healthcare environment

Infect Control Hosp Epidemiol. 2021 Dec 27;1-6. doi: 10.1017/ice.2021.530.
David Stein, Ernesto Oviedo-Orta, Wendy A Kampman et al.

Compassionate Use of REGEN-COV ® in Patients with COVID-19 and Immunodeficiency-Associated Antibody Disorders

Clin Infect Dis. 2021 Dec 31;ciab1059. doi: 10.1093/cid/ciab1059.
Katia J Bruxvoort, Bradley Ackerson, Lina S Sy et al.

Recombinant adjuvanted zoster vaccine and reduced risk of COVID-19 diagnosis and hospitalization in older adults

J Infect Dis. 2021 Dec 28;jiab633. doi: 10.1093/infdis/jiab633.
Joanna Luczkowiak, Nuria Labiod, Gonzalo Rivas et al.

Neutralizing response against SARS-CoV-2 variants 8 months after BNT162b2 vaccination in naïve and COVID-19 convalescent individuals

J Infect Dis. 2021 Dec 28;jiab634. doi: 10.1093/infdis/jiab634.
Jiankai Liu, Baoying Huang, Guifan Li et al.

Immunogenicity and Safety of a Three-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-blind, Placebo-controlled Phase 2 Trial

J Infect Dis. 2021 Dec 27;jiab627. doi: 10.1093/infdis/jiab627.
Winston E Abara, Julianne Gee, Mark Delorey et al.

Expected Rates of Select Adverse Events following Immunization for COVID-19 Vaccine Safety Monitoring

J Infect Dis. 2021 Dec 27;jiab628. doi: 10.1093/infdis/jiab628.
Annette K Regan, Onyebuchi Arah, Deshayne B Fell, Sheena G Sullivan

SARS-CoV-2 infection during pregnancy and associated perinatal health outcomes: a national US cohort study

J Infect Dis. 2021 Dec 27;jiab626. doi: 10.1093/infdis/jiab626.
Tianyang Li, Yang Yang, Yongqi Li et al.

Platelets mediate inflammatory monocyte activation by SARS-CoV-2 Spike protein

J Clin Invest. 2021 Dec 29;e150101. doi: 10.1172/JCI150101.
Robert L Gottlieb, Carlos E Vaca, Roger Paredes et al.

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

N Engl J Med. 2021 Dec 22. doi: 10.1056/NEJMoa2116846.
Scott A Halperin, Lingyun Ye, Donna MacKinnon-Cameron et al.

Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial

Lancet. 2021 Dec 23;S0140-6736(21)02753-7. doi: 10.1016/S0140-6736(21)02753-7.
ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

Lancet Infect Dis. 2021 Dec 23;S1473-3099(21)00751-9. doi: 10.1016/S1473-3099(21)00751-9.
Joseph A Lewnard, Ayesha Mahmud, Tejas Narayan et al.

All-cause mortality during the COVID-19 pandemic in Chennai, India: an observational study

Lancet Infect Dis. 2021 Dec 22;S1473-3099(21)00746-5. doi: 10.1016/S1473-3099(21)00746-5.
Joan B Soriano, Srinivas Murthy, John C Marshall et al.

A clinical case definition of post-COVID-19 condition by a Delphi consensus

Lancet Infect Dis. 2021 Dec 21;S1473-3099(21)00703-9. doi: 10.1016/S1473-3099(21)00703-9.
Herman Goossens, Lennie Derde, Peter Horby, Marc Bonten

The European clinical research response to optimise treatment of patients with COVID-19: lessons learned, future perspective, and recommendations

Lancet Infect Dis. 2021 Dec 21;S1473-3099(21)00705-2. doi: 10.1016/S1473-3099(21)00705-2.
Rosanna W Peeling, David L Heymann, Yik-Ying Teo, Patricia J Garcia

Diagnostics for COVID-19: moving from pandemic response to control

Lancet. 2021 Dec 20;S0140-6736(21)02346-1. doi: 10.1016/S0140-6736(21)02346-1.
Wanwisa Dejnirattisai, Robert H Shaw, Piyada Supasa et al.

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum

Lancet. 2021 Dec 20;S0140-6736(21)02844-0. doi: 10.1016/S0140-6736(21)02844-0.
Christof Prugger, Angela Spelsberg, Ulrich Keil, Juan Erviti, Peter Doshi

Evaluating covid-19 vaccine efficacy and safety in the post-authorisation phase

BMJ. 2021 Dec 23;375:e067570. doi: 10.1136/bmj-2021-067570.
Adeel A Butt, Soha R Dargham, Hiam Chemaitelly et al.

Severity of Illness in Persons Infected With the SARS-CoV-2 Delta Variant vs Beta Variant in Qatar

JAMA Intern Med. 2021 Dec 22;e217949. doi: 10.1001/jamainternmed.2021.7949.
Nir Kugelman, Chen Nahshon, Pninit Shaked-Mishan et al.

Maternal and Neonatal SARS-CoV-2 Immunoglobulin G Antibody Levels at Delivery After Receipt of the BNT162b2 Messenger RNA COVID-19 Vaccine During the Second Trimester of Pregnancy

JAMA Pediatr. 2021 Dec 21;e215683. doi: 10.1001/jamapediatrics.2021.5683.
Michael Levy, Morgan Recher, Hervé Hubert et al.

Multisystem Inflammatory Syndrome in Children by COVID-19 Vaccination Status of Adolescents in France

JAMA. 2021 Dec 20;e2123262. doi: 10.1001/jama.2021.23262.
Roman Reindl-Schwaighofer, Andreas Heinzel, Manuel Mayrdorfer et al.

Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial

JAMA Intern Med. 2021 Dec 20;e217372. doi: 10.1001/jamainternmed.2021.7372.
George N Ioannou, Emily R Locke, Ann M O'Hare et al.

COVID-19 Vaccination Effectiveness Against Infection or Death in a National U.S. Health Care System : A Target Trial Emulation Study

Ann Intern Med. 2021 Dec 21;M21-3256. doi: 10.7326/M21-3256.
ACTIV-3/TICO Bamlanivimab Study Group

Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial

Ann Intern Med. 2021 Dec 21. doi: 10.7326/M21-3507.
Lucy G Thorne, Mehdi Bouhaddou, Ann-Kathrin Reuschl et al.

Evolution of enhanced innate immune evasion by SARS-CoV-2

Nature. 2021 Dec 23. doi: 10.1038/s41586-021-04352-y.
Vanessa L Hale, Patricia M Dennis, Dillon S McBride et al.

SARS-CoV-2 infection in free-ranging white-tailed deer

Nature. 2021 Dec 23. doi: 10.1038/s41586-021-04353-x.
Masahiro Yoshida, Kaylee B Worlock, Ni Huang et al.

Local and systemic responses to SARS-CoV-2 infection in children and adults

Nature. 2021 Dec 22. doi: 10.1038/s41586-021-04345-x.
Lorenz Ulrich, Nico Joel Halwe, Adriano Taddeo et al.

Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta

Nature. 2021 Dec 22. doi: 10.1038/s41586-021-04342-0.
Joseph L Ward, Rachel Harwood, Clare Smith et al.

Risk factors for PICU admission and death among children and young people hospitalized with COVID-19 and PIMS-TS in England during the first pandemic year

Nat Med. 2021 Dec 20. doi: 10.1038/s41591-021-01627-9.
Ravindra K Gupta, Eric J Topol

COVID-19 vaccine breakthrough infections

Science. 2021 Dec 24;374(6575):1561-1562. doi: 10.1126/science.abl8487.
Bryan A Johnson, Vineet D Menachery

A new tool to probe SARS-CoV-2 variants

Science. 2021 Dec 24;374(6575):1557-1558. doi: 10.1126/science.abn3781.
William A Fischer 2nd, Joseph J Eron Jr, Wayne Holman et al.

A Phase 2a clinical trial of Molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus

Sci Transl Med. 2021 Dec 23;eabl7430. doi: 10.1126/scitranslmed.abl7430.
Catherine Riou, Roanne Keeton, Thandeka Moyo-Gwete et al.

Escape from recognition of SARS-CoV-2 Beta variant spike epitopes but overall preservation of T cell immunity

Sci Transl Med. 2021 Dec 21;eabj6824.
Markus Hoffmann, Nadine Krüger, Sebastian Schulz et al.

The Omicron variant is highly resistant against antibody-mediated neutralization – implications for control of the COVID-19 pandemic

Cell. 2021 Dec 23;S0092-8674(21)01495-1. doi: 10.1016/j.cell.2021.12.032.
Katherine J Siddle, Lydia A Krasilnikova, Gage K Moreno et al.

Transmission from vaccinated individuals in a large SARS-CoV-2 Delta variant outbreak

Cell. 2021 Dec 22;S0092-8674(21)01490-2. doi: 10.1016/j.cell.2021.12.027.
Nathan D Grubaugh, Sarah Cobey

Of variants and vaccines

Cell. 2021 Dec 22;184(26):6222-6223. doi: 10.1016/j.cell.2021.11.013.
Philip A Mudd, Anastasia A Minervina, Mikhail V Pogorelyy et al.

SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans

Cell. 2021 Dec 22;S0092-8674(21)01489-6. doi: 10.1016/j.cell.2021.12.026.
Wei-Yen Lim, Glorijoy Shi En Tan, Htet Lin Htun et al.

The first nosocomial cluster of COVID-19 due to the Delta variant in a major acute-care hospital in Singapore - investigations and outbreak response

J Hosp Infect. 2021 Dec 20;S0195-6701(21)00443-6. doi: 10.1016/j.jhin.2021.12.011.
Auliya A Suwantika, Inge Dhamanti, Yulianto Suharto, Fredrick D Purba, Rizky Abdulah

The cost-effectiveness of social distancing measures for mitigating the COVID-19 pandemic in a highly-populated country: A case study in Indonesia

Travel Med Infect Dis. 2021 Dec 23;45:102245. doi: 10.1016/j.tmaid.2021.102245.
Shohei Yamamoto, Kenji Maeda, Kouki Matsuda et al.

COVID-19 breakthrough infection and post-vaccination neutralizing antibody among healthcare workers in a referral hospital in Tokyo: a case-control matching study

Clin Infect Dis. 2021 Dec 24;ciab1048. doi: 10.1093/cid/ciab1048.
Kristin L Andrejko, Jake Pry, Jennifer F Myers et al.

Predictors of SARS-CoV-2 infection following high-risk exposure

Clin Infect Dis. 2021 Dec 21;ciab1040. doi: 10.1093/cid/ciab1040.
Harmony L Tyner, Jefferey L Burgess, Lauren Grant et al.

Neutralizing Antibody Response to Pseudotype SARS-CoV-2 Differs between mRNA-1273 and BNT162b2 COVID-19 Vaccines and by History of SARS-CoV-2 Infection

Clin Infect Dis. 2021 Dec 20;ciab1038. doi: 10.1093/cid/ciab1038.
Darpun D Sachdev, Rilene Chew Ng, Madeline Sankaran et al.

Contact tracing outcomes among household contacts of fully vaccinated COVID-19 patients - San Francisco, California, January 29-July 2, 2021

Clin Infect Dis. 2021 Dec 20;ciab1042. doi: 10.1093/cid/ciab1042.
Veronique Nussenblatt, Allison E Roder, Sanchita Das et al.

Year-long COVID-19 infection reveals within-host evolution of SARS-CoV-2 in a patient with B cell depletion

J Infect Dis. 2021 Dec 23;jiab622. doi: 10.1093/infdis/jiab622.
Nathaniel M Lewis, Eric A Naioti, Wesley H Self et al.

Effectiveness of mRNA vaccines in preventing COVID-19 hospitalization by age and burden of chronic medical conditions among immunocompetent US adults, March-August 2021

J Infect Dis. 2021 Dec 21;jiab619. doi: 10.1093/infdis/jiab619.
Myrthe L Verburgh, Anders Boyd, Ferdinand W N M Wit et al.

Similar risk of SARS-CoV-2 infection and similar nucleocapsid antibody levels in people with well-controlled HIV and a comparable cohort of people without HIV

J Infect Dis. 2021 Dec 20;jiab616. doi: 10.1093/infdis/jiab616.
Angélica Jayk Bernal, Monica M Gomes da Silva, Dany B Musungaie et al.

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

N Engl J Med. 2021 Dec 16. doi: 10.1056/NEJMoa2116044.
Lisa M Dunkle, Karen L Kotloff, Cynthia L Gay et al.

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico

N Engl J Med. 2021 Dec 15. doi: 10.1056/NEJMoa2116185.
Hiam Chemaitelly, Roberto Bertollini, Laith J Abu-Raddad, National Study Group for COVID-19 Epidemiology

Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant

N Engl J Med. 2021 Dec 15. doi: 10.1056/NEJMc2110300.
Benjamin A Fisher, Tonny Veenith, Daniel Slade et al.

Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial

Lancet Respir Med. 2021 Dec 16;S2213-2600(21)00460-4. doi: 10.1016/S2213-2600(21)00460-4.
Melinda C Mills, Tobias Rüttenauer

The effect of mandatory COVID-19 certificates on vaccine uptake: synthetic-control modelling of six countries

Lancet Public Health. 2021 Dec 13;S2468-2667(21)00273-5. doi: 10.1016/S2468-2667(21)00273-5.
Anders Husby, Jørgen Vinsløv Hansen, Emil Fosbøl et al.

SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study

BMJ. 2021 Dec 16;375:e068665. doi: 10.1136/bmj-2021-068665.
Katia J Bruxvoort, Lina S Sy, Lei Qian et al.

Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study

BMJ. 2021 Dec 15;375:e068848. doi: 10.1136/bmj-2021-068848.
Timothy A Bates, Savannah K McBride, Bradie Winders et al.

Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection

JAMA. 2021 Dec 16. doi: 10.1001/jama.2021.22898.
Mila B Ortigoza, Hyunah Yoon, Keith S Goldfeld et al.

Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial

JAMA Intern Med. 2021 Dec 13. doi: 10.1001/jamainternmed.2021.6850.
Giovanna Elsa Ute Muti-Schüenemann, Wojciech Szczeklik, Karla Solo et al.

Update Alert 3: Ventilation Techniques and Risk for Transmission of Coronavirus Disease, Including COVID-19

Ann Intern Med. 2021 Dec 14. doi: 10.7326/L21-0424.
Shuchi Anand, Maria E Montez-Rath, Jialin Han et al.

SARS-CoV-2 Vaccine Antibody Response and Breakthrough Infection in Patients Receiving Dialysis

Ann Intern Med. 2021 Dec 14. doi: 10.7326/M21-4176.
Martina Patone, Xue W Mei, Lahiru Handunnetthi et al.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection

Nat Med. 2021 Dec 14. doi: 10.1038/s41591-021-01630-0.
Behdad Afzali, Marina Noris, Bart N Lambrecht, Claudia Kemper

The state of complement in COVID-19

Nat Rev Immunol. 2021 Dec 15;1-8. doi: 10.1038/s41577-021-00665-1.
Jonathan W Yewdell

Antigenic drift: Understanding COVID-19

Immunity. 2021 Dec 14;54(12):2681-2687. doi: 10.1016/j.immuni.2021.11.016.
Kimberly Harris-McCoy, Veronica C Lee, Cortney Munna, Andrea A Kim

Evaluation of a Test to Stay Strategy in Transitional Kindergarten Through Grade 12 Schools ― Los Angeles County, California, August 16–October 31, 2021

MMWR Morb Mortal Wkly Rep. 2021 Dec 17. doi: 10.15585/mmwr.mm705152e1.
Natsumi Nemoto, Soneet Dhillon, Steven Fink, et al.

Evaluation of Test to Stay Strategy on Secondary and Tertiary Transmission of SARS-CoV-2 in K–12 Schools ― Lake County, Illinois, August 9–October 29, 2021

MMWR Morb Mortal Wkly Rep. 2021 Dec 17. doi: 10.15585/mmwr.mm705152e2.
Kimberly H Nguyen, David Yankey, Peng-Jun Lu et al.

Report of Health Care Provider Recommendation for COVID-19 Vaccination Among Adults, by Recipient COVID-19 Vaccination Status and Attitudes - United States, April-September 2021

MMWR Morb Mortal Wkly Rep. 2021 Dec 17;70(50):1723-1730. doi: 10.15585/mmwr.mm7050a1.
Homer Mejía-Santos, Sandra Montoya, Rafael Chacón-Fuentes et al.

Notes from the Field: Mucormycosis Cases During the COVID-19 Pandemic - Honduras, May-September 2021

MMWR Morb Mortal Wkly Rep. 2021 Dec 17;70(50):1747-1749. doi: 10.15585/mmwr.mm7050a2.
Theresa M Dulski, Megan DeLong, Kelley Garner et al.

Notes from the Field: COVID-19-Associated Mucormycosis - Arkansas, July-September 2021

MMWR Morb Mortal Wkly Rep. 2021 Dec 17;70(50):1750-1751. doi: 10.15585/mmwr.mm7050a3.
Sukhyun Ryu, Dasom Kim, Jun-Sik Lim, Sheikh Taslim Ali, Benjamin J Cowling

Serial Interval and Transmission Dynamics during SARS-CoV-2 Delta Variant Predominance, South Korea

Emerg Infect Dis. 2021 Dec 14;28(2). doi: 10.3201/eid2802.211774.
Solène Grayo, Cécile Troupin, Moussa Moïse Diagne et al.

SARS-CoV-2 Circulation, Guinea, March 2020-July 2021

Emerg Infect Dis. 2021 Dec 14;28(2). doi: 10.3201/eid2802.212182.
Jennifer Kertes, Sharon Baruch Gez, Yaki Saciuk et al.

Effectiveness of mRNA BNT162b2 Vaccine 6 Months after Vaccination among Patients in Large Health Maintenance Organization, Israel

Emerg Infect Dis. 2021 Dec 14;28(2). doi: 10.3201/eid2802.211834.
Lin T Brandal, Emily MacDonald, Lamprini Veneti et al.

Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021

Euro Surveill. 2021 Dec;26(50). doi: 10.2807/1560-7917.ES.2021.26.50.2101147.
Laura Espenhain, Tjede Funk, Maria Overvad et al.

Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 2021

Euro Surveill. 2021 Dec;26(50). doi: 10.2807/1560-7917.ES.2021.26.50.2101146.
Nick Bundle, Nishi Dave, Anastasia Pharris et al.

COVID-19 trends and severity among symptomatic children aged 0-17 years in 10 European Union countries, 3 August 2020 to 3 October 2021

Euro Surveill. 2021 Dec;26(50). doi: 10.2807/1560-7917.ES.2021.26.50.2101098.
Shelly Bolotin, Vanessa Tran, Shelley L Deeks et al.

Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020

Euro Surveill. 2021 Dec;26(50). doi: 10.2807/1560-7917.ES.2021.26.50.2001559.
Bexultan Kazybay, Ashfaq Ahmad, Chenglin Mu, Diana Mengdesh, Yingqiu Xie

Omicron N501Y mutation among SARS-CoV-2 lineages: In-silico analysis of potent binding to tyrosine kinase and hypothetical repurposed medicine

Travel Med Infect Dis. 2021 Dec 17;102242. doi: 10.1016/j.tmaid.2021.102242.
Sujan Poudel, Angela Ishak, Javier Perez-Fernandez et al.

Highly mutated SARS-CoV-2 Omicron variant sparks significant concern among global experts - What is known so far?

Travel Med Infect Dis. 2021 Dec 8;45:102234. doi: 10.1016/j.tmaid.2021.102234.
Anna C Sick-Samuels, Sara Cosgrove, Clare Rock et al.

Improving physical distancing among healthcare workers in a pediatric intensive care unit

Infect Control Hosp Epidemiol. 2021 Dec 14;1-6. doi: 10.1017/ice.2021.501.
Chun Huai Luo, C Paul Morris, Jaiprasath Sachithanandham et al.

Infection with the SARS-CoV-2 Delta Variant is Associated with Higher Recovery of Infectious Virus Compared to the Alpha Variant in both Unvaccinated and Vaccinated Individuals

Clin Infect Dis. 2021 Dec 18;ciab986. doi: 10.1093/cid/ciab986.
Lu Lu, Bobo Wing-Yee Mok, Lin-Lei Chen et al.

Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients

Clin Infect Dis. 2021 Dec 16;ciab1041. doi: 10.1093/cid/ciab1041.
Brian T Garibaldi, Kunbo Wang, Matthew L Robinson et al.

Real-World Effectiveness Of Remdesivir In Adults Hospitalized With Covid-19: A Retrospective, Multicenter Comparative Effectiveness Study

Clin Infect Dis. 2021 Dec 15;ciab1035. doi: 10.1093/cid/ciab1035.
Dana Danino, Shalom Ben-Shimol, Bart Adriaan Van Der Beek et al.

Decline in Pneumococcal Disease in Young Children during the COVID-19 Pandemic in Israel Associated with Suppression of seasonal Respiratory Viruses, despite Persistent Pneumococcal Carriage: A Prospective Cohort Study

Clin Infect Dis. 2021 Dec 14;ciab1014. doi: 10.1093/cid/ciab1014.
Jennifer L Welch, Jinhua Xiang, Qing Chang, Jon C D Houtman, Jack T Stapleton

Human T cells express Angiotensin Converting Enzyme 2 at levels sufficient to interact with the SARS-CoV-2 Spike protein

J Infect Dis. 2021 Dec 16;jiab595. doi: 10.1093/infdis/jiab595.
Felipe Pérez-García, María Martin-Vicente, Rosa Lía Rojas-García et al.

High SARS-CoV-2 viral load and low CCL5 expression levels in the upper respiratory tract are associated with COVID-19 severity

J Infect Dis. 2021 Dec 15;jiab604. doi: 10.1093/infdis/jiab604.
Yinon M Bar-On, Yair Goldberg, Micha Mandel et al.

Protection against Covid-19 by BNT162b2 Booster across Age Groups

N Engl J Med. 2021 Dec 8. doi: 10.1056/NEJMoa2115926.
Ronen Arbel, Ariel Hammerman, Ruslan Sergienko et al.

BNT162b2 Vaccine Booster and Mortality Due to Covid-19

N Engl J Med. 2021 Dec 8. doi: 10.1056/NEJMoa2115624.
Brian E McGarry, Michael L Barnett, David C Grabowski, Ashvin D Gandhi

Nursing Home Staff Vaccination and Covid-19 Outcomes

N Engl J Med. 2021 Dec 8. doi: 10.1056/NEJMc2115674.
A Sarah Walker, Karina-Doris Vihta, Owen Gethings et al.

Tracking the Emergence of SARS-CoV-2 Alpha Variant in the United Kingdom

N Engl J Med. 2021 Dec 8. doi: 10.1056/NEJMc2103227.
Gang Zeng, Qianhui Wu, Hongxing Pan et al.

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials

Lancet Infect Dis. 2021 Dec 7;S1473-3099(21)00681-2. doi: 10.1016/S1473-3099(21)00681-2.
Arabella S V Stuart, Robert H Shaw, Xinxue Liu et al.

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

Lancet. 2021 Dec 6;S0140-6736(21)02718-5. doi: 10.1016/S0140-6736(21)02718-5.
Marie I Samanovic, Amber R Cornelius, Sophie L Gray-Gaillard et al.

Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals

Sci Transl Med. 2021 Dec 7;eabi8961. doi: 10.1126/scitranslmed.abi8961
Matthew Gagne, Kizzmekia S Corbett, Barbara J Flynn et al.

Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques is coincident with anamnestic antibody response in the lung

Cell. 2021 Dec 2;S0092-8674(21)01405-7. doi: 10.1016/j.cell.2021.12.002.
CDC COVID-19 Response Team

SARS-CoV-2 B.1.1.529 (Omicron) Variant ― United States, December 1–8, 2021

MMWR Morb Mortal Wkly Rep. 2021 Dec 10. doi: 10.15585/mmwr.mm7050e1.
Hannah E Fast, Elizabeth Zell, Bhavini Patel Murthy et al.

Booster and Additional Primary Dose COVID-19 Vaccinations Among Adults Aged ≥65 Years ― United States, August 13, 2021–November 19, 2021

MMWR Morb Mortal Wkly Rep. 2021 Dec 10. doi: 10.15585/mmwr.mm7050e2.
Kristina L Bajema, Rebecca M Dahl, Steve L Evener et al.

Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021

MMWR Morb Mortal Wkly Rep. 2021 Dec 10;70(49):1700-1705. doi: 10.15585/mmwr.mm7049a2.
Mark F Miller, Min Shi, Alison Motsinger-Reif et al.

Community-Based Testing Sites for SARS-CoV-2 - United States, March 2020-November 2021

MMWR Morb Mortal Wkly Rep. 2021 Dec 10;70(49):1706-1711. doi: 10.15585/mmwr.mm7049a3.
Irina Kislaya, Eduardo Freire Rodrigues, Vítor Borges et al.

Comparative Effectiveness of Coronavirus Vaccine in Preventing Breakthrough Infections among Vaccinated Persons Infected with Delta and Alpha Variants

Emerg Infect Dis. 2021 Dec 8;28(2). doi: 10.3201/eid2802.211789.
Carl Suetens, Pete Kinross, Pilar Gallego Berciano et al.

Increasing risk of breakthrough COVID-19 in outbreaks with high attack rates in European long-term care facilities, July to October 2021

Euro Surveill. 2021 Dec;26(49). doi: 10.2807/1560-7917.ES.2021.26.49.2101070.
Ria Lassaunière, Charlotta Polacek, Jannik Fonager et al.

Neutralisation of the SARS-CoV-2 Delta variant sub-lineages AY.4.2 and B.1.617.2 with the mutation E484K by Comirnaty (BNT162b2 mRNA) vaccine-elicited sera, Denmark, 1 to 26 November 2021

Euro Surveill. 2021 Dec;26(49). doi: 10.2807/1560-7917.ES.2021.26.49.2101059.
Sallie Permar, C Buddy Creech, Kathryn M Edwards, Emmanuel B Walter

Proposals to Accelerate Novel Vaccine Development for Children

Pediatrics. 2021 Dec 10;e2021054593. doi: 10.1542/peds.2021-054593.
Charles E Marvil, Ahmed Babiker, Aaron Preston et al.

Outbreak of SARS-CoV-2 in hospitalized hemodialysis patients: an epidemiologic and genomic investigation

Infect Control Hosp Epidemiol. 2021 Dec 6;1-14. doi: 10.1017/ice.2021.465.
Yves Longtin, Leighanne Parkes, Hugues Charest et al.

Persistence of Infectivity in Elderly Individuals Diagnosed with SARS-CoV-2 Infection 10 Days after Onset of Symptoms: A Cross-Sectional Study

Infect Control Hosp Epidemiol. 2021 Dec 6;1-11. doi: 10.1017/ice.2021.502.
Jamil N Kanji, Nathan Zelyas, Kanti Pabbaraju et al.

Respiratory virus co-infections with SARS-CoV-2 continue to be rare one year into the pandemic in Alberta, Canada (June 2020 - May 2021)

Infect Control Hosp Epidemiol. 2021 Dec 6;1-21. doi: 10.1017/ice.2021.495.
Thomas Bruneau, Maxime Wack, Geoffroy Poulet et al.

Circulating ubiquitous RNA, a highly predictive and prognostic biomarker in hospitalized COVID-19 patients

Clin Infect Dis. 2021 Dec 11;ciab997. doi: 10.1093/cid/ciab997.
Li Tang, Sean Cherry, Elaine I Tuomanen et al.

Host predictors of broadly cross-reactive antibodies against SARS-CoV-2 variants of concern differ between infection and vaccination

Clin Infect Dis. 2021 Dec 10;ciab996. doi: 10.1093/cid/ciab996.
Marta Fernández-González, Vanesa Agulló, Sergio Padilla et al.

Clinical performance of a standardized SARS-CoV-2 interferon-γ release assay for simple detection of T-cell responses after infection or vaccination

Clin Infect Dis. 2021 Dec 10;ciab1021. doi: 10.1093/cid/ciab1021.
Joseph M Rocco, Christina Mallarino-Haeger, Attiya H Randolph et al.

Hyperinflammatory syndromes after SARS-CoV-2 mRNA vaccination in individuals with underlying immune dysregulation

Clin Infect Dis. 2021 Dec 10;ciab1024. doi: 10.1093/cid/ciab1024.
Stephen M Bart, Adora Harizaj, Claire L Pearson et al.

SARS-CoV-2 Delta outbreak among fully vaccinated nursing home residents likely initiated by a fully vaccinated staff member - Connecticut, July-August 2021

Clin Infect Dis. 2021 Dec 10;ciab1025. doi: 10.1093/cid/ciab1025.
Adeel A Butt, Peng Yan, Obaid S Shaikh, Florian B Mayr, Saad B Omer

Rate and Risk Factors for Severe/Critical Disease Among Fully Vaccinated Persons with Breakthrough SARS-CoV-2 Infection in a High-risk National Population

Clin Infect Dis. 2021 Dec 10;ciab1023. doi: 10.1093/cid/ciab1023.
Khadija Khan, Gila Lustig, Mallory Bernstein et al.

Immunogenicity of SARS-CoV-2 infection and Ad26.CoV2.S vaccination in people living with HIV

Clin Infect Dis. 2021 Dec 10;ciab1008. doi: 10.1093/cid/ciab1008.
Matthew A Spinelli, Michael J Peluso, Kara L Lynch et al.

Differences in Post-mRNA Vaccination SARS-CoV-2 IgG Concentrations and Surrogate Virus Neutralization Test Response by HIV Status and Type of Vaccine: a Matched Case-Control Observational Study

Clin Infect Dis. 2021 Dec 5;ciab1009. doi: 10.1093/cid/ciab1009.
Kathryn A Ryan, Katarzyna E Schewe, Jonathan Crowe et al.

Sequential delivery of LAIV and SARS-CoV-2 in the ferret model can reduce SARS-CoV-2 shedding and does not result in enhanced lung pathology

J Infect Dis. 2021 Dec 11;jiab594. doi: 10.1093/infdis/jiab594.
Vivek Naranbhai, Wilfredo F Garcia-Beltran, Christina C Chang et al.

Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines

J Infect Dis. 2021 Dec 9;jiab593. doi: 10.1093/infdis/jiab593.
Mark A Brockman, Francis Mwimanzi, Hope R Lapointe et al.

Reduced magnitude and durability of humoral immune responses to COVID-19 mRNA vaccines among older adults

J Infect Dis. 2021 Dec 9;jiab592. doi: 10.1093/infdis/jiab592.
Peter Halfmann, Noriko Nakajima, Yuko Sato et al.

SARS-CoV-2 Interference of Influenza Virus Replication in Syrian Hamsters

J Infect Dis. 2021 Dec 7;jiab587. doi: 10.1093/infdis/jiab587.
Barbra A Dickerman, Hanna Gerlovin, Arin L Madenci et al.

Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans

N Engl J Med. 2021 Dec 1. doi: 10.1056/NEJMoa2115463.
Eli S Rosenberg, Vajeera Dorabawila, Delia Easton et al.

Covid-19 Vaccine Effectiveness in New York State

N Engl J Med. 2021 Dec 1. doi: 10.1056/NEJMc2116063.
Stephen M Kissler, Joseph R Fauver, Christina Mack et al.

Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons

N Engl J Med. 2021 Dec 1. doi: 10.1056/NEJMoa2102507.
Luke Milross, Joaquim Majo, Nigel Cooper et al.

Post-mortem lung tissue: the fossil record of the pathophysiology and immunopathology of severe COVID-19

Lancet Respir Med. 2021 Dec 3;S2213-2600(21)00408-2. doi: 10.1016/S2213-2600(21)00408-2.
Alasdair P S Munro, Leila Janani, Victoria Cornelius et al.

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Lancet. 2021 Dec 2;S0140-6736(21)02717-3. doi: 10.1016/S0140-6736(21)02717-3.
Zelalem Temesgen, Charles D Burger, Jason Baker et al.

Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial

Lancet Respir Med. 2021 Dec 1;S2213-2600(21)00494-X. doi: 10.1016/S2213-2600(21)00494-X.
Zahin Amin-Chowdhury, Marta Bertran, Carmen L Sheppard et al.

Does the rise in seasonal respiratory viruses foreshadow the return of invasive pneumococcal disease this winter?

Lancet Respir Med. 2021 Dec 1;S2213-2600(21)00538-5. doi: 10.1016/S2213-2600(21)00538-5.
Wenjing Gao, Jun Lv, Yuanjie Pang, Li-Ming Li

Role of asymptomatic and pre-symptomatic infections in covid-19 pandemic

BMJ. 2021 Dec 1;375:n2342. doi: 10.1136/bmj.n2342.
Zhijie An, Fuzhen Wang, An Pan et al.

Vaccination strategy and challenges for consolidating successful containment of covid-19 with population immunity in China

BMJ. 2021 Dec 1;375:e066125. doi: 10.1136/bmj-2021-066125.
Bin Du, Chunting Wang, Mervyn Singer

Learning for the next pandemic: the Wuhan experience of managing critically ill people

BMJ. 2021 Dec 1;375:e066090. doi: 10.1136/bmj-2021-066090.
Qiulan Chen, Lance Rodewald, Shengjie Lai, George F Gao

Rapid and sustained containment of covid-19 is achievable and worthwhile: implications for pandemic response

BMJ. 2021 Dec 1;375:e066169. doi: 10.1136/BMJ-2021-066169.
Yi Zhang, Ashley Quigley, Quanyi Wang, C Raina MacIntyre

Non-pharmaceutical interventions during the roll out of covid-19 vaccines

BMJ. 2021 Dec 1;375:n2314. doi: 10.1136/bmj.n2314.
Yongyue Wei, Feng Sha, Yang Zhao et al.

Better modelling of infectious diseases: lessons from covid-19 in China

BMJ. 2021 Dec 1;375:n2365. doi: 10.1136/bmj.n2365.
Yibiao Zhou, Honglin Jiang, Quanyi Wang et al.

Use of contact tracing, isolation, and mass testing to control transmission of covid-19 in China

BMJ. 2021 Dec 1;375:n2330. doi: 10.1136/bmj.n2330.
Hongwei Tu, Keqi Hu, Meng Zhang, Yali Zhuang, Tie Song

Effectiveness of 14 day quarantine strategy: Chinese experience of prevention and control

BMJ. 2021 Dec 1;375:e066121. doi: 10.1136/BMJ-2021-066121.
Jin-Ling Tang, Li-Ming Li

Importance of public health tools in emerging infectious diseases

BMJ. 2021 Dec 1;375:n2374. doi: 10.1136/bmj.n2374.
Harry Rutter, Simon Parker, Will Stahl-Timmins et al.

Visualising SARS-CoV-2 transmission routes and mitigations

BMJ. 2021 Dec 1;375:e065312. doi: 10.1136/bmj-2021-065312.
Brian Grunau, David M Goldfarb, Michael Asamoah-Boaheng et al.

Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals

JAMA. 2021 Dec 3;e2121921. doi: 10.1001/jama.2021.21921.
Julien Sourimant, Carolin M Lieber, Megha Aggarwal et al.

4'-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication

Science. 2021 Dec 2;eabj5508. doi: 10.1126/science.abj5508.
Jason Abaluck, Laura H Kwong, Ashley Styczynski et al.

Impact of community masking on COVID-19: A cluster-randomized trial in Bangladesh

Science. 2021 Dec 2;eabi9069. doi: 10.1126/science.abi9069.
Catherine J Reynolds, Joseph M Gibbons, Corinna Pade et al.

Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants

Science. 2021 Dec 2;eabm0811. doi: 10.1126/science.abm0811.
Katherine G Nabel, Sarah A Clark, Sundaresh Shankar et al.

Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain

Science. 2021 Dec 2;eabl6251. doi: 10.1126/science.abl6251.
Young Kyun Choi, Jae Young Moon, Jungok Kim et al.

Postvaccination Multisystem Inflammatory Syndrome in Adult with No Evidence of Prior SARS-CoV-2 Infection

Emerg Infect Dis. 2021 Dec 1;28(2). doi: 10.3201/eid2802.211938.
Haogao Gu, Pavithra Krishnan, Daisy Y M Ng et al.

Probable Transmission of SARS-CoV-2 Omicron Variant in Quarantine Hotel, Hong Kong, China, November 2021

Emerg Infect Dis. 2021 Dec 3;28(2). doi: 10.3201/eid2802.212422.
Yi-Shin Chang, Stockton Mayer, Elizabeth S Davis et al.

Transmission Dynamics of Large Coronavirus Disease Outbreak in Homeless Shelter, Chicago, Illinois, USA, 2020

Emerg Infect Dis. 2021 Dec 2;28(1). doi: 10.3201/eid2801.210780.
Haogao Gu, Samuel S M Cheng, Pavithra Krishnan et al.

Monitoring International Travelers Arriving in Hong Kong for Genomic Surveillance of SARS-CoV-2

Emerg Infect Dis. 2021 Dec 2;28(1). doi: 10.3201/eid2801.211804.
Mauricio Hernandez-Avila, Marcela Tamayo-Ortiz, Waldo Vieyra-Romero et al.

Use of Private Sector Workforce Respiratory Disease Short-Term Disability Claims to Assess SARS-CoV-2, Mexico, 2020

Emerg Infect Dis. 2021 Dec 2;28(1). doi: 10.3201/eid2801.211357.
Anthony Li, Kieran Moore, Lindsay Bowthorpe, Julie Sousa, T Hugh Guan

Limited Propagation of SARS-CoV-2 among Children in a Childcare Center, Canada, 2021

Emerg Infect Dis. 2021 Dec 2;28(1). doi: 10.3201/eid2801.211811.
Juliana F da Silva, Roberto J Esteves, Charlene Siza et al.

Cluster of SARS-CoV-2 Gamma Variant Infections, Parintins, Brazil, March 2021

Emerg Infect Dis. 2021 Dec 2;28(1). doi: 10.3201/eid2801.211817.
Nora Chea, Cedric J Brown, Taniece Eure et al.

Risk Factors for SARS-CoV-2 Infection Among US Healthcare Personnel, May-December 2020

Emerg Infect Dis. 2021 Dec 2;28(1). doi: 10.3201/eid2801.211803.
Nathalie Nicolay, Francesco Innocenti, Julien Beauté et al.

Initial assessment of the COVID-19 vaccination's impact on case numbers, hospitalisations and deaths in people aged 80 years and older, 15 EU/EEA countries, December 2020 to May 2021

Euro Surveill. 2021 Dec;26(48). doi: 10.2807/1560-7917.ES.2021.26.48.2101030.
Dimple Y Chudasama, Elise Tessier, Joe Flannagan et al.

Surge in SARS-CoV-2 transmission in school-aged children and household contacts, England, August to October 2021

Euro Surveill. 2021 Dec;26(48). doi: 10.2807/1560-7917.ES.2021.26.48.2101019.
Victoria Indenbaum, Yaniv Lustig, Ella Mendelson et al.

Under-diagnosis of SARS-CoV-2 infections among children aged 0-15 years, a nationwide seroprevalence study, Israel, January 2020 to March 2021

Euro Surveill. 2021 Dec;26(48). doi: 10.2807/1560-7917.ES.2021.26.48.2101040.
Yaniv Lustig, Carmit Cohen, Asaf Biber et al.

Immunoglobulin (Ig)A seropositivity against SARS-CoV-2 in healthcare workers in Israel, 4 April to 13 July 2020: an observational study

Euro Surveill. 2021 Dec;26(48). doi: 10.2807/1560-7917.ES.2021.26.48.2001690.
Laura Heavey, Patricia Garvey, Aoife M Colgan et al.

The Study to Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A seroprevalence study, June to July 2020

Euro Surveill. 2021 Dec;26(48). doi: 10.2807/1560-7917.ES.2021.26.48.2001741.
Paolo Bosetti, Bich-Tram Huynh, Armiya Youssouf Abdou et al.

Lockdown impact on age-specific contact patterns and behaviours, France, April 2020

Euro Surveill. 2021 Dec;26(48). doi: 10.2807/1560-7917.ES.2021.26.48.2001636.
Françoise Renard, Aline Scohy, Johan Van der Heyden et al.

Establishing an ad hoc COVID-19 mortality surveillance during the first epidemic wave in Belgium, 1 March to 21 June 2020

Euro Surveill. 2021 Dec;26(48). doi: 10.2807/1560-7917.ES.2021.26.48.2001402.
S J Dancer, K Cormack, M Loh et al.

Healthcare-acquired clusters of COVID-19 across multiple wards in a Scottish health board

J Hosp Infect. 2021 Dec 1;S0195-6701(21)00428-X. doi: 10.1016/j.jhin.2021.11.019.
Brian T Fisher, Anna Sharova, Craig L K Boge et al.

Evolution of SARS-CoV-2 Seroprevalence Among Employees of a United States Academic Children's Hospital During the COVID-19 Pandemic

Infect Control Hosp Epidemiol. 2021 Dec 2;1-24. doi: 10.1017/ice.2021.487.
Mohamad G Fakih, Richard Fogel, Allison Ottenbacher et al.

Is COVID-19 Vaccination Rate Among Healthcare Personnel Reflective of their Respective Community? An Evaluation of a Multistate Healthcare System

Infect Control Hosp Epidemiol. 2021 Dec 2;1-9. doi: 10.1017/ice.2021.485.
Priscilla Kim, Steven M Gordon, Megan M Sheehan, Michael B Rothberg

Duration of SARS-CoV-2 Natural Immunity and Protection against the Delta Variant: A Retrospective Cohort Study

Clin Infect Dis. 2021 Dec 3;ciab999. doi: 10.1093/cid/ciab999.
Pieter Pannus, Kristof Y Neven, Stéphane De Craeye et al.

Poor antibody response to BioNTech/Pfizer COVID-19 vaccination in SARS-CoV-2 naïve residents of nursing homes

Clin Infect Dis. 2021 Dec 3;ciab998. doi: 10.1093/cid/ciab998.
Ramon Larcade, Lise DeShea, Gillian A Lang et al.

Maternal-fetal immunologic response to SARS-CoV-2 infection in a symptomatic vulnerable population: A prospective cohort

J Infect Dis. 2021 Dec 2;jiab591. doi: 10.1093/infdis/jiab591.
Hari Hwang, Jun-Sik Lim, Sun-Ah Song et al.

Transmission dynamics of the Delta variant of SARS-CoV-2 infections in South Korea

J Infect Dis. 2021 Dec 2;jiab586. doi: 10.1093/infdis/jiab586.
Zoe L Lyski, Amanda E Brunton, Matt I Strnad et al.

SARS-CoV-2 specific memory B-cells from individuals with diverse disease severities recognize SARS-CoV-2 variants of concern

J Infect Dis. 2021 Dec 1;jiab585. doi: 10.1093/infdis/jiab585.
Yun Liao, Ying Zhang, Heng Zhao et al.

Intensified antibody response elicited by boost suggests immune memory in individuals administered two doses of SARS-CoV-2 inactivated vaccine

Emerg Microbes Infect. 2021 Dec;10(1):1112-1115. doi: 10.1080/22221751.2021.1937328.

不活化ワクチン2回接種から180日後にも免疫記憶が保たれていた
Yanan Zhao, Annie Lee, Kaelea Composto et al.

A novel diagnostic test to screen SARS-CoV-2 variants containing E484K and N501Y mutations

Emerg Microbes Infect. 2021 Dec;10(1):994-997. doi: 10.1080/22221751.2021.1929504.

Single-tube duplex molecular assayを用いたE484KおよびN501Yを含む変異ウイルスの診断方法
November 2021
Ting Shi, Jiafeng Pan, Srinivasa Vittal Katikireddi et al.

Risk of COVID-19 hospital admission among children aged 5-17 years with asthma in Scotland: a national incident cohort study

Lancet Respir Med. 2021 Nov 30;S2213-2600(21)00491-4. doi: 10.1016/S2213-2600(21)00491-4.
Anne-Sophie Jung, Victoria Haldane, Rachel Neill et al.

National responses to covid-19: drivers, complexities, and uncertainties in the first year of the pandemic

BMJ. 2021 Nov 28;375:e068954. doi: 10.1136/bmj-2021-068954.
Melisa Mei Jin Tan, Rachel Neill, Victoria Haldane et al.

Assessing the role of qualitative factors in pandemic responses

BMJ. 2021 Nov 28;375:e067512. doi: 10.1136/bmj-2021-067512.
Victoria Haldane, Anne-Sophie Jung, Chuan De Foo et al.

Strengthening the basics: public health responses to prevent the next pandemic

BMJ. 2021 Nov 28;375:e067510. doi: 10.1136/bmj-2021-067510.
Shishi Wu, Rachel Neill, Chuan De Foo et al.

Aggressive containment, suppression, and mitigation of covid-19: lessons learnt from eight countries

BMJ. 2021 Nov 28;375:e067508. doi: 10.1136/bmj-2021-067508.
Victoria Haldane, Anne-Sophie Jung, Rachel Neill et al.

From response to transformation: how countries can strengthen national pandemic preparedness and response systems

BMJ. 2021 Nov 28;375:e067507. doi: 10.1136/bmj-2021-067507.
Tal Patalon, Sivan Gazit, Virginia E Pitzer et al.

Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine

JAMA Intern Med. 2021 Nov 30;e217382. doi: 10.1001/jamainternmed.2021.7382.
Arash Alavi, Gireesh K Bogu, Meng Wang et al.

Real-time alerting system for COVID-19 and other stress events using wearable data

Nat Med. 2021 Nov 29. doi: 10.1038/s41591-021-01593-2.
Baoling Ying, Bradley Whitener, Laura A VanBlargan et al.

Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains

Sci Transl Med. 2021 Nov 30;eabm3302. doi: 10.1126/scitranslmed.abm3302.
Daniel Wendisch, Oliver Dietrich, Tommaso Mari et al.

SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis

Cell. 2021 Nov 26;S0092-8674(21)01383-0. doi: 10.1016/j.cell.2021.11.033.
Laurin Kasehagen, Paul Byers, Kathryn Taylor et al.

COVID-19-Associated Deaths After SARS-CoV-2 Infection During Pregnancy - Mississippi, March 1, 2020-October 6, 2021

MMWR Morb Mortal Wkly Rep. 2021 Nov 26;70(47):1646-1648. doi: 10.15585/mmwr.mm7047e2.
Cristina Rodríguez-Grande, Luis Alcalá, Agustín Estévez et al.

Systematic Genomic and Clinical Analysis of Severe Acute Respiratory Syndrome Coronavirus 2 Reinfections and Recurrences Involving the Same Strain

Emerg Infect Dis. 2021 Nov 29;28(1). doi: 10.3201/eid2801.211952.
Tom Lawton, Matt Butler, Christine Peters

Airborne protection for staff is associated with reduced hospital-acquired COVID-19 in English NHS Trusts

J Hosp Infect. 2021 Nov 30;S0195-6701(21)00427-8. doi: 10.1016/j.jhin.2021.11.018.
Brian Grunau, Michael Asamoah-Boaheng, Pascal M Lavoie et al.

A Higher Antibody Response Is Generated With a 6- to 7-Week (vs Standard) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Dosing Interval

Clin Infect Dis. 2021 Nov 30;ciab938. doi: 10.1093/cid/ciab938.
Maria Zavala, Georgina Ireland, Zahin Amin-Chowdhury, Mary E Ramsay, Shamez N Ladhani

Acute and persistent symptoms in children with PCR-confirmed SARS-CoV-2 infection compared to test-negative children in England: active, prospective, national surveillance

Clin Infect Dis. 2021 Nov 29;ciab991. doi: 10.1093/cid/ciab991.
Mayan Gilboa, Michal Mandelboim, Victoria Indenbaum et al.

Early Immunogenicity and safety of the third dose of BNT162b2 mRNA Covid-19 vaccine among adults older than 60 years; real world experience

J Infect Dis. 2021 Nov 29;jiab584. doi: 10.1093/infdis/jiab584.
Anna Jeffery-Smith, Alice R Burton, Sabela Lens et al.

SARS-CoV-2-specific memory B cells can persist in the elderly who have lost detectable neutralising antibodies

J Clin Invest. 2021 Nov 29;e152042. doi: 10.1172/JCI152042.
William J Murphy, Dan L Longo

A Possible Role for Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination

N Engl J Med. 2021 Nov 24. doi: 10.1056/NEJMcibr2113694.
Laith J Abu-Raddad, Hiam Chemaitelly, Roberto Bertollini, National Study Group for COVID-19 Epidemiology

Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections

N Engl J Med. 2021 Nov 24. doi: 10.1056/NEJMc2108120.
Constance Delaugerre, Frantz Foissac, Hendy Abdoul, et al.

Prevention of SARS-CoV-2 transmission during a large, live, indoor gathering (SPRING): a non-inferiority, randomised, controlled trial

Lancet Infect Dis. 2021 Nov 26;S1473-3099(21)00673-3. doi: 10.1016/S1473-3099(21)00673-3.
Jean-Pierre Gangneux, Eric Dannaoui, Arnaud Fekkar, et al.

Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study

Lancet Respir Med. 2021 Nov 26;S2213-2600(21)00442-2. doi: 10.1016/S2213-2600(21)00442-2.
Ramachandran Thiruvengadam, Amit Awasthi, Guruprasad Medigeshi et al.

Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses

Lancet Infect Dis. 2021 Nov 25;S1473-3099(21)00680-0. doi: 10.1016/S1473-3099(21)00680-0.
Meriem Bekliz, Kenneth Adea, Manel Essaidi-Laziosi et al.

SARS-CoV-2 antigen-detecting rapid tests for the delta variant

Lancet Microbe. 2021 Nov 24. doi: 10.1016/S2666-5247(21)00302-5.
Devashish Desai, Adil Rashid Khan, Manish Soneja et al.

Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study

Lancet Infect Dis. 2021 Nov 23;S1473-3099(21)00674-5. doi: 10.1016/S1473-3099(21)00674-5.
Peter G Kremsner, Rodolfo Andrés Ahuad Guerrero, Eunate Arana-Arri et al.

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

Lancet Infect Dis. 2021 Nov 23;S1473-3099(21)00677-0. doi: 10.1016/S1473-3099(21)00677-0.
Ariel Israel, Eugene Merzon, Alejandro A Schäffer et al.

Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study

BMJ. 2021 Nov 24;375:e067873. doi: 10.1136/bmj-2021-067873.
Annette Mollerup, Marius Henriksen, Sofus Christian Larsen et al.

Effect of PEP flute self-care versus usual care in early covid-19: non-drug, open label, randomised controlled trial in a Danish community setting

BMJ. 2021 Nov 24;375:e066952. doi: 10.1136/bmj-2021-066952.
Marie Joelle Jabagi, Jérémie Botton, Marion Bertrand et al.

Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older

JAMA. 2021 Nov 22. doi: 10.1001/jama.2021.21699.
Jeremy Samuel Faust, Alexander Junxiang Chen, Max Jordan Nguemeni Tiako et al.

Leading Causes of Death Among Adults Aged 25 to 44 Years by Race and Ethnicity in Texas During the COVID-19 Pandemic, March to December 2020

JAMA Intern Med. 2021 Nov 22. doi: 10.1001/jamainternmed.2021.6734.
Brian M Clemency, Renoj Varughese, Yaneicy Gonzalez-Rojas et al.

Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19: A Randomized Clinical Trial

JAMA Intern Med. 2021 Nov 22. doi: 10.1001/jamainternmed.2021.6759.
Heidi Preis, Marci Lobel, Brittain Mahaffey, Susmita Pati

Association of Discrimination and Health Care Experiences With Incomplete Infant Vaccination During COVID-19

JAMA Pediatr. 2021 Nov 22. doi: 10.1001/jamapediatrics.2021.4710.
Deepali Kumar, Victor H Ferreira, Victoria G Hall et al.

Neutralization of SARS-CoV-2 Variants in Transplant Recipients After Two and Three Doses of mRNA-1273 Vaccine : Secondary Analysis of a Randomized Trial

Ann Intern Med. 2021 Nov 23. doi: 10.7326/M21-3480.
Akatsuki Saito, Takashi Irie, Rigel Suzuki et al.

Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation

Nature. 2021 Nov 25. doi: 10.1038/s41586-021-04266-9.
Yang Liu, Jianying Liu, Kenneth S Plante et al.

The N501Y spike substitution enhances SARS-CoV-2 infection and transmission

Nature. 2021 Nov 24. doi: 10.1038/s41586-021-04245-0.
Jonas S Heitmann, Tatjana Bilich, Claudia Tandler et al.

A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity

Nature. 2021 Nov 23. doi: 10.1038/s41586-021-04232-5.
Lok-Yin Roy Wong, Stanley Perlman

Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses - are we our own worst enemy?

Nat Rev Immunol. 2021 Nov 26;1-10. doi: 10.1038/s41577-021-00656-2.
Peter B Gilbert, David C Montefiori, Adrian B McDermott et al.

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Science. 2021 Nov 23;eab3425. doi: 10.1126/science.abm3425.
Mary Bushman, Rebecca Kahn, Bradford P Taylor et al.

Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape

Cell. 2021 Nov 18;S0092-8674(21)01374-X. doi: 10.1016/j.cell.2021.11.026.
Anges Yadouleton, Anna-Lena Sander, Praise Adewumi et al.

Emergence of SARS-CoV-2 Delta Variant, Benin, May-July 2021

Emerg Infect Dis. 2021 Nov 22;28(1). doi: 10.3201/eid2801.211909.
Ido Somekh, Eric A F Simões, Eli Somekh

Coronavirus Disease Spread during Summer Vacation, Israel, 2020

Emerg Infect Dis. 2021 Nov 24;28(1). doi: 10.3201/eid2801.210177.
Chiara Sacco, Alberto Mateo-Urdiales, Daniele Petrone et al.

Estimating averted COVID-19 cases, hospitalisations, intensive care unit admissions and deaths by COVID-19 vaccination, Italy, January-September 2021

Euro Surveill. 2021 Nov;26(47). doi: 10.2807/1560-7917.ES.2021.26.47.2101001.
Margaux Mi Meslé, Jeremy Brown, Piers Mook et al.

Estimated number of deaths directly averted in people 60 years and older as a result of COVID-19 vaccination in the WHO European Region, December 2020 to November 2021

Euro Surveill. 2021 Nov;26(47). doi: 10.2807/1560-7917.ES.2021.26.47.2101021.
David Leeman, Thomas Ma, Melanie Pathiraja et al.

COVID-19 Nosocomial Transmission Dynamics, a Retrospective Cohort Study of Two Healthcare Associated Clusters in a District Hospital in England during March and April 2020

Infect Control Hosp Epidemiol. 2021 Nov 22;1-18. doi: 10.1017/ice.2021.483.
Ermias D Belay, Shana Godfred Cato, Agam K Rao et al.

Multisystem Inflammatory Syndrome in Adults after SARS-CoV-2 infection and COVID-19 vaccination

Clin Infect Dis. 2021 Nov 28;ciab936. doi: 10.1093/cid/ciab936.
Chloé Dimeglio, Fabrice Herin, Isabelle Da-Silva et al.

Post-vaccination SARS-CoV-2 antibody kinetics and protection duration

Clin Infect Dis. 2021 Nov 27;ciab984. doi: 10.1093/cid/ciab984.
Sabina Sahanic, Piotr Tymoszuk, Dietmar Ausserhofer et al.

Phenotyping of acute and persistent COVID-19 features in the outpatient setting: exploratory analysis of an international cross-sectional online survey

Clin Infect Dis. 2021 Nov 26;ciab978. doi: 10.1093/cid/ciab978.
Sivan Gazit, Barak Mizrahi, Nir Kalkstein et al.

BNT162b2 mRNA Vaccine Effectiveness Given Confirmed Exposure: Analysis of Household Members of COVID-19 Patients

Clin Infect Dis. 2021 Nov 24;ciab973. doi: 10.1093/cid/ciab973.
Katie R Mollan, Joseph J Eron, Taylor J Krajewski et al.

Infectious SARS-CoV-2 Virus in Symptomatic COVID-19 Outpatients: Host, Disease, and Viral Correlates

Clin Infect Dis. 2021 Nov 23;ciab968. doi: 10.1093/cid/ciab968.
Jonathon D Kotwa, Alainna J Jamal, Hamza Mbareche et al.

Surface and air contamination with SARS-CoV-2 from hospitalized COVID-19 patients in Toronto, Canada, March-May 2020

J Infect Dis. 2021 Nov 27;jiab578. doi: 10.1093/infdis/jiab578.
Ji Yeun Kim, So Yun Lim, Soonju Park et al.

Immune responses to the ChAdOx1 nCoV-19 and BNT162b2 vaccines and to natural COVID-19 infections over a three-month period

J Infect Dis. 2021 Nov 25;jiab579. doi: 10.1093/infdis/jiab579.
Valeria Ochoa, Fernando Erra Díaz, Ezequiel Ramirez et al.

Infants younger than 6 months old infected by SARS-CoV-2 show the highest respiratory viral loads

J Infect Dis. 2021 Nov 24;jiab577. doi: 10.1093/infdis/jiab577.
RECOVERY Collaborative Group

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Lancet. 2021 Nov 17;S0140-6736(21)01825-0. doi: 10.1016/S0140-6736(21)01825-0.
Seth Toback, Eva Galiza, Catherine Cosgrove et al.

Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial

Lancet Respir Med. 2021 Nov 17;S2213-2600(21)00409-4. doi: 10.1016/S2213-2600(21)00409-4.
Scarlett Sett, Carolina Dos Santos Ribeiro, Christine Prat et al.

Access and benefit-sharing by the European Virus Archive in response to COVID-19

Lancet Microbe. 2021 Nov 16. doi: 10.1016/S2666-5247(21)00211-1.
Saad B Omer, Regina M Benjamin, Noel T Brewer et al.

Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA

Lancet. 2021 Nov 15;S0140-6736(21)02507-1. doi: 10.1016/S0140-6736(21)02507-1.
Deborah Cromer, Megan Steain, Arnold Reynaldi et al.

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis

Lancet Microbe. 2021 Nov 15. doi: 10.1016/S2666-5247(21)00267-6.
Stella Talic, Shivangi Shah, Holly Wild et al.

Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis

BMJ. 2021 Nov 17;375:e068302. doi: 10.1136/bmj-2021-068302.
M Kit Delgado, Anna U Morgan, David A Asch et al.

Comparative Effectiveness of an Automated Text Messaging Service for Monitoring COVID-19 at Home

Ann Intern Med. 2021 Nov 16. doi: 10.7326/M21-2019.
Roger Chou, Tracy Dana, David I Buckley et al.

Update Alert 10: Epidemiology of and Risk Factors for Coronavirus Infection in Health Care Workers

Ann Intern Med. 2021 Nov 16;M21-4294. doi: 10.7326/M21-4294.
Makda S Gebre, Susanne Rauch, Nicole Roth et al.

Optimization of Non-Coding Regions for a Non-Modified mRNA COVID-19 Vaccine

Nature. 2021 Nov 18. doi: 10.1038/s41586-021-04231-6.
Manuel Ruiz-Aravena, Clifton McKee, Amandine Gamble et al.

Ecology, evolution and spillover of coronaviruses from bats

Nat Rev Microbiol. 2021 Nov 19;1-16. doi: 10.1038/s41579-021-00652-2.
Michael Worobey

Dissecting the early COVID-19 cases in Wuhan

Science. 2021 Nov 18;eabm4454. doi: 10.1126/science.abm4454.
Yinghong Xiao, Peter V Lidsky, Yuta Shirogane

A defective viral genome strategy elicits broad protective immunity against respiratory viruses

Cell. 2021 Nov 17;S0092-8674(21)01338-6. doi: 10.1016/j.cell.2021.11.023.
Carla L DeSisto, Bailey Wallace, Regina M Simeone et al.

Risk for Stillbirth Among Women With and Without COVID-19 at Delivery Hospitalization - United States, March 2020-September 2021

MMWR Morb Mortal Wkly Rep. 2021 Nov 26;70(47):1640-1645. doi: 10.15585/mmwr.mm7047e1.
Allison L Naleway, Holly C Groom, Phil M Crawford et al.

Incidence of SARS-CoV-2 Infection, Emergency Department Visits, and Hospitalizations Because of COVID-19 Among Persons Aged ≥12 Years, by COVID-19 Vaccination Status - Oregon and Washington, July 4-September 25, 2021

MMWR Morb Mortal Wkly Rep. 2021 Nov 19;70(46):1608-1612. doi: 10.15585/mmwr.mm7046a4.
Gail L Sondermeyer Cooksey, Christina Morales, Lauren Linde et al.

Severe Acute Respiratory Syndrome Coronavirus 2 and Respiratory Virus Sentinel Surveillance, California, USA, May 10, 2020–June 12, 2021

Emerg Infect Dis. 2021 Nov 15;28(1). doi: 10.3201/eid2801.211682.
Susan S Chiu, Benjamin J Cowling, J S Malik Peiris et al.

Effects of Nonpharmaceutical COVID-19 Interventions on Pediatric Hospitalizations for Other Respiratory Virus Infections, Hong Kong

Emerg Infect Dis. 2021 Nov 15;28(1). doi: 10.3201/eid2801.211099.
Radhika Gharpure, Samira Sami, Johanna Vostok et al.

Multistate Outbreak of SARS-CoV-2 Infections, Including Vaccine Breakthrough Infections, Associated with Large Public Gatherings, United States

Emerg Infect Dis. 2021 Nov 18;28(1). doi: 10.3201/eid2801.212220.
Rebecca Giddings, Maria Krutikov, Tom Palmer et al.

Changes in COVID-19 outbreak severity and duration in long-term care facilities following vaccine introduction, England, November 2020 to June 2021

Euro Surveill. 2021 Nov;26(46). doi: 10.2807/1560-7917.ES.2021.26.46.2100995.
Liselotte Diaz Högberg, Vera Vlahović-Palčevski, Cátia Pereira et al.

Decrease in community antibiotic consumption during the COVID-19 pandemic, EU/EEA, 2020

Euro Surveill. 2021 Nov;26(46). doi: 10.2807/1560-7917.ES.2021.26.46.2101020.
Viviane Maria de Carvalho Hessel Dias, Felipe Francisco Tuon, Patrícia de Jesus Capelo et al.

Trend analysis of carbapenem-resistant Gram-negative bacteria and antimicrobial consumption in the post-COVID-19 era, an extra challenge for healthcare institutions

J Hosp Infect. 2021 Nov 19;S0195-6701(21)00409-6. doi: 10.1016/j.jhin.2021.11.011.
Rohit Vijh, H Carmen, Mehdi Shirmaleki, Aamir Bharmal

Factors associated with transmission of COVID-19 in long-term care facility outbreaks

J Hosp Infect. 2021 Nov 19;S0195-6701(21)00406-0. doi: 10.1016/j.jhin.2021.11.008.
Helen L Zhang, Brendan J Kelly, Michael Z David et al.

SARS-CoV-2 surface contamination in staff common areas and impact on healthcare worker infection: prospective surveillance during the COVID-19 pandemic

Infect Control Hosp Epidemiol. 2021 Nov 15;1-10. doi: 10.1017/ice.2021.468.
David H Canaday, Oladayo A Oyebanji, Debbie Keresztesy et al.

Significant reduction in vaccine-induced antibody levels and neutralization activity among healthcare workers and nursing home residents 6 months following COVID-19 BNT162b2 mRNA vaccination

Clin Infect Dis. 2021 Nov 19;ciab963. doi: 10.1093/cid/ciab963.
Chuan Huan Chuah, Ting Soo Chow, Chee Peng Hor et al.

Efficacy of Early Treatment with Favipiravir on Disease Progression among High Risk COVID-19 Patients: A Randomized, Open-Label Clinical Trial

Clin Infect Dis. 2021 Nov 19;ciab962. doi: 10.1093/cid/ciab962.
Jennifer Gilner, Namita Kansal, Joseph R Biggio et al.

Universal SARS-CoV-2 testing for obstetric inpatient units across the United States

Clin Infect Dis. 2021 Nov 17;ciab955. doi: 10.1093/cid/ciab955.
Tiffany G Harris, Edward Jaszi, Matthew R Lamb et al.

Effects of the COVID-19 Pandemic on HIV Services: Findings from 11 Sub-Saharan African Countries

Clin Infect Dis. 2021 Nov 15;ciab951. doi: 10.1093/cid/ciab951.
Lara J Akinbami, Brad J Biggerstaff, Philip A Chan et al.

Reinfection with SARS-CoV-2 among previously infected healthcare personnel and first responders

Clin Infect Dis. 2021 Nov 15;ciab952. doi: 10.1093/cid/ciab952.
John B Lynch, Perica Davitkov, Deverick J Anderson et al.

Infectious Diseases Society of America Guidelines on Infection Prevention for Healthcare Personnel Caring for Patients with Suspected or Known COVID-19

Clin Infect Dis. 2021 Nov 15;ciab953. doi: 10.1093/cid/ciab953.
Cristina Lorca-Oró, Jordi Vila, Patricia Pleguezuelos et al.

Rapid SARS-CoV-2 inactivation in hospital-room like conditions using a mobile and autonomous ultraviolet C (UVC)-light robot

J Infect Dis. 2021 Nov 20;jiab551. doi: 10.1093/infdis/jiab551.
Donna Ambrosino, Htay Htay Han, Branda Hu et al.

Immunogenicity of SCB-2019 COVID-19 Vaccine Compared With Four Approved Vaccines

J Infect Dis. 2021 Nov 19;jiab574. doi: 10.1093/infdis/jiab574.
Ai-Ris Y Collier, Jingyou Yu, Katherine Mcmahan et al.

COVID-19 mRNA Vaccine Immunogenicity in Immunosuppressed Individuals

J Infect Dis. 2021 Nov 18;jiab569. doi: 10.1093/infdis/jiab569.
Dennis M Bierle, Ravindra Ganesh, Sidna Tulledge-Scheitel et al.

Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities

J Infect Dis. 2021 Nov 16;jiab570. doi: 10.1093/infdis/jiab570.
Katharine J Bar, Pamela A Shaw, Grace H Choi et al.

A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia

J Clin Invest. 2021 Nov 17;e155114. doi: 10.1172/JCI155114.
Emmanuel B Walter, Kawsar R Talaat, Charu Sabharwal et al.

Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age

N Engl J Med. 2021 Nov 9. doi: 10.1056/NEJMoa2116298.
Raches Ella, Siddarth Reddy, William Blackwelder et al.

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial

Lancet. 2021 Nov 11;S0140-6736(21)02000-6. doi: 10.1016/S0140-6736(21)02000-6.
Rajeka Lazarus, Sarah Baos, Heike Cappel-Porter et al.

Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial

Lancet. 2021 Nov 11;S0140-6736(21)02329-1. doi: 10.1016/S0140-6736(21)02329-1.
Aurélien Mazeraud, Matthieu Jamme, Rossella Letizia Mancusi et al.

Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial

Lancet Respir Med. 2021 Nov 11;S2213-2600(21)00440-9. doi: 10.1016/S2213-2600(21)00440-9.
Prashant Nasa, Elie Azoulay, Arunaloke Chakrabarti et al.

Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method

Lancet Infect Dis. 2021 Nov 10;S1473-3099(21)00626-5. doi: 10.1016/S1473-3099(21)00626-5.
Sampath Weerakkody, Pietro Arina, James Glenister et al.

Non-invasive respiratory support in the management of acute COVID-19 pneumonia: considerations for clinical practice and priorities for research

Lancet Respir Med. 2021 Nov 9;S2213-2600(21)00414-8. doi: 10.1016/S2213-2600(21)00414-8.
Adrienn Angyal, Stephanie Longet, Shona C Moore et al.

T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study

Lancet Microbe. 2021 Nov 9. doi: 10.1016/S2666-5247(21)00275-5.
Sudhvir Singh, Christine McNab, Rose McKeon Olson et al.

How an outbreak became a pandemic: a chronological analysis of crucial junctures and international obligations in the early months of the COVID-19 pandemic

Lancet. 2021 Nov 8;S0140-6736(21)01897-3. doi: 10.1016/S0140-6736(21)01897-3.
Bridget E Young, Antti E Seppo, Nichole Diaz et al.

Association of Human Milk Antibody Induction, Persistence, and Neutralizing Capacity With SARS-CoV-2 Infection vs mRNA Vaccination

JAMA Pediatr. 2021 Nov 10. doi: 10.1001/jamapediatrics.2021.4897.
Joane Matta, Emmanuel Wiernik, Olivier Robineau et al.

Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic

JAMA Intern Med. 2021 Nov 8. doi: 10.1001/jamainternmed.2021.6454.
Leo Swadling, Mariana O Diniz, Nathalie M Schmidt et al.

Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2

Nature. 2021 Nov 10. doi: 10.1038/s41586-021-04186-8.
Clare Smith, David Odd, Rachel Harwood et al.

Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year

Nat Med. 2021 Nov 11. doi: 10.1038/s41591-021-01578-1.
Matthew McCallum, Alexandra C Walls, Kaitlin R Sprouse et al.

Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants

Science. 2021 Nov 9;eabl8506. doi: 10.1126/science.abl8506.
Kate R Woodworth, Danielle Moulia, Jennifer P Collins et al.

The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5-11 Years - United States, November 2021

MMWR Morb Mortal Wkly Rep. 2021 Nov 12;70(45):1579-1583. doi: 10.15585/mmwr.mm7045e1.
Maria Skaalum Petersen, Marin Strøm, Jógvan Páll Fjallsbak et al.

Low Seroprevalence among Undetected COVID-19 Cases, Faroe Islands, November 2020

Emerg Infect Dis. 2021 Nov 10;28(1). doi: 10.3201/eid2801.210917.
Hyon Jin Jeon, Florian Marks, Jonathan Sugimoto et al.

Surge of Typhoid Intestinal Perforations as Possible Result of COVID-19-Associated Delays in Seeking Care, Madagascar

Emerg Infect Dis. 2021 Nov 8;27(12). doi: 10.3201/eid2712.210516.
Neta Zuckerman, Ital Nemet, Limor Kliker et al.

The SARS-CoV-2 Lambda variant and its neutralisation efficiency following vaccination with Comirnaty, Israel, April to June 2021

Euro Surveill. 2021 Nov;26(45). doi: 10.2807/1560-7917.ES.2021.26.45.2100974.
Kimberley Sm Benschop, Jan Albert, Andres Anton et al.

Re-emergence of enterovirus D68 in Europe after easing the COVID-19 lockdown, September 2021

Euro Surveill. 2021 Nov;26(45). doi: 10.2807/1560-7917.ES.2021.26.45.2100998.
Ivo Van Walle, Katrin Leitmeyer, Eeva K Broberg, European COVID-19 microbiological laboratories group

Meta-analysis of the clinical performance of commercial SARS-CoV-2 nucleic acid and antibody tests up to 22 August 2020

Euro Surveill. 2021 Nov;26(45). doi: 10.2807/1560-7917.ES.2021.26.45.2001675.
Yueyang Zhong, Kai Wang, Yanan Zhu et al.

Ocular manifestations in COVID-19 patients: A systematic review and meta-analysis

Travel Med Infect Dis. 2021 Nov 8;44:102191. doi: 10.1016/j.tmaid.2021.102191.
Pierre-Henri Moury, Ann-Claire Gourinat, Olivier Riou et al.

Successful COVID-19 elimination after an alpha variant outbreak in a "safe travel zone"

Travel Med Infect Dis. 2021 Nov 10;44:102202. doi: 10.1016/j.tmaid.2021.102202.
Ellen Kim, Charles Morris, Michael Klompas et al.

COVID-19 screening system utilizing daily symptom attestation helps identify hospital employees who should be tested to protect patients and co-workers

Infect Control Hosp Epidemiol. 2021 Nov 10;1-17. doi: 10.1017/ice.2021.461.
L Leigh Smith, Aaron M Milstone, Morgan Jibowu et al.

Transmission of SARS-CoV-2 Virus, Delta Variant, Between Two Fully Vaccinated Healthcare Personnel

Infect Control Hosp Epidemiol. 2021 Nov 8;1-5. doi: 10.1017/ice.2021.469.
Zhong-Jie Li, Lin-Jie Yu, Hai-Yang Zhang et al.

Broad impacts of COVID-19 pandemic on acute respiratory infections in China: an observational study

Clin Infect Dis. 2021 Nov 12;ciab942. doi: 10.1093/cid/ciab942.
David J Bean, Janet Monroe, Jacquelyn Turcinovic et al.

SARS-CoV-2 reinfection associates with unstable housing and occurs in the presence of antibodies

Clin Infect Dis. 2021 Nov 10;ciab940. doi: 10.1093/cid/ciab940.
Karina-Doris Vihta, Koen B Pouwels, Tim Peto et al.

Symptoms and SARS-CoV-2 positivity in the general population in the UK

Clin Infect Dis. 2021 Nov 8;ciab945. doi: 10.1093/cid/ciab945.
Kathrine Agergård Kaspersen, Lotte Hindhede, Jens Kjærgaard Boldsen et al.

Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark

J Infect Dis. 2021 Nov 12;jiab566. doi: 10.1093/infdis/jiab566.
Anne-Laure Lebreil, Vincent Greux, Marie Glenet et al.

Surfaces and Air contamination by SARS-CoV-2 using High-flow Nasal Oxygenation or Assisted Mechanical Ventilation System in ICU rooms of COVID-19 Patients

J Infect Dis. 2021 Nov 12;jiab564. doi: 10.1093/infdis/jiab564.
Susan Johnson, Clarissa I Martinez, Sarah N Tedjakusuma et al.

Oral vaccination protects against SARS-CoV-2 in a Syrian hamster challenge model

J Infect Dis. 2021 Nov 10;jiab561. doi: 10.1093/infdis/jiab561.
Dung Nguyen, Julie Xiao, Peter Simmonds et al.

Effects of SARS-CoV-2 strain variation on virus neutralisation titres: therapeutic use of convalescent plasma

J Infect Dis. 2021 Nov 9;jiab563. doi: 10.1093/infdis/jiab563.
Federica Pulvirenti, Cinzia Milito, Francesco Cinetto et al.

SARS-CoV-2 monoclonal antibody combination therapy in patients with COVID-19 and primary antibody deficiency

J Infect Dis. 2021 Nov 8;jiab554. doi: 10.1093/infdis/jiab554.
Lindsey R Baden, Hana M El Sahly, Brandon Essink et al.

Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge

N Engl J Med. 2021 Nov 3. doi: 10.1056/NEJMc2115597.
Keiya Uriu, Izumi Kimura, Kotaro Shirakawa et al.

Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum

N Engl J Med. 2021 Nov 3. doi: 10.1056/NEJMc2114706.
Lucy A McNamara, Ryan E Wiegand, Rachel M Burke et al.

Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance data

Lancet. 2021 Nov 3;S0140-6736(21)02226-1. doi: 10.1016/S0140-6736(21)02226-1.
Nazrul Islam, Dmitri A Jdanov, Vladimir M Shkolnikov et al.

Effects of covid-19 pandemic on life expectancy and premature mortality in 2020: time series analysis in 37 countries

BMJ. 2021 Nov 3;375:e066768. doi: 10.1136/bmj-2021-066768.
Nicole Ezer, Sara Belga, Nick Daneman et al.

Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial

BMJ. 2021 Nov 2;375:e068060. doi: 10.1136/bmj-2021-068060.
Noa Eliakim-Raz, Yaara Leibovici-Weisman, Amos Stemmer et al.

Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years

JAMA. 2021 Nov 5. doi: 10.1001/jama.2021.19885.
Mark W Tenforde, Wesley H Self, Katherine Adams et al.

Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity

JAMA. 2021 Nov 4. doi: 10.1001/jama.2021.19499.
Diana Zhong, Shaoming Xiao, Amanda K Debes et al.

Durability of Antibody Levels After Vaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection

JAMA. 2021 Nov 1. doi: 10.1001/jama.2021.19996.
Laith J Abu-Raddad, Hiam Chemaitelly, Houssein H Ayoub et al.

Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar

JAMA. 2021 Nov 1. doi: 10.1001/jama.2021.19623.
Aneel A Ashrani, Daniel J Crusan, Tanya Petterson, Kent Bailey, John A Heit

Age- and Sex-Specific Incidence of Cerebral Venous Sinus Thrombosis Associated With Ad26.COV2.S COVID-19 Vaccination

JAMA Intern Med. 2021 Nov 1. doi: 10.1001/jamainternmed.2021.6352.
César Boggiano, Robert W Eisinger, Andrea M Lerner et al.

Update on and Future Directions for Use of Anti-SARS-CoV-2 Antibodies: National Institutes of Health Summit on Treatment and Prevention of COVID-19

Ann Intern Med. 2021 Nov 2;M21-3669. doi: 10.7326/M21-3669.
Matan Levine-Tiefenbrun, Idan Yelin, Hillel Alapi et al.

Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2

Nat Med. 2021 Nov 2. doi: 10.1038/s41591-021-01575-4.
Patrick Tang, Mohammad R Hasan, Hiam Chemaitelly et al.

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar

Nat Med. 2021 Nov 2. doi: 10.1038/s41591-021-01583-4.
Abdullah M Syed, Taha Y Taha, Takako Tabata et al.

Rapid assessment of SARS-CoV-2 evolved variants using virus-like particles

Science. 2021 Nov 4;eabl6184. doi: 10.1126/science.abl6184.
Barbara A Cohn, Piera M Cirillo, Caitlin C Murphy, Nickilou Y Krigbaum, Arthur W Wallace

SARS-CoV-2 vaccine protection and deaths among US veterans during 2021

Science. 2021 Nov 4;eabm0620. doi: 10.1126/science.abm0620.
Paul Elliott, David Haw, Haowei Wang et al.

Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant

Science. 2021 Nov 2;eabl9551. doi: 10.1126/science.abl9551.
Dafydd R Owen, Charlotte M N Allerton, Annaliesa S Anderson et al.

An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19

Science. 2021 Nov 2;eabl4784. doi: 10.1126/science.abl4784.
Mona Khan, Seung-Jun Yoo, Marnick Clijsters et al.

Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb

Cell. 2021 Nov 2;S0092-8674(21)01282-4. doi: 10.1016/j.cell.2021.10.027.
Peter J Embi, Matthew E Levy, Allison L Naleway et al.

Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021

MMWR Morb Mortal Wkly Rep. 2021 Nov 5;70(44):1553-1559. doi: 10.15585/mmwr.mm7044e3.
Fabian Heinrich, Ann Sophie Schröder, Anna-Lina Gerberding et al.

Postmortem Antigen-Detecting Rapid Diagnostic Tests to Predict Infectivity of SARS-CoV-2-Associated Deaths

Emerg Infect Dis. 2021 Nov 2;28(1). doi: 10.3201/eid2801.211749.
Brechje de Gier, Stijn Andeweg, Jantien A Backer et al.

Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), the Netherlands, August to September 2021

Euro Surveill. 2021 Nov;26(44). doi: 10.2807/1560-7917.ES.2021.26.44.2100977.
Andreas Puyskens, Eva Krause, Janine Michel et al.

Establishment of a specimen panel for the decentralised technical evaluation of the sensitivity of 31 rapid diagnostic tests for SARS-CoV-2 antigen, Germany, September 2020 to April 2021

Euro Surveill. 2021 Nov;26(44). doi: 10.2807/1560-7917.ES.2021.26.44.2100442.
Heinrich Scheiblauer, Angela Filomena, Andreas Nitsche et al.

Comparative sensitivity evaluation for 122 CE-marked rapid diagnostic tests for SARS-CoV-2 antigen, Germany, September 2020 to April 2021

Euro Surveill. 2021 Nov;26(44). doi: 10.2807/1560-7917.ES.2021.26.44.2100441.
Sebastian Duchene, Leo Featherstone, Birgitte Freiesleben de Blasio et al.

The impact of public health interventions in the Nordic countries during the first year of SARS-CoV-2 transmission and evolution

Euro Surveill. 2021 Nov;26(44). doi: 10.2807/1560-7917.ES.2021.26.44.2001996.
Angelique E Boutzoukas, Kanecia O Zimmerman, Tara K Mann et al.

A School-Based SARS-CoV-2 Testing Program: Testing Uptake and Quarantine Length Following In-School Exposures

Pediatrics. 2021 Nov 4;e2021054268J. doi: 10.1542/peds.2021-054268J.
Kanecia O Zimmerman, Jennifer L Goldman, Jennifer E Schuster et al.

Building a National Framework to Pair Scientists and Schools During a Global Pandemic

Pediatrics. 2021 Nov 4;e2021054268D. doi: 10.1542/peds.2021-054268D.
Jennifer L Goldman, Jennifer E Schuster, Vanessa F Maier et al.

Urban Classification, Not COVID-19 Community Rates, Was Associated With Modes of Learning in US K-12 Schools

Pediatrics. 2021 Nov 4;e2021054268M. doi: 10.1542/peds.2021-054268M.
Ganga S Moorthy, Tara K Mann, Angelique E Boutzoukas et al.

Masking Adherence in K-12 Schools and SARS-CoV-2 Secondary Transmission

Pediatrics. 2021 Nov 4;e2021054268I. doi: 10.1542/peds.2021-054268I.
Angelique E Boutzoukas, Kanecia O Zimmerman, Daniel K Benjamin Jr et al.

Quarantine Elimination for K-12 Students With Mask-on-Mask Exposure to SARS-CoV-2

Pediatrics. 2021 Nov 4;e2021054268L. doi: 10.1542/peds.2021-054268L.
Angelique E Boutzoukas, Kanecia O Zimmerman, Daniel K Benjamin et al.

Secondary Transmission of COVID-19 in K-12 Schools: Findings From Two States

Pediatrics. 2021 Nov 4;e2021054268K. doi: 10.1542/peds.2021-054268K.
Emily E Haroz, Luther G Kalb, Jason G Newland et al.

Implementation of School-Based COVID-19 Testing Programs in Underserved Populations

Pediatrics. 2021 Nov 4;e2021054268G. doi: 10.1542/peds.2021-054268G.
Peter de Man, Marco Ortiz, Philomena M Bluyssen et al.

Airborne SARS-CoV-2 in home- and hospital environment investigated with a high-powered air sampler

J Hosp Infect. 2021 Nov 6;S0195-6701(21)00382-0. doi: 10.1016/j.jhin.2021.10.018.
Lisa Ferland, Carlos Carvalho, Joana Gomes Dias et al.

Risk of hospitalization and risk of death for health care workers with COVID-19 in nine European countries, January 2020-January 2021

J Hosp Infect. 2021 Nov 6;S0195-6701(21)00379-0. doi: 10.1016/j.jhin.2021.10.015.
Arthur H Totten, Ann Marie Matlock, Heike Bailin et al.

Experience with Voluntary SARS-CoV-2 Testing of Asymptomatic Staff at the National Institutes of Health for One Year

Infect Control Hosp Epidemiol. 2021 Nov 2;1-9. doi: 10.1017/ice.2021.458.
Elena Beam, Michelle L Meyer, John C O' Horo, Laura Breeher

False-negative nasopharyngeal severe acute respiratory coronavirus virus 2 (SARS-CoV-2) reverse-transcription polymerase chain reaction (RT-PCR) in immunocompromised patients resulting in healthcare worker exposures

infect Control Hosp Epidemiol. 2021 Nov 2;1-2. doi: 10.1017/ice.2021.447.
Sonali D Advani, Andrea Cromer, Brittain Wood et al.

The Impact of SARS-COV-2 Response on Hospital Infection Prevention Programs and Practices in Southeastern United States

Infect Control Hosp Epidemiol. 2021 Nov 2;1-12. doi: 10.1017/ice.2021.460.
Sharon Fawcett, Meghan Madhusudhan, Emily Gaddam et al.

Transmission risk of SARS-CoV-2 to healthcare personnel following unanticipated exposure to aerosol generating procedures: Experience from epidemiologic investigations at an academic medical center

Infect Control Hosp Epidemiol. 2021 Nov 2;1-10. doi: 10.1017/ice.2021.472.
Vicki Myers, Mor Saban, Shani Ben-Shetrit, Rachel Wilf-Miron

Uptake of coronavirus disease 2019 (COVID-19) vaccination among general hospital staff in Israel

Infect Control Hosp Epidemiol. 2021 Nov 2;1-3. doi: 10.1017/ice.2021.451.
Chia-En Lien, Tsun-Yung Kuo, Yi-Jiun Lin et al.

Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern

Clin Infect Dis. 2021 Nov 5;ciab711. doi: 10.1093/cid/ciab711.
Alexander L Greninger, Jennifer Dien Bard, Robert C Colgrove et al.

Clinical and Infection Prevention Applications of SARS-CoV-2 Genotyping: An IDSA/ASM Consensus Review Document

Clin Infect Dis. 2021 Nov 3;ciab761. doi: 10.1093/cid/ciab761.
Yalile Perez, Emily R Levy, Avni Y Joshi et al.

Myocarditis Following COVID-19 mRNA Vaccine: A Case Series and Incidence Rate Determination

Clin Infect Dis. 2021 Nov 3;ciab926. doi: 10.1093/cid/ciab926.
Wendelyn Bosch, Jennifer B Cowart, Shivang Bhakta et al.

COVID-19 Vaccine-Breakthrough Infections Requiring Hospitalization in Mayo Clinic Florida through August 2021

Clin Infect Dis. 2021 Nov 2;ciab932. doi: 10.1093/cid/ciab932.
Amy C Sherman, Michaël Desjardins, Chi An Cheng et al.

SARS-CoV-2 mRNA Vaccines in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Immunogenicity and Reactogenicity

Clin Infect Dis. 2021 Nov 2;ciab930. doi: 10.1093/cid/ciab930.
Yaki Saciuk, Jennifer Kertes, Naama Shamir Stein, Anat Ekka Zohar

Effectiveness of a third dose of BNT162b2 mRNA vaccine

J Infect Dis. 2021 Nov 2;jiab556. doi: 10.1093/infdis/jiab556.
Catherine H Bozio, Shaun J Grannis, Allison L Naleway et al.

Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021

MMWR Morb Mortal Wkly Rep. 2021 Nov 5;70(44):1539-1544. doi: 10.15585/mmwr.mm7044e1.
Sarah Mbaeyi, Sara E Oliver, Jennifer P Collins et al.

The Advisory Committee on Immunization Practices’ Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines - United States, 2021

MMWR Morb Mortal Wkly Rep. 2021 Nov 5;70(44):1545-1552. doi: 10.15585/mmwr.mm7044e2.
October 2021
Erica K Susky, Susy Hota, Irene E Armstrong et al.

Hospital Outbreak of the SARS-CoV-2 Delta Variant in Partially and Fully Vaccinated Patients and Healthcare Workers in Toronto, Canada

Infect Control Hosp Epidemiol. 2021 Oct 28;1-10. doi: 10.1017/ice.2021.471.
Halah Ibrahim, Husameldeen M Korgly, Sarah A Misfar et al.

The effect of surgical face masks on oxygenation and respiratory rate in hospitalized patients with coronavirus disease 2019 (COVID-19)

Infect Control Hosp Epidemiol. 2021 Oct 27;1-3. doi: 10.1017/ice.2021.470.
Denis Mongin, Gaud Catho, Anne Iten, Stephan Harbarth, Delphine S Courvoisier

Incidence of healthcare-associated coronavirus disease 2019 (COVID-19) in the state of Geneva

Infect Control Hosp Epidemiol. 2021 Oct 25;1-3. doi: 10.1017/ice.2021.453.
Anil Gupta, Yaneicy Gonzalez-Rojas, Erick Juarez et al.

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

N Engl J Med. 2021 Oct 27. doi: 10.1056/NEJMoa2107934.
Yair Goldberg, Micha Mandel, Yinon M Bar-On et al.

Waning Immunity after the BNT162b2 Vaccine in Israel

N Engl J Med. 2021 Oct 27. doi: 10.1056/NEJMoa2114228.
Noam Barda, Noa Dagan, Cyrille Cohen et al.

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study

Lancet. 2021 Oct 29;S0140-6736(21)02249-2. doi: 10.1016/S0140-6736(21)02249-2.
Anika Singanayagam, Seran Hakki, Jake Dunning, et al.

Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study

Lancet Infect Dis. 2021 Oct 29;S1473-3099(21)00648-4. doi: 10.1016/S1473-3099(21)00648-4.
Zoe Grange, Audrey Buelo, Christopher Sullivan et al.

Characteristics and risk of COVID-19-related death in fully vaccinated people in Scotland

Lancet. 2021 Oct 28;S0140-6736(21)02316-3. doi: 10.1016/S0140-6736(21)02316-3.
Raphael Sonabend, Lilith K Whittles, Natsuko Imai et al.

Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study

Lancet. 2021 Oct 27;S0140-6736(21)02276-5. doi: 10.1016/S0140-6736(21)02276-5.
Ivana Knezevic, Giada Mattiuzzo, Mark Page et al.

WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community

Lancet Microbe. 2021 Oct 26. doi: 10.1016/S2666-5247(21)00266-4.
Marwan Saad, Kevin F Kennedy, Hafiz Imran et al.

Association Between COVID-19 Diagnosis and In-Hospital Mortality in Patients Hospitalized With ST-Segment Elevation Myocardial Infarction

JAMA. 2021 Oct 29. doi: 10.1001/jama.2021.18890.
Charlene A Wong, William Pilkington, Irene A Doherty et al.

Guaranteed Financial Incentives for COVID-19 Vaccination: A Pilot Program in North Carolina

JAMA Intern Med. 2021 Oct 25. doi: 10.1001/jamainternmed.2021.6170.
David L Paterson, Claire M Rickard

Letter From Australia: A Never-Ending Pandemic?

Ann Intern Med. 2021 Oct 26. doi: 10.7326/M21-3295.
Jessica T Davis, Matteo Chinazzi, Nicola Perra et al.

Cryptic transmission of SARS-CoV-2 and the first COVID-19 wave

Nature. 2021 Oct 25. doi: 10.1038/s41586-021-04130-w.
Mario Witkowski, Caroline Tizian, Marta Ferreira-Gomes et al.

Untimely TGFβ responses in COVID-19 limit antiviral functions of NK cells

Nature. 2021 Oct 25. doi: 10.1038/s41586-021-04142-6.
Martina Patone, Lahiru Handunnetthi, Defne Saatci et al.

Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection

Nat Med. 2021 Oct 25. doi: 10.1038/s41591-021-01556-7.
Kentaro Fukumoto, Charles T McClean, Kuninori Nakagawa

No causal effect of school closures in Japan on the spread of COVID-19 in spring 2020

Nat Med. 2021 Oct 27. doi: 10.1038/s41591-021-01571-8.
Zeynep Ertem, Elissa M Schechter-Perkins, Emily Oster et al.

The impact of school opening model on SARS-CoV-2 community incidence and mortality

Nat Med. 2021 Oct 27. doi: 10.1038/s41591-021-01563-8.
Jun Zhang, Tianshu Xiao, Yongfei Cai et al.

Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant

Science. 2021 Oct 26;eabl9463. doi: 10.1126/science.abl9463.
Simone Lanini, Stefania Capone, Andrea Antinori et al.

GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults

Sci Transl Med. 2021 Oct 26;eabj1996. doi: 10.1126/scitranslmed.abj1996.
Deborah L Burnett, Katherine J L Jackson, David B Langley et al.

Immunizations with diverse sarbecovirus receptor binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability

Immunity. 2021 Oct 28. doi: 10.1016/j.immuni.2021.10.019.
Ravi Kant, Phuoc Truong Nguyen, Soile Blomqvist et al.

Incidence Trends for SARS-CoV-2 Alpha and Beta Variants, Finland, Spring 2021

Emerg Infect Dis. 2021 Oct 27;27(12). doi: 10.3201/eid2712.211631.
Daniel Lule Bugembe, My V T Phan, Abe G Abias et al.

SARS-CoV-2 Variants, South Sudan, January-March 2021

Emerg Infect Dis. 2021 Oct 27;27(12). doi: 10.3201/eid2712.211488.
Victoria L Fields, Ian T Kracalik, Christina Carthel et al.

Coronavirus Disease Contact Tracing Outcomes and Cost, Salt Lake County, Utah, USA, March-May 2020

Emerg Infect Dis. 2021 Oct 26;27(12). doi: 10.3201/eid2712.210505.
Claudia Schulz, Byron Martina, Monica Mirolo et al.

SARS-CoV-2-Specific Antibodies in Domestic Cats during First COVID-19 Wave, Europe

Emerg Infect Dis. 2021 Oct 25;27(12). doi: 10.3201/eid2712.211252.
Maximilian Stich, Roland Elling, Hanna Renk et al.

Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 in Households with Children, Southwest Germany, May-August 2020

Emerg Infect Dis. 2021 Oct 25;27(12). doi: 10.3201/eid2712.210978.
Bode Shobayo, Mitali Mishra, Stephen Sameroff et al.

SARS-CoV-2 Sequence Analysis during COVID-19 Case Surge, Liberia, 2021

Emerg Infect Dis. 2021 Oct 27;27(12). doi: 10.3201/eid2712.211818.
Kaitlyn E Johnson, Spencer Woody, Michael Lachmann et al.

Real-time Projections of SARS-CoV-2 B.1.1.7 Variant in a University Setting, Texas, USA

Emerg Infect Dis. 2021 Oct 27;27(12). doi: 10.3201/eid2712.210652.
Silvia Stringhini, María-Eugenia Zaballa, Nick Pullen et al.

Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021

Euro Surveill. 2021 Oct;26(43). doi: 10.2807/1560-7917.ES.2021.26.43.2100830.
Neil J Saad, Felix Moek, Fabienne Steitz et al.

A longitudinal study on symptom duration and 60-day clinical course in non-hospitalised COVID-19 cases in Berlin, Germany, March to May, 2020

Euro Surveill. 2021 Oct;26(43). doi: 10.2807/1560-7917.ES.2021.26.43.2001757.
Maximilian Muenchhoff, Alexander Graf, Stefan Krebs et al.

Genomic epidemiology reveals multiple introductions of SARS-CoV-2 followed by community and nosocomial spread, Germany, February to May 2020

Euro Surveill. 2021 Oct;26(43). doi: 10.2807/1560-7917.ES.2021.26.43.2002066.
Mehmet Sami Islamoglu, Mahir Cengiz, Betul Borku Uysal et al.

COVID-19 seroconversion in the aircrew from Turkey

Travel Med Infect Dis. 2021 Oct 30. doi: 10.1016/j.tmaid.2021.102190.
Andrew Conway Morris, Katherine Sharrocks, Rachel Bousfield et al.

The removal of airborne SARS-CoV-2 and other microbial bioaerosols by air filtration on COVID-19 surge units

Clin Infect Dis. 2021 Oct 30;ciab933. doi: 10.1093/cid/ciab933.
Bingyi Yang, Tim K Tsang, Huizhi Gao et al.

Universal community nucleic acid testing for COVID-19 in Hong Kong reveals insights into transmission dynamics: a cross-sectional and modelling study

Clin Infect Dis. 2021 Oct 28;ciab925. doi: 10.1093/cid/ciab925.
Nobuyuki Horita, Hideaki Kato, Keisuke Watanabe et al.

Declined mortality due to seasonal influenza in Japan during the coronavirus disease 2019 pandemic

Clin Infect Dis. 2021 Oct 28;ciab922. doi: 10.1093/cid/ciab922.
Michael Dougan, Masoud Azizad, Bharat Mocherla et al.

A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high viral load

Clin Infect Dis. 2021 Oct 28;ciab912. doi: 10.1093/cid/ciab912.
John A Lednicky, Massimiliano S Tagliamonte, Sarah K White et al.

Isolation of a Novel Recombinant Canine Coronavirus from a Visitor to Haiti: Further Evidence of Transmission of Coronaviruses of Zoonotic Origin to Humans

Clin Infect Dis. 2021 Oct 28;ciab924. doi: 10.1093/cid/ciab924.
Khitam Muhsen, Nimrod Maimon, Ami Mizrahi et al.

Effectiveness of BNT162b2 mRNA COVID-19 vaccine against acquisitions of SARS-CoV-2 among health care workers in long-term care facilities: a prospective cohort study

Clin Infect Dis. 2021 Oct 26;ciab918. doi: 10.1093/cid/ciab918.
Bezawit A Woldemeskel, Caroline C Garliss, Joel N Blankson

mRNA Vaccine-Elicited SARS-CoV-2-Specific T cells Persist at 6 Months and Recognize the Delta Variant

Clin Infect Dis. 2021 Oct 25;ciab915. doi: 10.1093/cid/ciab915.
Sarah E Waldman, Tara Buehring, Daniel J Escobar et al.

Secondary Cases of Delta-Variant COVID-19 Among Vaccinated Healthcare Workers with Breakthrough Infections is Rare

Clin Infect Dis. 2021 Oct 25;ciab916. doi: 10.1093/cid/ciab916.
Jonathan Klein, Anderson F Brito, Paul Trubin et al.

Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient

J Infect Dis. 2021 Oct 29;jiab553. doi: 10.1093/infdis/jiab553.
Green Kim, Dong Ho Kim, Hanseul Oh et al.

Germinal center-induced immunity is correlated with protection against SARS-CoV-2 reinfection but not lung damage

J Infect Dis. 2021 Oct 28;jiab535. doi: 10.1093/infdis/jiab535.
Héctor Meijide Míguez, Miguel Ochando Gómez, Iñaki Montes García, Isabel M García Merino, Alejandro De La Torre

Cellular and humoral response, six months after two doses of BNT162b2 mRNA Covid 19 vaccination, in residents and staff of nursing homes for the elderly

J Infect Dis. 2021 Oct 28;jiab546. doi: 10.1093/infdis/jiab546.
Ben Y Reis, Noam Barda, Michael Leshchinsky et al.

Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents

N Engl J Med. 2021 Oct 20. doi: 10.1056/NEJMc2114290.
Maria C Magnus, Håkon K Gjessing, Helena N Eide et al.

Covid-19 Vaccination during Pregnancy and First-Trimester Miscarriage

N Engl J Med. 2021 Oct 20. doi: 10.1056/NEJMc2114466.
Elizabeth T Chin, David Leidner, Yifan Zhang et al.

Effectiveness of the mRNA-1273 Vaccine during a SARS-CoV-2 Delta Outbreak in a Prison

N Engl J Med. 2021 Oct 20. doi: 10.1056/NEJMc2114089.
Aziz Sheikh, Chris Robertson, Bob Taylor

BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant

N Engl J Med. 2021 Oct 20. doi: 10.1056/NEJMc2113864.
Kushalinii Hillson, Sue Costa Clemens, Shabir A Madhi et al.

Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination

Lancet. 2021 Oct 21;S0140-6736(21)02282-0. doi: 10.1016/S0140-6736(21)02282-0.
Gregory Milne, Thomas Hames, Chris Scotton et al.

Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?

Lancet Respir Med. 2021 Oct 21;S2213-2600(21)00407-0. doi: 10.1016/S2213-2600(21)00407-0.
RECOVERY Collaborative Group

Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Lancet Respir Med. 2021 Oct 18;S2213-2600(21)00435-5. doi: 10.1016/S2213-2600(21)00435-5.
Michelle Sholzberg, Grace H Tang, Hassan Rahhal et al.

Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial

BMJ. 2021 Oct 14;375:n2400. doi: 10.1136/bmj.n2400.
The COVID STEROID 2 Trial Group

Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial

JAMA. 2021 Oct 21. doi: 10.1001/jama.2021.18295.
Federica Novazzi, Stefano Taborelli, Andreina Baj, Daniele Focosi, Fabrizio Maggi

Asymptomatic SARS-CoV-2 Vaccine Breakthrough Infections in Health Care Workers Identified Through Routine Universal Surveillance Testing

Ann Intern Med. 2021 Oct 19;M21-3486. doi: 10.7326/M21-3486.
Bruno Pozzetto, Vincent Legros, Sophia Djebali et al.

Immunogenicity and efficacy of heterologous ChadOx1/BNT162b2 vaccination

Nature. 2021 Oct 21. doi: 10.1038/s41586-021-04120-y.
Emanuele Andreano, Ida Paciello, Giulia Piccini et al.

Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants

Nature. 2021 Oct 20. doi: 10.1038/s41586-021-04117-7.
Rosemary J Boyton, Daniel M Altmann

The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions?

Nat Rev Immunol. 2021 Oct 19;1-7. doi: 10.1038/s41577-021-00631-x.
Caroline Atyeo, Elizabeth A DeRiso, Christine Davis et al.

COVID-19 mRNA vaccines drive differential antibody Fc-functional profiles in pregnant, lactating, and non-pregnant women

Sci Transl Med. 2021 Oct 27;13(617):eabi8631. doi: 10.1126/scitranslmed.abi8631.
Cristian Ovies, Eleanor C Semmes, Carolyn B Coyne

Pregnancy Influences Immune Responses to SARS-CoV-2

Sci Transl Med. 2021 Oct 27;13(617):eabm2070. doi: 10.1126/scitranslmed.abm2070.
Evan A Bordt, Lydia L Shook, Caroline Atyeo et al.

Maternal SARS-CoV-2 infection elicits sexually dimorphic placental immune responses

Sci Transl Med. 2021 Oct 27;13(617):eabi7428. doi: 10.1126/scitranslmed.abi7428.
Rebecca P Payne, Stephanie Longet, James A Austin et al.

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine

Cell. 2021 Oct 15;S0092-8674(21)01221-6. doi: 10.1016/j.cell.2021.10.011.
Christopher A Taylor, Kadam Patel, Huong Pham et al.

Severity of Disease Among Adults Hospitalized with Laboratory-Confirmed COVID-19 Before and During the Period of SARS-CoV-2 B.1.617.2 (Delta) Predominance ― COVID-NET, 14 States, January–August 2021

MMWR Morb Mortal Wkly Rep. 2021 Oct 29;70(43):1513-1519. doi: 10.15585/mmwr.mm7043e1.
Stanley Xu, Runxin Huang, Lina S Sy et al.

COVID-19 Vaccination and Non–COVID-19 Mortality Risk ― Seven Integrated Health Care Organizations, United States, December 14, 2020–July 31, 2021

MMWR Morb Mortal Wkly Rep. 2021 Oct 29;70(43):1520–1524. doi: 10.15585/mmwr.mm7043e2.
Samantha M Olson, Margaret M Newhams, Natasha B Halasa et al.

Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12-18 Years - United States, June-September 2021

MMWR Morb Mortal Wkly Rep. 2021 Oct 22;70(42):1483-1488. doi: 10.15585/mmwr.mm7042e1.
Irena Klavs, Mojca Serdt, Veronika Učakar et al.

Enhanced national surveillance of severe acute respiratory infections (SARI) within COVID-19 surveillance, Slovenia, weeks 13 to 37 2021

Euro Surveill. 2021 Oct;26(42). doi: 10.2807/1560-7917.ES.2021.26.42.2100937.
Natalia Ruetalo, Ramona Businger, Michael Schindler

Rapid, dose-dependent and efficient inactivation of surface dried SARS-CoV-2 by 254 nm UV-C irradiation

Euro Surveill. 2021 Oct;26(42). doi: 10.2807/1560-7917.ES.2021.26.42.2001718.
Cornelia Betsch, Lars Korn, Tanja Burgard et al.

The four weeks before lockdown during the COVID-19 pandemic in Germany: a weekly serial cross-sectional survey on risk perceptions, knowledge, public trust and behaviour, 3 to 25 March 2020

Euro Surveill. 2021 Oct;26(42). doi: 10.2807/1560-7917.ES.2021.26.42.2001900.
Rebecca C Woodruff, Angela P Campbell, Christopher A Taylor et al.

Risk Factors for Severe COVID-19 in Children

Pediatrics. 2021 Oct 22;e2021053418. doi: 10.1542/peds.2021-053418.
Cesariana P V Martins, Carolina S F Xavier, Luís Cobrado

Disinfection methods against SARS-CoV-2: a systematic review

J Hosp Infect. 2021 Oct 18;S0195-6701(21)00362-5. doi: 10.1016/j.jhin.2021.07.014.
Clotilde El Guerche-Séblain, Lina Chakir, Gopinath Nageshwaran et al.

Experience from five Asia-Pacific countries during the first wave of the COVID-19 pandemic: Mitigation strategies and epidemiology outcomes

Travel Med Infect Dis. 2021 Oct 12;44:102171. doi: 10.1016/j.tmaid.2021.102171.
Debaprasad Parai, Hari Ram Choudhary, Girish Chandra Dash et al.

Single-dose of BBV-152 and AZD1222 increases antibodies against spike glycoprotein among healthcare workers recovered from SARS-CoV-2 infection

Travel Med Infect Dis. 2021 Oct 13;44:102170. doi: 10.1016/j.tmaid.2021.102170.
Zhongyan Lu, Eric D Laing, Jarina Pena DaMata et al.

Durability of SARS-CoV-2-specific T cell responses at 12-months post-infection

J Infect Dis. 2021 Oct 21;jiab543. doi: 10.1093/infdis/jiab543.
Zoe N Memel, Jenny J Lee, Andrea S Foulkes et al.

Association of Statins and 28-Day Mortality in Patients Hospitalized with SARS CoV-2 Infection

J Infect Dis. 2021 Oct 19;jiab539. doi: 10.1093/infdis/jiab539.
Allison T Chamberlain, Kathleen E Toomey, Heather Bradley et al.

Cumulative incidence of SARS-CoV-2 infections among adults in Georgia, USA, August-December 2020

J Infect Dis. 2021 Oct 18;jiab522. doi: 10.1093/infdis/jiab522.
Szu-Min Hsieh, Ming-Che Liu, Yen-Hsu Chen et al.

Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan

Lancet Respir Med. 2021 Oct 13;S2213-2600(21)00402-1. doi: 10.1016/S2213-2600(21)00402-1.
Wing Ying Au, Peter Pak Hang Cheung

Diagnostic performances of common nucleic acid tests for SARS-CoV-2 in hospitals and clinics: a systematic review and meta-analysis

Lancet Microbe. 2021 Oct 13. doi: 10.1016/S2666-5247(21)00214-7.
Esther Saiag, Hanoch Goldshmidt, Eli Sprecher, Ronen Ben-Ami, David Bomze

Immunogenicity of a BNT162b2 vaccine booster in health-care workers

Lancet Microbe. 2021 Oct 11. doi: 10.1016/S2666-5247(21)00272-X.
Jean M Connors, Maria M Brooks, Frank C Sciurba et al.

Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial

JAMA. 2021 Oct 11. doi: 10.1001/jama.2021.17272.
Peter Nordström, Marcel Ballin, Anna Nordström

Association Between Risk of COVID-19 Infection in Nonimmune Individuals and COVID-19 Immunity in Their Family Members

JAMA Intern Med. 2021 Oct 11. doi: 10.1001/jamainternmed.2021.5814.
Harald S Vöhringer, Theo Sanderson, Matthew Sinnott et al.

Genomic reconstruction of the SARS-CoV-2 epidemic in England

Nature. 2021 Oct 14. doi: 10.1038/s41586-021-04069-y.
Carolina Lucas, Chantal B F Vogels, Inci Yildirim et al.

Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity

Nature. 2021 Oct 11. doi: 10.1038/s41586-021-04085-y.
Koen B Pouwels, Emma Pritchard, Philippa C Matthews et al.

Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK

Nat Med. 2021 Oct 14. doi: 10.1038/s41591-021-01548-7.
Inna Ricardo-Lax, Joseph M Luna, Tran Thi Nhu Thao et al.

Replication and single-cycle delivery of SARS-CoV-2 replicons

Science. 2021 Oct 14;eabj8430. doi: 10.1126/science.abj8430.
Felice D'Agnillo, Kathie-Anne Walters, Yongli Xiao et al.

Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19

Sci Transl Med. 2021 Oct 14;eabj7790. doi: 10.1126/scitranslmed.abj7790.
Mahesh S Dhar, Robin Marwal, Radhakrishnan Vs et al.

Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India

Science. 2021 Oct 14;eabj9932. doi: 10.1126/science.abj9932.
Rishi R Goel, Mark M Painter, Sokratis A Apostolidis et al.

mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern

Science. 2021 Oct 14;eabm0829. doi: 10.1126/science.abm0829.
Lawrence J Purpura, Joseph Alukal, Alexander M Chong et al.

SARS-CoV-2 Shedding in Semen and Oligozoospermia of Patient with Severe Coronavirus Disease 11 Weeks after Infection

Emerg Infect Dis. 2021 Oct 13;28(1). doi: 10.3201/eid2801.211521.
Bingyi Yang, Sheena G Sullivan, Zhanwei Du, Tim K Tsang, Benjamin J Cowling

Effectiveness of International Travel Controls for Delaying Local Outbreaks of COVID-19

Emerg Infect Dis. 2021 Oct 13;28(1). doi: 10.3201/eid2801.211944.
Jacob Riley, Jamie M Huntley, Jennifer A Miller, Amelia L B Slaichert, Grant D Brown

Mask Effectiveness for Preventing Secondary Cases of COVID-19, Johnson County, Iowa, USA

Emerg Infect Dis. 2021 Oct 12;28(1). doi: 10.3201/eid2801.211591.
Patrick K Mitchell, Mathias Martins, Tara Reilly et al.

SARS-CoV-2 B.1.1.7 Variant Infection in Malayan Tigers, Virginia, USA

Emerg Infect Dis. 2021 Oct 14;27(12). doi: 10.3201/eid2712.211234.
Shih-Chieh Shao, Chien-Ho Wang, Kai-Cheng Chang et al.

Guillain-Barré Syndrome Associated with COVID-19 Vaccination

Emerg Infect Dis. 2021 Oct 14;27(12). doi: 10.3201/eid2712.211634.
Thomas Harder, Wiebe Külper-Schiek, Sarah Reda et al.

Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021

Euro Surveill. 2021 Oct;26(41). doi: 10.2807/1560-7917.ES.2021.26.41.2100920.
Laith J Abu-Raddad, Hiam Chemaitelly, Houssein H Ayoub et al.

Severity, criticality, and fatality of the SARS-CoV-2 Beta variant

Clin Infect Dis. 2021 Oct 17;ciab909. doi: 10.1093/cid/ciab909.
Lisa M Brosseau, Kevin Escandón, Angela K Ulrich et al.

SARS-CoV-2 Dose, Infection, and Disease Outcomes for COVID-19 - A Review

Clin Infect Dis. 2021 Oct 15;ciab903. doi: 10.1093/cid/ciab903.
Elizabeth V Robilotti, Karissa Whiting, Anabella Lucca et al.

Clinical and Genomic Characterization of SARS CoV-2 infections in mRNA Vaccinated Health Care Personnel in New York City

Clin Infect Dis. 2021 Oct 13;ciab886. doi: 10.1093/cid/ciab886.
Jessica Schulze, Christin Mache, Anita Balázs et al.

Analysis of SARS-CoV-2 replication in explant cultures of the human upper respiratory tract reveals broad tissue tropism of wild-type and B.1.1.7 variant viruses

J Infect Dis. 2021 Oct 15;jiab523. doi: 10.1093/infdis/jiab523.
Lael M Yonker, Julie Boucau, James Regan et al.

Virologic features of SARS-CoV-2 infection in children

J Infect Dis. 2021 Oct 14;jiab509. doi: 10.1093/infdis/jiab509.
Brian T Montague, Matthew F Wipperman, Andrea T Hooper et al.

Anti-SARS-CoV-2 IgA Identifies Asymptomatic Infection in First Responders

J Infect Dis. 2021 Oct 12;jiab524. doi: 10.1093/infdis/jiab524.
Einav G Levin, Yaniv Lustig, Carmit Cohen et al.

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

N Engl J Med. 2021 Oct 6. doi: 10.1056/NEJMoa2114583.
Hiam Chemaitelly, Patrick Tang, Mohammad R Hasan et al.

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar

N Engl J Med. 2021 Oct 6. doi: 10.1056/NEJMoa2114114.
Dror Mevorach, Emilia Anis, Noa Cedar et al.

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel

N Engl J Med. 2021 Oct 6. doi: 10.1056/NEJMoa2109730.
Guy Witberg, Noam Barda, Sara Hoss et al.

Myocarditis after Covid-19 Vaccination in a Large Health Care Organization

N Engl J Med. 2021 Oct 6. doi: 10.1056/NEJMoa2110737.
Maria Prendecki, Tina Thomson, Candice L Clarke et al.

Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients

Lancet. 2021 Oct 4;S0140-6736(21)02096-1. doi: 10.1016/S0140-6736(21)02096-1.
Sara Y Tartof, Jeff M Slezak, Heidi Fischer et al.

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Lancet. 2021 Oct 4;S0140-6736(21)02183-8. doi: 10.1016/S0140-6736(21)02183-8.
Angèle Gayet-Ageron, Khaoula Ben Messaoud, Mark Richards, Sara Schroter

Female authorship of covid-19 research in manuscripts submitted to 11 biomedical journals: cross sectional study

BMJ. 2021 Oct 6;375:n2288. doi: 10.1136/bmj.n2288.
Fatimah S Dawood, Christina A Porucznik, Vic Veguilla et al.

Incidence Rates, Household Infection Risk, and Clinical Characteristics of SARS-CoV-2 Infection Among Children and Adults in Utah and New York City, New York

JAMA Pediatr. 2021 Oct 8. doi: 10.1001/jamapediatrics.2021.4217.
Emily Jane Woo, Adamma Mba-Jonas, Rositsa B Dimova et al.

Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021

JAMA. 2021 Oct 7. doi: 10.1001/jama.2021.16496.
Lana Wahid, Thomas L Ortel

Anticoagulant Therapy in Patients Hospitalized With COVID-19

JAMA Intern Med. 2021 Oct 7. doi: 10.1001/jamainternmed.2021.6212.
Neal Marquez, Julie A Ward, Kalind Parish, Brendan Saloner, Sharon Dolovich

COVID-19 Incidence and Mortality in Federal and State Prisons Compared With the US Population, April 5, 2020, to April 3, 2021

JAMA. 2021 Oct 6. doi: 10.1001/jama.2021.17575.
Anthony Simone, John Herald, Aiyu Chen et al.

Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older

JAMA Intern Med. 2021 Oct 4. doi: 10.1001/jamainternmed.2021.5511.
Writing Committee for the REMAP-CAP Investigators

Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial

JAMA. 2021 Oct 4. doi: 10.1001/jama.2021.18178.
Meredith S Shiels, Anika T Haque, Emily A Haozous et al.

Racial and Ethnic Disparities in Excess Deaths During the COVID-19 Pandemic, March to December 2020

Ann Intern Med. 2021 Oct 5;M21-2134. doi: 10.7326/M21-2134.
Alice Cho, Frauke Muecksch, Dennis Schaefer-Babajew et al.

Anti-SARS-CoV-2 receptor binding domain antibody evolution after mRNA vaccination

Nature. 2021 Oct 7. doi: 10.1038/s41586-021-04060-7.
Deborah E Malden, Katia J Bruxvoort, Hung Fu Tseng et al.

Distribution of SARS-CoV-2 Variants in a Large Integrated Health Care System - California, March-July 2021

MMWR Morb Mortal Wkly Rep. 2021 Oct 8;70(40):1415-1419. doi: 10.15585/mmwr.mm7040a4.
Richard Molenkamp, Ewout Fanoy, Leonie Derickx et al.

Supplementing SARS-CoV-2 genomic surveillance with PCR-based variant detection for real-time actionable information, the Netherlands, June to July 2021

Euro Surveill. 2021 Oct;26(40). doi: 10.2807/1560-7917.ES.2021.26.40.2100921.
Cornelia Adlhoch, Miriam Sneiderman, Oksana Martinuka et al.

Spotlight influenza: The 2019/20 influenza season and the impact of COVID-19 on influenza surveillance in the WHO European Region

Euro Surveill. 2021 Oct;26(40). doi: 10.2807/1560-7917.ES.2021.26.40.2100077.
Jessica E Stockdale, Renny Doig, Joosung Min et al.

Long time frames to detect the impact of changing COVID-19 measures, Canada, March to July 2020

Euro Surveill. 2021 Oct;26(40). doi: 10.2807/1560-7917.ES.2021.26.40.2001204.
Karin Magnusson, Karin Nygård, Fredrik Methi, Line Vold, Kjetil Telle

Occupational risk of COVID-19 in the first versus second epidemic wave in Norway, 2020

Euro Surveill. 2021 Oct;26(40). doi: 10.2807/1560-7917.ES.2021.26.40.2001875.
Angelique E Boutzoukas, Kanecia O Zimmerman, Daniel K Benjamin Jr, ABC Science Collaborative

School Safety, Masking, and the Delta Variant

Pediatrics. 2021 Oct 8;e2021054396. doi: 10.1542/peds.2021-054396.
Maria Jesús Pérez-Granda, Carlos Sánchez Carrillo, Pablo Martín Rabadán et al.

INCREASE IN THE FREQUENCY OF CATHETER-RELATED BLOODSTREAM INFECTIONS DURING THE COVID-19 PANDEMIC: A PLEA FOR CONTROL

J Hosp Infect. 2021 Oct 7;S0195-6701(21)00347-9. doi: 10.1016/j.jhin.2021.09.020.
Abdel-Naser Elzouki, Maab A M Osman, Mohanad A E Ahmed et al.

COVID-19 infection presented as Guillain-Barre Syndrome: Report of two new cases and review of 116 reported cases and case series

Travel Med Infect Dis. 2021 Oct 6;44:102169. doi: 10.1016/j.tmaid.2021.102169.
Jie Zhang, Hao Lin, Beiwei Ye et al.

One-year sustained cellular and humoral immunities of COVID-19 convalescents

Clin Infect Dis. 2021 Oct 5;ciab884. doi: 10.1093/cid/ciab884.
Abie Rohrig, Nir Eyal

The Ethics of Human Challenge Trials Using Emerging SARS-CoV-2 Virus Variants

J Infect Dis. 2021 Oct 8;jiab488. doi: 10.1093/infdis/jiab488.
Yun Lu, Yixin Jiao, David J Graham et al.

Risk factors for COVID-19 deaths among elderly nursing home Medicare beneficiaries in the pre-vaccine period

J Infect Dis. 2021 Oct 7;jiab515. doi: 10.1093/infdis/jiab515.
C Mertz, R Glowinski, S H Cohen et al.

SARS-CoV-2 RNAemia and clinical outcomes in children with COVID-19

J Infect Dis. 2021 Oct 7;jiab491. doi: 10.1093/infdis/jiab491.
Adeel A Butt, Hiam Chemaitelly, Abdullatif Al Khal et al.

SARS-CoV-2 vaccine effectiveness in preventing confirmed infection in pregnant women

J Clin Invest. 2021 Oct 6;e153662. doi: 10.1172/JCI153662.
Tanushree Dangi, Nicole Palacio, Sarah Sanchez et al.

Cross-protective immunity following coronavirus vaccination and coronavirus infection

J Clin Invest. 2021 Oct 8;e151969. doi: 10.1172/JCI151969.
Jeffrey P Townsend, Hayley B Hassler, Zheng Wang et al.

The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study

Lancet Microbe. 2021 Oct 1. doi: 10.1016/S2666-5247(21)00219-6
Ryan P Barbaro, Graeme MacLaren, Philip S Boonstra et al.

Extracorporeal membrane oxygenation for COVID-19: evolving outcomes from the international Extracorporeal Life Support Organization Registry

Lancet. 2021 Oct 2;398(10307):1230-1238. doi: 10.1016/S0140-6736(21)01960-7.
Kim Van Naarden Braun, Mark Drexler, Ranna A Rozenfeld et al.

Multicomponent Strategies to Prevent SARS-CoV-2 Transmission ― Nine Overnight Youth Summer Camps, United States, June–August 2021

MMWR Morb Mortal Wkly Rep. 2021 Oct 1. doi: 10.15585/mmwr.mm7040e1.
Julius L Tonzel, Theresa Sokol

COVID-19 Outbreaks at Youth Summer Camps ― Louisiana, June–July 2021

MMWR Morb Mortal Wkly Rep. 2021 Oct 1. doi: 10.15585/mmwr.mm7040e2.
A Blythe Ryerson, Catherine E Rice, Mei-Chuan Hung et al.

Disparities in COVID-19 Vaccination Status, Intent, and Perceived Access for Noninstitutionalized Adults, by Disability Status - National Immunization Survey Adult COVID Module, United States, May 30-June 26, 2021

MMWR Morb Mortal Wkly Rep. 2021 Oct 1;70(39):1365-1371. doi: 10.15585/mmwr.mm7039a2.
Anne M Hause, James Baggs, Julianne Gee et al.

Safety Monitoring of an Additional Dose of COVID-19 Vaccine - United States, August 12-September 19, 2021

MMWR Morb Mortal Wkly Rep. 2021 Oct 1;70(39):1379-1384. doi: 10.15585/mmwr.mm7039e4.
Michael Klompas, Shangyuan Ye, Vineeta Vaidya et al.

Association between Airborne Infection Isolation Room Utilization Rates and Healthcare Worker COVID-19 Infections in Two Academic Hospitals

Clin Infect Dis. 2021 Oct 2;ciab849. doi: 10.1093/cid/ciab849.
Nina Zhu, Timothy M Rawson, Siddharth Mookerjee et al.

Changing patterns of bloodstream infections in the community and acute care across two COVID-19 epidemic waves: a retrospective analysis using data linkage

Clin Infect Dis. 2021 Oct 1;ciab869. doi: 10.1093/cid/ciab869.
Essy Mozaffari, Aastha Chandak, Zhiji Zhang et al.

Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of in-hospital all-cause mortality in a large multi-center observational cohort

Clin Infect Dis. 2021 Oct 1;ciab875. doi: 10.1093/cid/ciab875.
September 2021
Ann R Falsey, Magdalena E Sobieszczyk, Ian Hirsch et al.

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine

N Engl J Med. 2021 Sep 29. doi: 10.1056/NEJMoa2105290.
Yigang Tong, Wenli Liu, Peipei Liu et al.

The origins of viruses: discovery takes time, international resources, and cooperation

Lancet. 2021 Sep 30;S0140-6736(21)02180-2. doi: 10.1016/S0140-6736(21)02180-2.
Utkarsh Agrawal, Srinivasa Vittal Katikireddi, Colin McCowan et al.

COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study

Lancet Respir Med. 2021 Sep 29;S2213-2600(21)00380-5. doi: 10.1016/S2213-2600(21)00380-5.
Dinesh Aggarwal, Richard Myers, William L Hamilton et al.

The role of viral genomics in understanding COVID-19 outbreaks in long-term care facilities

Lancet Microbe. 2021 Sep 29. doi: 10.1016/S2666-5247(21)00208-1.
Eileen Barrett, Susan Thompson Hingle, Cynthia D Smith, Darilyn V Moyer

Getting Through COVID-19: Keeping Clinicians in the Workforce

Ann Intern Med. 2021 Sep 28. doi: 10.7326/M21-3381.
Rachna T Shroff, Pavani Chalasani, Ran Wei et al.

Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors

Nat Med. 2021 Sep 30. doi: 10.1038/s41591-021-01542-z.
Shuo Feng, Daniel J Phillips, Thomas White et al.

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Nat Med. 2021 Sep 29. doi: 10.1038/s41591-021-01540-1.
Rustom Antia, M Elizabeth Halloran

Transition to endemicity: Understanding COVID-19

Immunity. 2021 Sep 23. doi: 10.1016/j.immuni.2021.09.019.
Samir Joshi, Rahul Telang, Muralidhar Tambe et al.

Outbreak of Mucormycosis in Coronavirus Disease Patients, Pune, India

Emerg Infect Dis. 2021 Sep 29;28(1). doi: 10.3201/eid2801.211636.
Aharona Glatman-Freedman, Yael Hershkovitz, Zalman Kaufman et al.

Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021

Emerg Infect Dis. 2021 Sep 27;27(11). doi: 10.3201/eid2711.211886.
Iván Martínez-Baz, Camino Trobajo-Sanmartín, Ana Miqueleiz et al.

Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021

Euro Surveill. 2021 Sep;26(39). doi: 10.2807/1560-7917.ES.2021.26.39.2100894.
Natalia Mazur-Panasiuk, Lukasz Rabalski, Tomasz Gromowski et al.

Expansion of a SARS-CoV-2 Delta variant with an 872 nt deletion encompassing ORF7a, ORF7b and ORF8, Poland, July to August 2021

Euro Surveill. 2021 Sep;26(39). doi: 10.2807/1560-7917.ES.2021.26.39.2100902.
Pnina Shitrit, Neta S Zuckerman, Orna Mor, Bat-Sheva Gottesman, Michal Chowers

Nosocomial outbreak caused by the SARS-CoV-2 Delta variant in a highly vaccinated population, Israel, July 2021

Euro Surveill. 2021 Sep;26(39). doi: 10.2807/1560-7917.ES.2021.26.39.2100822.
Samuel Clifford, Billy J Quilty, Timothy W Russell et al.

Strategies to reduce the risk of SARS-CoV-2 importation from international travellers: modelling estimations for the United Kingdom, July 2020

Euro Surveill. 2021 Sep;26(39). doi: 10.2807/1560-7917.ES.2021.26.39.2001440.
Hana M El Sahly, Lindsey R Baden, Brandon Essink et al.

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

N Engl J Med. 2021 Sep 22. doi: 10.1056/NEJMoa2113017.
Tamara Pilishvili, Ryan Gierke, Katherine E Fleming-Dutra et al.

Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel

N Engl J Med. 2021 Sep 22. doi: 10.1056/NEJMoa2106599.
Eric J Haas, John M McLaughlin, Farid Khan et al.

Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study

Lancet Infect Dis. 2021 Sep 22;S1473-3099(21)00566-1. doi: 10.1016/S1473-3099(21)00566-1.
Reed Ac Siemieniuk, Jessica J Bartoszko, Juan Pablo Díaz Martinez et al.

Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis

BMJ. 2021 Sep 23;374:n2231. doi: 10.1136/bmj.n2231.
Jan M Stratil, Renke L Biallas, Jacob Burns et al.

Non-pharmacological measures implemented in the setting of long-term care facilities to prevent SARS-CoV-2 infections and their consequences: a rapid review

Cochrane Database Syst Rev. 2021 Sep 15;9(9):CD015085. doi: 10.1002/14651858.CD015085.pub2.
Fabian Schmidt, Yiska Weisblum, Magdalena Rutkowska et al.

High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape

Nature. 2021 Sep 20. doi: 10.1038/s41586-021-04005-0.
Jack M Lawrence, Gideon Meyerowitz-Katz, James A J Heathers, Nicholas J L Brown, Kyle A Sheldrick

The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable

Nat Med. 2021 Sep 22. doi: 10.1038/s41591-021-01535-y.
Kathryn M Hastie, Haoyang Li, Daniel Bedinger et al.

Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study

Science. 2021 Sep 23;eabh2315. doi: 10.1126/science.abh2315.
Aurélien Sokal, Giovanna Barba-Spaeth, Ignacio Fernández et al.

mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants

Immunity. 2021 Sep 20. doi: 10.1016/j.immuni.2021.09.011.
Gail Cross, Jessica S Y Ho, William Zacharias, Anand D Jeyasekharan, Ivan Marazzi

Emergency drug use in a pandemic: Harsh lessons from COVID-19

Cell. 2021 Sep 21;S0092-8674(21)01108-9. doi: 10.1016/j.cell.2021.09.025.
Megan Jehn, J Mac McCullough, Ariella P Dale et al.

Association Between K-12 School Mask Policies and School-Associated COVID-19 Outbreaks - Maricopa and Pima Counties, Arizona, July-August 2021

MMWR Morb Mortal Wkly Rep. 2021 Oct 1;70(39):1372-1373. doi: 10.15585/mmwr.mm7039e1.
Samantha E Budzyn, Mark J Panaggio, Sharyn E Parks et al.

Pediatric COVID-19 Cases in Counties With and Without School Mask Requirements - United States, July 1-September 4, 2021

MMWR Morb Mortal Wkly Rep. 2021 Oct 1;70(39):1377-1378. doi: 10.15585/mmwr.mm7039e3.
Logan C Ray, Jennifer P Collins, Patricia M Griffin et al.

Decreased Incidence of Infections Caused by Pathogens Transmitted Commonly Through Food During the COVID-19 Pandemic - Foodborne Diseases Active Surveillance Network, 10 U.S. Sites, 2017-2020

MMWR Morb Mortal Wkly Rep. 2021 Sep 24;70(38):1332-1336. doi: 10.15585/mmwr.mm7038a4.
Kathleen Dooling, Julia W Gargano, Danielle Moulia et al.

Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, September 2021

MMWR Morb Mortal Wkly Rep. 2021 Sep 24;70(38):1344-1348. doi: 10.15585/mmwr.mm7038e2.
Liesl M Hagan, David W McCormick, Christine Lee et al.

Outbreak of SARS-CoV-2 B.1.617.2 (Delta) Variant Infections Among Incarcerated Persons in a Federal Prison - Texas, July-August 2021

MMWR Morb Mortal Wkly Rep. 2021 Sep 24;70(38):1349-1354. doi: 10.15585/mmwr.mm7038e3.
Sophie A Valkenburg, Samuel M S Cheng, Asmaa Hachim, Malik Peiris, John Nicholls

Postmortem Stability of SARS-CoV-2 in Mouse Lung Tissue

Emerg Infect Dis. 2021 Sep 24;27(12). doi: 10.3201/eid2712.211621.
Taweewun Hunsawong, Stefan Fernandez, Rome Buathong et al.

Limited Protection of Inactivated SARS-CoV-2 Vaccine against Wuhan Strain and Variants of Concern

Emerg Infect Dis. 2021 Sep 24;27(12). doi: 10.3201/eid2712.211772.
Kimberly H Nguyen, David Yankey, Kelsey C Coy et al.

COVID-19 Vaccination Coverage, Intent, Knowledge, Attitudes, and Beliefs among Essential Workers, United States

Emerg Infect Dis. 2021 Sep 29;27(11). doi: 10.3201/eid2711.211557.
Kyle R Rizzo, Cora Hoover, Seema Jain et al.

Influenza and SARS-CoV-2 Coinfections in California, USA, September 2020-April 2021

Emerg Infect Dis. 2021 Sep 29;27(11). doi: 10.3201/eid2711.211129.
Dustin W Currie, Gage K Moreno, Miranda J Delahoy et al.

Interventions to Disrupt Coronavirus Disease Transmission at a University, Wisconsin, USA, August-October 2020

Emerg Infect Dis. 2021 Sep 29;27(11). doi: 10.3201/eid2711.211306.
John Paul Bigouette, Laura Ford, Hannah E Segaloff et al.

Association of Shared Living Spaces and COVID-19 in University Students, Wisconsin, USA, 2020

Emerg Infect Dis. 2021 Sep 22;27(11). doi: 10.3201/eid2711.211000.
Baltazar Nunes, Ana Paula Rodrigues, Irina Kislaya et al.

mRNA vaccine effectiveness against COVID-19-related hospitalisations and deaths in older adults: a cohort study based on data linkage of national health registries in Portugal, February to August 2021

Euro Surveill. 2021 Sep;26(38). doi: 10.2807/1560-7917.ES.2021.26.38.2100833.
Ruggero Giuliani, Cristina Cairone, Lara Tavoschi et al.

COVID-19 outbreak investigation and response in a penitentiary setting: the experience of a prison in Italy, February to April 2020

Euro Surveill. 2021 Sep;26(38). doi: 10.2807/1560-7917.ES.2021.26.38.2001385.
Aki Hirabayashi, Toshiki Kajihara, Koji Yahara, Keigo Shibayama, Motoyuki Sugai

Impact of the COVID-19 pandemic on the surveillance of antimicrobial resistance

J Hosp Infect. 2021 Sep 22;S0195-6701(21)00335-2. doi: 10.1016/j.jhin.2021.09.011.
Scott C Roberts, Michael J Aniskiewicz, Steven J Choi, Christian M Pettker, Richard A Martinello

Correlation of healthcare worker vaccination with inpatient healthcare-associated coronavirus disease 2019 (COVID-19)

Infect Control Hosp Epidemiol. 2021 Sep 21;1-6. doi: 10.1017/ice.2021.414.
Yael Tene, Katia Levytskyi, Amos Adler et al.

An outbreak of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infections among hospital personnel with high mRNA vaccine uptake

Infect Control Hosp Epidemiol. 2021 Sep 20;1-12. doi: 10.1017/ice.2021.412.
Safa Browne, Kristen Feemster, Angela Shen et al.

COVID-19 Vaccine Hesitancy among Physicians, Physician Assistants, Nurse Practitioners, and Nurses in Two Academic Hospitals in Philadelphia

Infect Control Hosp Epidemiol. 2021 Sep 20;1-24. doi: 10.1017/ice.2021.410.
Elizabeth Fraley, Cas LeMaster, Santosh Khanal et al.

Prior infection and age impacts antibody persistence after SARS-CoV-2 mRNA vaccine

Clin Infect Dis. 2021 Sep 22;ciab850. doi: 10.1093/cid/ciab850.
Fengcai Zhu, Pengfei Jin, Tao Zhu et al.

Safety and immunogenicity of a recombinant adenovirus type-5-vectored COVID-19 vaccine with a homologous prime-boost regimen in healthy participants aged 6 years and above: a randomised, double-blind, placebo-controlled, phase 2b trial

Clin Infect Dis. 2021 Sep 22;ciab845. doi: 10.1093/cid/ciab845.
Lakshmi Chauhan, Jack Pattee, Joshay Ford et al.

A Multi-center, Prospective, Observational-cohort controlled study of Clinical Outcomes following COVID-19 Convalescent plasma therapy in hospitalized COVID-19 patients

Clin Infect Dis. 2021 Sep 21;ciab834. doi: 10.1093/cid/ciab834.
Maogui Hu, Jinfeng Wang, Hui Lin et al.

Risk of SARS-CoV-2 Transmission among Air Passengers in China

Clin Infect Dis. 2021 Sep 21;ciab836. doi: 10.1093/cid/ciab836.
Susan M Bueno, Katia Abarca, Pablo A González et al.

Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in a Subgroup of Healthy Adults in Chile

Clin Infect Dis. 2021 Sep 19;ciab823. doi: 10.1093/cid/ciab823.
Jasper Fuk-Woo Chan, Vincent Kwok-Man Poon, Chris Chung-Sing Chan et al.

Low Environmental Temperature Exacerbates Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Golden Syrian Hamsters

Clin Infect Dis. 2021 Sep 18;ciab817. doi: 10.1093/cid/ciab817.
Rena C Moon, Rachel H Mackey, Zhun Cao et al.

Is COVID-19 Less Deadly Now? -- Trends of In-Hospital Mortality Among Hospitalized COVID-19 Patients in the United States

Clin Infect Dis. 2021 Sep 17;ciab830. doi: 10.1093/cid/ciab830.
Rodric V Francis, Harriet Billam, Mitch Clarke et al.

The impact of real-time whole genome sequencing in controlling healthcare-associated SARS-CoV-2 outbreaks

J Infect Dis. 2021 Sep 23;jiab483. doi: 10.1093/infdis/jiab483.
Michael Karbiener, Maria R Farcet, Julia Schwaiger et al.

Plasma from post-COVID-19 and COVID-19-Vaccinated Donors Results in Highly Potent SARS-CoV-2 Neutralization by Intravenous Immunoglobulins

J Infect Dis. 2021 Sep 20;jiab482. doi: 10.1093/infdis/jiab482.
Yinon M Bar-On, Yair Goldberg, Micha Mandel et al.

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

N Engl J Med. 2021 Sep 15;NEJMoa2114255. doi: 10.1056/NEJMoa2114255.
Stephen J Thomas, Edson D Moreira Jr, Nicholas Kitchin et al.

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

N Engl J Med. 2021 Sep 15;NEJMoa2110345. doi: 10.1056/NEJMoa2110345.
Ann R Falsey, Robert W Frenck Jr, Edward E Walsh et al.

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3

N Engl J Med. 2021 Sep 15;NEJMc2113468. doi: 10.1056/NEJMc2113468.
Farid Salih, Linda Schönborn, Siegfried Kohler et al.

Vaccine-Induced Thrombocytopenia with Severe Headache

N Engl J Med. 2021 Sep 15. doi: 10.1056/NEJMc2112974.
ShengLi Xia, YunTao Zhang, YanXia Wang et al.

Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial

Lancet Infect Dis. 2021 Sep 15;S1473-3099(21)00462-X. doi: 10.1016/S1473-3099(21)00462-X.
Bernadette C Young, David W Eyre, Saroj Kendrick et al.

Daily testing for contacts of individuals with SARS-CoV-2 infection and attendance and SARS-CoV-2 transmission in English secondary schools and colleges: an open-label, cluster-randomised trial

Lancet. 2021 Sep 14;S0140-6736(21)01908-5. doi: 10.1016/S0140-6736(21)01908-5.
Darius Mostaghimi, Caroline N Valdez, Haleigh T Larson, Chaney C Kalinich, Akiko Iwasaki

Prevention of host-to-host transmission by SARS-CoV-2 vaccines

Lancet Infect Dis. 2021 Sep 14;S1473-3099(21)00472-2. doi: 10.1016/S1473-3099(21)00472-2.
Florence Ader, Maude Bouscambert-Duchamp, Maya Hites et al.

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

Lancet Infect Dis. 2021 Sep 14;S1473-3099(21)00485-0. doi: 10.1016/S1473-3099(21)00485-0.
Julia Hippisley-Cox, Carol Ac Coupland, Nisha Mehta et al.

Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study

BMJ. 2021 Sep 17;374:n2244. doi: 10.1136/bmj.n2244.
Brian E McGarry, Karen Shen, Michael L Barnett, David C Grabowski, Ashvin D Gandhi

Association of Nursing Home Characteristics With Staff and Resident COVID-19 Vaccination Coverage

JAMA Intern Med. 2021 Sep 16;e215890. doi: 10.1001/jamainternmed.2021.5890.
Angela Choi, Matthew Koch, Kai Wu et al.

Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis

Nat Med. 2021 Sep 15. doi: 10.1038/s41591-021-01527-y.
Richard A Koup, Ruben O Donis, Peter B Gilbert et al.

A government-led effort to identify correlates of protection for COVID-19 vaccines

Nat Med. 2021 Sep;27(9):1493-1494. doi: 10.1038/s41591-021-01484-6.
Haitao Yang, Zihe Rao

Structural biology of SARS-CoV-2 and implications for therapeutic development

Nat Rev Microbiol. 2021 Sep 17;1-16. doi: 10.1038/s41579-021-00630-8.
Jose Mateus, Jennifer M Dan, Zeli Zhang et al.

Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells

Science. 2021 Sep 14;eabj9853. doi: 10.1126/science.abj9853.
Muge Cevik, Nathan D Grubaugh, Akiko Iwasaki, Peter Openshaw

COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants

Cell. 2021 Sep 16;S0092-8674(21)01057-6. doi: 10.1016/j.cell.2021.09.010.
Wesley H Self, Mark W Tenforde, Jillian P Rhoads et al.

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021

MMWR Morb Mortal Wkly Rep. 2021 Sep 24;70(38):1337-1343. doi: 10.15585/mmwr.mm7038e1.
Joshua J Quint, Miriam E Van Dyke, Hailey Maeda et al.

Disaggregating Data to Measure Racial Disparities in COVID-19 Outcomes and Guide Community Response - Hawaii, March 1, 2020-February 28, 2021

MMWR Morb Mortal Wkly Rep. 2021 Sep 17;70(37):1267-1273. doi: 10.15585/mmwr.mm7037a1.
Kyle Yomogida, Sophie Zhu, Francesca Rubino et al.

Post-Acute Sequelae of SARS-CoV-2 Infection Among Adults Aged ≥18 Years - Long Beach, California, April 1-December 10, 2020

MMWR Morb Mortal Wkly Rep. 2021 Sep 17;70(37):1274-1277. doi: 10.15585/mmwr.mm7037a2.
Eli S Rosenberg, David R Holtgrave, Vajeera Dorabawila et al.

New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status - New York, May 3-July 25, 2021

MMWR Morb Mortal Wkly Rep. 2021 Sep 17;70(37):1306-1311. doi: 10.15585/mmwr.mm7037a7.
Douglas Adamoski, Jaqueline Carvalho de Oliveira, Ana Claudia Bonatto et al.

Large-Scale Screening of Asymptomatic Persons for SARS-CoV-2 Variants of Concern and Gamma Takeover, Brazil

Emerg Infect Dis. 2021 Sep 17;27(12). doi: 10.3201/eid2712.211326.
Nico A F Janssen, Rémy Nyga, Lore Vanderbeke et al.

Multinational Observational Cohort Study of COVID-19-Associated Pulmonary Aspergillosis 1

Emerg Infect Dis. 2021 Sep 14;27(11). doi: 10.3201/eid2711.211174.
François Blanquart, Clémence Abad, Joëvin Ambroise et al.

Characterisation of vaccine breakthrough infections of SARS-CoV-2 Delta and Alpha variants and within-host viral load dynamics in the community, France, June to July 2021

Euro Surveill. 2021 Sep;26(37). doi: 10.2807/1560-7917.ES.2021.26.37.2100824.
Olivier Capeyron, Fabien Squinazi, Philippe Dumoulin et al.

A simple method for SARS-CoV-2 RNA detection in the air of an enclosed space

J Hosp Infect. 2021 Sep 18;S0195-6701(21)00316-9. doi: 10.1016/j.jhin.2021.09.003.
Noritoshi Hatanaka, Bingting Xu, Mayo Yasugi et al.

Chlorine dioxide is a more potent antiviral agent against SARS-CoV-2 than sodium hypochlorite

J Hosp Infect. 2021 Sep 15;S0195-6701(21)00320-0. doi: 10.1016/j.jhin.2021.09.006.
Roberto Alfonso Accinelli, Grisel Jesús Ynga-Melendez, Juan Alonso Leon-Abarca et al.

Hydroxychloroquine / azithromycin in COVID-19: The association between time to treatment and case fatality rate

Travel Med Infect Dis. 2021 Sep 14;44:102163. doi: 10.1016/j.tmaid.2021.102163.
John Strutner, Nanda Ramchandar, Shruti Dubey et al.

Comparison of RT-PCR Cycle Threshold Values from Respiratory Specimens in Symptomatic and Asymptomatic Children with SARS-CoV-2 Infection

Clin Infect Dis. 2021 Sep 15;ciab403. doi: 10.1093/cid/ciab403.
Jintanat Ananworanich, Robin Mogg, Michael W Dunne et al.

Randomized study of rivaroxaban vs. placebo on disease progression and symptoms resolution in high-risk adults with mild COVID-19

Clin Infect Dis. 2021 Sep 15;ciab813. doi: 10.1093/cid/ciab813.
Oluwasanmi O Adenaiye, Jianyu Lai, P Jacob Bueno de Mesquita et al.

Infectious SARS-CoV-2 in Exhaled Aerosols and Efficacy of Masks During Early Mild Infection

Clin Infect Dis. 2021 Sep 14;ciab797. doi: 10.1093/cid/ciab797.
Aleksandra Kovacevic, Rosalind M Eggo, Marc Baguelin, Matthieu Domenech de Cellès, Lulla Opatowski

The impact of co-circulating pathogens on SARS-CoV-2/COVID-19 Surveillance How concurrent epidemics may introduce bias and decrease the observed SARS-CoV-2 percent positivity

J Infect Dis. 2021 Sep 13;jiab459. doi: 10.1093/infdis/jiab459.
Jens T Van Praet, Stefaan Vandecasteele, Anneleen De Roo et al.

Dynamics of the cellular and humoral immune response after BNT162b2 mRNA Covid-19 vaccination in Covid-19 naive nursing home residents

J Infect Dis. 2021 Sep 13;jiab458. doi: 10.1093/infdis/jiab458.
Linda Schönborn, Thomas Thiele, Lars Kaderali, Andreas Greinacher

Decline in Pathogenic Antibodies over Time in VITT

N Engl J Med. 2021 Sep 8. doi: 10.1056/NEJMc2112760.
Mark G Thompson, Edward Stenehjem, Shaun Grannis et al.

Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings

N Engl J Med. 2021 Sep 8. doi: 10.1056/NEJMoa2110362.
Anoop S V Shah, Ciara Gribben, Jennifer Bishop et al.

Effect of Vaccination on Transmission of SARS-CoV-2

N Engl J Med. 2021 Sep 8. doi: 10.1056/NEJMc2106757.
Hong Sun

On Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons

N Engl J Med. 2021 Sep 8;10.1056/NEJMc2113516#sa1. doi: 10.1056/NEJMc2113516.
Denis Sauré, Miguel O'Ryan, Juan Pablo Torres et al.

Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study

Lancet Infect Dis. 2021 Sep 9;S1473-3099(21)00479-5. doi: 10.1016/S1473-3099(21)00479-5.
Elyse O Kharbanda, Jacob Haapala, Malini DeSilva et al.

Spontaneous Abortion Following COVID-19 Vaccination During Pregnancy

JAMA. 2021 Sep 8. doi: 10.1001/jama.2021.15494.
Petra Mlcochova, Steven Kemp, Mahesh Shanker Dhar et al.

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion

Nature. 2021 Sep 6. doi: 10.1038/s41586-021-03944-y.
Philippe Bégin, Jeannie Callum, Erin Jamula et al.

Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial

Nat Med. 2021 Sep 9. doi: 10.1038/s41591-021-01488-2.
Bas B Oude Munnink, Nathalie Worp, David F Nieuwenhuijse et al.

The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology

Nat Med. 2021 Sep 9. doi: 10.1038/s41591-021-01472-w.
Noa Dagan, Noam Barda, Tal Biron-Shental et al.

Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy

Nat Med. 2021 Sep 7. doi: 10.1038/s41591-021-01490-8.
Eduan Wilkinson, Marta Giovanetti, Houriiyah Tegally et al.

A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa

Science. 2021 Sep 9;eabj4336. doi: 10.1126/science.abj4336.
Lisa H Tostanoski, Jingyou Yu, Noe B Mercado et al.

Immunity elicited by natural infection or Ad26.COV2.S vaccination protects hamsters against SARS-CoV-2 variants of concern

Sci Transl Med. 2021 Sep 7;eabj3789. doi: 10.1126/scitranslmed.abj3789.
Benjamin Krämer, Rainer Knoll, Lorenzo Bonaguro et al.

Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19

Cell. 2021 Sep 3;S1074-7613(21)00365-4. doi: 10.1016/j.cell.2021.09.002.
Darren P Martin, Steven Weaver, Houriiyah Tegally et al.

The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages

Cell. 2021 Sep 6;S0092-8674(21)01050-3. doi: 10.1016/j.cell.2021.09.003.
Heather M Scobie, Amelia G Johnson, Amitabh B Suthar et al.

Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status ― 13 U.S. Jurisdictions, April 4–July 17, 2021

MMWR Morb Mortal Wkly Rep. 2021 Sep 10. doi: 10.15585/mmwr.mm7037e1.
Shaun J Grannis, Elizabeth A Rowley, Toan C Ong et al.

Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19–Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance ― Nine States, June–August 2021

MMWR Morb Mortal Wkly Rep. 2021 Sep 10. doi: 10.15585/mmwr.mm7037e2.
Kristina L Bajema, Rebecca M Dahl, Mila M Prill et al.

Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalization ― Five Veterans Affairs Medical Centers, United States, February 1–August 6, 2021

MMWR Morb Mortal Wkly Rep. 2021 Sep 10. doi: 10.15585/mmwr.mm7037e3.
Valentine Wanga, Jennifer R Chevinsky, Lina V Dimitrov et al.

Long-Term Symptoms Among Adults Tested for SARS-CoV-2 - United States, January 2020-April 2021

MMWR Morb Mortal Wkly Rep. 2021 Sep 10;70(36):1235-1241. doi: 10.15585/mmwr.mm7036a1.
Amy E Kirby, Maroya Spalding Walters, Wiley C Jennings et al.

Using Wastewater Surveillance Data to Support the COVID-19 Response - United States, 2020-2021

MMWR Morb Mortal Wkly Rep. 2021 Sep 10;70(36):1242-1244. doi: 10.15585/mmwr.mm7036a2.
Terri Rebmann, Travis M Loux, Lauren D Arnold et al.

SARS-CoV-2 Transmission to Masked and Unmasked Close Contacts of University Students with COVID-19 - St. Louis, Missouri, January-May 2021

MMWR Morb Mortal Wkly Rep. 2021 Sep 10;70(36):1245-1248. doi: 10.15585/mmwr.mm7036a3.
Andreina Baj, Federica Novazzi, Renee Pasciuta et al.

Breakthrough Infections of E484K-Harboring SARS-CoV-2 Delta Variant, Lombardy, Italy

Emerg Infect Dis. 2021 Sep 9;27(12). doi: 10.3201/eid2712.211792.
Tomoya Saito, Kaori Muto, Mikihito Tanaka et al.

Proactive Engagement of the Expert Meeting in Managing the Early Phase of the COVID-19 Epidemic, Japan, February–June 2020

Emerg Infect Dis. 2021 Sep 8;27(10). doi: 10.3201/eid2710.204685.
Jet G Sanders, Pita Spruijt, Mart van Dijk et al.

Understanding a national increase in COVID-19 vaccination intention, the Netherlands, November 2020-March 2021

Euro Surveill. 2021 Sep;26(36). doi: 10.2807/1560-7917.ES.2021.26.36.2100792.
Baptiste Panaget, Aurélie Velay, Louise Gontard et al.

High SARS-CoV-2 seroconversion rate among geriatric staff from Strasbourg University Hospitals

Infect Control Hosp Epidemiol. 2021 Sep 6;1-12. doi: 10.1017/ice.2021.402.
Catherine DeVoe, Mark R Segal, Lusha Wang et al.

Increased Rates of Secondary Bacterial Infections, Including Enterococcus Bacteremia, in Patients Hospitalized with COVID-19

Infect Control Hosp Epidemiol. 2021 Sep 6;1-33. doi: 10.1017/ice.2021.391.
Aaron J Tande, Benjamin D Pollock, Nilay D Shah, Matthew Binnicker, Elie F Berbari

mRNA Vaccine Effectiveness Against Asymptomatic SARS-CoV-2 Infection Over a Seven-Month Period

Infect Control Hosp Epidemiol. 2021 Sep 6;1-7. doi: 10.1017/ice.2021.399.
Kelvin Kai-Wang To, Xin Li, David Christopher Lung et al.

False Coronavirus Disease 2019 Cases due to Contamination by Inactivated Virus Vaccine

Clin Infect Dis. 2021 Sep 9;ciab684. doi: 10.1093/cid/ciab684.
Daniel J Grint, Kevin Wing, Catherine Houlihan et al.

Severity of SARS-CoV-2 alpha variant (B.1.1.7) in England

Clin Infect Dis. 2021 Sep 6;ciab754. doi: 10.1093/cid/ciab754.
Anita Boyapati, Matthew F Wipperman, Peter J Ehmann et al.

Baseline SARS-CoV-2 Viral Load is Associated With COVID-19 Disease Severity and Clinical Outcomes: Post-Hoc Analyses of a Phase 2/3 Trial

J Infect Dis. 2021 Sep 8;jiab445. doi: 10.1093/infdis/jiab445.
Sara S Kim, Jessie R Chung, Edward A Belongia et al.

mRNA Vaccine Effectiveness against COVID-19 among Symptomatic Outpatients Aged ≥16 Years in the United States, February - May 2021

J Infect Dis. 2021 Sep 8;jiab451. doi: 10.1093/infdis/jiab451.
Joseph T Hicks, Smita Das, Almea Matanock, Anastacia Griego-Fisher, Daniel Sosin

Characteristics of Persons with Secondary Detection of SARS-CoV-2 ≥90 days After First Detection - New Mexico, 2020

J Infect Dis. 2021 Sep 7;jiab448. doi: 10.1093/infdis/jiab448.
Jocelyn Keehner, Lucy E Horton, Nancy J Binkin et al.

Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce

N Engl J Med. 2021 Sep 1. doi: 10.1056/NEJMc2112981.
Amy Flaxman, Natalie G Marchevsky, Daniel Jenkin et al.

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Lancet. 2021 Sep 1;S0140-6736(21)01699-8. doi: 10.1016/S0140-6736(21)01699-8.
Michela Antonelli, Rose S Penfold, Jordi Merino et al.

Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study

Lancet Infect Dis. 2021 Sep 1;S1473-3099(21)00460-6. doi: 10.1016/S1473-3099(21)00460-6.
Lynda Fenton, Ciara Gribben, David Caldwell et al.

Risk of hospital admission with covid-19 among teachers compared with healthcare workers and other adults of working age in Scotland, March 2020 to July 2021: population based case-control study

BMJ. 2021 Sep 1;374:n2060. doi: 10.1136/bmj.n2060.
Nicola P Klein, Ned Lewis, Kristin Goddard et al.

Surveillance for Adverse Events After COVID-19 mRNA Vaccination

JAMA. 2021 Sep 3. doi: 10.1001/jama.2021.15072.
Jefferson M Jones, Mars Stone, Hasan Sulaeman et al.

Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021

JAMA. 2021 Sep 2. doi: 10.1001/jama.2021.15161.
Sophie Uyoga, Ifedayo M O Adetifa, Mark Otiende et al.

Prevalence of SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors, January-March 2021

JAMA. 2021 Sep 2. doi: 10.1001/jama.2021.15265.
Evdoxia Kyriazopoulou, Garyfallia Poulakou, Haralampos Milionis et al.

Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial

Nat Med. 2021 Sep 3. doi: 10.1038/s41591-021-01499-z.
David A Siegel, Hannah E Reses, Andrea J Cool et al.

Trends in COVID-19 Cases, Emergency Department Visits, and Hospital Admissions Among Children and Adolescents Aged 0-17 Years - United States, August 2020-August 2021

MMWR Morb Mortal Wkly Rep. 2021 Sep 10;70(36):1249-1254. doi: 10.15585/mmwr.mm7036e1.
Miranda J Delahoy, Dawud Ujamaa, Michael Whitaker et al.

Hospitalizations Associated with COVID-19 Among Children and Adolescents - COVID-NET, 14 States, March 1, 2020-August 14, 2021

MMWR Morb Mortal Wkly Rep. 2021 Sep 10;70(36):1255-1260. doi: 10.15585/mmwr.mm7036e2.
Kate Doyle, Richard A Teran, Jennita Reefhuis et al.

Multiple Variants of SARS-CoV-2 in a University Outbreak After Spring Break - Chicago, Illinois, March-May 2021

MMWR Morb Mortal Wkly Rep. 2021 Sep 3;70(35):1195-1200. doi: 10.15585/mmwr.mm7035a3.
Kayleigh J Nerhood, Emily R James, Allen Hardin et al.

Screening Programs for SARS-CoV-2 Infections on a University Campus - Austin, Texas, September 30-November 30, 2020

MMWR Morb Mortal Wkly Rep. 2021 Sep 3;70(35):1201-1205. doi: 10.15585/mmwr.mm7035a4.
James Matthias, Sarah Patrick, Ann Wiringa et al.

Epidemiologically Linked COVID-19 Outbreaks at a Youth Camp and Men's Conference - Illinois, June-July 2021

MMWR Morb Mortal Wkly Rep. 2021 Sep 3;70(35):1223-1227. doi: 10.15585/mmwr.mm7035e4.
Tegan K Boehmer, Lyudmyla Kompaniyets, Amy M Lavery et al.

Association Between COVID-19 and Myocarditis Using Hospital-Based Administrative Data - United States, March 2020-January 2021

MMWR Morb Mortal Wkly Rep. 2021 Sep 3;70(35):1228-1232. doi: 10.15585/mmwr.mm7035e5.
Krishna Surasi, Kristin J Cummings, Carl Hanson et al.

Effectiveness of Abbott BinaxNOW Rapid Antigen Test for Detection of SARS-CoV-2 Infections in Outbreak among Horse Racetrack Workers, California, USA

Emerg Infect Dis. 2021 Sep 1;27(11). doi: 10.3201/eid2711.211449.
Gary K K Chung, Siu-Ming Chan, Yat-Hang Chan et al.

Socioeconomic Patterns of COVID-19 Clusters in Low-Incidence City, Hong Kong

Emerg Infect Dis. 2021 Sep 1;27(11). doi: 10.3201/eid2711.204840.
Elina Seppälä, Lamprini Veneti, Jostein Starrfelt et al.

Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021

Euro Surveill. 2021 Sep;26(35). doi: 10.2807/1560-7917.ES.2021.26.35.2100793.
Gábor Tomisa, Alpár Horváth, Árpád Farkas et al.

Real-life measurement of size-fractionated aerosol concentration in a plethysmography box during the COVID-19 pandemic and estimation of the associated viral load

J Hosp Infect. 2021 Sep 3;S0195-6701(21)00312-1. doi: 10.1016/j.jhin.2021.08.025.
Kenneth A Feder, Ami Patel, Venkata R Vepachedu et al.

Association of E484K spike protein mutation with SARS-CoV-2 infection in vaccinated persons---Maryland, January - May 2021

Clin Infect Dis. 2021 Sep 2;ciab762. doi: 10.1093/cid/ciab762.
Massimiliano S Tagliamonte, Carla Mavian, Kayvan Zainabadi et al.

Rapid emergence and spread of SARS-CoV-2 gamma (P.1) variant in Haiti

Clin Infect Dis. 2021 Sep 2;ciab736. doi: 10.1093/cid/ciab736.
Elke Wynberg, Hugo D G van Willigen, Maartje Dijkstra et al.

Evolution of COVID-19 symptoms during the first 12 months after illness onset

Clin Infect Dis. 2021 Sep 2;ciab759. doi: 10.1093/cid/ciab759.
Jumari Snyman, Shi-Hsia Hwa, Robert Krause et al.

Similar antibody responses against SARS-CoV-2 in HIV uninfected and infected individuals on antiretroviral therapy during the first South African infection wave

Clin Infect Dis. 2021 Sep 2;ciab758. doi: 10.1093/cid/ciab758.
Jeffrey R Strich, Xin Tian, Mohamed Samour et al.

Fostamatinib for the treatment of hospitalized adults with COVD-19 A randomized trial

Clin Infect Dis. 2021 Sep 1;ciab732. doi: 10.1093/cid/ciab732.
Jana Shaw, Samantha Hanley, Telisa Stewart et al.

Health Care Personnel (HCP) attitudes about COVID-19 vaccination after emergency use authorization

Clin Infect Dis. 2021 Sep 1;ciab731. doi: 10.1093/cid/ciab731.
Peter C Richmond, Lara Hatchuel, Filippo Pacciarini et al.

Persistence of the immune responses and cross-neutralizing activity with Variants of Concern following two doses of adjuvanted SCB-2019 COVID-19 vaccine

J Infect Dis. 2021 Sep 4;jiab447. doi: 10.1093/infdis/jiab447.
Cristina Avendaño-Solá, Antonio Ramos-Martínez, Elena Muñez-Rubio et al.

A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia

J Clin Invest. 2021 Sep 2;152740. doi: 10.1172/JCI152740.
Anthony T Tan, Joey M E Lim, Nina Le Bert et al.

Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals

J Clin Invest. 2021 Sep 1;152379. doi: 10.1172/JCI152379.
Peter J Hotez, Carolina Batista, Yanis Ben Amor et al.

Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic

EClinicalMedicine. 2021 Sep;39:101053. doi: 10.1016/j.eclinm.2021.101053.

COVID-19パンデミック中のワクチンや治療法に対する国際的公衆衛生的な視点からの安全性と公正性についての論説
August 2021
Vincent C Marconi, Athimalaipet V Ramanan, Stephanie de Bono et al.

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

Lancet Respir Med. 2021 Aug 31;S2213-2600(21)00331-3. doi: 10.1016/S2213-2600(21)00331-3.
Deborah Steensels, Noella Pierlet, Joris Penders, Dieter Mesotten, Line Heylen

Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273

JAMA. 2021 Aug 30. doi: 10.1001/jama.2021.15125.
Patrick Davies, Pascale du Pré, Jon Lillie, Hari Krishnan Kanthimathinathan

One-Year Outcomes of Critical Care Patients Post-COVID-19 Multisystem Inflammatory Syndrome in Children

JAMA Pediatr. 2021 Aug 30. doi: 10.1001/jamapediatrics.2021.2993.
Parakkal Deepak, Wooseob Kim, Michael A Paley et al.

Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study

Ann Intern Med. 2021 Aug 31. doi: 10.7326/M21-1757.
A David Paltiel, Jason L Schwartz

Assessing COVID-19 Prevention Strategies to Permit the Safe Opening of Residential Colleges in Fall 2021

Ann Intern Med. 2021 Aug 31. doi: 10.7326/M21-2965.
Florian A Lempp, Leah Soriaga, Martin Montiel-Ruiz et al.

Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies

Nature. 2021 Aug 31. doi: 10.1038/s41586-021-03925-1.
Lucie Loyal, Julian Braun, Larissa Henze et al.

Cross-reactive CD4 + T cells enhance SARS-CoV-2 immune responses upon infection and vaccination

Science. 2021 Aug 31;eabh1823. doi: 10.1126/science.abh1823.
Yolanda M Brooks, Bailey Gryskwicz, Shawn Sheehan et al.

Detection of SARS-CoV-2 in Wastewater at Residential College, Maine, USA, August-November 2020

Emerg Infect Dis. 2021 Aug 31;27(12). doi: 10.3201/eid2712.211199.
Leigh Smith, Sara Pau, Susan Fallon et al.

Impact of Weekly Asymptomatic Testing for SARS-CoV-2 Virus in Inpatients at an Academic Hospital

Infect Control Hosp Epidemiol. 2021 Aug 27;1-8. doi: 10.1017/ice.2021.384.
N Esther Babady, Bevin Cohen, Tara McClure et al.

Variable Duration of Viral Shedding in Cancer Patients with COVID-19

Infect Control Hosp Epidemiol. 2021 Aug 27;1-15. doi: 10.1017/ice.2021.378.
Diego A Martinez, Eili Y Klein, Cassandra Parent et al.

Latino Household Transmission of SARS-CoV-2

Clin Infect Dis. 2021 Aug 31;ciab753. doi: 10.1093/cid/ciab753.
Sara Carazo, Denis Talbot, Nicole Boulianne et al.

Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec, Canada

Clin Infect Dis. 2021 Aug 30;ciab739. doi: 10.1093/cid/ciab739.
Shanna A Arnold Egloff, Angela Junglen, Joseph Sa Restivo et al.

Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19

J Clin Invest. 2021 Aug 31;151788. doi: 10.1172/JCI151788.
Sixten Körper, Manfred Weiss, Daniel Zickler et al.

Results of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients

J Clin Invest. 2021 Aug 31;152264. doi: 10.1172/JCI152264.
Noam Barda, Noa Dagan, Yatir Ben-Shlomo et al.

Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting

N Engl J Med. 2021 Aug 25. doi: 10.1056/NEJMoa2110475.

イスラエル最大の医療機関グループのデータを用いたPfizer社製の新型コロナワクチン（BNT162b2）の安全性に関する研究
Günalp Uzun, Karina Althaus, Tamam Bakchoul

No Correlation between Anti-PF4 and Anti-SARS-CoV-2 Antibodies after ChAdOx1 nCoV-19 Vaccination

N Engl J Med. 2021 Aug 25. doi: 10.1056/NEJMc2111305.

AstraZeneca社製の新型コロナワクチン（ChAdOx1-S）接種後の抗PF4抗体と抗SARS-CoV-2抗体の相関関係
Lixue Huang, Qun Yao, Xiaoying Gu et al.

1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study

Lancet. 2021 Aug 28;398(10302):747-758. doi: 10.1016/S0140-6736(21)01755-4.

新型コロナウイルスで入院していた生存者の半年後および1年間の転帰をみた病院ベースのコホート研究
Vimvara Vacharathit, Pakorn Aiewsakun, Suwimon Manopwisedjaroen et al.

CoronaVac induces lower neutralising activity against variants of concern than natural infection

Lancet Infect Dis. 2021 Aug 26;S1473-3099(21)00568-5. doi: 10.1016/S1473-3099(21)00568-5.

中国Sinovac Biotech社製不活化ワクチン（CoronaVac）で誘導される懸念される変異株に対する中和抗体価は自然免疫で誘導される抗体価よりも低い
Julia Hippisley-Cox, Martina Patone, Xue W Mei et al.

Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study

BMJ. 2021 Aug 26;374:n1931. doi: 10.1136/bmj.n1931.

新型コロナワクチン接種した者またはSARS-CoV-2陽性者における血栓症および血小板減少症のリスクを検討した自己対照ケースシリーズ
Yang Ge, Leonardo Martinez, Shengzhi Sun et al.

COVID-19 Transmission Dynamics Among Close Contacts of Index Patients With COVID-19: A Population-Based Cohort Study in Zhejiang Province, China

JAMA Intern Med. 2021 Aug 23. doi: 10.1001/jamainternmed.2021.4686.

感染源の発症からの日数と2次感染率の関係や感染源の発症の有無と2次感染者の症状の相関について検討した接触者追跡調査
Marike Andreas, Vanessa Piechotta, Nicole Skoetz et al.

Interventions for palliative symptom control in COVID-19 patients

Cochrane Database Syst Rev. 2021 Aug 23;8:CD015061. doi: 10.1002/14651858.CD015061.

COVID-19患者の緩和ケアに関するコクランレビュー
Sen Pei, Teresa K Yamana, Sasikiran Kandula, Marta Galanti, Jeffrey Shaman

Burden and characteristics of COVID-19 in the United States during 2020

Nature. 2021 Aug 26. doi: 10.1038/s41586-021-03914-4.

米国における2020年のCOVID-19の疾患負荷を郡レベルで検討したモデリングと血清疫学調査結果を用いた検証
Medini K Annavajhala, Hiroshi Mohri, Pengfei Wang et al.

Emergence and expansion of SARS-CoV-2 B.1.526 after identification in New York

Nature. 2021 Aug 24. doi: 10.1038/s41586-021-03908-2.

米国のNY州で確認されたB.1.526系統の変異株（イオタ株）の出現とB.1.1.7系統（アルファ株）やB.1.617.2系統（デルタ株）の台頭前の流行
Chia C Wang, Kimberly A Prather, Josué Sznitman et al.

Airborne transmission of respiratory viruses

Science. 2021 Aug 27;373(6558):eabd9149. doi: 10.1126/science.abd9149.

SARS-CoV-2を含む呼吸器系ウイルスのエアロゾル感染に関するナラティブレビュー
Monique G P van der Wijst, Sara E Vazquez, George C Hartoularos et al.

Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19

Sci Transl Med. 2021 Aug 24;eabh2624. doi: 10.1126/scitranslmed.abh2624.

COVID-19患者におけるI型インターフェロンに対する自己抗体とこれに関連する免疫的異常の解析
Laura A VanBlargan, Lucas J Adams, Zhuoming Liu et al.

A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope

Immunity. 2021 Aug 18. doi: 10.1016/j.immuni.2021.08.016.

SARS-CoV-2の懸念すべき変異株を中和可能なモノクローナル抗体の解析
Bhavini Patel Murthy, Elizabeth Zell, Ryan Saelee et al.

COVID-19 Vaccination Coverage Among Adolescents Aged 12-17 Years - United States, December 14, 2020-July 31, 2021

MMWR Morb Mortal Wkly Rep. 2021 Sep 3;70(35):1206-1213. doi: 10.15585/mmwr.mm7035e1.

米国における、2021年7月時点の12-17歳児の新型コロナワクチン接種率
Tracy Lam-Hine, Stephen A McCurdy, Lisa Santora et al.

Outbreak Associated with SARS-CoV-2 B.1.617.2 (Delta) Variant in an Elementary School - Marin County, California, May-June 2021

MMWR Morb Mortal Wkly Rep. 2021 Sep 3;70(35):1214-1219. doi: 10.15585/mmwr.mm7035e2.

米国カリフォルニア州の小学校で発生した、ワクチン未接種の教師から生徒へ感染したSARS-CoV-2のB.1.617.2系統の変異株（デルタ株）によるアウトブレイク事例
Ashley Fowlkes, Manjusha Gaglani, Kimberly Groover et al.

Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance - Eight U.S. Locations, December 2020-August 2021

MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1167-1169. doi: 10.15585/mmwr.mm7034e4.

2020年12月から2021年8月に米国6州・8地域で行われた、デルタ株（B.1.617.2系統）出現前後の新型コロナワクチン有効性の比較
Jennifer B Griffin, Meredith Haddix, Phoebe Danza et al.

SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status - Los Angeles County, California, May 1-July 25, 2021

MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1170-1176. doi: 10.15585/mmwr.mm7034e5.

SARS-CoV-2感染者とCOVID-19入院者における新型コロナワクチン接種歴の有無の検討（2021年5月～7月；米国カリフォルニア州ロサンゼルス郡）
Hae-Young Kim, In-Hwan Oh, Jacob Lee et al.

Policy Review and Modeling Analysis of Mitigation Measures for Coronavirus Disease Epidemic Control, Health System, and Disease Burden, South Korea

Emerg Infect Dis. 2021 Aug 24;27(11). doi: 10.3201/eid2711.203779.

COVID-19流行初期の段階で、全員入院とはせず、無症状～中等症の患者の治療センターで外来中心の治療をうける方針とすることで、医療資源を有効に活用できるとする数理モデルによるポリシーレビュー
Haogao Gu, Daniel K W Chu, Lydia D J Chang et al.

Genetic Diversity of SARS-CoV-2 among Travelers Arriving in Hong Kong

Emerg Infect Dis. 2021 Aug 23;27(10). doi: 10.3201/eid2710.211028.

香港に到着した国際線旅客におけるSARS-CoV-2のゲノムの多様性
David W McCormick, Kiersten J Kugeler, Grace E Marx et al.

Effects of COVID-19 Pandemic on Reported Lyme Disease, United States, 2020

Emerg Infect Dis. 2021 Aug 23;27(10). doi: 10.3201/eid2710.210903.

米国におけるパンデミックのライム病報告への影響
Peter Willeit, Benoît Bernar, Christoph Zurl et al.

Sensitivity and specificity of the antigen-based anterior nasal self-testing programme for detecting SARS-CoV-2 infection in schools, Austria, March 2021

Euro Surveill. 2021 Aug;26(34). doi: 10.2807/1560-7917.ES.2021.26.34.2100797.

鼻前庭から自己採取する抗原検査による、学校（6歳-16歳）におけるスクリーニング検査は、特異度は高かったが、感度が低～中程度であり、2次感染予防には基本的な感染予防策が重要とする報告（オーストラリア、2021年3月）
Stefanie Theuring, Marlene Thielecke, Welmoed van Loon et al.

SARS-CoV-2 infection and transmission in school settings during the second COVID-19 wave: a cross-sectional study, Berlin, Germany, November 2020

Euro Surveill. 2021 Aug;26(34). doi: 10.2807/1560-7917.ES.2021.26.34.2100184.

ドイツ第2波（2020年秋～冬）期間中の学校(9歳-18歳）においては、学校内での2次感染は認めず、学校が感染拡大をもたらす要因ではなかったとする報告（ベルリン、2020年11月における横断的研究）
Kavin M Patel, Amyn A Malik, Aiden Lee et al.

COVID-19 Vaccine Uptake Among US Child Care Providers

Pediatrics. 2021 Aug 27;e2021053813. doi: 10.1542/peds.2021-053813.

米国におけるチャイルドケアプロバイダーの新型コロナワクチン接種率
Mohamed Abbas, Tomás Robalo Nunes, Anne Cori et al.

Explosive nosocomial outbreak of SARS-CoV-2 in a rehabilitation clinic: the limits of genomics for outbreak reconstruction

J Hosp Infect. 2021 Aug 27;S0195-6701(21)00308-X. doi: 10.1016/j.jhin.2021.07.013.

リハビリテーションクリニックにおけるクラスター調査と調査におけるウイルスゲノム解析の有用性と限界
Christina D Mack, Caroline Tai, Robby Sikka et al.

SARS-CoV-2 Reinfection: A Case Series from a 12-Month Longitudinal Occupational Cohort

Clin Infect Dis. 2021 Aug 28;ciab738. doi: 10.1093/cid/ciab738.

SARS-CoV-2再感染:12ヶ月長期追跡した職場コホートの症例
Hualei Xin, Yu Li, Peng Wu et al.

Estimating the latent period of coronavirus disease 2019 (COVID-19)

Clin Infect Dis. 2021 Aug 28;ciab746. doi: 10.1093/cid/ciab746.

COVID-19の感染暴露から感染性を有するまでの期間(Latent period)の推定
Sean Wei Xiang Ong, Calvin J Chiew, Li Wei Ang et al.

Clinical and virological features of SARS-CoV-2 variants of concern: a retrospective cohort study comparing B.1.1.7 (Alpha), B.1.315 (Beta), and B.1.617.2 (Delta)

Clin Infect Dis. 2021 Aug 23;ciab721. doi: 10.1093/cid/ciab721.

SARS-CoV-2変異株の臨床的、ウイルス学的特徴: B.1.1.7 (アルファ株), B.1.351(ベータ株), and B.1.617.2 (デルタ株)の後ろ向きコホート研究
Felix Buder, Markus Bauswein, Clara L Magnus et al.

SARS-CoV-2 infectivity correlates with high viral loads and detection of viral antigen and is terminated by seroconversion

J Infect Dis. 2021 Aug 24;jiab415. doi: 10.1093/infdis/jiab415.

SARS-CoV-2の感染性と高ウイルス量、ウイルス抗原、セロコンバージョンとの関連
Yiu Chung Lau, Tim K Tsang, Lee Kennedy-Shaffer et al.

Joint Estimation Of Generation Time And Incubation Period For Coronavirus Disease (Covid-19)

J Infect Dis. 2021 Aug 23;jiab424. doi: 10.1093/infdis/jiab424.

COVID-19の世代時間と潜伏期間の推定
Frederick K Korley, Valerie Durkalski-Mauldin, Sharon D Yeatts et al.

Early Convalescent Plasma for High-Risk Outpatients with Covid-19

N Engl J Med. 2021 Aug 18. doi: 10.1056/NEJMoa2103784.

発症早期のCOVID-19患者に対する、COVID-19回復期血漿投与に関する多施設単盲検ランダム化比較試験
Chee-Wah Tan, Wan-Ni Chia, Barnaby E Young et al.

Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors

N Engl J Med. 2021 Aug 18. doi: 10.1056/NEJMoa2108453.

SARSからの回復者におけるPfizer社製の新型コロナワクチン（BNT162b2）接種後のSarbecovirus亜属（SARS-CoV-1、SARS-CoV-2などが含まれる）に対する中和抗体
Amanda K Verma, Kory J Lavine, Chieh-Yu Lin

Myocarditis after Covid-19 mRNA Vaccination

N Engl J Med. 2021 Aug 18. doi: 10.1056/NEJMc2109975.

mRNAワクチン（Pfizer社製の新型コロナワクチン、Moderna社製の新型コロナワクチン）接種後に心筋炎を発症した2症例の概要
Stephan Ehrmann, Jie Li, Miguel Ibarra-Estrada et al.

Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial

Lancet Respir Med. 2021 Aug 20;S2213-2600(21)00356-8. doi: 10.1016/S2213-2600(21)00356-8.

酸素投与を要するCOVID-19患者に対する腹臥位の有効性について検討した、6臨床試験共同の非盲検ランダム化比較試験
Georg Mn Behrens, Anne Cossmann, Metodi V Stankov et al.

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination

Lancet. 2021 Aug 17;S0140-6736(21)01891-2. doi: 10.1016/S0140-6736(21)01891-2.

AstraZeneca社製の新型コロナワクチン2回接種群と、AstraZeneca社製ワクチン接種後にPfizer社製ワクチンを接種した群におけるSARS-CoV-2変異株（アルファ株、ベータ株、ガンマ株、デルタ株）に対する中和活性
Davies Adeloye, Omer Elneima, Luke Daines et al.

The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease

Lancet Respir Med. 2021 Aug 17;S2213-2600(21)00286-1. doi: 10.1016/S2213-2600(21)00286-1.

Long COVIDに関する優先度の高い研究についての国際的コンセンサス
Eric Yuk Fai Wan, Celine Sze Ling Chui, Francisco Tsz Tsun Lai et al.

Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study

Lancet Infect Dis. 2021 Aug 16;S1473-3099(21)00451-5. doi: 10.1016/S1473-3099(21)00451-5.

香港における、Pfizer社製の新型コロナワクチン（BNT162b2）と中国Sinovac Biotech社製不活化ワクチン（CoronaVac）接種後のベル麻痺発症に関する、症例集積研究およびコホート内症例対照研究
Ho Kwong Li, Myrsini Kaforou, Jesus Rodriguez-Manzano et al.

Discovery and validation of a three-gene signature to distinguish COVID-19 and other viral infections in emergency infectious disease presentations: a case-control and observational cohort study

Lancet Microbe. 2021 Aug 16. doi: 10.1016/S2666-5247(21)00145-2.

救急外来におけるCOVID-19を含めたウイルス感染症と細菌感染症を識別する遺伝子パターンの検討とこれにより同定された宿主の3つの遺伝子発現パターンの精度評価
Hannah Chung, Siyi He, Sharifa Nasreen et al.

Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study

BMJ. 2021 Aug 20;374:n1943. doi: 10.1136/bmj.n1943.

カナダのオンタリオ州における、Pfizer社製の新型コロナワクチン（BNT162b2）とModerna社製の新型コロナワクチン（mRNA-1273）のCOVID-19発症、および重症化（入院、死亡）予防効果を検討した症例対照研究（test negative design）
Otavio T Ranzani, Matt D T Hitchings, Murilo Dorion et al.

Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study

BMJ. 2021 Aug 20;374:n2015. doi: 10.1136/bmj.n2015.

ブラジルのサンパウロにおける、中国Sinovac Biotech社製不活化ワクチン（CoronaVac）のCOVID-19発症、および重症化（入院、死亡）予防を検討した症例対照研究（test negative design）
Carmen Cabezas, Ermengol Coma, Nuria Mora-Fernandez et al.

Associations of BNT162b2 vaccination with SARS-CoV-2 infection and hospital admission and death with covid-19 in nursing homes and healthcare workers in Catalonia: prospective cohort study

BMJ. 2021 Aug 18;374:n1868. doi: 10.1136/bmj.n1868.

スペインのカタルーニャ州で実施された、高齢者施設入居者、職員と医療従事者における、Pfizer社製の新型コロナワクチンのCOVID-19感染、および重症化（入院、死亡）予防を検討した前向きコホート研究
Amanda K Debes, Shaoming Xiao, Elizabeth Colantuoni et al.

Association of Vaccine Type and Prior SARS-CoV-2 Infection With Symptoms and Antibody Measurements Following Vaccination Among Health Care Workers

JAMA Intern Med. 2021 Aug 16. doi: 10.1001/jamainternmed.2021.4580.

SARS-CoV-2感染の既往の有無と、新型コロナワクチン接種後の抗体価、副反応の関連（医療従事者を対象とした、Moderna社製（mRNA-1273）とPfizer社製（BNT162b2）比較）
Joshua R Vest, Justin Blackburn, Shama Cash-Goldwasser, Eleanor Peters Bergquist, Peter J Embi

Mask-Wearing Behavior at the 2021 NCAA Men's Basketball Tournament

JAMA. 2021 Aug 16. doi: 10.1001/jama.2021.14057.

全米大学体育協会（NCAA）のバスケットボールトーナメントの観客におけるマスクの着用状況
Lauren A Paul, Nick Daneman, Kevin L Schwartz et al.

Association of Age and Pediatric Household Transmission of SARS-CoV-2 Infection

JAMA Pediatr. 2021 Aug 16. doi: 10.1001/jamapediatrics.2021.2770.

0－17歳の年齢層では、年少の小児ほど家庭内感染させる可能性が高かったとする報告（カナダ、2020年6月-12月における観察研究）
Carina Wagner, Mirko Griesel, Agata Mikolajewska et al.

Systemic corticosteroids for the treatment of COVID-19

Cochrane Database Syst Rev. 2021 Aug 16;8:CD014963. doi: 10.1002/14651858.CD014963.

COVID‐19に対するステロイドの全身的投与の効果に関するシステマティックレビュー
David N Fisman, Amy L Greer, Gabrielle Brankston et al.

COVID-19 Case Age Distribution: Correction for Differential Testing by Age

Ann Intern Med. 2021 Aug 17;M20-7003. doi: 10.7326/M20-7003.

受診行動を考慮にいれた数理モデルによる、年齢群別報告数の推定
Emily Breza, Fatima Cody Stanford, Marcella Alsan et al.

Effects of a large-scale social media advertising campaign on holiday travel and COVID-19 infections: a cluster randomized controlled trial

Nat Med. 2021 Aug 19. doi: 10.1038/s41591-021-01487-3.

医療従事者によるSNSを利用した、外出自粛の呼びかけの効果（米国におけるクラスターランダム化比較試験）
Caroline E Wagner, Chadi M Saad-Roy, Sinead E Morris et al.

Vaccine nationalism and the dynamics and control of SARS-CoV-2

Science. 2021 Aug 17;e. doi: 10.1126/science.abj7364.

ワクチン・ナショナリズムのSARS-CoV-2の流行への影響を検討したモデリング
Irfan Ullah, Jérémie Prévost, Mark S Ladinsky et al.

Live Imaging of SARS-CoV-2 Infection in Mice Reveals that Neutralizing Antibodies Require Fc Function for Optimal Efficacy

Immunity. 2021 Aug 17. doi: 10.1016/j.immuni.2021.08.015.

マウスのlive imagingを用いてモノクローナル抗体療法におけるエフェクター機能の必要性を検討した研究
Edward C Holmes, Stephen A Goldstein, Angela L Rasmussen et al.

The Origins of SARS-CoV-2: A Critical Review

Cell. 2021 Aug 18;S0092-8674(21)00991-0. doi: 10.1016/j.cell.2021.08.017.

SARS-CoV-2の起源についてのナラティブレビュー
Benedetta Sposito, Achille Broggi, Laura Pandolfi et al.

The interferon landscape along the respiratory tract impacts the severity of COVID-19

Cell. 2021 Aug 18;S0092-8674(21)00990-9. doi: 10.1016/j.cell.2021.08.016.

気道内のインターフェロン産生状況が重症度に影響を与えるとする報告
Ben Jackson, Maciej F Boni, Matthew J Bull et al.

Generation and transmission of inter-lineage recombinants in the SARS-CoV-2 pandemic

Cell. 2021 Aug 16;S0092-8674(21)00984-3. doi: 10.1016/j.cell.2021.08.014.

異なる系統間の遺伝子組換えにより発生したと推定されるSARS-CoV-2の伝播
Aaron J Schmitz, Jackson S Turner, Zhuoming Liu et al.

A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants

Immunity. 2021 Aug 16. doi: 10.1016/j.immuni.2021.08.013.

複数懸念すべき変異株（VOC）を含むSARS-CoV-2を中和可能なワクチンで付与されたモノクローナル抗体の解析
Lauren M Rossen, Farida B Ahmad, Robert N Anderson et al.

Disparities in Excess Mortality Associated with COVID-19 - United States, 2020

MMWR Morb Mortal Wkly Rep. 2021 Aug 20;70(33):1114-1119. doi: 10.15585/mmwr.mm7033a2.

2020年の超過死亡は、65歳以上の黒人、ヒスパニック系において最も高かった
Ellen Hodges, Brian Lefferts, Elizabeth Bates et al.

Use of Rapid Antigen Testing for SARS-CoV-2 in Remote Communities - Yukon-Kuskokwim Delta Region, Alaska, September 15, 2020-March 1, 2021

MMWR Morb Mortal Wkly Rep. 2021 Aug 20;70(33):1120-1123. doi: 10.15585/mmwr.mm7033a3.

アラスカ州の僻地におけるSARS-CoV-2抗原検査キットの使用とその有用性の検討
Eli S Rosenberg, David R Holtgrave, Vajeera Dorabawila et al.

New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status - New York, May 3-July 25, 2021

MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1150-1155. doi: 10.15585/mmwr.mm7034e1.

ニューヨークにおけるワクチン接種有無別、成人の新規COVID-19感染者数と入院者数 (2021年5月3日から7月25日）
Mark W Tenforde, Wesley H Self, Eric A Naioti et al.

Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021

MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1156-1162. doi: 10.15585/mmwr.mm7034e2.

米国におけるPfizer社製の新型コロナワクチン（BNT162b2)とModerna社製の新型コロナワクチン（mRNA-1273）のCOVID-19関連の入院予防効果の6ヶ月後までの持続 (2021年3月-7月)
Srinivas Nanduri, Tamara Pilishvili, Gordana Derado et al.

Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021

MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1163-1166. doi: 10.15585/mmwr.mm7034e3.

高齢者施設におけるSARS-CoV-2 B.1.617.2 (デルタ株)蔓延前後のPfizer社製の新型コロナワクチン（BNT162b2)とModerna社製の新型コロナワクチン（mRNA-1273）による感染予防効果
Sarah C Tinker, Christine M Szablewski, Anastasia P Litvintseva et al.

Point-of-Care Antigen Test for SARS-CoV-2 in Asymptomatic College Students

Emerg Infect Dis. 2021 Aug 16;27(10). doi: 10.3201/eid2710.210080.

無症状の大学生を対象としたSARS-CoV-2の抗原検査キットの有用性検討
Eunju Lee, Yeon-Kyeong Lee, Tae Eun Kim et al.

Reports of anaphylaxis after coronavirus disease 2019 vaccination, South Korea, 26 February to 30 April 2021

Euro Surveill. 2021 Aug;26(33). doi: 10.2807/1560-7917.ES.2021.26.33.2100694.

韓国における新型コロナワクチン接種後のアナフィラキシーの報告 (2021年2月-4月)
Dolores Sabina Romero Ramìreza, Marìa Magdalena Lara Pérez, Mercedes Carretero Pérez et al.

SARS-CoV-2 Antibodies in Breast Milk After Vaccination

Pediatrics. 2021 Aug 18;e2021052286. doi: 10.1542/peds.2021-052286.

新型コロナワクチン接種後の母乳中の抗SARS-CoV-2抗体
Sofia Myhrman, Josefin Olausson, Johan Ringlander et al.

Unexpected details regarding nosocomial transmission revealed by whole-genome sequencing of SARS-CoV-2

Infect Control Hosp Epidemiol. 2021 Aug 20;1-19. doi: 10.1017/ice.2021.374.

SARS-CoV-2の全ゲノム解析によって明らかにされた院内感染　病院ベースの後ろ向きコホート調査
Carlos K H Wong, Kristy T K Lau, Ivan C H Au et al.

Optimal timing of remdesivir initiation in hospitalized COVID-19 patients administered with dexamethasone

Clin Infect Dis. 2021 Aug 22;ciab728. doi: 10.1093/cid/ciab728.

デキサメサゾンによる治療を受けている新型コロナウイルス入院患者へのレムデシビル投与開始の最適なタイミングを検討した後ろ向きコホート観察研究
Shivakumar Narayanan, Joel V Chua, John W Baddley

COVID-19 associated Mucormycosis (CAM): risk factors and mechanisms of disease

Clin Infect Dis. 2021 Aug 22;ciab726. doi: 10.1093/cid/ciab726.

COVID-19関連のムコール症についてのナラティブレビュー
Ioannis Baltas, Florencia A T Boshier, Charlotte A Williams et al.

Post-vaccination COVID-19: A case-control study and genomic analysis of 119 breakthrough infections in partially vaccinated individuals

Clin Infect Dis. 2021 Aug 19;ciab714. doi: 10.1093/cid/ciab714.

Pfizer社製の新型コロナワクチン（BNT162b2）もしくはAstraZeneca社製の新型コロナワクチン（ChAdOx1-S）を1回接種した後に罹患したCOVID-19感染者の臨床経過および感染したウイルスゲノムを未接種者と比較した症例対照研究
Fatimah S Dawood, Michael Varner, Alan Tita et al.

Incidence, Clinical Characteristics, and Risk Factors of SARS-CoV-2 Infection among Pregnant Individuals in the United States

Clin Infect Dis. 2021 Aug 19;ciab713. doi: 10.1093/cid/ciab713.

米国の3施設における妊婦のSARS-CoV-2の感染率、臨床的特徴、および危険因子を見た後ろ向きコホート研究
Jonathan Fintzi, Tyler Bonnett, Daniel A Sweeney et al.

Deconstructing the Treatment Effect of Remdesivir in the Adaptive COVID-19 Treatment Trial-1: Implications for Critical Care Resource Utilization

Clin Infect Dis. 2021 Aug 19;ciab712. doi: 10.1093/cid/ciab712.

レムデシビルによる入院期間短縮が示唆されたランダム化比較試験ACTT-1の臨床経過の事後解析
Can Li, Yanxia Chen, Yan Zhao et al.

Intravenous injection of COVID-19 mRNA vaccine can induce acute myopericarditis in mouse model

Clin Infect Dis. 2021 Aug 18;ciab707. doi: 10.1093/cid/ciab707.

マウスモデルにおけるmRNAベースの新型コロナワクチンの経静脈接種による心筋炎の誘発
Kashif Ali, Gary Berman, Honghong Zhou et al.

Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents

N Engl J Med. 2021 Aug 11. doi: 10.1056/NEJMoa2109522.

12歳-17歳を対象にしたModerna社製の新型コロナワクチン（mRNA-1273）の第2-3相ランダム化比較試験の中間報告
Victoria G Hall, Victor H Ferreira, Terrance Ku et al.

Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients

N Engl J Med. 2021 Aug 11. doi: 10.1056/NEJMc2111462.

臓器移植者における3回目のModerna社製の新型コロナワクチン（mRNA-1273）接種の免疫応答への効果を検討したランダム化比較試験
Sue Pavord, Marie Scully, Beverley J Hunt et al.

Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis

N Engl J Med. 2021 Aug 11. doi: 10.1056/NEJMoa2109908.

AstraZeneca社製の新型コロナワクチン（ChAdOx1）接種後の血小板減少症を伴う血栓症の臨床像
Luke B Snell, Penelope R Cliff, Themoula Charalampous et al.

Rapid genome sequencing in hospitals to identify potential vaccine-escape SARS-CoV-2 variants

Lancet Infect Dis. 2021 Aug 13;S1473-3099(21)00482-5. doi: 10.1016/S1473-3099(21)00482-5.

免疫逃避が疑われる新規の変異を認めたB.1.621系統のウイルスに個別に感染したと考えられる2例の症例報告：ブレイクスルー感染における迅速なウイルスゲノム解析の有用性
David Hillus, Tatjana Schwarz, Pinkus Tober-Lau et al.

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study

Lancet Respir Med. 2021 Aug 12;S2213-2600(21)00357-X. doi: 10.1016/S2213-2600(21)00357-X.

新型コロナワクチンの1回目接種と2回目接種の種類が同じ場合と異なる場合の安全性、副反応、免疫原性の比較（Moderna社製（mRNA-1273）とAstraZeneca社製（ChAdOx1）を用いた前向きコホート研究）
Rachael Pung, Tze Minn Mak, CMMID COVID-19 working group, Adam J Kucharski, Vernon J Lee

Serial intervals in SARS-CoV-2 B.1.617.2 variant cases

Lancet. 2021 Aug 10;S0140-6736(21)01697-4. doi: 10.1016/S0140-6736(21)01697-4.

新規変異株（B.1.617.2系統）の発症間隔の推定
Ly-Mee Yu, Mona Bafadhel, Jienchi Dorward et al.

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Lancet. 2021 Aug 10;S0140-6736(21)01744-X. doi: 10.1016/S0140-6736(21)01744-X.

英国における自宅療養中の重症化リスクの高いCOVID-19患者を対象とした吸入ステロイド (ブデソニド)のランダム化比較試験
Kathy Leung, Joseph T Wu, Gabriel M Leung

Effects of adjusting public health, travel, and social measures during the roll-out of COVID-19 vaccination: a modelling study

Lancet Public Health. 2021 Aug 10;S2468-2667(21)00167-5. doi: 10.1016/S2468-2667(21)00167-5.

新型コロナワクチン導入後の公衆衛生的・社会的対策や移動制限と流行状況との相関を検討したモデリング
Zion Congrave-Wilson, Yesun Lee, Jaycee Jumarang et al.

Change in Saliva RT-PCR Sensitivity Over the Course of SARS-CoV-2 Infection

JAMA. 2021 Aug 13. doi: 10.1001/jama.2021.13967.

SARS-CoV-2感染診断後・発症後の日数によって変化する唾液のRT-PCR検査の感度
Abigail I Leibowitz, Mark J Siedner, Alexander C Tsai, Amir M Mohareb

Association Between Prison Crowding and COVID-19 Incidence Rates in Massachusetts Prisons, April 2020-January 2021

JAMA Intern Med. 2021 Aug 9;e214392. doi: 10.1001/jamainternmed.2021.4392.

米国マサチューセッツ州の刑務所における刑務所の密集度とCOVID-19発生率との関係
John S Tregoning, Katie E Flight, Sophie L Higham, Ziyin Wang, Benjamin F Pierce

Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape

Nat Rev Immunol. 2021 Aug 9;1-11. doi: 10.1038/s41577-021-00592-1.

新型コロナワクチンの包括的なナラティブレビュー：ウイルス、ワクチン、変異株と、ワクチン効果と免疫回避
Setu M Vora, Judy Lieberman, Hao Wu

Inflammasome activation at the crux of severe COVID-19

Nat Rev Immunol. 2021 Aug 9;1-10. doi: 10.1038/s41577-021-00588-x.

SARS-CoV-2におけるインフラマソームの役割についてのナラティブレビュー
Amarendra Pegu, Sarah O'Connell, Stephen D Schmidt et al.

Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants

Science. 2021 Aug 12;eabj4176. doi: 10.1126/science.abj4176.

Moderna社製の新型コロナワクチン（mRNA-1273）によって産生されるSARS-CoV-2変異株に対する抗体の持続性
Richard A Urbanowicz, Theocharis Tsoleridis, Hannah J Jackson et al.

Two doses of the SARS-CoV-2 BNT162b2 vaccine enhances antibody responses to variants in individuals with prior SARS-CoV-2 infection

Sci Transl Med. 2021 Aug 10;eabj0847. doi: 10.1126/scitranslmed.abj0847.

SARS-CoV-2既感染者のPfizer社製の新型コロナワクチン（BNT162b2）2回接種後の変異株に対する抗体反応
Mark M Painter, Divij Mathew, Rishi R Goel et al.

Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immune responses to SARS-CoV-2 mRNA vaccination

Immunity. 2021 Aug 12. doi: 10.1016/j.immuni.2021.08.001.

mRNAベースの新型コロナワクチン接種後のCD+4 T細胞の迅速な誘導とその後の液性および細胞性免疫応答
Paula Yoon, Jeffrey Hall, Jennifer Fuld et al.

Alternative Methods for Grouping Race and Ethnicity to Monitor COVID-19 Outcomes and Vaccination Coverage

MMWR Morb Mortal Wkly Rep. 2021 Aug 13;70(32):1075-1080. doi: 10.15585/mmwr.mm7032a2.

SARS-CoV-2感染および新型コロナワクチン接種率を把握するための人種および民族の欠損値の取扱いについての比較検討
Hannah G Rosenblum, Stephen C Hadler, Danielle Moulia et al.

Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021

MMWR Morb Mortal Wkly Rep. 2021 Aug 13;70(32):1094-1099. doi: 10.15585/mmwr.mm7032e4.

米国ワクチン接種に関する諮問委員会（ACIP）によるmRNAベースの新型コロナワクチン2種およびJanssen/Johnson and Johnson社製のワクチン（Ad26.COV2.S）接種のリスク・ベネフィット解析
Catherine A Hogan, Agatha N Jassem, Hind Sbihi et al.

Rapid Increase in SARS-CoV-2 P.1 Lineage Leading to Codominance with B.1.1.7 Lineage, British Columbia, Canada, January-April 2021

Emerg Infect Dis. 2021 Aug 13;27(11). doi: 10.3201/eid2711.211190.

カナダのブリティッシュコロンビアにおけるSARS-CoV-2の変異株B.1.1.7系統（アルファ株）、B.1.351系統（ベータ株）、P.1系統（ガンマ株）の推移
Jordan Douglas, Jemma L Geoghegan, James Hadfield et al.

Real-Time Genomics for Tracking Severe Acute Respiratory Syndrome Coronavirus 2 Border Incursions after Virus Elimination, New Zealand

Emerg Infect Dis. 2021 Aug 10;27(9). doi: 10.3201/eid2709.211097.

ニュージーランドにおけるSARS-CoV-2排除後の輸入例から発展した複数のクラスターの迅速なウイルスゲノム解析
Jožko Račnik, Ana Kočevar, Brigita Slavec et al.

Transmission of SARS-CoV-2 from Human to Domestic Ferret

Emerg Infect Dis. 2021 Aug 10;27(9). doi: 10.3201/eid2709.210774.

ヒトからフェレットへのSARS-CoV-2の伝播
Supriya S Jain, Jeremy M Steele, Brian Fonseca et al.

COVID-19 Vaccination-Associated Myocarditis in Adolescents

Pediatrics. 2021 Aug 13;e2021053427. doi: 10.1542/peds.2021-053427.

米国において21歳未満の青少年の新型コロナワクチン接種後に発症した心筋炎とMIS-C患者のコホートの臨床像を比較した後ろ向きコホート研究
David W McCormick, LaTonia Clay Richardson, Paul R Young et al.

Deaths in Children and Adolescents Associated With COVID-19 and MIS-C in the United States

Pediatrics. 2021 Aug 12;e2021052273. doi: 10.1542/peds.2021-052273.

米国における21歳未満の小児・青少年の新型コロナウイルス感染・MIS-C関連死の後ろ向きケースシリーズ
Jonathan B Gubbay, Heather Rilkoff, Heather L Kristjanson et al.

Impact of COVID-19 pre-test probability on positive predictive value of high cycle threshold SARS-CoV-2 real-time reverse transcription PCR test results

Infect Control Hosp Epidemiol. 2021 Aug 9;1-18. doi: 10.1017/ice.2021.369.

PCRのCt値の高い検体（RNA量の少ない検体）における陽性的中率への検査前確率の影響
John T Wilkins, Lisa R Hirschhorn, Elizabeth L Gray et al.

Serologic Status and SARS CoV-2 Infection over 6-Months of Follow-Up in Healthcare Workers in Chicago: A Cohort Study

Infect Control Hosp Epidemiol. 2021 Aug 9;1-29. doi: 10.1017/ice.2021.367.

米国シカゴの医療従事者における抗SARS-CoV-2抗体保有の有無と6ヶ月後までのSARS-CoV-2感染を検討した前向きコホート研究
Tingting Liu, Di Wu, Weiming Yan et al.

Twelve-month systemic consequences of COVID-19 in patients discharged from hospital: a prospective cohort study in Wuhan, China

Clin Infect Dis. 2021 Aug 14;ciab703. doi: 10.1093/cid/ciab703.

中国武漢におけるCOVID-19入院患者の罹患12ヶ月後の後遺症を追跡した前向きコホート研究
Jorge Calderón-Parra, Elena Múñez-Rubio, Ana Fernández-Cruz et al.

Incidence, clinical presentation, relapses and outcome of SARS-CoV-2 infection in patients treated with anti-CD20 monoclonal antibodies

Clin Infect Dis. 2021 Aug 12;ciab700. doi: 10.1093/cid/ciab700.

抗CD20抗体使用者におけるSARS-CoV-2感染の転帰
Carla Cerami, Zachary R Popkin-Hall, Tyler Rapp et al.

Household transmission of SARS-CoV-2 in the United States: living density, viral load, and disproportionate impact on communities of color

Clin Infect Dis. 2021 Aug 12;ciab701. doi: 10.1093/cid/ciab701.

米国における家の密度、感染源と考えられる者のウイルスRNA量、人種と家庭内2次感染の有無の相関を検討した前向きコホート研究
Catharine I Paules, Shannon K Gallagher, Rekha R Rapaka et al.

Remdesivir for the prevention of invasive mechanical ventilation or death in COVID-19 - A post-hoc analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data

Clin Infect Dis. 2021 Aug 11;ciab695. doi: 10.1093/cid/ciab695.

レムデシビルの重症化予防（人工換気、死亡）と重症化リスク因子に関する検討（ACTT-1の事後解析）
Steven J Clipman, Amy Wesolowski, Shruti H Mehta et al.

Improvements in SARS-CoV-2 Testing Cascade in the US: Data from Serial Cross-sectional Assessments

Clin Infect Dis. 2021 Aug 10;ciab683. doi: 10.1093/cid/ciab683.

米国10州におけるSARS-CoV-2検査のアクセス、実施状況等に関する繰り返し横断研究
Jana L Jacobs, William Bain, Asma Naqvi et al.

SARS-CoV-2 Viremia is Associated with COVID-19 Severity and Predicts Clinical Outcomes

Clin Infect Dis. 2021 Aug 10;ciab686. doi: 10.1093/cid/ciab686.

SARS-CoV-2感染者でウイルスRNA血症を認める者における電子顕微鏡を利用したウイルス血症の有無の検討
Ralf Duerr, Dacia Dimartino, Christian Marier et al.

Dominance of alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City

J Clin Invest. 2021 Aug 10;152702. doi: 10.1172/JCI152702.

米国ニューヨーク市における新型コロナワクチン接種の有無とSARS-CoV-2変異株（アルファ株（B.1.1.7）とイオタ株（B.1.526）)の頻度の検討
Lawrence Corey, Chris Beyrer, Myron S Cohen et al.

SARS-CoV-2 Variants in Patients with Immunosuppression

N Engl J Med. 2021 Aug 5;385(6):562-566. doi: 10.1056/NEJMsb2104756.

免疫抑制状態にある患者におけるSARS-CoV-2変異蓄積についての論説
REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

N Engl J Med. 2021 Aug 4. doi: 10.1056/NEJMoa2103417.

重症COVID-19患者に対するヘパリンによる抗凝固療法の治療用量と予防用量を比較したランダム化比較試験
ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19

N Engl J Med. 2021 Aug 4. doi: 10.1056/NEJMoa2105911.

非重症COVID-19患者に対するヘパリンによる抗凝固療法の治療用量と予防用量を比較したランダム化比較試験
Meagan P O'Brien, Eduardo Forleo-Neto, Bret J Musser et al.

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

N Engl J Med. 2021 Aug 4. doi: 10.1056/NEJMoa2109682.

抗体カクテル療法（カシリビマブ／イムデビマブ;ロナプリーブ）の皮下注による濃厚接触者におけるSARS-CoV-2感染およびCOVID-19発症予防を検討したランダム化比較試験
Richard J Perry, Arina Tamborska, Bhagteshwar Singh et al.

Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study

Lancet. 2021 Aug 6;S0140-6736(21)01608-1. doi: 10.1016/S0140-6736(21)01608-1.

英国におけるCOVID-19ワクチン接種後の脳内静脈血栓症：多施設共同コホート研究
Xinxue Liu, Robert H Shaw, Arabella S V Stuart et al.

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

Lancet. 2021 Aug 6;S0140-6736(21)01694-9. doi: 10.1016/S0140-6736(21)01694-9.

アデノウイルスベクターおよびmRNAを用いた新型コロナワクチンの交互接種および単一接種を2通りの接種間隔を用いてこの安全性と免疫原性を検討したランダム化比較試験（Com-COV）
Laura Boekel, Maurice Steenhuis, Femke Hooijberg et al.

Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies

Lancet Rheumatol. 2021 Aug 6;S2665-9913(21)00222-8. doi: 10.1016/S2665-9913(21)00222-8.

オランダにおける自己免疫疾患患者での新型コロナワクチン接種後の抗体応答：2つの前向きコホート研究のデータを用いたサブスタディ
Louise Sigfrid, Thomas M Drake, Ellen Pauley et al.

Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol

Lancet Reg Health Eur. 2021 Aug 5;100186. doi: 10.1016/j.lanepe.2021.100186.

COVID-19の後に英国の病院から退院した成人におけるCOVID後遺症：ISARIC WHO Clinical Characterisation Protocolを用いた前向き多施設コホート研究
Theresa Ryckman, Elizabeth T Chin, Lea Prince et al.

Outbreaks of COVID-19 variants in US prisons: a mathematical modelling analysis of vaccination and reopening policies

Lancet Public Health. 2021 Aug 5;S2468-2667(21)00162-6. doi: 10.1016/S2468-2667(21)00162-6.

米国の刑務所で発生したCOVID-19変異株のアウトブレイク：ワクチン接種と操業再開の数理モデルによる分析
Khushboo Chauhan, Deepak Soni, Deepayan Sarkar et al.

Mucormycosis after COVID-19 in a patient with diabetes

Lancet. 2021 Aug 4;S0140-6736(21)01641-X. doi: 10.1016/S0140-6736(21)01641-X.

糖尿病患者におけるCOVID-19後のムコール症の症例報告
Waasila Jassat, Cheryl Cohen, Stefano Tempia et al.

Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study

Lancet HIV. 2021 Aug 4;S2352-3018(21)00151-X. doi: 10.1016/S2352-3018(21)00151-X.

HIVと結核がまん延する南アフリカにおけるCOVID-19関連の入院と死亡のリスク因子
Erika Molteni, Carole H Sudre, Liane S Canas et al.

Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2

Lancet Child Adolesc Health. 2021 Aug 3;S2352-4642(21)00198-X. doi: 10.1016/S2352-4642(21)00198-X.

英国におけるSARS-CoV-2感染した有症状の学生(5-17歳)の症状持続期間と症状の特徴
Mark Anderson, Michael Stec, Ayesan Rewane et al.

SARS-CoV-2 Antibody Responses in Infection-Naive or Previously Infected Individuals After 1 and 2 Doses of the BNT162b2 Vaccine

JAMA Netw Open. 2021 Aug 2;4(8):e2119741. doi: 10.1001/jamanetworkopen.2021.19741.

未感染者および既感染者におけるPfizer社製の新型コロナワクチン（BNT162b2）の接種後のAbbottの検査系を用いた抗体応答
George A Diaz, Guilford T Parsons, Sara K Gering et al.

Myocarditis and Pericarditis After Vaccination for COVID-19

JAMA. 2021 Aug 4. doi: 10.1001/jama.2021.13443.

新型コロナワクチン接種後の心筋炎と心膜炎
Kushal T Kadakia, Michael D Howell, Karen B DeSalvo

Modernizing Public Health Data Systems: Lessons From the Health Information Technology for Economic and Clinical Health (HITECH) Act

JAMA. 2021 Aug 3;326(5):385-386. doi: 10.1001/jama.2021.12000.

公衆衛生データシステムの現代化：米国HITECH（Health Information Technology for Economic and Clinical Health Act）法からの教訓
Todd C Lee, Julien Senecal, Jimmy M Hsu, Emily G McDonald

Ongoing Citations of a Retracted Study Involving Cardiovascular Disease, Drug Therapy, and Mortality in COVID-19

JAMA Intern Med. 2021 Aug 2;e214112. doi: 10.1001/jamainternmed.2021.4112.

心血管疾患、薬剤とCOVID-19関連死について検討したが撤回された論文の持続的な引用
Daniel Munblit, Louise Sigfrid, John O Warner

Setting Priorities to Address Research Gaps in Long-term COVID-19 Outcomes in Children

JAMA Pediatr. 2021 Aug 2. doi: 10.1001/jamapediatrics.2021.2281.

小児のLong-COVIDに関する研究の必要性を議論した論説
Kelly Ansems, Felicitas Grundeis, Karolina Dahms et al.

Remdesivir for the treatment of COVID‐19

Cochrane Database Syst Rev. 2021 Aug 5;CD014962. doi: 10.1002/14651858.CD014962.

レムデシビルは、入院後の臨床経過や死亡の予後の改善に対して、明らかな効果はなかったとするシステマティックレビュー
Hengchen Dai, Silvia Saccardo, Maria A Han et al.

Behavioral Nudges Increase COVID-19 Vaccinations

Nature. 2021 Aug 2. doi: 10.1038/s41586-021-03843-2.

ワクチン接種に関するリマインダーは接種を向上させたとする報告（Sequential RCT）
Natalia Ortega, Marta Ribes, Marta Vidal et al.

Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses

Nat Commun. 2021 Aug 6;12(1):4740. doi: 10.1038/s41467-021-24979-9.

医療従事者における、SARS-CoV-2抗体の7か月間の血中動態とヒトコロナウイルス抗体の影響
Shasha Han, Jun Cai, Juan Yang et al.

Time-varying optimization of COVID-19 vaccine prioritization in the context of limited vaccination capacity

Nat Commun. 2021 Aug 3;12(1):4673. doi: 10.1038/s41467-021-24872-5.

数理モデルによる、流行状況の推移を考慮した優先すべきワクチン接種対象の設定
Dora Pinto, Maximilian M Sauer, Nadine Czudnochowski et al.

Broad betacoronavirus neutralization by a stem helix-specific human antibody

Science. 2021 Aug 3;eabj3321. doi: 10.1126/science.abj3321.

広汎なベータコロナウイルスを中和可能なstem helixに対するモノクローナル抗体の解析
Karin Bok, Sandra Sitar, Barney S Graham, John R Mascola

Accelerated COVID-19 vaccine development: milestones, lessons, and prospects

Immunity. 2021 Aug 10;54(8):1636-1651. doi: 10.1016/j.immuni.2021.07.017.

新型コロナワクチンの迅速開発の経緯に関する論説
Madison Ashworth, Linda Thunström, Todd L Cherry, Stephen C Newbold, David C Finnoff

Emphasize personal health benefits to boost COVID-19 vaccination rates

Proc Natl Acad Sci U S A. 2021 Aug 10;118(32):e2108225118. doi: 10.1073/pnas.2108225118.

米国で行われた、新型コロナワクチンの接種希望に有効なメッセージに関するアンケート調査の結果の報告
Alyson M Cavanaugh, Kevin B Spicer, Douglas Thoroughman, Connor Glick, Kathleen Winter

Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination - Kentucky, May-June 2021

MMWR Morb Mortal Wkly Rep. 2021 Aug 13;70(32):1081-1083. doi: 10.15585/mmwr.mm7032e1.

米国ケンタッキー州における、COVID-19既感染の新型コロナウイルスワクチンの接種による再感染の予防について調べた症例対照研究
Rachel Herlihy, Wendy Bamberg, Alexis Burakoff et al.

Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - Mesa County, Colorado, April-June 2021

MMWR Morb Mortal Wkly Rep. 2021 Aug 13;70(32):1084-1087. doi: 10.15585/mmwr.mm7032e2.

米国コロラド州メサ郡におけるデルタ株感染症例の記述疫学報告
Heidi L Moline, Michael Whitaker, Li Deng et al.

Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years - COVID-NET, 13 States, February-April 2021

MMWR Morb Mortal Wkly Rep. 2021 Aug 13;70(32):1088-1093. doi: 10.15585/mmwr.mm7032e3.

65歳以上の高齢者における新型コロナワクチンの入院に対する有効性を調べた報告
Aurélie Truffot, Julien Andréani, Marion Le Maréchal et al.

SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody Monotherapy

Emerg Infect Dis. 2021 Aug 5;27(10). doi: 10.3201/eid2710.211509.

SARS-CoV-2持続陽性の免疫不全患者におけるモノクローナル抗体療法使用後のSARS-CoV-2の変異
Dominique A Badr, Olivier Picone, Elisa Bevilacqua et al.

Severe Acute Respiratory Syndrome Coronavirus 2 and Pregnancy Outcomes According to Gestational Age at Time of Infection

Emerg Infect Dis. 2021 Aug 5;27(10). doi: 10.3201/eid2710.211394.

SARS-CoV-2感染時の在胎週数と妊娠のアウトカムを検討した後ろ向きコホート研究
Haruka Maeda, Eiichiro Sando, Michiko Toizumi et al.

Epidemiology of Coronavirus Disease Outbreak among Crewmembers on Cruise Ship, Nagasaki City, Japan, April 2020

Emerg Infect Dis. 2021 Aug 5;27(9). doi: 10.3201/eid2709.204596.

COVID-19クラスターが発生し長崎に停泊したクルーズ船におけるCOVID-19の記述疫学
Brechje de Gier, Stijn Andeweg, Rosa Joosten et al.

Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands, February to May 2021

Euro Surveill. 2021 Aug;26(31). doi: 10.2807/1560-7917.ES.2021.26.31.2100640.

新型コロナワクチンの濃厚接触者における有効性評価
Kimberly Marsh, Emily Griffiths, Johanna J Young, Carrie-Anne Gibb, Jim McMenamin

Contributions of the EURO 2020 football championship events to a third wave of SARS-CoV-2 in Scotland, 11 June to 7 July 2021

Euro Surveill. 2021 Aug;26(31). doi: 10.2807/1560-7917.ES.2021.26.31.2100707.

スコットランドにおける、サッカー大会EURO 2020の感染拡大への寄与を電話インタビューによる接触者追跡データを用いて調査した報告
Adeel A Butt, Hanaa Nafady-Hego, Hiam Chemaitelly et al.

Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination: Breakthrough SARS-CoV-2 infection

Int J Infect Dis. 2021 Aug 7;S1201-9712(21)00639-1. doi: 10.1016/j.ijid.2021.08.008.

Pfizer社製の新型コロナワクチン（BNT162b2）接種後の感染者における重症度について調査した症例対象研究
Decreased neutralization of the Eta SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals

J Infect. 2021 Aug 6;S0163-4453(21)00388-1. doi: 10.1016/j.jinf.2021.08.005.

SARS-CoV-2変異株イータ株（η）の既感染者およびワクチン接種者の抗体による中和能
Georgia Lamb, Joseph Heskin, Paul Randell et al.

Real-world evaluation of COVID-19 lateral flow device (LFD) mass-testing in healthcare workers at a London hospital; a prospective cohort analysis

J Infect. 2021 Aug 5;S0163-4453(21)00383-2. doi: 10.1016/j.jinf.2021.07.038.

ロンドンの病院の医療従事者に対する抗体検査（LFD）の質と量を評価した前向きコホート分析
Alex R Tanner, Hang Phan, Nathan J Brendish et al.

SARS-CoV-2 Viral load at presentation to hospital is independently associated with the risk of death

J Infect. 2021 Aug 4;S0163-4453(21)00384-4. doi: 10.1016/j.jinf.2021.08.003.

入院時のRNAウイルス量と死亡率およびICU入室との関連の検討
Elizabeth Miller, Pauline A Waight, Nick J Andrews et al.

Transmission of SARS-CoV-2 in the household setting: a prospective cohort study in children and adults in England

J Infect. 2021 Aug 1;S0163-4453(21)00380-7. doi: 10.1016/j.jinf.2021.07.037.

英国における子供および大人を対象とした新型コロナウイルスの家庭内感染を見た前向きコホート研究
A Baumeister, T Corrin, H Abid et al.

The Quality of Systematic Reviews and other Synthesis in the Time of COVID-19

Epidemiol Infect. 2021 Aug 3;149:e182. doi: 10.1017/S0950268821001758.

新型コロナウイルスに関するシステマティックレビュー及びその他の総合研究の質の評価
Crystal M North, Amy Barczak, Robert H Goldstein et al.

Determining the Incidence of Asymptomatic SARS-CoV-2 among Early Recipients of COVID-19 Vaccines: A Prospective Cohort Study of Healthcare Workers before, during and after Vaccination [DISCOVER-COVID-19]

Clin Infect Dis. 2021 Aug 7;ciab643. doi: 10.1093/cid/ciab643.

米国のワクチン接種済み医療従事者における無症候性COVID-19の発生率に関する前向きコホート研究
Kristen K Coleman, Douglas Jie Wen Tay, Kai Sen Tan et al.

Viral Load of SARS-CoV-2 in Respiratory Aerosols Emitted by COVID-19 Patients while Breathing, Talking, and Singing

Clin Infect Dis. 2021 Aug 6;ciab691. doi: 10.1093/cid/ciab691.

呼吸、会話、歌唱で発生するエアロゾル中のSARS-CoV-2ウイルスRNA量
Mark W Tenforde, Manish M Patel, Adit A Ginde et al.

Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States

Clin Infect Dis. 2021 Aug 6;ciab687. doi: 10.1093/cid/ciab687.

米国におけるmRNAベースの新型コロナワクチンによる入院予防効果の検討
Alexander Lawandi, Sarah Warner, Junfeng Sun et al.

Suspected SARS-CoV-2 Reinfections: Incidence, Predictors, and Healthcare Use among Patients at 238 U.S. Healthcare Facilities, June 1, 2020- February 28, 2021

Clin Infect Dis. 2021 Aug 5;ciab671. doi: 10.1093/cid/ciab671.

米国の医療従事者におけるSARS-CoV-2再感染発生率と予測因子
Anne M Hause, Julianne Gee, James Baggs et al.

COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years - United States, December 14, 2020-July 16, 2021

MMWR Morb Mortal Wkly Rep. 2021 Aug 6;70(31):1053-1058. doi: 10.15585/mmwr.mm7031e1.

米国の副反応報告（VAERS）/追跡システム（v-safe）にもとづいた、若年層（12-17歳）におけるPfizer社製新型コロナワクチン（BNT162b2）の安全性の評価
Catherine M Brown, Johanna Vostok, Hillary Johnson et al.

Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings - Barnstable County, Massachusetts, July 2021

MMWR Morb Mortal Wkly Rep. 2021 Aug 6;70(31):1059-1062. doi: 10.15585/mmwr.mm7031e2.

ワクチン接種後のブレークスルー感染を含む、大規模集会と関連したアウトブレイク（米国マサチューセッツ州、2021年7月）
Rachelle P Mendoza, Chongfeng Bi, Hui-Ting Cheng et al.

Implementation of a pooled surveillance testing program for asymptomatic SARS-CoV-2 infections in K-12 schools and universities

EClinicalMedicine. 2021 Aug;38:101028. doi: 10.1016/j.eclinm.2021.101028.

英国における幼稚園から大学までの学校の無症候性新型コロナウイルス感染に対する唾液を用いたサーベイランステストプログラム実施の効果
Simon Galmiche, Tiffany Charmet, Laura Schaeffer et al.

Exposures associated with SARS-CoV-2 infection in France: A nationwide online case-control study

Lancet Reg Health Eur. 2021 Aug;7:100148. doi: 10.1016/j.lanepe.2021.100148.

フランスにおけるSARS-CoV-2感染と行動歴との相関を検討した全国オンラインアンケート式の症例対照研究
July 2021
Moriah Bergwerk, Tal Gonen, Yaniv Lustig et al.

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

N Engl J Med. 2021 Jul 28. doi: 10.1056/NEJMoa2109072.

ワクチン接種を完了したイスラエルの医療従事者におけるSARS-CoV-2感染の臨床的特徴および感染時の抗体価
Ioannis Katsoularis, Osvaldo Fonseca-Rodríguez, Paddy Farrington, Krister Lindmark, Anne-Marie Fors Connolly

Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study

Lancet. 2021 Jul 29;S0140-6736(21)00896-5. doi: 10.1016/S0140-6736(21)00896-5.

スウェーデンにおけるCOVID-19後の急性心筋梗塞・脳梗塞発症リスクを検討した自己対照研究・コホート研究
Matthias Tenbusch, Sofie Schumacher, Emanuel Vogel et al.

Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2

Lancet Infect Dis. 2021 Jul 29;S1473-3099(21)00420-5. doi: 10.1016/S1473-3099(21)00420-5.

AstraZeneca社製（ChAdOx1-S）とPfizer社製（BNT162b2）の新型コロナワクチンの異種ブースト接種における抗体価
Liane S Canas, Carole H Sudre, Joan Capdevila Pujol et al.

Early detection of COVID-19 in the UK using self-reported symptoms: a large-scale, prospective, epidemiological surveillance study

Lancet Digit Health. 2021 Jul 29;S2589-7500(21)00131-X. doi: 10.1016/S2589-7500(21)00131-X.

英国におけるスマートフォンアプリを用いた症状の自己申告によるCOVID-19の早期探知を検討した前向きコホート研究
Christopher C Butler, Ly-Mee Yu, Jienchi Dorward et al.

Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Lancet Respir Med. 2021 Jul 27;S2213-2600(21)00310-6. doi: 10.1016/S2213-2600(21)00310-6.

重症化リスクの高いCOVID-19疑い症例に対するドキシサイクリン治療の有効性を検討したランダム化比較試験
Ewoud Schuit, Irene K Veldhuijzen, Roderick P Venekamp et al.

Diagnostic accuracy of rapid antigen tests in asymptomatic and presymptomatic close contacts of individuals with confirmed SARS-CoV-2 infection: cross sectional study

BMJ. 2021 Jul 27;374:n1676. doi: 10.1136/bmj.n1676.

無症状および発症前のCOVID-19濃厚接触者における抗原検査キットの精度を検討した横断研究
Harry Crook, Sanara Raza, Joseph Nowell, Megan Young, Paul Edison

Long covid-mechanisms, risk factors, and management

BMJ. 2021 Jul 26;374:n1648. doi: 10.1136/bmj.n1648.

COVID-19後遺症に関するナラティブレビュー
Jonne J Sikkens, David T P Buis, Edgar J G Peters et al.

Serologic Surveillance and Phylogenetic Analysis of SARS-CoV-2 Infection Among Hospital Health Care Workers

JAMA Netw Open. 2021 Jul 1;4(7):e2118554. doi: 10.1001/jamanetworkopen.2021.18554.

病院の医療従事者におけるSARS-CoV-2感染の血清学的サーベイランスと系統的解析
Henri C Santos, Amir Goren, Christopher F Chabris, Michelle N Meyer

Effect of Targeted Behavioral Science Messages on COVID-19 Vaccination Registration Among Employees of a Large Health System: A Randomized Trial

JAMA Netw Open. 2021 Jul 1;4(7):e2118702. doi: 10.1001/jamanetworkopen.2021.18702.

大規模医療機関の従業員におけるCOVID-19ワクチン接種登録に対する行動科学的メッセージの効果を検討したランダム化比較試験
Felicia Ceban, Danica Nogo, Isidro P Carvalho et al.

Association Between Mood Disorders and Risk of COVID-19 Infection, Hospitalization, and Death: A Systematic Review and Meta-analysis

JAMA Psychiatry. 2021 Jul 28. doi: 10.1001/jamapsychiatry.2021.1818.

気分障害とSARS-CoV-2感染、COVID-19による入院、死亡のリスクとの関連についてのシステマティックレビュー・メタアナリシス
Eric Dean Merrill, Sakeen W Kashem, Erin H Amerson et al.

Association of Facial Pustular Neutrophilic Eruption With Messenger RNA-1273 SARS-CoV-2 Vaccine

JAMA Dermatol. 2021 Jul 28. doi: 10.1001/jamadermatol.2021.2474.

Moderna社製の新型コロナワクチン（mRNA-1273）接種後に発症した顔面膿疱性好中球性発疹2例
Victor M Castro, Thomas H McCoy, Roy H Perlis

Assessment of the Performance Consistency of an Adverse Outcome Prediction Tool for Patients Hospitalized With COVID-19

JAMA Netw Open. 2021 Jul 1;4(7):e2118413. doi: 10.1001/jamanetworkopen.2021.18413.

COVID-19入院患者の重症化予測ツールの時系列的な一貫性の評価
Suze G Berkhout, Kathleen A Sheehan, Susan E Abbey

Individual- and Institutional-level Concerns of Health Care Workers in Canada During the COVID-19 Pandemic: A Qualitative Analysis

JAMA Netw Open. 2021 Jul 1;4(7):e2118425. doi: 10.1001/jamanetworkopen.2021.18425.

COVID-19パンデミック時のカナダにおける医療従事者の個人レベルおよび組織レベルでの懸念事項:質的分析
Guillaume Fond, Katlyn Nemani, Damien Etchecopar-Etchart et al.

Association Between Mental Health Disorders and Mortality Among Patients With COVID-19 in 7 Countries: A Systematic Review and Meta-analysis

JAMA Psychiatry. 2021 Jul 27. doi: 10.1001/jamapsychiatry.2021.2274.

世界7カ国のCOVID-19患者における精神疾患とCOVID-19関連死の関連についてのシステマティックレビュー・メタアナリシス
Matthew S Krantz, Jason H Kwah, Cosby A Stone Jr et al.

Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose

JAMA Intern Med. 2021 Jul 26. doi: 10.1001/jamainternmed.2021.3779.

メッセンジャーRNA COVID-19ワクチンの初回投与で即時反応を示した患者への2回目投与の安全性評価
Maria Popp, Miriam Stegemann, Maria-Inti Metzendorf et al.

Ivermectin for preventing and treating COVID-19

Cochrane Database Syst Rev. 2021 Jul 28;7:CD015017. doi: 10.1002/14651858.CD015017.pub2.

イベルメクチンによるCOVID-19の予防と治療効果を検討したコクランレビュー
Ezekiel J Emanuel, David J Skorton

Mandating COVID-19 Vaccination for Health Care Workers

Ann Intern Med. 2021 Jul 30. doi: 10.7326/M21-3150.

医療従事者における新型コロナワクチン接種義務化についての論説
Valerie Oberhardt, Hendrik Luxenburger, Janine Kemming et al.

Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine

Nature. 2021 Jul 28. doi: 10.1038/s41586-021-03841-4.

SARS-CoV-2 mRNAワクチンによるCD8+T細胞の迅速かつ安定した誘導
Ana C Medeiros-Ribeiro, Nadia E Aikawa, Carla G S Saad et al.

Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial

Nat Med. 2021 Jul 30. doi: 10.1038/s41591-021-01469-5.

自己免疫疾患患者におけるSinoVac社製の新型コロナワクチン（CoronaVac）の免疫原性と安全性：第4相試験
Tina Schmidt, Verena Klemis, David Schub et al.

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination

Nat Med. 2021 Jul 26. doi: 10.1038/s41591-021-01464-w.

AstraZeneca社製の新型コロナワクチン（ChAdOx1-S）とmRNAベースの新型コロナワクチンの交互接種による免疫原性と反応原性
Gita A Pathak, Kritika Singh, Tyne W Miller-Fleming et al.

Integrative genomic analyses identify susceptibility genes underlying COVID-19 hospitalization

Nat Commun. 2021 Jul 27;12(1):4569. doi: 10.1038/s41467-021-24824-z.

COVID-19入院患者を対象とした感受性に関与する遺伝子特定のための統合的遺伝子解析
Satoshi Ikegame, Mohammed N A Siddiquey, Chuan-Tien Hung et al.

Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants

Nat Commun. 2021 Jul 26;12(1):4598. doi: 10.1038/s41467-021-24909-9.

新型コロナワクチン（スプートニクV）接種者のSARS-CoV-2変異株に対する中和抗体反応
Kizzmekia S Corbett, Martha C Nason, Britta Flach et al.

Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates

Science. 2021 Jul 29;eabj0299. doi: 10.1126/science.abj0299.

霊長類モデルにおけるモデルナ社製の新型コロナワクチン（mRNA-1263）による免疫付加と感染予防との相関
Chang Liu, Wei Shi, Scott T Becker et al.

Structural basis of mismatch recognition by a SARS-CoV-2 proofreading enzyme

Science. 2021 Jul 27;eabi9310. doi: 10.1126/science.abi9310.

SARS-CoV-2のプルーフリーディング酵素のミスマッチ識別の構造的基盤
Neeltje van Doremalen, Jyothi N Purushotham, Jonathan E Schulz et al.

Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models

Sci Transl Med. 2021 Jul 27;eabh0755. doi: 10.1126/scitranslmed.abh0755.

アストラゼネカ社製の新型コロナワクチン（AZD1222）の経鼻接種の動物モデルにおける効果
Frauke Muecksch, Yiska Weisblum, Christopher O Barnes et al.

Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations

Immunity. 2021 Jul 29;S1074-7613(21)00294-6. doi: 10.1016/j.immuni.2021.07.008.

SARS-CoV-2の抗体親和性成熟により変異株への中和能が向上する
Mark Zeller, Karthik Gangavarapu, Catelyn Anderson et al.

Emergence of an early SARS-CoV-2 epidemic in the United States

Cell. 2021 Jul 26;S0092-8674(21)00889-8. doi: 10.1016/j.cell.2021.07.030.

米国における初期のSARS-CoV-2流行の疫学
Arinjay Banerjee, Karen Mossman, Nathalie Grandvaux

Molecular determinants of SARS-CoV-2 variants

Trends Microbiol. 2021 Jul 26;S0966-842X(21)00162-1. doi: 10.1016/j.tim.2021.07.002.

SARS-CoV-2変異株出現の分子決定因子
Athalia Christie, John T Brooks, Lauri A Hicks et al.

Guidance for Implementing COVID-19 Prevention Strategies in the Context of Varying Community Transmission Levels and Vaccination Coverage

MMWR Morb Mortal Wkly Rep. 2021 Jul 27;70(30):1044-1047. doi: 10.15585/mmwr.mm7030e2.

地域の流行状況と新型コロナワクチン接種率に応じた、米国におけるCOVID-19対策のガイダンス
Susana Monge, Carmen Olmedo, Belén Alejos et al.

Direct and Indirect Effectiveness of mRNA Vaccination against Severe Acute Respiratory Syndrome Coronavirus 2 in Long-Term Care Facilities, Spain

Emerg Infect Dis. 2021 Jul 27;27(10). doi: 10.3201/eid2710.211184.

長期療養施設のおけるPfizer社製の新型コロナワクチン（BNT162b2）の直接的および間接的予防効果
Kanecia O Zimmerman, M Alan Brookhart, Ibukunoluwa C Kalu et al.

Community SARS-CoV-2 Surge and Within-School Transmission

Pediatrics. 2021 Jul 28;e2021052686. doi: 10.1542/peds.2021-052686.

2020- 21年冬季、市中感染が急増していた時期においても、基本的な予防策を実施することにより、学校内での感染伝播は稀であったとする報告（米国ノースカロライナ州）
Iivo Hetemäki, Sohvi Kääriäinen, Pirjo Alho et al.

An outbreak caused by the SARS-CoV-2 Delta variant (B.1.617.2) in a secondary care hospital in Finland, May 2021

Euro Surveill. 2021 Jul;26(30). doi: 10.2807/1560-7917.ES.2021.26.30.2100636.

医療従事者のブレークスルー感染を含む、デルタ株（B.1.617.2系統）による医療機関におけるアウトブレイクの報告
Inge Kroidl, Ingo Mecklenburg, Peter Schneiderat et al.

Vaccine breakthrough infection and onward transmission of SARS-CoV-2 Beta (B.1.351) variant, Bavaria, Germany, February to March 2021

Euro Surveill. 2021 Jul;26(30). doi: 10.2807/1560-7917.ES.2021.26.30.2100673.

新規変異株ベータ株 (B.1.351系統) のブレークスルー感染とその2次感染の症例報告（ドイツ）
Sheila F Lumley, Bede Constantinides, Nicholas Sanderson et al.

Epidemiological data and genome sequencing reveals that nosocomial transmission of SARS-CoV-2 is underestimated and mostly mediated by a small number of highly infectious individuals

J Infect. 2021 Jul 28;S0163-4453(21)00377-7. doi: 10.1016/j.jinf.2021.07.034.

4つの病院における、疫学調査とゲノム解析によって院内感染の頻度を調査した報告
Chuang-Xing Lin, Hao-bin Lian, Guang-Yu Lin et al.

Pathogen spectrum changes of respiratory tract infections in children in Chaoshan area under the influence of COVID-19

Epidemiol Infect. 2021 Jul 30;1-19. doi: 10.1017/S0950268821001606.

中国・Chaoshanにおけるパンデミック前と後での小児の呼吸器感染症の病原体の変化を示した報告
Lauren H Carlton, Tiffany Chen, Alana L Whitcombe et al.

Charting Elimination in the Pandemic: A SARS-CoV-2 Serosurvey of Blood Donors in New Zealand

Epidemiol Infect. 2021 Jul 30;1-12. doi: 10.1017/S0950268821001643.

ニュージーランドにおいて2020年末に行われた血液ドナーの血液を用いた血清疫学調査の結果報告
Tara MacCannell, Joshua Batson, Brandon Bonin et al.

Genomic epidemiology and transmission dynamics of SARS-CoV-2 in congregate healthcare facilities in Santa Clara County, California

Clin Infect Dis. 2021 Jul 30;ciab553. doi: 10.1093/cid/ciab553.

米国の長期療養施設において、居住者およびスタッフを対象に毎週1回のスクリーニング検査とSARS-CoV-2の全ゲノム解析によって施設内の感染連鎖を調査した報告
Motoyuki Tsuboi, Masahiko Hachiya, Hiroshi Ohtsu et al.

Epidemiology and risk of COVID-19 among travelers at airport and port quarantine stations across Japan: a nationwide descriptive analysis and an individually matched case-control study

Clin Infect Dis. 2021 Jul 28;ciab659. doi: 10.1093/cid/ciab659.

日本の空港または海港検疫所で実施されたSARS-CoV2検査結果を用いて感染リスク因子を検討した症例対照研究
Hannah E Segaloff, Devlin Cole, Hannah G Rosenblum et al.

Risk Factors for SARS-CoV-2 Infection and Presence of Anti-SARS-CoV-2 Antibodies among University Student Dormitory Residents, September–November 2020

Open Forum Infect Dis. 2021 Jul 31;ofab405. doi: 10.1093/ofid/ofab405.

ウィスコンシン大学の寮生におけるSARS-CoV-2感染と抗SARS-CoV-2抗体陽性のリスク因子解析（2020年9月から11月）
Shilpa Hakre, Aaron D Sanborn, Stephen W Krauss et al.

Serological and RT-PCR surveillance for COVID-19 in an asymptomatic U.S. Army trainee population

Open Forum Infect Dis. 2021 Jul 29;ofab407. doi: 10.1093/ofid/ofab407.

無症候の米軍陸軍訓練生の抗体検査およびRT-PCRによるスクリーニングの有効性検討
Jamie Lopez Bernal, Nick Andrews, Charlotte Gower et al.

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

N Engl J Med. 2021 Jul 21. doi: 10.1056/NEJMoa2108891.

Pfizer社製の新型コロナワクチン（BNT162b2）とAstraZeneca社製の新型コロナワクチン（ChAdOx1-S）のB.1.1.7系統（アルファ株）およびB.1.617.2（デルタ株）に対する効果を検討した症例対照研究
Garth Rapeport, Emma Smith, Anthony Gilbert et al.

SARS-CoV-2 Human Challenge Studies - Establishing the Model during an Evolving Pandemic

N Engl J Med. 2021 Jul 21. doi: 10.1056/NEJMp2106970.

パンデミック時における新型コロナウイルスのヒトでのchallenge研究に関する論説
Victoria T Chu, Anna R Yousaf, Karen Chang et al.

Household Transmission of SARS-CoV-2 from Children and Adolescents

N Engl J Med. 2021 Jul 21. doi: 10.1056/NEJMc2031915.

家庭内における小児や青年からの新型コロナウイルス感染をみた後ろ向きコホート研究
Julian Stumpf, Torsten Siepmann, Tom Lindner et al.

Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine

Lancet Reg Health Eur. 2021 Jul 22;100178. doi: 10.1016/j.lanepe.2021.100178.

腎移植患者と透析患者におけるModerna社製の新型コロナワクチン（mRNA-1273）とPfizer社製の新型コロナワクチン（BNT162b2）接種後の液性および細胞性免疫応答の検討
Carole H Sudre, Ayya Keshet, Mark S Graham et al.

Anosmia, ageusia, and other COVID-19-like symptoms in association with a positive SARS-CoV-2 test, across six national digital surveillance platforms: an observational study

Lancet Digit Health. 2021 Jul 22;S2589-7500(21)00115-1. doi: 10.1016/S2589-7500(21)00115-1.

英国・米国・イスラエル3か国のデジタルサーベイランスプラットフォームを使用したSARS-CoV-2検査陽性例と関連する無嗅覚症、味覚消失、およびその他のCOVID-19様症状をみた観察研究
Mikhail N Kosiborod, Russell Esterline, Remo H M Furtado et al.

Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet Diabetes Endocrinol. 2021 Jul 21;S2213-8587(21)00180-7. doi: 10.1016/S2213-8587(21)00180-7.

新型コロナウイルス感染症で入院した心臓代謝の危険因子を有する患者におけるダパグリフロジン（SGLT2阻害薬）の効果を検討した第3相無作為化二重盲検ランダム化比較試験の（DARE-19）
Renaud Felten, Lou Kawka, Maxime Dubois et al.

Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study

Lancet Rheumatol. 2021 Jul 21;S2665-9913(21)00221-6. doi: 10.1016/S2665-9913(21)00221-6.

全身性エリテマトーデス患者における新型コロナワクチン接種後の増悪の有無を評価した横断研究（International VACOLUP study）
Ilies Benotmane, Gabriela Gautier, Peggy Perrin et al.

Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses

JAMA. 2021 Jul 23. doi: 10.1001/jama.2021.12339.

Moderna社製の新型コロナワクチン（mRNA-1273）2回目接種後の免疫反応が弱かった腎移植レシピエントにおける、3回目接種後の抗体反応
Timothy A Bates, Hans C Leier, Zoe L Lyski et al.

Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune Serum Samples

JAMA. 2021 Jul 21. doi: 10.1001/jama.2021.11656.

Pfizer-BioNTech社製の新型コロナワクチン（BNT162b2）のP.1系統（ガンマ株）に対する年代別免疫反応
Roberto Caricchio, Antonio Abbate, Ivan Gordeev et al.

Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial

JAMA. 2021 Jul 20;326(3):230-239. doi: 10.1001/jama.2021.9508.

COVID-19入院患者における、侵襲的人工呼吸を使用しない生存に対するカナキヌマブ治療のランダム化比較試験
Adeel A Butt, Saad B Omer, Peng Yan, Obaid S Shaikh, Florian B Mayr

SARS-CoV-2 Vaccine Effectiveness in a High-Risk National Population in a Real-World Setting

Ann Intern Med. 2021 Jul 20. doi: 10.7326/M21-1577.

重症化リスクの高い米国の退役軍人における新型コロナワクチンの現実社会での有効性を検討した症例対照研究
Josep M Llibre, Sebastià Videla, Bonaventura Clotet, Boris Revollo

Screening for SARS-CoV-2 Antigen Before a Live Indoor Music Concert: An Observational Study

Ann Intern Med. 2021 Jul 20;M21-2278. doi: 10.7326/M21-2278.

5000人単位の屋内音楽ライブ前の抗原検査キットを用いたスクリーニングの有用性を検討した観察研究
Moritz U G Kraemer, Verity Hill, Christopher Ruis et al.

Spatiotemporal invasion dynamics of SARS-CoV-2 lineage B.1.1.7 emergence

Science. 2021 Jul 22;eabj0113. doi: 10.1126/science.abj0113.

英国におけるSARS-CoV-2系統のB.1.1.7出現の時空間的な置き換わり
Nir Drayman, Jennifer K DeMarco, Krysten A Jones et al.

Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2

Science. 2021 Jul 20;eabg5827. doi: 10.1126/science.abg5827.

MasitinibはSARS-CoV-2の複製を培養細胞およびマウスで阻害する
Cristina Bergamaschi, Evangelos Terpos, Margherita Rosati et al.

Systemic IL-15, IFN-γ and IP-10/CXCL10 Signature Associated with Effective Immune Response to SARS-CoV-2 in BNT162b2 mRNA Vaccine Recipients

Cell Rep. 2021 Jul 22;109504. doi: 10.1016/j.celrep.2021.109504.

Pfizer社製の新型コロナワクチン（BNT162b2）接種者のSARS-CoV-2に対する免疫応答に関連するサイトカインの特徴
Pei Tong, Avneesh Gautam, Ian W Windsor et al.

Memory B Cell Repertoire for Recognition of Evolving SARS-CoV-2 Spike

Cell. 2021 Jul 22;S0092-8674(21)00884-9. doi: 10.1016/j.cell.2021.07.025.

B細胞レパトアと変異株への対応能力
Carly G K Ziegler, Vincent N Miao, Anna H Owings et al.

Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19

Cell. 2021 Jul 22;S0092-8674(21)00882-5. doi: 10.1016/j.cell.2021.07.023.

COVID-19重症例における上気道の細胞レベル・分子レベルでの変化
Jakob Trimpert, Kristina Dietert, Theresa C Firsching et al.

Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by genome recoding

Cell Rep. 2021 Jul 20;109493. doi: 10.1016/j.celrep.2021.109493.

ゲノム書き換えによる弱毒生SARS-CoV-2ワクチン候補の開発とハムスターモデルにおける検討
Anthony T DiPiazza, Sarah R Leist, Olubukola M Abiona et al.

COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge

Immunity. 2021 Jul 2;S1074-7613(21)00262-4. doi: 10.1016/j.immuni.2021.06.018.

Moderna社製の新型コロナワクチン（mRNA-1273）はマウスにおいてSARS-CoV-2におけるワクチン関連疾患増悪を伴わない保護的な免疫プロファイルをもたらす
David Rubin, Maggie Eisen, Sophia Collins et al.

SARS-CoV-2 Infection in Public School District Employees Following a District-Wide Vaccination Program ― Philadelphia County, Pennsylvania, March 21–April 23, 2021

MMWR Morb Mortal Wkly Rep. 2021 Jul 30;70(30):1040-1043. doi: 10.15585/mmwr.mm7030e1.

米国ペンシルベニア州の学校区のワクチン接種プログラムでの学校職員におけるSARS-CoV-2感染 (2021年3月-4月)
Sonja J Olsen, Amber K Winn, Alicia P Budd et al.

Changes in Influenza and Other Respiratory Virus Activity During the COVID-19 Pandemic - United States, 2020-2021

MMWR Morb Mortal Wkly Rep. 2021 Jul 23;70(29):1013-1019. doi: 10.15585/mmwr.mm7029a1.

米国におけるCOVID-19パンデミック下での、インフルエンザやその他の呼吸器ウイルスの流行状況の変化 (2020-2021年)
Nicolas Vignier, Vincent Bérot, Nathalie Bonnave et al.

Breakthrough Infections of SARS-CoV-2 Gamma Variant in Fully Vaccinated Gold Miners, French Guiana, 2021

Emerg Infect Dis. 2021 Jul 21;27(10). doi: 10.3201/eid2710.211427.

フランス領ギニアにおけるワクチン接種完了した金鉱採掘者のSARS-CoV-2ブレイクスルー感染
Seth A Hoffman, Cristina Costales, Malaya K Sahoo et al.

SARS-CoV-2 Neutralization Resistance Mutations in Patient with HIV/AIDS, California, USA

Emerg Infect Dis. 2021 Jul 23;27(10). doi: 10.3201/eid2710.211461.

SARS-CoV-2に持続感染したHIV/AIDS患者で確認された、中和に対して耐性をもたらす変異の出現
Esther Kissling, Mariette Hooiveld, Virginia Sandonis Martín et al.

Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021

Euro Surveill. 2021 Jul;26(29). doi: 10.2807/1560-7917.ES.2021.26.29.2100670.

欧州における65歳以上の有症状SARS-CoV-2感染に対するワクチン有効性（2020年12月-2021年5月）
Thomas C Williams, Ian Sinha, Ian G Barr, Maria Zambon

Transmission of paediatric respiratory syncytial virus and influenza in the wake of the COVID-19 pandemic

Euro Surveill. 2021 Jul;26(29). doi: 10.2807/1560-7917.ES.2021.26.29.2100186.

COVID-19パンデミック下での、小児におけるRSウイルスとインフルエンザウイルス感染
Aditi S Shah, Min Hyung Ryu, Cameron J Hague et al.

Changes in pulmonary function and patient-reported outcomes during COVID-19 recovery: a longitudinal, prospective cohort study

ERJ Open Res. 2021 Jul 22;7(3):00243-2021. doi: 10.1183/23120541.00243-2021.

COVID-19回復期の呼吸機能の変化と呼吸器症状の変化:前向きコホート研究
Anna Gidari, Samuele Sabbatini, Sabrina Bastianelli et al.

Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected

J Infect. 2021 Jul 25;S0163-4453(21)00362-5. doi: 10.1016/j.jinf.2021.07.019.

ワクチン接種者、回復者およびP.1系統の変異株（ガンマ株）感染者におけるSARS-CoV-2 B.1.1.7系統（アルファ株）およびP.1（ガンマ株）系統の変異株に対する中和能
Lama Bou-Karroum, Joanne Khabsa, Mathilda Jabbour et al.

Public Health Effects of Travel-Related Policies on the COVID-19 Pandemic: A Mixed-Methods Systematic Review

J Infect. 2021 Jul 24;S0163-4453(21)00360-1. doi: 10.1016/j.jinf.2021.07.017.

COVID-19パンデミック下における渡航関連政策の公衆衛生的影響：Mixed-Methodsシステマティックレビュー
Akane Takamatsu, Hitoshi Honda, Tomoya Kojima, Kengo Murata, Hilary M Babcock

Promoting coronavirus disease 2019 (COVID-19) vaccination among healthcare personnel: A multifaceted intervention at a tertiary-care center in Japan

Infect Control Hosp Epidemiol. 2021 Jul 21;1-6. doi: 10.1017/ice.2021.325.

医療従事者を対象としたCOVID-19ワクチンの接種促進：日本の三次医療機関における多面的な介入策
Xinhua Chen, Zhiyuan Chen, Andrew S Azman et al.

Neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination: a systematic review and pooled meta-analysis

Clin Infect Dis. 2021 Jul 24;ciab646. doi: 10.1093/cid/ciab646.

自然感染またはワクチン接種により誘導されたSARS-CoV-2変異株に対する中和抗体：システマティックレビューおよびメタ分析
Kristin L Andrejko, Jake Pry, Jennifer F Myers et al.

Prevention of COVID-19 by mRNA-based vaccines within the general population of California

Clin Infect Dis. 2021 Jul 20;ciab640. doi: 10.1093/cid/ciab640.

米国カリフォルニア州におけるPfizer-BioNTech社製の新型コロナワクチン（BNT162b2）とモデルナ社製の新型コロナワクチン（mRNA-1273）の有効性を検討した症例対照研究（2021年2月-4月）
Kristen K Bjorkman, Tassa K Saldi, Erika Lasda et al.

Higher viral load drives infrequent SARS-CoV-2 transmission between asymptomatic residence hall roommates

J Infect Dis. 2021 Jul 24;jiab386. doi: 10.1093/infdis/jiab386.

米国コロラド大学の学生寮における毎週のスクリーニングにおけるウイルス量と二次感染の頻度について調べた報告
Michael Dougan, Ajay Nirula, Masoud Azizad et al.

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

N Engl J Med. 2021 Jul 14. doi: 10.1056/NEJMoa2102685.

COVID-19に対する中和モノクローナル抗体合剤Bamlanivimab+Etesevimabの効果を調べた第3相ランダム化比較試験の結果
Johan Normark, Linnea Vikström, Yong-Dae Gwon et al.

Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination

N Engl J Med. 2021 Jul 14. doi: 10.1056/NEJMc2110716.

英国におけるAstraZeneca社製の新型コロナワクチン（ChAdOx1-S）とPfizer社製の新型コロナワクチン（BNT162b2）の交互接種による免疫原性
Dan H Barouch, Kathryn E Stephenson, Jerald Sadoff et al.

Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination

N Engl J Med. 2021 Jul 14. doi: 10.1056/NEJMc2108829.

Johnson & Johnson/Janssen社製の新型コロナワクチン（Ad26.COV2.S）接種8ヶ月後の免疫評価
Thomas M Drake, Aya M Riad, Cameron J Fairfield et al.

Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study

Lancet. 2021 Jul 17;398(10296):223-237. doi: 10.1016/S0140-6736(21)00799-6.

COVID-19入院患者における合併症を検討した多施設コホート研究
Madhumita Shrotri, Annalan M D Navaratnam, Vincent Nguyen et al.

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1

Lancet. 2021 Jul 15;398(10298):385-387. doi: 10.1016/S0140-6736(21)01642-1.

AstraZeneca社製の新型コロナワクチン（ChAdOx1-S）とPfizer社製の新型コロナワクチン（BNT162b2）接種後の抗体の減衰
Wey Wen Lim, Loretta Mak, Gabriel M Leung, Benjamin J Cowling, Malik Peiris

Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19

Lancet Microbe. 2021 Jul 16. doi: 10.1016/S2666-5247(21)00177-4.

Pfizer社製の新型コロナワクチン（BNT162b2）接種者とSinoVac社製の新型コロナワクチン（CoronaVac）接種後の抗体応答の比較
Gareth H Williams, Alexander Llewelyn, Ruben Brandao et al.

SARS-CoV-2 testing and sequencing for international arrivals reveals significant cross border transmission of high risk variants into the United Kingdom

EClinicalMedicine. 2021 Jul 14;101021. doi: 10.1016/j.eclinm.2021.101021.

英国における海外からの入国者全員に対するPCR検査とウイルスゲノム解析
Diana M Tordoff, Alexander L Greninger, Pavitra Roychoudhury et al.

Phylogenetic estimates of SARS-CoV-2 introductions into Washington State

Lancet Reg Health Americas. 2021 Jul 13;100018. doi: 10.1016/j.lana.2021.100018.

米国ワシントン州における感染者の流入と流出を公開全ゲノム情報から解析した報告
A Danielle Iuliano, Howard H Chang, Neha N Patel et al.

Estimating Under-recognized COVID-19 Deaths, United States, March 2020-May 2021 using an Excess Mortality Modelling Approach

Lancet Reg Health Americas. 2021 Jul 13;100019. doi: 10.1016/j.lana.2021.100019.

米国における2020年3月～2021年5月の超過死亡を推定した米国CDCの著者による報告
Rabah Redjoul, Anne Le Bouter, Florence Beckerich, Slim Fourati, Sébastien Maury

Antibody response after second BNT162b2 dose in allogeneic HSCT recipients

Lancet. 2021 Jul 24;398(10297):298-299. doi: 10.1016/S0140-6736(21)01594-4.

同種末梢血幹細胞移植を受けた者におけるPfizer社製の新型コロナワクチン（BNT162b2）接種後の抗体応答
Elizabeth J Williamson, Helen I McDonald, Krishnan Bhaskaran et al.

Risks of covid-19 hospital admission and death for people with learning disability: population based cohort study using the OpenSAFELY platform

BMJ. 2021 Jul 14;374:n1592. doi: 10.1136/bmj.n1592.

OpenSAFELYプラットフォームを使用した学習障害のある者のCOVIDー19による入院と死亡のリスクを検討したコホート研究
Yuki Yoshikawa, Ichiro Kawachi

Association of Socioeconomic Characteristics With Disparities in COVID-19 Outcomes in Japan

JAMA Netw Open. 2021 Jul 1;4(7):e2117060. doi: 10.1001/jamanetworkopen.2021.17060.

日本におけるCOVID-19の転帰と社会経済学的特徴の相関を検討した横断研究
Binu V John, Yangyang Deng, Andrew Scheinberg et al.

Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis

JAMA Intern Med. 2021 Jul 13;e214325. doi: 10.1001/jamainternmed.2021.4325.

肝硬変患者におけるPfizer社製の新型コロナワクチン（BNT162b2）およびModerna社製の新型コロナワクチン（mRNA-1273）による新型コロナウイルス感染および入院との関連を見た後ろ向きコホート研究
Inbal Goldshtein, Daniel Nevo, David M Steinberg et al.

Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women

JAMA. 2021 Jul 12. doi: 10.1001/jama.2021.11035.

妊婦へのPfizer社製の新型コロナワクチン（BNT162b2）とSARS-CoV-2感染の発生率との関連を見た後ろ向きコホート研究
Catherine E Oldenburg, Benjamin A Pinsky, Jessica Brogdon et al.

Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection: A Randomized Clinical Trial

JAMA. 2021 Jul 16. doi: 10.1001/jama.2021.11517.

SARS-CoV-2感染者に対する外来でのアジスロマイシン経口の有効性を検討したランダム化比較試験
Francesco Sanmarchi, Davide Golinelli, Jacopo Lenzi et al.

Exploring the Gap Between Excess Mortality and COVID-19 Deaths in 67 Countries

JAMA Netw Open. 2021 Jul 1;4(7):e2117359. doi: 10.1001/jamanetworkopen.2021.17359.

67カ国の過剰死亡と新型コロナウイルス罹患による死亡の差を検討した横断研究
Michael E Ohl, Donald R Miller, Brian C Lund et al.

Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19

JAMA Netw Open. 2021 Jul 1;4(7):e2114741. doi: 10.1001/jamanetworkopen.2021.14741.

米国退役軍人のCOVID-19入院患者におけるレムデシビル治療と生存率および入院期間との関連を検討したコホート研究
Mena Said, Peter Davis, Stephanie Davis et al.

A Rapid Olfactory Test as a Potential Screening Tool for COVID-19

JAMA Otolaryngol Head Neck Surg. 2021 Jul 15. doi: 10.1001/jamaoto.2021.1456.

COVID-19スクリーニングツールとしての迅速嗅覚検査の精度評価
Thomas Radtke, Agne Ulyte, Milo A Puhan, Susi Kriemler

Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents

JAMA. 2021 Jul 15. doi: 10.1001/jama.2021.11880.

スイスの小児および青年におけるSARS-CoV-2感染後の長期的な症状を検討したコホート研究
Andreas Barratt-Due, Inge Christoffer Olsen, Katerina Nezvalova-Henriksen et al.

Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial

Ann Intern Med. 2021 Jul 13. doi: 10.7326/M21-0653.

ノルウェーにおけるレムデシビルおよびヒドロキシクロロキンのSARS-CoV-2 RNAのクリアランスへの有効性を検討したランダム化比較試験（Solidarity Trialのアドオントライアル）
Tyler N Starr, Nadine Czudnochowski, Zhuoming Liu et al.

SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape

Nature. 2021 Jul 14. doi: 10.1038/s41586-021-03807-6.

SARS-CoV-2受容体結合ドメインに対する抗体パネルのin vitroでの評価
Julio S Solís Arce, Shana S Warren, Niccolò F Meriggi et al.

COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries

Nat Med. 2021 Jul 16. doi: 10.1038/s41591-021-01454-y.

低・中所得国におけるワクチン忌避について検討した横断研究
Joana Barros-Martins, Swantje I Hammerschmidt, Anne Cossmann et al.

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

Nat Med. 2021 Jul 14. doi: 10.1038/s41591-021-01449-9.

1回目をAstraZeneca社製の新型コロナワクチン（ChAdOx1-S）、2回目を Pfizer社製の新型コロナワクチン（BNT162b2）で接種した後のSARS-CoV-2変異体に対する免疫応答を2回ChAdOx1-Sを接種した際の抗体応答と比較したコホート研究
Rémy Robinot, Mathieu Hubert, Guilherme Dias de Melo et al.

SARS-CoV-2 infection induces the dedifferentiation of multiciliated cells and impairs mucociliary clearance

Nat Commun. 2021 Jul 16;12(1):4354. doi: 10.1038/s41467-021-24521-x.

SARS-CoV-2感染による多繊毛細胞の脱分化誘発と粘液線毛クリアランスの低下
Maria Pino, Talha Abid, Susan Pereira Ribeiro et al.

A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates

Sci Immunol. 2021 Jul 15;6(61):eabh3634. doi: 10.1126/sciimmunol.abh3634.

3M-052-alumアジュバントを付加した酵母発現RBDベースの新型コロナワクチンの霊長類モデルにおける予防効果の検討
Kanta Subbarao

The success of SARS-CoV-2 vaccines and challenges ahead

Cell Host Microbe. 2021 Jul 14;29(7):1111-1123. doi: 10.1016/j.chom.2021.06.016.

新型コロナワクチンの開発と今後の展望に関するナラティブレビュー
Ahmed O Hassan, Swathi Shrihari, Matthew J Gorman et al.

An intranasal vaccine durably protects against SARS-CoV-2 variants in mice

Cell Rep. 2021 Jul 13:109452. doi: 10.1016/j.celrep.2021.109452.

マウスにおける経鼻によるチンパンジーアデノウイルスベクターワクチン接種での変異株を含むSARS-CoV-2に対する感染防御
Woo Dae Jang, Sangeun Jeon, Seungtaek Kim, Sang Yup Lee

Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay

Proc Natl Acad Sci U S A. 2021 Jul 27;118(30):e2024302118. doi: 10.1073/pnas.2024302118.

6,218種類の薬剤仮想スクリーニングと細胞ベースの測定によるCOVID-19への薬剤再利用
Nash D Rochman, Yuri I Wolf, Guilhem Faure et al.

Ongoing global and regional adaptive evolution of SARS-CoV-2

Proc Natl Acad Sci U S A. 2021 Jul 20;118(29):e2104241118. doi: 10.1073/pnas.e2104241118.

SARS-CoV-2の世界レベル・地域レベルでの進化
Chamandi S Dampalla, Jian Zheng, Krishani Dinali Perera et al.

Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection

Proc Natl Acad Sci U S A. 2021 Jul 20;118(29):e2101555118. doi: 10.1073/pnas.2101555118.

プロテアーゼ阻害剤による感染後治療での致命的なSARS-CoV-2感染マウスの生存率の上昇
Ying Wang, Chen Yang, Yutong Song et al.

Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy

Proc Natl Acad Sci U S A. 2021 Jul 20;118(29):e2102775118. doi: 10.1073/pnas.2102775118.

弱毒生ワクチンの新型コロナワクチン候補の前臨床試験
Alina Tscherne, Jan Hendrik Schwarz, Cornelius Rohde et al.

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination

Proc Natl Acad Sci U S A. 2021 Jul 13;118(28):e2026207118. doi: 10.1073/pnas.2026207118.

MVAベクターベースの新型コロナワクチン候補（MVA-SARS-2-S）の前臨床試験
Cassandra Pingali, Mehreen Meghani, Hilda Razzaghi et al.

COVID-19 Vaccination Coverage Among Insured Persons Aged ≥16 Years, by Race/Ethnicity and Other Selected Characteristics - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 15, 2021

MMWR Morb Mortal Wkly Rep. 2021 Jul 16;70(28):985-990. doi: 10.15585/mmwr.mm7028a1.

米国の8つの医療保険システムのデータを利用した16歳以上の人種/民族別およびその他の特性別の新型コロナワクチン接種率（2020年12月14日～2021年5月15日）
Annabel A Powell, Linda Power, Samantha Westrop et al.

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-June 2021, England

Euro Surveill. 2021 Jul;26(28). doi: 10.2807/1560-7917.ES.2021.26.28.2100634.

英国におけるAstraZeneca社製の新型コロナワクチン（ChAdOx1-S）とPfizer社製の新型コロナワクチン（BNT162b2）の交互接種による反応原性（2021年3月～6月）
Samuel Alizon, Stéphanie Haim-Boukobza, Vincent Foulongne et al.

Rapid spread of the SARS-CoV-2 Delta variant in some French regions, June 2021

Euro Surveill. 2021 Jul;26(28). doi: 10.2807/1560-7917.ES.2021.26.28.2100573.

2021年6月フランスの一部地域におけるSARS-CoV-2 B.1.617.2系統（デルタ株）の急速な拡大
Thomas Harder, Judith Koch, Sabine Vygen-Bonnet et al.

Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021

Euro Surveill. 2021 Jul;26(28). doi: 10.2807/1560-7917.ES.2021.26.28.2100563.

新型コロナワクチンの有効性に関するリビングシステマティックレビューの中間結果（2021年1月1日～5月14日）
Paul R Hunter, Felipe J Colón-González, Julii Brainard, Steven Rushton

Impact of non-pharmaceutical interventions against COVID-19 in Europe in 2020: a quasi-experimental non-equivalent group and time series design study

Euro Surveill. 2021 Jul;26(28). doi: 10.2807/1560-7917.ES.2021.26.28.2001401.

2020年の欧州におけるCOVID-19と非薬物的介入の相関を検討した時系列解析
Leya Timur, Yingqiu Xie

Is border closure effective in containing COVID-19?

Travel Med Infect Dis. 2021 Jul 9;102137. doi: 10.1016/j.tmaid.2021.102137.

国境閉鎖はCOVID-19の拡散防止に有効かについての論説
David J Weber, Jaffar Al-Tawfiq, Hilary Babcock et al.

Multisociety Statement on COVID-19 Vaccination as a Condition of Employment for Healthcare Personnel

Infect Control Hosp Epidemiol. 2021 Jul 13;1-46. doi: 10.1017/ice.2021.322.

医療従事者への雇用条件としての新型コロナワクチン接種に関する学会の声明
C Paul Morris, Chun Huai Luo, Adannaya Amadi et al.

An Update on SARS-CoV-2 Diversity in the United States National Capital Region: Evolution of Novel and Variants of Concern

Clin Infect Dis. 2021 Jul 17;ciab636. doi: 10.1093/cid/ciab636.

米国の首都周辺におけるSARS-CoV-2の多様性と変異株
Carlos K H Wong, Kristy T K Lau, Ivan C H Au et al.

Clinical improvement, outcomes, antiviral activity, and costs associated with early treatment with remdesivir for patients with COVID-19

Clin Infect Dis. 2021 Jul 15;ciab631. doi: 10.1093/cid/ciab631.

新型コロナウイルス患者に対するレムデシビルの早期投与と治療効果やウイルス量、治療コストとの関連性
Isabella Ferreira, Steven Kemp, Rawlings Datir et al.

SARS-CoV-2 B.1.617 mutations L452 and E484Q are not synergistic for antibody evasion

J Infect Dis. 2021 Jul 14;jiab368. doi: 10.1093/infdis/jiab368.

SARS-CoV-2変異株（B.1.617.1系統）で認めるL452RとE484Q変異はシュードタイプウイルスにおいて免疫逃避の相乗効果をもたらさない
Jiaxing Xie, Zhufeng Wang, Jingyi Liang et al.

A Critical Review of the Scientific Evidence and Recommendations in COVID-19 Management Guidelines

Open Forum Infect Dis. 2021 Jul 14;ofab376. doi: 10.1093/ofid/ofab376.

COVID-19患者管理ガイドラインに記載されている科学的エビデンスと推奨項目のレビュー
Theo Dähne, Wolfgang Bauer, Andreas Essig et al.

The impact of the SARS-CoV-2 pandemic on the prevalence of respiratory tract pathogens in patients with community-acquired pneumonia in Germany

Emerg Microbes Infect. 2021 Jul 16;1-8. doi: 10.1080/22221751.2021.1957402.

ドイツにおける、SARS-CoV-2流行の、市中肺炎の病原体の検出割合への影響
Sally H Adams, Jason P Schaub, Jason M Nagata et al.

Young Adult Perspectives on COVID-19 Vaccinations

J Adolesc Health. 2021 Jul 10;S1054-139X(21)00285-8. doi: 10.1016/j.jadohealth.2021.06.003.

米国の若年層（18-25歳）における新型コロナワクチンに対する意識（全国横断調査）
Hannah E Davis, Gina S Assaf, Lisa McCorkell et al.

Characterizing long COVID in an international cohort: 7 months of symptoms and their impact

EClinicalMedicine. 2021 Jul 15;101019. doi: 10.1016/j.eclinm.2021.101019.

Long COVIDの特徴と生活への影響：国際的コホートによる発症7か月時点の調査
Alejandro Jara, Eduardo A Undurraga, Cecilia González et al.

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile

N Engl J Med. 2021 Jul 7. doi: 10.1056/NEJMoa2107715.

チリにおけるSinovac社製の新型コロナワクチン（CoronaVac)のリアルワールドでの有効性を評価した全国レベルでの前向きコホート研究
Venkata-Viswanadh Edara, Benjamin A Pinsky, Mehul S Suthar et al.

Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants

N Engl J Med. 2021 Jul 7. doi: 10.1056/NEJMc2107799.

SARS-CoV-2感染後およびワクチン接種後に負荷される抗体のSARS-CoV-2変異株であるB.1.617.2系統（デルタ株）に対する中和能
Courtney R Lane, Norelle L Sherry, Ashleigh F Porter et al.

Genomics-informed responses in the elimination of COVID-19 in Victoria, Australia: an observational, genomic epidemiological study

Lancet Public Health. 2021 Jul 9;S2468-2667(21)00133-X. doi: 10.1016/S2468-2667(21)00133-X.

ゲノム分子解析を用いた疫学調査と公衆衛生対応により、オーストラリア・ビクトリア州からSARS-CoV-2 を排除した：ゲノム分子疫学を用いた観察研究
Mine Durusu Tanriover, Hamdi Levent Doğanay, Murat Akova et al.

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

Lancet. 2021 Jul 8;S0140-6736(21)01429-X. doi: 10.1016/S0140-6736(21)01429-X.

Sinovac社製の新型コロナワクチン（CoronaVac)の有効性と安全性に関する評価：トルコにおけるフェーズ3臨床試験（二重盲検プラセボ対照無作為化試験）の中間報告
William M Souza, Mariene R Amorim, Renata Sesti-Costa et al.

Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study

Lancet Microbe. 2021 Jul 8;S2666-5247(21)00129-4. doi: 10.1016/S2666-5247(21)00129-4.

自然感染および不活化ワクチン接種後に産生された抗体のSARS-CoV-2の変異株であるP.1（ガンマ株）に対する中和能の評価
Thomas R Frieden, Christopher T Lee, Aaron F Bochner, Marine Buissonnière, Amanda McClelland

7-1-7: an organising principle, target, and accountability metric to make the world safer from pandemics

Lancet. 2021 Jul 6;S0140-6736(21)01250-2. doi: 10.1016/S0140-6736(21)01250-2.

アウトブレイク対応のための国際的な目標設定　（7-1-7 target)の提言
Marta García-Fiñana, David M Hughes, Christopher P Cheyne et al.

Performance of the Innova SARS-CoV-2 antigen rapid lateral flow test in the Liverpool asymptomatic testing pilot: population based cohort study

BMJ. 2021 Jul 6;374:n1637. doi: 10.1136/bmj.n1637.

英国リバプールでの無症状病原体保有者のスクリーニングにおける抗原検査キット（Innova）の精度評価
Tal Goshen-Lago, Ithai Waldhorn, Roy Holland et al.

Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer

JAMA Oncol. 2021 Jul 8. doi: 10.1001/jamaoncol.2021.2675.

イスラエルにおいて、がん患者におけるPfizer-BioNTech製ワクチンによる抗体応答および副作用に関して調査したコホート研究
Aaron Kofman, Rami Kantor, Eli Y Adashi

Potential COVID-19 Endgame Scenarios: Eradication, Elimination, Cohabitation, or Conflagration?

JAMA. 2021 Jul 8. doi: 10.1001/jama.2021.11042.

パンデミックの転帰のシナリオについての論説
Jennifer M Radin, Giorgio Quer, Edward Ramos et al.

Assessment of Prolonged Physiological and Behavioral Changes Associated With COVID-19 Infection

JAMA Netw Open. 2021 Jul 1;4(7):e2115959. doi: 10.1001/jamanetworkopen.2021.15959.

ウェアラブル機器により心拍数、歩数、睡眠時間を計測することで、COVID-19後遺症を調査したコホート研究
WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis

JAMA. 2021 Jul 6;e2111330. doi: 10.1001/jama.2021.11330.

COVID-19入院患者の死亡に対するIL-6阻害薬の有効性を検討したランダム化比較試験の前向きメタアナリシス
Piero Poletti, Marcello Tirani, Danilo Cereda et al.

Seroprevalence of and Risk Factors Associated With SARS-CoV-2 Infection in Health Care Workers During the Early COVID-19 Pandemic in Italy

JAMA Netw Open. 2021 Jul 1;4(7):e2115699. doi: 10.1001/jamanetworkopen.2021.15699.

イタリア、ロンバルディア州における医療従事者の血清抗体価を調査し、感染リスクの高い職種を調べた研究
Yarden Golan, Mary Prahl, Arianna Cassidy et al.

Evaluation of Messenger RNA From COVID-19 BTN162b2 and mRNA-1273 Vaccines in Human Milk

JAMA Pediatr. 2021 Jul 6;e211929. doi: 10.1001/jamapediatrics.2021.1929.

Pfizer社製の新型コロナワクチン（BNT162b2）およびModerna社製の新型コロナワクチン（mRNA-1273）から母乳中へのmRNAの移行の評価
Mayssam Nehme, Olivia Braillard, François Chappuis, Delphine S Courvoisier, Idris Guessous

Prevalence of Symptoms More Than Seven Months After Diagnosis of Symptomatic COVID-19 in an Outpatient Setting

Ann Intern Med. 2021 Jul 6. doi: 10.7326/M21-0878.

COVID-19からの回復者における診断7-9ヶ月後までのLong COVIDによる症状オンライン診療で評価したコホート研究
Sameer S Kadri, Junfeng Sun, Alexander Lawandi et al.

Association Between Caseload Surge and COVID-19 Survival in 558 U.S. Hospitals, March to August 2020

Ann Intern Med. 2021 Jul 6. doi: 10.7326/M21-1213.

米国において2020年3月から8月までの558の病院における症例数増加と新型コロナウイルス感染による死亡の関連をみた後ろ向きコホート研究
COVID-19 Host Genetics Initiative

Mapping the human genetic architecture of COVID-19

Nature. 2021 Jul 8. doi: 10.1038/s41586-021-03767-x.

COVID-19における重症度別のヒトのゲノムワイド関連解析のメタアナリシス
Delphine Planas, David Veyer, Artem Baidaliuk et al.

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Nature. 2021 Jul 8. doi: 10.1038/s41586-021-03777-9.

SARS-CoV-2の変異株であるB.1.617.2系統（デルタ株）の中和抗体に対する感受性の低下
Hiam Chemaitelly, Hadi M Yassine, Fatiha M Benslimane et al.

mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

Nat Med. 2021 Jul 9. doi: 10.1038/s41591-021-01446-y.

カタールにおけるModerna社製の新型コロナワクチン（mRNA-1273）のSARS-CoV-2の変異株であるB.1.1.7系統（アルファ株）およびB.1.351系統（ベータ株）に対する有効性を評価した症例対照研究
C S Pramesh, Giridhara R Babu, Joyeeta Basu et al.

Choosing Wisely for COVID-19: ten evidence-based recommendations for patients and physicians

Nat Med. 2021 Jul 5. doi: 10.1038/s41591-021-01439-x.

COVID-19におけるChoosing Wisely initiativeの推奨
Allison J Greaney, Tyler N Starr, Christopher O Barnes et al.

Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies

Nat Commun. 2021 Jul 7;12(1):4196. doi: 10.1038/s41467-021-24435-8.

異なるクラスの抗体から逃避するスパイクタンパクのレセプター結合部位の変異のマッピング
Cesheng Li, Ding Yu, Xiao Wu et al.

Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan

Nat Commun. 2021 Jul 6;12(1):4144. doi: 10.1038/s41467-021-24230-5.

中国武漢における新型コロナウイルス感染患者の回復期血漿ドナーのSARS-CoV-2受容体結合ドメインに対する12か月の特異的IgGの反応をみた横断研究
Muge Cevik, Stefan D Baral

Networks of SARS-CoV-2 transmission

Science. 2021 Jul 9;373(6551):162-163. doi: 10.1126/science.abg0842.

SARS-CoV-2の伝播パターンに関する論説
Saya Moriyama, Yu Adachi, Takashi Sato et al.

Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants

Immunity. 2021 Jul 2;S1074-7613(21)00259-4. doi: 10.1016/j.immuni.2021.06.015.

新型コロナウイルスに対する中和抗体の経時的な質的変化
Lin Kang, Guijuan He, Amanda K Sharp et al.

A selective sweep in the Spike gene has driven SARS-CoV-2 human adaptation

Cell. 2021 Jul 6;S0092-8674(21)00833-3. doi: 10.1016/j.cell.2021.07.007.

新型コロナウイルスのスパイクたんぱく遺伝子の変異によるヒトへの適応
Aaron M Scherer, Amber M Gedlinske, Andrew M Parker et al.

Acceptability of Adolescent COVID-19 Vaccination Among Adolescents and Parents of Adolescents ― United States, April 15–23, 2021

MMWR Morb Mortal Wkly Rep. 2021 Jul 16;70(28):997-1003. doi: 10.15585/mmwr.mm7028e1.

米国における青年期人口およびその親の新型コロナワクチン接種意向
Kendra Dougherty, Mike Mannell, Ozair Naqvi, Dakota Matson, Jolianne Stone

SARS-CoV-2 B.1.617.2 (Delta) Variant COVID-19 Outbreak Associated with a Gymnastics Facility ― Oklahoma, April–May 2021

MMWR Morb Mortal Wkly Rep. 2021 Jul 16;70(28):1004-1007. doi: 10.15585/mmwr.mm7028e2.

米国オクラホマにおけるSARS-CoV-2の変異株であるB.1.617.2系統（デルタ株）の運動施設に関連するアウトブレイク
Jessica S Rogers-Brown, Valentine Wanga, Catherine Okoro et al.

Outcomes Among Patients Referred to Outpatient Rehabilitation Clinics After COVID-19 diagnosis - United States, January 2020-March 2021

MMWR Morb Mortal Wkly Rep. 2021 Jul 9;70(27). doi: 10.15585/mmwr.mm7027a2.

米国におけるCOVID-19回復後のリハビリ外来患者のアウトカム
Julia W Gargano, Megan Wallace, Stephen C Hadler et al.

Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021

MMWR Morb Mortal Wkly Rep. 2021 Jul 9;70(27):977-982. doi: 10.15585/mmwr.mm7027e2.

米国予防接種の実施に関する諮問委員会によるmRNAベースの新型コロナワクチン接種後の心筋炎の報告とこれらワクチンの接種に関する勧告
Kimihito Ito, Chayada Piantham, Hiroshi Nishiura

Predicted dominance of variant Delta of SARS-CoV-2 before Tokyo Olympic Games, Japan, July 2021

Euro Surveill. 2021 Jul;26(27). doi: 10.2807/1560-7917.ES.2021.26.27.2100570.

東京オリンピック前の日本におけるSARS-CoV-2のデルタ株を含む流行のモデリング
Xiaoyu Song, Jiayi Ji, Boris Reva et al.

Post-anticoagulant D-dimer is a highly prognostic biomarker of COVID-19 mortality

ERJ Open Res. 2021 Jul 5;7(3):00018-2021. doi: 10.1183/23120541.00018-2021.

抗凝固薬使用後のD-ダイマー値とCOVID-19による死亡の相関
Sabrina Jegerlehner, Franziska Suter-Riniker, Philipp Jent, Pascal Bittel, Michael Nagler

Diagnostic accuracy of a SARS-CoV-2 rapid antigen test in real-life clinical settings

Int J Infect Dis. 2021 Jul 6;S1201-9712(21)00565-8. doi: 10.1016/j.ijid.2021.07.010.

実臨床における抗原検査キット（Roche/SD Biosensor rapid antigen test）の精度検討
Jad A Elharake, Bayan Galal, Saleh A Alqahtani et al.

COVID-19 Vaccine Acceptance among Health Care Workers in the Kingdom of Saudi Arabia

Int J Infect Dis. 2021 Jul 6;S1201-9712(21)00559-2. doi: 10.1016/j.ijid.2021.07.004.

サウジアラビアの医療従事者における新型コロナワクチンの接種意向
Jennie Wilson, Gail Garson, Shaun Fitzgerald et al.

What is the evidence that medical procedures which induce coughing or involve respiratory suctioning are associated with increased generation of aerosols and risk of SARS-CoV-2 infection? A rapid systematic review

J Hosp Infect. 2021 Jul 7;S0195-6701(21)00261-9. doi: 10.1016/j.jhin.2021.06.011.

咳嗽を誘発する医療行為や吸引とエアロゾル発生およびSARS-CoV-2感染リスクとの相関に関する迅速システマティックレビュー
Upasana Das Adhikari, George Eng, Mara Farcasanu et al.

Fecal SARS-CoV-2 RNA is associated with decreased COVID-19 survival

Clin Infect Dis. 2021 Jul 10;ciab623. doi: 10.1093/cid/ciab623.

糞便中のSARS-CoV-2 RNAとCOVID-19の生存率との相関
Patrick Sean Sullivan, Aaron J Siegler, Kayoko Shioda et al.

SARS-CoV-2 cumulative incidence, United States, August-December 2020

Clin Infect Dis. 2021 Jul 10;ciab626. doi: 10.1093/cid/ciab626.

2020年8月～12月での米国におけるSARS-CoV-2累積発生率
Danuta M Skowronski, Solmaz Setayeshgar, Macy Zou et al.

Single-dose mRNA vaccine effectiveness against SARS-CoV-2, including Alpha and Gamma variants: a test-negative design in adults 70 years and older in British Columbia, Canada

Clin Infect Dis. 2021 Jul 9;ciab616. doi: 10.1093/cid/ciab616.

カナダにおける70歳以上でのmRNAベースの新型コロナワクチンの単回接種の有効性を評価した検査陰性デザインの症例対照研究（SARS-CoV-2の変異株であるB.1.1.7系統（アルファ株）・B.1.617.2系統（デルタ株）を含む）
Chantal Williams, Dana Al-Bargash, Celeste Macalintal et al.

COVID-19 Outbreak Associated with a SARS-CoV-2 P.1 Lineage in a Long-Term Care Home after Implementation of a Vaccination Program - Ontario, April-May 2021

Clin Infect Dis. 2021 Jul 8;ciab617. doi: 10.1093/cid/ciab617.

カナダのオンタリオ州における新型コロナワクチン接種後に長期療養施設で発生したSARS-CoV-2 P.1系統関連アウトブレイク（2021年4月～5月）
Jessica Seeßle, Tim Waterboer, Theresa Hippchen et al.

Persistent symptoms in adult patients one year after COVID-19: a prospective cohort study

Clin Infect Dis. 2021 Jul 5;ciab611. doi: 10.1093/cid/ciab611.

COVID-19から1年後の成人患者における持続的な症状と抗核抗体を検討した前向きコホート研究
Andrew Hill, Anna Garratt, Jacob Levi et al.

Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection

Open Forum Infect Dis. 2021 Jul 6;ofab358. doi: 10.1093/ofid/ofab358.

COVID-19に対するイベルメクチンの有効性を評価したランダム化比較試験のメタアナリシス
Yijia Li, Alexis M Schneider, Arnav Mehta et al.

SARS-CoV-2 viremia is associated with distinct proteomic pathways and predicts COVID-19 outcomes

J Clin Invest. 2021 Jul 1;131(13):e148635. doi: 10.1172/JCI148635.

SARS-CoV-2ウイルスRNA量とプロテオミクスの経路やCOVID-19患者の転帰との関係
Yaniv Lustig, Einav Sapir, Gili Regev-Yochay et al.

BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers

Lancet Respir Med. 2021 Jul 2;S2213-2600(21)00220-4. doi: 10.1016/S2213-2600(21)00220-4.

Pfizer社製新型コロナワクチン(BNT162b2)接種後の液性免疫応答とこの推移
Andreas Schuppert, Katja Polotzek, Jochen Schmitt et al.

Different spreading dynamics throughout Germany during the second wave of the COVID-19 pandemic: a time series study based on national surveillance data

Lancet Reg Health Eur. 2021 Jul;6:100151. doi: 10.1016/j.lanepe.2021.100151.

2020年9月以降のドイツにおける第2波で、全ての年齢層において陽性例の明確な減少に効果があったのは、学校や小売店閉鎖を含む広範な社会活動の制限だった（国のサーベイランスデータを用いた時系列研究）
Mayte Sánchez van Kammen, Mirjam R Heldner, Justine Brodard et al.

Frequency of Thrombocytopenia and Platelet Factor 4/Heparin Antibodies in Patients With Cerebral Venous Sinus Thrombosis Prior to the COVID-19 Pandemic

JAMA. 2021 Jul 2. doi: 10.1001/jama.2021.9889.

COVID-19パンデミック前の脳静脈洞血栓症における血小板減少および血小板第4因子（PF4）/ヘパリンに対する抗体保有の頻度
Aubrey Brown, Leilani Schwarcz, Catherine R Counts et al.

Risk for Acquiring COVID-19 Illness among Emergency Medical Service Personnel Exposed to Aerosol-Generating Procedures

Emerg Infect Dis. 2021 Jul 1;27(9). doi: 10.3201/eid2709.210363.

米国ワシントン州における、救急医療スタッフのSARS-CoV-2感染リスクを調査した後ろ向きコホート研究
Yaniv Lustig, Neta Zuckerman, Ital Nemet et al.

Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel

Euro Surveill. 2021 Jul;26(26). doi: 10.2807/1560-7917.ES.2021.26.26.2100557.

Pfizer社製の新型コロナワクチン（BNT162b2）接種後医療従事者の血清のB.1.617.2系統の変異株（デルタ株）および他のVOCsに対する中和能の検討
Ismail M Osmanov, Ekaterina Spiridonova, Polina Bobkova et al.

Risk factors for long covid in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study

Eur Respir J. 2021 Jul 1;2101341. doi: 10.1183/13993003.01341-2021.

COVID-19で入院した小児におけるlong COVIDに関する前向きコホート研究
Julien Favresse, Jonathan Douxfils

Importance of Sample Dilution in the Evaluation of the Antibody Response after SARS-CoV-2 Vaccination

J Infect. 2021 Jul 4;S0163-4453(21)00327-3. doi: 10.1016/j.jinf.2021.07.001.

新型コロナワクチン接種後の抗体応答の評価におけるサンプル希釈の重要性
Sheila F Lumley, Gillian Rodger, Bede Constantinides et al.

An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status

Clin Infect Dis. 2021 Jul 3;ciab608. doi: 10.1093/cid/ciab608.

抗体保有状況およびワクチン接種状況別の医療従事者におけるSARS-CoV-2感染、B.1.1.7変異株感染の発生率に関する観察コホート研究
Marco Capassoni, Sheyda Ketabchi, Angelo Cassisa et al.

AstraZeneca (AZD1222) Covid 19 vaccine-associated adverse drug event: a case report

J Med Virol. 2021 Jul 2. doi: 10.1002/jmv.27175.

AstraZeneca社製の新型コロナワクチン（AZD1222）関連副反応イベント：症例報告
Masaki Imai, Peter J Halfmann, Seiya Yamayoshi et al.

Characterization of a new SARS-CoV-2 variant that emerged in Brazil

Proc Natl Acad Sci U S A. 2021 Jul 6;118(27):e2106535118. doi: 10.1073/pnas.2106535118.

SARS-CoV-2のP.1系統の変異株（ガンマ株）のin vitroおよびハムスターモデル・マウスモデルにおける評価
Felicity Aiano, Anna A Mensah, Kelsey McOwat et al.

COVID-19 outbreaks following full reopening of primary and secondary schools in England: Cross-sectional national surveillance, November 2020

Lancet Reg Health Eur. 2021 Jul;6:100120. doi: 10.1016/j.lanepe.2021.100120.

英国における小中学校の全面再開後のCOVID-19アウトブレイク発生報告：2020年11月の横断的ナショナルサーベイランス
Krishnan Bhaskaran, Sebastian Bacon, Stephen Jw Evans et al.

Factors associated with deaths due to COVID-19 versus other causes: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform

Lancet Reg Health Eur. 2021 Jul;6:100109. doi: 10.1016/j.lanepe.2021.100109.

英国のOpenSAFELYプラットフォームを利用したCOVID-19死亡に影響する要因に関するコホート研究
June 2021
Atul Patel, Ritesh Agarwal, Shivaprakash M Rudramurthy et al.

Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India

Emerg Infect Dis. 2021 Jun 4;27(9). doi: 10.3201/eid2709.210934.

インドにおけるCOVID-19後のムコール症の症例集積
Paul T Heath, Eva P Galiza, David N Baxter et al.

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

N Engl J Med. 2021 Jun 30. doi: 10.1056/NEJMoa2107659.

Novavax社製新型コロナワクチン(NVX-CoV2373)の安全性と効果（第3相臨床試験)
Mark G Thompson, Jefferey L Burgess, Allison L Naleway et al.

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

N Engl J Med. 2021 Jun 30. doi: 10.1056/NEJMoa2107058.

Pfizer社製新型コロナワクチン(BNT162b2)とModerna社製新型ワクチン(mRNA-1273)のCOVID-19予防とウイルス量減少効果
Suzanne Pickering, Rahul Batra, Blair Merrick et al.

Comparative performance of SARS-CoV-2 lateral flow antigen tests and association with detection of infectious virus in clinical specimens: a single-centre laboratory evaluation study

Lancet Microbe. 2021 Jun 30. doi: 10.1016/S2666-5247(21)00143-9.

抗原検査キットの精度評価と感染性のあるウイルス検出との相関の検討
Emma C Wall, Mary Wu, Ruth Harvey et al.

AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC

Lancet. 2021 Jun 28;S0140-6736(21)01462-8. doi: 10.1016/S0140-6736(21)01462-8.

Oxford–AstraZeneca社製新型コロナワクチン(ChAdOx1 nCoV-19)によって誘導されるSARS-CoV-2デルタ株に対する中和抗体
Bihua Han, Yufei Song, Changgui Li et al.

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial

Lancet Infect Dis. 2021 Jun 28;S1473-3099(21)00319-4. doi: 10.1016/S1473-3099(21)00319-4.

Sinovac社製の新型コロナワクチン（CoronaVac）の健康な小児や若者に対する安全性と免疫原性を評価した第1/2相臨床試験
Angalee Nadesalingam, Diego Cantoni, David A Wells et al.

Paucity and discordance of neutralising antibody responses to SARS-CoV-2 VOCs in vaccinated immunodeficient patients and health-care workers in the UK

Lancet Microbe. 2021 Jun 28. doi: 10.1016/S2666-5247(21)00157-9.

英国におけるワクチン接種した免疫不全患者と医療従事者のSARS-CoV-2変異株に対する中和抗体応答の違い
Mary K Foley, Samuel D Searle, Ali Toloue et al.

Centenarians and extremely old people living with frailty can elicit durable SARS-CoV-2 spike specific IgG antibodies with virus neutralization functions following virus infection as determined by serological study

EClinicalMedicine. 2021 Jun 27;100975. doi: 10.1016/j.eclinm.2021.100975.

フレイル状態にある100歳以上を含む超高齢者におけるSARS-CoV-2感染後の中和抗体産生能と持続性
Vinicius Fontanesi Blum, Sérgio Cimerman, James R Hunter et al.

Nitazoxanide superiority to placebo to treat moderate COVID-19 - A Pilot prove of concept randomized double-blind clinical trial

EClinicalMedicine. 2021 Jun 27;100981. doi: 10.1016/j.eclinm.2021.100981.

中等症患者においてNitazoxanideは、入院期間を短縮し、RT-PCR検査の陰性化を促進した（パイロットランダム化比較試験）
Alex Crozier, Jake Dunning, Selina Rajan, Malcolm G Semple, Iain E Buchan

Could expanding the covid-19 case definition improve the UK's pandemic response?

BMJ. 2021 Jun 30;374:n1625. doi: 10.1136/bmj.n1625.

RT-PCR検査の対象となる症例定義は、症状、感染経路のパターン、変異株、接種状況に応じて、柔軟に修正し迅速な対応に結びつけるべき
Jay Montgomery, Margaret Ryan, Renata Engler et al.

Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military

JAMA Cardiol. 2021 Jun 29. doi: 10.1001/jamacardio.2021.2833.

mRNAワクチン接種後、心筋炎の発生率が通常より高くなったが、発症の頻度は低かった（米軍関係者計280万回接種後の心筋炎23例のケースシリーズ）
Han W Kim, Elizabeth R Jenista, David C Wendell et al.

Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination

JAMA Cardiol. 2021 Jun 29. doi: 10.1001/jamacardio.2021.2828.

mRNAワクチン2回接種後に発症した心筋炎4症例の報告
Wei Yee Wan, Koh Cheng Thoon, Liat Hui Loo et al.

Trends in Respiratory Virus Infections During the COVID-19 Pandemic in Singapore, 2020

JAMA Netw Open. 2021 Jun 1;4(6):e2115973. doi: 10.1001/jamanetworkopen.2021.15973.

シンガポールにおけるCOVID-19流行期の呼吸器ウイルス感染症の発生状況
Lisa LaVange, Stacey J Adam, Judith S Currier et al.

Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): Designing Master Protocols for Evaluation of Candidate COVID-19 Therapeutics

Ann Intern Med. 2021 Jun 29. doi: 10.7326/M21-1269.

ACTIVのマスタープロトコルのデザインについての論説
Dami A Collier, Isabella A T M Ferreira, Prasanti Kotagiri et al.

Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2

Nature. 2021 Jun 30. doi: 10.1038/s41586-021-03739-1.

Pfizer社製の新型コロナワクチン（BNT162b2）接種後の液性免疫および細胞性応答（変異株に対する免疫を含む）は80代以上の高齢者では弱く、多様性に乏しかった
Jackson S Turner, Jane A O'Halloran, Elizaveta Kalaidina et al.

SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses

Nature. 2021 Jun 28. doi: 10.1038/s41586-021-03738-2.

mRNAベースの新型コロナワクチン接種後の胚中心における免疫応答
Muhammad Suleman Rana, Muhammad Masroor Alam, Aamer Ikram et al.

Emergence of measles during the COVID-19 pandemic threatens Pakistan's children and the wider region

Nat Med. 2021 Jun 28. doi: 10.1038/s41591-021-01430-6.

パキスタンにおけるCOVID-19パンデミック下の麻疹の流行
Jae Hyung Jung, Min-Seok Rha, Moa Sa et al.

SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells

Nat Commun. 2021 Jun 30;12(1):4043. doi: 10.1038/s41467-021-24377-1.

SARS-CoV-2感染10ヶ月後までのT細胞応答
Pinja Jalkanen, Pekka Kolehmainen, Hanni K Häkkinen et al.

COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants

Nat Commun. 2021 Jun 28;12(1):3991. doi: 10.1038/s41467-021-24285-4.

Pfizer-BioNTech製ワクチン接種後の医療従事者の血清を用いて、新型コロナウイルスの変異株に対する中和抗体を調べた報告
Colin Pawlowski, Patrick Lenehan, Arjun Puranik et al.

FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system

Med (N Y). 2021 Jun 29. doi: 10.1016/j.medj.2021.06.007.

米国メイヨークリニックの医療システムの医療従事者13万6532人を対象としたPfizer-BioNTech製ワクチンとモデルナ社製ワクチンの有効性を調べた後ろ向きコホート研究
Reid McMurry, Patrick Lenehan, Samir Awasthi et al.

Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines

Med (N Y). 2021 Jun 28. doi: 10.1016/j.medj.2021.06.006.

米国メイヨークリニックの医療システムの医療従事者13万6532人を対象としたPfizer-BioNTech製ワクチンとモデルナ社製ワクチン接種後の副作用の出現頻度を調査した後ろ向きコホート研究
Rachel M Burke, Laura Calderwood, Marie E Killerby et al.

Patterns of Virus Exposure and Presumed Household Transmission among Persons with Coronavirus Disease, United States, January-April 2020

Emerg Infect Dis. 2021 Jun 30;27(9). doi: 10.3201/eid2709.204577.

米国におけるパンデミック初期（2020年1月～4月）のSARS-CoV-2への曝露パターン
Weimin Liu, Ronnie M Russell, Frederic Bibollet-Ruche et al.

Predictors of Nonseroconversion after SARS-CoV-2 Infection

Emerg Infect Dis. 2021 Jun 30;27(9). doi: 10.3201/eid2709.211042.

SARS-CoV-2感染後にノンセロコンバージョンと相関する因子
Michal Paret, Karim Lalani, Carine Hedari et al.

SARS-CoV-2 Among Infants <90 days of age admitted for serious bacterial infection evaluation

Pediatrics. 2021 Jun 30;e2020044685. doi: 10.1542/peds.2020-044685.

重症細菌感染症疑いの精査目的に入院した生後90日未満の乳児におけるSARS-CoV-2感染
Andreas Walker, Torsten Houwaart, Patrick Finzer et al.

Characterization of SARS-CoV-2 infection clusters based on integrated genomic surveillance, outbreak analysis and contact tracing in an urban setting

Clin Infect Dis. 2021 Jun 28;ciab588. doi: 10.1093/cid/ciab588.

ドイツにおけるゲノムサーベイランス、アウトブレイク分析、接触者追跡調査による、都市部でのクラスター特性評価
Manish C Choudhary, Charles R Crain, Xueting Qiu, William Hanage, Jonathan Z Li

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Sequence Characteristics of Coronavirus Disease 2019 (COVID-19) Persistence and Reinfection

Clin Infect Dis. 2021 Jun 27;ciab380. doi: 10.1093/cid/ciab380.

再感染、持続感染がみられたSARS-CoV-2ゲノム配列の特徴を検討したシステマティックレビュー
Rebecca L Smith, Laura L Gibson, Pamela P Martinez et al.

Longitudinal assessment of diagnostic test performance over the course of acute SARS-CoV-2 infection

J Infect Dis. 2021 Jun 30;jiab337. doi: 10.1093/infdis/jiab337.

急性SARS-CoV-2感染症の経過における診断テストの性能の長期的評価
Laura Matrajt, Holly Janes, Joshua T Schiffer, Dobromir Dimitrov

Quantifying the impact of lifting community non-pharmaceutical interventions for COVID-19 during vaccination rollout in the United States

Open Forum Infect Dis. 2021 Jun 30;ofab341. doi: 10.1093/ofid/ofab341.

米国における予防接種展開中でのCOVID-19に対する地域社会の非医薬品的介入の解除による影響の定量化
Philip R Krause, Thomas R Fleming, Ira M Longini et al.

SARS-CoV-2 Variants and Vaccines

N Engl J Med. 2021 Jun 23. doi: 10.1056/NEJMsr2105280.

SARS-CoV-2変異株とワクチンについての論説
Nassim Kamar, Florence Abravanel, Olivier Marion et al.

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

N Engl J Med. 2021 Jun 23. doi: 10.1056/NEJMc2108861.

固形臓器移植者でのPfizer社製の新型コロナワクチン（BNT162b2）の3回接種後抗体応答
Ross J Harris, Jennifer A Hall, Asad Zaidi et al.

Effect of Vaccination on Household Transmission of SARS-CoV-2 in England

N Engl J Med. 2021 Jun 23. doi: 10.1056/NEJMc2107717.

英国におけるSARS-CoV-2家庭内2次感染への新型コロナワクチンの有効性評価
Alberto M Borobia, Antonio J Carcas, Mayte Pérez-Olmeda et al.

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Lancet. 2021 Jun 25;S0140-6736(21)01420-3. doi: 10.1016/S0140-6736(21)01420-3.

1回目接種がAstraZeneca社製の新型コロナワクチン（ChAdOx1-S）で2回目接種がPfizer社製の新型コロナワクチン（BNT162b2）である者における免疫原性・反応原性：多施設非盲検ランダム化比較試験（第2相）
Madhumita Shrotri, Maria Krutikov, Tom Palmer et al.

Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study

Lancet Infect Dis. 2021 Jun 23;S1473-3099(21)00289-9. doi: 10.1016/S1473-3099(21)00289-9.

英国における介護施設入居者でのSARS-CoV-2感染に対するAstraZeneca社製の新型コロナワクチン（ChAdOx1 nCoV-19）とPfizer社製の新型コロナワクチン（BNT162b2）1回接種のワクチン有効性評価を検討した前向きコホート研究
Catherine Hyams, Robin Marlow, Zandile Maseko et al.

Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study

Lancet Infect Dis. 2021 Jun 23;S1473-3099(21)00330-3. doi: 10.1016/S1473-3099(21)00330-3.

Pfizer社製の新型コロナワクチン（BNT162b2）とAstraZeneca社製の新型コロナワクチン（ChAdOx1 nCoV-19）1回接種の年齢80歳以上におけるCOVID-19による入院に対する有効性を評価したtest-negative designの症例対照研究
Brittany E Kula, Cornelius J Clancy, M Hong Nguyen, Ilan S Schwartz

Invasive mould disease in fatal COVID-19: a systematic review of autopsies

Lancet Microbe. 2021 Jun 23. doi: 10.1016/S2666-5247(21)00091-4.

COVID-19剖検例における侵襲性真菌症のシステマティックレビュー
Peter Bager, Jan Wohlfahrt, Jannik Fonager et al.

Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study

Lancet Infect Dis. 2021 Jun 22;S1473-3099(21)00290-5. doi: 10.1016/S1473-3099(21)00290-5.

デンマークにおけるSARS-CoV-2のB.1.1.7系統の変異株（アルファ株）感染に伴う入院のリスク：観察コホート研究
Martina Patone, Karen Thomas, Rob Hatch et al.

Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study

Lancet Infect Dis. 2021 Jun 22;S1473-3099(21)00318-2. doi: 10.1016/S1473-3099(21)00318-2.

英国におけるSARS-CoV-2のB.1.1.7系統の変異株（アルファ株）と死亡率および集中治療室入室との相関を検討したコホート研究
Zulfiqar A Bhutta, Sameen Siddiqi, Assad Hafeez et al.

Beyond the numbers: understanding the diversity of covid-19 epidemiology and response in South Asia

BMJ. 2021 Jun 25;373:n1544. doi: 10.1136/bmj.n1544.

南アジアにおけるCOVID-19の疫学と公衆衛生対応に関する論説
Reshma Ramachandran, Meera Dhodapkar, Joseph S Ross, Jason L Schwartz

Future of covid-19 vaccine pricing: lessons from influenza

BMJ. 2021 Jun 22;373:n1467. doi: 10.1136/bmj.n1467.

インフルエンザワクチンからみた新型コロナワクチンに関する論説
Davidson H Hamer, Laura F White, Helen E Jenkins et al.

Assessment of a COVID-19 Control Plan on an Urban University Campus During a Second Wave of the Pandemic

JAMA Netw Open. 2021 Jun 1;4(6):e2116425. doi: 10.1001/jamanetworkopen.2021.16425.

米国ボストン大学のキャンパスにおけるCOVID-19対応策
Sumedha Gupta, Archelle Georgiou, Soumya Sen, Kosali Simon, Pinar Karaca-Mandic

US Trends in COVID-19–Associated Hospitalization and Mortality Rates Before and After Reopening Economies

JAMA Health Forum. 2021 Jun 25; 2(6):e211262. doi: 10.1001/jamahealthforum.2021.1262.

米国における経済活動の再開と、COVID-19関連の入院者数や死亡者数との相関
Defne Saatci, Tom A Ranger, Cesar Garriga et al.

Association Between Race and COVID-19 Outcomes Among 2.6 Million Children in England

JAMA Pediatr. 2021 Jun 21. doi: 10.1001/jamapediatrics.2021.1685.

英国260万人の小児を対象とした人種とCOVID-19の転帰との関連解析
Christopher M Whaley, Jonathan Cantor, Megan Pera, Anupam B Jena

Assessing the Association Between Social Gatherings and COVID-19 Risk Using Birthdays

JAMA Intern Med. 2021 Jun 21. doi: 10.1001/jamainternmed.2021.2915.

家庭内での集会・会食の機会である誕生会は COVID-19感染伝播の機会となりうる（米国における国レベルの横断研究）
Jingyou Yu, Lisa H Tostanoski, Noe B Mercado et al.

Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques

Nature. 2021 Jun 23. doi: 10.1038/s41586-021-03732-8.

アカゲザルモデルにおけるJohnson and Johnson社製の新型コロナワクチン（Ad26.COV2.S）接種後のSARS-CoV-2のB.1.351系統（ベータ株）に対する防御効果検討
Rita E Chen, Emma S Winkler, James Brett Case et al.

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains

Nature. 2021 Jun 21. doi: 10.1038/s41586-021-03720-y.

マウスモデル・ハムスターモデルにおける複数のモノクローナル抗体のcombination therapyの有効性の検討
Andrew C Yang, Fabian Kern, Patricia M Losada et al.

Dysregulation of brain and choroid plexus cell types in severe COVID-19

Nature. 2021 Jun 21. doi: 10.1038/s41586-021-03710-0.

COVID-19重症例における脳細胞の機能不全
Bjørn Blomberg, Kristin Greve-Isdahl Mohn, Karl Albert Brokstad et al.

Long COVID in a prospective cohort of home-isolated patients

Nat Med. 2021 Jun 23. doi: 10.1038/s41591-021-01433-3.

軽症の若年成人（16-30歳）も遷延するCOVID-19症状（Long COVID）のリスクがある（前向きコホート研究、発症後6か月のフォローアップの結果）
Changchang Cao, Zhaokui Cai, Xia Xiao et al.

The architecture of the SARS-CoV-2 RNA genome inside virion

Nat Commun. 2021 Jun 24;12(1):3917. doi: 10.1038/s41467-021-22785-x.

SARS-CoV-2のウイルス学的構造のレビュー
Jonathan Sprent, Cecile King

COVID-19 vaccine side effects: The positives about feeling bad

Sci Immunol. 2021 Jun 22;6(60):eabj9256. doi: 10.1126/sciimmunol.abj9256.

mRNAワクチン接種後のIFN-1産生に関するナラティブレビュー・論説
Heather Kalish, Carleen Klumpp-Thomas, Sally Hunsberger et al.

Undiagnosed SARS-CoV-2 Seropositivity During the First Six Months of the COVID-19 Pandemic in the United States

Sci Transl Med. 2021 Jun 22;eabh3826. doi: 10.1126/scitranslmed.abh3826.

米国の18歳以上の人口におけるCOVID-19未診断の集団での血清疫学調査（2020年5月-7月）
Edward S Knock, Lilith K Whittles, John A Lees et al.

Key epidemiological drivers and impact of interventions in the 2020 SARS-CoV-2 epidemic in England

Sci Transl Med. 2021 Jun 22;eabg4262. doi: 10.1126/scitranslmed.abg4262.

英国における公衆衛生的社会的対策ではロックダウンだけが感染伝播の制御に効果的だったとするモデリング
Sophie M-C Gobeil, Katarzyna Janowska, Shana McDowell et al.

Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity

Science. 2021 Jun 24;eabi6226. doi: 10.1126/science.abi6226.

SARS-CoV-2の変異によるスパイクタンパクの構造や抗原性への影響
Yongfei Cai, Jun Zhang, Tianshu Xiao et al.

Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants

Science. 2021 Jun 24;eabi9745. doi: 10.1126/science.abi9745.

SARS-CoV-2のB.1.1.7系統の変異株（アルファ株）およびB.1.351（ベータ株）の感染性増加と免疫逃避能に関係する構造基盤
Sarah P. Otto, Troy Day, Julien Arino

The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic

Curr Biol. 2021 Jun 23;S0960-9822(21)00878-2. doi: 10.1016/j.cub.2021.06.049.

懸念される変異株（VOCs; Variant of Concern）の起源、過程、予想される進化と対策を論じたナラティブレビュー
Thomas P Smith, Seth Flaxman, Amanda S Gallinat et al.

Temperature and population density influence SARS-CoV-2 transmission in the absence of nonpharmaceutical interventions

Proc Natl Acad Sci U S A. 2021 Jun 22;118(25):e2019284118. doi: 10.1073/pnas.2019284118.

実効再生産数と気温、湿度、紫外線等の気象データ、人口密度との関連を調べた研究
Jesse Bonwitt, Ruth W Deya, Dustin W Currie et al.

COVID-19 Surveillance and Investigations in Workplaces - Seattle & King County, Washington, June 15-November 15, 2020

MMWR Morb Mortal Wkly Rep. 2021 Jun 25;70(25):916-921. doi: 10.15585/mmwr.mm7025a3.

アメリカ・ワシントン州における、通常の疫学調査に加えて職場に関する追加調査の有用性の報告
Jill Diesel, Natalie Sterrett, Sharoda Dasgupta et al.

COVID-19 Vaccination Coverage Among Adults - United States, December 14, 2020-May 22, 2021

MMWR Morb Mortal Wkly Rep. 2021 Jun 25;70(25):922-927. doi: 10.15585/mmwr.mm7025e1.

米国におけるワクチン接種率の変遷（2020年12月14日～2021年5月22日）
Brittney N Baack, Neetu Abad, David Yankey et al.

COVID-19 Vaccination Coverage and Intent Among Adults Aged 18-39 Years - United States, March-May 2021

MMWR Morb Mortal Wkly Rep. 2021 Jun 25;70(25):928-933. doi: 10.15585/mmwr.mm7025e2.

米国における若年層のワクチン接種率と接種希望の有無（2021年3-5月）
Maureen Lynch, Guerrino Macori, Séamus Fanning et al.

Genomic Evolution of SARS-CoV-2 Virus in Immunocompromised Patient, Ireland

Emerg Infect Dis. 2021 Jun 23;27(9). doi: 10.3201/eid2709.211159.

免疫不全患者におけるSARS-CoV-2への遷延する感染における変異蓄積
Lex EX Leong, Julien Soubrier, Mark Turra et al.

Whole-Genome Sequencing of SARS-CoV-2 from Quarantine Hotel Outbreak

Emerg Infect Dis. 2021 Jun 22;27(8). doi: 10.3201/eid2708.204875.

オーストラリアにおける、海外からの入国者の隔離用ホテルにおけるアウトブイレイクで、全ゲノムシーケンスによって感染連鎖を究明した報告
Alberto Mateo-Urdiales, Stefania Spila Alegiani, Massimo Fabiani et al.

Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine administration, Italy, 27 December 2020 to mid-April 2021

Euro Surveill. 2021 Jun;26(25). doi: 10.2807/1560-7917.ES.2021.26.25.2100507.

イタリアにおける、新型コロナワクチン接種による感染率、入院率、死亡率の低下を調べたコホート研究
Francesco Bonfante, Paola Costenaro, Anna Cantarutti et al.

Mild SARS-CoV-2 Infections and Neutralizing Antibody Titers

Pediatrics. 2021 Jun 22;e2021052173. doi: 10.1542/peds.2021-052173.

軽症または無症状の小児COVID-19患者における中和抗体、IgG/IgMを長期間調査したコホート研究
Abbye E McEwen, Seth Cohen, Chloe Bryson-Cahn et al.

Variants of concern are overrepresented among post-vaccination breakthrough infections of SARS-CoV-2 in Washington State

Clin Infect Dis. 2021 Jun 24;ciab581. doi: 10.1093/cid/ciab581.

米国ワシントン州におけるブレイクスルー感染のウイルスゲノム解析
Kimberly E Hanson, Osama Altayar, Angela M Caliendo et al.

The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Antigen Testing

Clin Infect Dis. 2021 Jun 23;ciab557. doi: 10.1093/cid/ciab557.

新型コロナウイルスの抗原検査に関する米国感染症学会のガイドライン
Jessica Penney, Sajani Shah, Shira Doron

First do no harm: Moving beyond universal pre-procedural testing for COVID-19

Open Forum Infect Dis. 2021 Jun 24;ofab342. doi: 10.1093/ofid/ofab342.

いつまで臨床検査前のスクリーニングPCR検査を継続するかについて検討した論説
Mary Beth F Son, Nancy Murray, Kevin Friedman et al.

Multisystem Inflammatory Syndrome in Children - Initial Therapy and Outcomes

N Engl J Med. 2021 Jun 16. doi: 10.1056/NEJMoa2102605.

米国における小児多系統炎症性症候群のサーベイランスデータを利用した初期治療の比較
Andrew J McArdle, Ortensia Vito, Harsita Patel et al.

Treatment of Multisystem Inflammatory Syndrome in Children

N Engl J Med. 2021 Jun 16. doi: 10.1056/NEJMoa2102968.

小児多系統炎症性症候群の初期治療を比較した国際前向きコホート研究
Patrícia O Guimarães, Daniel Quirk, Remo H Furtado et al.

Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia

N Engl J Med. 2021 Jun 16. doi: 10.1056/NEJMoa2101643.

COVID-19入院患者におけるトファシチニブ（ヤヌスキナーゼ（JAK）阻害薬）の有効性を検討したランダム化比較試験
Elizabeth Fearon, Iain E Buchan, Rajenki Das et al.

SARS-CoV-2 antigen testing: weighing the false positives against the costs of failing to control transmission

Lancet Respir Med. 2021 Jun 14;S2213-2600(21)00234-4. doi: 10.1016/S2213-2600(21)00234-4.

抗原検査キットを用いる際の偽陽性と流行抑制とのトレードオフ
Aziz Sheikh, Jim McMenamin, Bob Taylor, Chris Robertson, Public Health Scotland and the EAVE II Collaborators

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness

Lancet. 2021 Jun 14;S0140-6736(21)01358-1. doi: 10.1016/S0140-6736(21)01358-1.

スコットランドにおけるデルタ株（B.1.617.2系統）による入院リスクとワクチン有効性評価
Jurjan Aman, Erik Duijvelaar, Liza Botros et al.

Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial

Lancet Respir Med. 2021 Jun 17;S2213-2600(21)00237-X. doi: 10.1016/S2213-2600(21)00237-X.

COVID-19重症患者におけるイマチニブの有効性を評価したランダム化比較試験
Youn Ho Shin, Jae Il Shin, Sung Yong Moon et al.

Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study

Lancet Rheumatol. 2021 Jun 18;S2665-9913(21)00151-X. doi: 10.1016/S2665-9913(21)00151-X.

韓国における自己免疫疾患とCOVID-19のリスクとの相関の検討
John Frater, Katie J Ewer, Ane Ogbe et al.

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

Lancet HIV. 2021 Jun 18;S2352-3018(21)00103-X. doi: 10.1016/S2352-3018(21)00103-X.

HIV感染者におけるAstraZeneca社製の新型コロナワクチン（ChAdOx1-S）の安全性と免疫原性
Tommy Nyberg, Katherine A Twohig, Ross J Harris et al.

Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis

BMJ. 2021 Jun 15;373:n1412. doi: 10.1136/bmj.n1412.

新規変異株（B.1.1.7系統）感染患者の入院リスク：後ろ向きコホート研究
Xintong Li, Anna Ostropolets, Rupa Makadia et al.

Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study

BMJ. 2021 Jun 15;373:n1435. doi: 10.1136/bmj.n1435.

8カ国のデータベースを解析したCOVID-19ワクチンの特に注目すべき有害事象のベースラインの発生率の比較
Kali S Thomas, Wenhan Zhang, David M Dosa et al.

Estimation of Excess Mortality Rates Among US Assisted Living Residents During the COVID-19 Pandemic

JAMA Netw Open. 2021 Jun 1;4(6):e2113411. doi: 10.1001/jamanetworkopen.2021.13411.

COVID-19パンデミック下の米国における老人ホームでの超過死亡
Daniel C Gonzalez, Daniel E Nassau, Kajal Khodamoradi et al.

Sperm Parameters Before and After COVID-19 mRNA Vaccination

JAMA. 2021 Jun 17. doi: 10.1001/jama.2021.9976.

mRNAベースの新型コロナワクチン接種前後での精子の指標
Michael A Thompson, Jeffrey P Henderson, Pankil K Shah et al.

Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19

JAMA Oncol. 2021 Jun 17. doi: 10.1001/jamaoncol.2021.1799.

血液がんのあるCOVID-19患者における回復期患者血漿療法の使用と30日後死亡率との相関を検討した後ろ向きコホート研究
Meghan Matheny, Noble Maleque, Natalie Channell et al.

Severe Exacerbations of Systemic Capillary Leak Syndrome After COVID-19 Vaccination: A Case Series

Ann Intern Med. 2021 Jun 15. doi: 10.7326/L21-0250.

新型コロナワクチン接種後の全身性毛細血管漏出症候群の増悪の症例集積
William A Werbel, Brian J Boyarsky, Michael T Ou et al.

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series

Ann Intern Med. 2021 Jun 15. doi: 10.7326/L21-0282.

固形臓器被移植者における新型コロナワクチンの3回接種の安全性と免疫原性を検討した症例集積
Christina DeFilippo Mack, Michael Osterholm, Erin B Wasserman et al.

Optimizing SARS-CoV-2 Surveillance in the United States: Insights From the National Football League Occupational Health Program

Ann Intern Med. 2021 Jun 15. doi: 10.7326/M21-0319.

米国におけるSARS-CoV-2スクリーニングの最適化：米国ナショナルフットボールリーグ（NFL）の労働衛生プログラムからの知見
Zijun Wang, Frauke Muecksch, Dennis Schaefer-Babajew et al.

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

Nature. 2021 Jun 14. doi: 10.1038/s41586-021-03696-9.

SARS-CoV-2感染1年後までの抗体の質の変化
Talia Kustin, Noam Harel, Uriah Finkel et al.

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals

Nat Med. 2021 Jun 14. doi: 10.1038/s41591-021-01413-7.

Pfizer社製の新型コロナワクチン（BNT162b2）接種後のSARS-CoV-2変異株によるブレイクスルー感染割合の増加
Yiqun Ma, Sen Pei, Jeffrey Shaman, Robert Dubrow, Kai Chen

Role of meteorological factors in the transmission of SARS-CoV-2 in the United States

Nat Commun. 2021 Jun 14;12(1):3602. doi: 10.1038/s41467-021-23866-7.

米国における気象情報とSARS-CoV-2流行の相関
Haoxiang Yang, Özge Sürer, Daniel Duque et al.

Design of COVID-19 staged alert systems to ensure healthcare capacity with minimal closures

Nat Commun. 2021 Jun 18;12(1):3767. doi: 10.1038/s41467-021-23989-x.

最小限のロックダウンで医療システムを維持するためのCOVID-19アラートシステム
Sohee Kwon, Amit D Joshi, Chun-Han Lo et al.

Association of social distancing and face mask use with risk of COVID-19

Nat Commun. 2021 Jun 18;12(1):3737. doi: 10.1038/s41467-021-24115-7.

スマートフォンのアプリを利用したソーシャルディスタンスやマスク着用の程度とSARS-CoV-2感染との相関
Dapeng Li, Robert J Edwards, Kartik Manne et al.

In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies

Cell. 2021 Jun 18;S0092-8674(21)00756-X. doi: 10.1016/j.cell.2021.06.021.

SARS-CoV-2の感染を増強させるまたは中和する抗体のin vitroおよびin vivoでの機能
Alfredo Addeo, Pankil K Shah, Natacha Bordry et al.

Immunogenicity of SARS-CoV-2 messenger RNA Vaccines in Patients with Cancer

Cancer Cell. 2021 Jun 18;S1535-6108(21)00330-5. doi: 10.1016/j.ccell.2021.06.009.

担がん患者においてもmRNAワクチン2回接種による効果は認められるが、血液悪性疾患では効果が低い
Chihiro Motozono, Mako Toyoda, Jiri Zahradnik et al.

SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity

Cell Host Microbe. 2021 Jun 14;S1931-3128(21)00284-5. doi: 10.1016/j.chom.2021.06.006.

L452R変異を含むリコンビナントウイルスはin vitroで細胞性免疫を回避し感染性を高める
Katharina Röltgen, Scott D Boyd

Antibody and B cell responses to SARS-CoV-2 infection and vaccination

Cell Host Microbe. 2021 Jun 16;S1931-3128(21)00287-0. doi: 10.1016/j.chom.2021.06.009.

SARS-CoV-2感染およびワクチン接種後の抗体とB細胞の反応に関するナラティブレビュー
Chang Liu, Helen M Ginn, Wanwisa Dejnirattisai et al.

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Cell. 2021 Jun 16;S0092-8674(21)00755-8. doi: 10.1016/j.cell.2021.06.020.

ワクチン接種者および複数のSARS-CoV-2変異株既感染者の血清を用いたデルタ株（B.1.617.2系統）の中和能
Hilda Razzaghi, Mehreen Meghani, Cassandra Pingali et al.

COVID-19 Vaccination Coverage Among Pregnant Women During Pregnancy - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 8, 2021

MMWR Morb Mortal Wkly Rep. 2021 Jun 18;70(24):895-899. doi: 10.15585/mmwr.mm7024e2.

米国の妊婦におけるワクチン接種率は16.3%であった（2020年12月14日－2021年5月8日）
Victor Williams, Bassey Edem, Marianne Calnan, Kennedy Otwombe, Charles Okeahalam

Considerations for Establishing Successful Coronavirus Disease Vaccination Programs in Africa

Emerg Infect Dis. 2021 Jun 17;27(8). doi: 10.3201/eid2708.203870.

アフリカにおける新型コロナワクチンプログラムの確立のために検討すべきこと
Nicholas B Lehnertz, Xiong Wang, Jacob Garfin et al.

Transmission Dynamics of Severe Acute Respiratory Syndrome Coronavirus 2 in High-Density Settings, Minnesota, USA, March-June 2020

Emerg Infect Dis. 2021 Jun 17;27(8). doi: 10.3201/eid2708.204838.

密な環境になりやすい施設（老健施設、刑務所、食肉加工工場）で発生したクラスターの特徴
Finlay Campbell, Brett Archer, Henry Laurenson-Schafer et al.

Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021

Euro Surveill. 2021 Jun;26(24). doi: 10.2807/1560-7917.ES.2021.26.24.2100509.

懸念される変異株（VOCs; Variant of Concern）が世界的に拡大しており、特にB.1.617.2 は感染・伝播性が高く、主要なウイルスになる可能性がある（2021年6月時点）
Zaid A Alhinai, Nagi Elsidig

Countries with similar Covid-19 vaccination rates yet divergent outcomes: are all vaccines created equal?

Int J Infect Dis. 2021 Jun 19;S1201-9712(21)00527-0. doi: 10.1016/j.ijid.2021.06.040.

新型コロナワクチンのうちの不活化ワクチンを主に使用している国と、不活化ワクチンではないワクチンを使用している国の新規感染者数、死亡者数を比較したエコロジカル研究
Gokhan Tanisali, Ahmet Sozak, Abdul Samet Bulut et al.

Effectiveness of different types of Masks in Aerosol Dispersion in SARS-CoV-2 Infection

Int J Infect Dis. 2021 Jun 17;S1201-9712(21)00518-X. doi: 10.1016/j.ijid.2021.06.029.

飛沫に対するマスクの効果をマスクの種類別に調査したシミュレーション
Abraar Karan, Michael Klompas, Robert Tucker et al.

The Risk of SARS-CoV-2 Transmission from Patients with Undiagnosed Covid-19 to Roommates in a Large Academic Medical Center

Clin Infect Dis. 2021 Jun 18;ciab564. doi: 10.1093/cid/ciab564.

未診断の新型コロナウイルス感染者と同室になった入院患者の感染リスクを調べた後ろ向きコホート研究
Karen B Jacobson, Benjamin A Pinsky, Maria E Montez Rath et al.

Post-vaccination SARS-CoV-2 infections and incidence of presumptive B.1.427/B.1.429 variant among healthcare personnel at a northern California academic medical center

Clin Infect Dis. 2021 Jun 17;ciab554. doi: 10.1093/cid/ciab554.

米国カリフォルニア州における、新型コロナウイルスワクチン接種後の新規変異株（B.1.427/B.1.429系統）への感染リスクの評価
Mattia Manica, Serena Pancheri, Piero Poletti et al.

The risk of symptomatic infection during a second COVID-19 wave, in SARS-CoV-2 seropositive individuals

Clin Infect Dis. 2021 Jun 16;ciab556. doi: 10.1093/cid/ciab556.

イタリアにおける血清抗体保有者のCOVID-19発症に対する相対リスクを調べた前向きコホート研究
Keri N Althoff, David J Schlueter, Hoda Anton-Culver et al.

Antibodies to SARS-CoV-2 in All of Us Research Program Participants, January 2-March 18, 2020

Clin Infect Dis. 2021 Jun 15;ciab519. doi: 10.1093/cid/ciab519.

米国の各州の最初のSARS-CoV-2探知事例前の抗体保有者を調査した後ろ向き研究（All of Usという前向きコホート研究の検体を利用）
Chaogeng Zhu, Guiyun He, Qinqin Yin et al.

Molecular biology of the SARs-CoV-2 spike protein: A review of current knowledge

J Med Virol. 2021 Jun 14. doi: 10.1002/jmv.27132.

SARS-CoV-2スパイクタンパクの分子生物学的知識に関するナラティブレビュー
Claude Kwe Yinda, Julia R Port, Trenton Bushmaker et al.

Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant

Emerg Microbes Infect. 2021 Jun 14;1-20. doi: 10.1080/22221751.2021.1943539.

ハムスターモデルにおいてSARS-CoV-2 A系統へのエアロゾルによる既感染はベータ株（B.1.351系統）の発症からは防御するが感染からは防御しない
W Kyle Resurreccion, Joseph Hulsizer, Zhuqing Shi et al.

Association of Sickle Cell Trait with Risk and Mortality of COVID-19: Results from the United Kingdom Biobank

Am J Trop Med Hyg. 2021 Jun 15;tpmd201657. doi: 10.4269/ajtmh.20-1657.

英国バイオバンクのデータを利用した鎌状赤血球症とCOVID-19の罹患および死亡との相関
Judith Ju Ming Wong, Qalab Abbas, Soo Lin Chuah et al.

Comparative Analysis of Pediatric COVID-19 Infection in Southeast Asia, South Asia, Japan, and China

Am J Trop Med Hyg. 2021 Jun 15;tpmd210299. doi: 10.4269/ajtmh.21-0299.

アジアにおける小児のCOVID-19患者のレジストリデータの解析
Alex Bourguignon, Donald M Arnold, Theodore E Warkentin et al.

Adjunct Immune Globulin for Vaccine-Induced Thrombotic Thrombocytopenia

N Engl J Med. 2021 Jun 9. doi: 10.1056/NEJMoa2107051.

AstraZeneca社製の新型コロナワクチン（ChAdOx1-S）使用によるワクチン誘発性血小板減少症に対する補助的免疫グロブリン療法に関しての症例報告（3例）
Upeka Samarakoon, Santiago Alvarez-Arango, Kimberly G Blumenthal

Delayed Large Local Reactions to mRNA Covid-19 Vaccines in Blacks, Indigenous Persons, and People of Color

N Engl J Med. 2021 Jun 9. doi: 10.1056/NEJMc2108620.

黒人、先住民、および有色人種のmRNAワクチンに対する広範囲な局所遅延反応に関する症例集積
Scott J Becker, Jill Taylor, Joshua M Sharfstein

Identifying and Tracking SARS-CoV-2 Variants - A Challenge and an Opportunity

N Engl J Med. 2021 Jun 9. doi: 10.1056/NEJMp2103859.

変異株の同定と監視に関する論説
Sarin Kc, Aparna Ananthakrishnan, Christopher Painter, Dimple Butani, Yot Teerawattananon

Research collaboration is needed to inform quarantine policies for health-care workers

Lancet. 2021 Jun 7;S0140-6736(21)01224-1. doi: 10.1016/S0140-6736(21)01224-1.

低中所得国における新型コロナワクチン接種後の医療従事者の健康観察の調査に関する研究提言
Evangelos Kontopantelis, Mamas A Mamas, Roger T Webb et al.

Excess deaths from COVID-19 and other causes by region, neighbourhood deprivation level and place of death during the first 30 weeks of the pandemic in England and Wales: A retrospective registry study

Lancet Reg Health Eur. 2021 Jun 7;100144. doi: 10.1016/j.lanepe.2021.100144.

英国におけるパンデミック初期30週間の超過死亡に関するレジストリデータの後ろ向き解析
Samira Zoa-Assoumou, Bénédicte Ndeboko, Gédéon Prince Manouana et al.

SARS-CoV-2 emerging variants in Africa: view from Gabon

Lancet Microbe. 2021 Jun 8. doi: 10.1016/S2666-5247(21)00125-7.

ガボンにおけるSARS-CoV-2変異株への対応
Andrea Rubbert-Roth, Nicolas Vuilleumier, Burkhard Ludewig et al.

Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis

Lancet Rheumatol. 2021 Jun 8. doi: 10.1016/S2665-9913(21)00186-7.

mRNAワクチン接種後の関節リウマチ患者の抗体応答
Jackeline J Rodriguez-Smith, Emely L Verweyen, Gwendolyn M Clay et al.

Inflammatory biomarkers in COVID-19-associated multisystem inflammatory syndrome in children, Kawasaki disease, and macrophage activation syndrome: a cohort study

Lancet Rheumatol. 2021 Jun 8. doi: 10.1016/S2665-9913(21)00139-9.

MIS-C、川崎病、およびマクロファージ活性化症候群における炎症性バイオマーカーを調べたコホート研究
Thomas J Bollyky, Christopher J L Murray, Robert C Reiner Jr

Epidemiology, not geopolitics, should guide COVID-19 vaccine donations

Lancet. 2021 Jun 8;S0140-6736(21)01323-4. doi: 10.1016/S0140-6736(21)01323-4.

ワクチンの寄付は流行に応じて分配されるべきとする論説
Laurens J Ceulemans, Mona Khan, Seung-Jun Yoo et al.

Persistence of SARS-CoV-2 RNA in lung tissue after mild COVID-19

Lancet Respir Med. 2021 Jun 9;S2213-2600(21)00240-X. doi: 10.1016/S2213-2600(21)00240-X.

COVID-19軽症例から回復後の肺移植ドナーの肺組織におけるSARS-CoV-2 RNAの持続的検出
Alejandro Fernandez-Montero, Josepmaria Argemi, José Antonio Rodríguez, Arturo H Ariño, Laura Moreno-Galarraga

Validation of a rapid antigen test as a screening tool for SARS-CoV-2 infection in asymptomatic populations. Sensitivity, specificity and predictive values

EClinicalMedicine. 2021 Jun 9;100954. doi: 10.1016/j.eclinm.2021.100954.

無症状の集団におけるスクリーニング検査としての抗原検査キットの性能評価
Eduardo A Oliveira, Enrico A Colosimo, Ana Cristina Simões E Silva et al.

Clinical characteristics and risk factors for death among hospitalised children and adolescents with COVID-19 in Brazil: an analysis of a nationwide database

Lancet Child Adolesc Health. 2021 Jun 10;S2352-4642(21)00134-6. doi: 10.1016/S2352-4642(21)00134-6.

ブラジルにおけるCOVID-19で入院した小児の臨床的特徴と死亡の危険因子に関するサーベイランスデータの解析
The Lancet Infectious Diseases

Should we vaccinate children against SARS-CoV-2?

Lancet Infect Dis. 2021 Jun 10;S1473-3099(21)00339-X. doi: 10.1016/S1473-3099(21)00339-X.

小児にワクチンを接種すべきかどうかのeditorial
Axel Bauer, Michael Schreinlechner, Nikolay Sappler et al.

Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial

Lancet Respir Med. 2021 Jun 11;S2213-2600(21)00214-9. doi: 10.1016/S2213-2600(21)00214-9.

COVID-19罹患時におけるレニン-アンギオテンシン系阻害剤の中止と継続に関する多施設非盲検ランダム化比較試験
John W Ayers, Brian Chu, Zechariah Zhu et al.

Spread of Misinformation About Face Masks and COVID-19 by Automated Software on Facebook

JAMA Intern Med. 2021 Jun 7;e212498. doi: 10.1001/jamainternmed.2021.2498.

マスク着用を検討したランダム化比較試験の論文掲載後のFacebookにおける自動ソフトを利用したマスク着用についての誤情報の拡散
Daniel P Sulmasy

Are SARS-CoV-2 Human Challenge Trials Ethical?

JAMA Intern Med. 2021 Jun 7. doi: 10.1001/jamainternmed.2021.2614.

Human challenge trialsの倫理的妥当性についての論説
Lawrence O Gostin, Jana Shaw, Daniel A Salmon

Mandatory SARS-CoV-2 Vaccinations in K-12 Schools, Colleges/Universities, and Businesses

JAMA. 2021 Jun 7. doi: 10.1001/jama.2021.9342.

学校や店舗等における新型コロナワクチンの義務化についての論説
Gabriel Chodick, Lilac Tene, Tal Patalon et al.

Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization

JAMA Netw Open. 2021 Jun 1;4(6):e2115985. doi: 10.1001/jamanetworkopen.2021.15985.

イスラエルにおけるPfizer社製の新型コロナワクチン（BNT162b2）一回接種での有効性
Lyudmyla Kompaniyets, Nickolas T Agathis, Jennifer M Nelson et al.

Underlying Medical Conditions Associated With Severe COVID-19 Illness Among Children

JAMA Netw Open. 2021 Jun 1;4(6):e2111182. doi: 10.1001/jamanetworkopen.2021.11182.

小児におけるCOVOID-19重症化に関わる基礎疾患に関する横断的研究
Scott D Landes, Margaret A Turk, Marco R Damiani, Philip Proctor, Sarah Baier

Risk Factors Associated With COVID-19 Outcomes Among People With Intellectual and Developmental Disabilities Receiving Residential Services

JAMA Netw Open. 2021 Jun 1;4(6):e2112862. doi: 10.1001/jamanetworkopen.2021.12862.

在宅介護サービスを受けている知的障害または発達障害のある人々でのSARS-CoV-2感染およびCOVID-19重症化の危険因子
Roberto Bertollini, Hiam Chemaitelly, Hadi M Yassine et al.

Associations of Vaccination and of Prior Infection With Positive PCR Test Results for SARS-CoV-2 in Airline Passengers Arriving in Qatar

JAMA. 2021 Jun 9;e219970. doi: 10.1001/jama.2021.9970.

カタール入国者における空港検疫でのスクリーニング検査陽性とワクチン接種歴・既感染の相関
Amanda B Payne, Zunera Gilani, Shana Godfred-Cato et al.

Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2

JAMA Netw Open. 2021 Jun 1;4(6):e2116420. doi: 10.1001/jamanetworkopen.2021.16420.

米国におけるSARS-CoV-2感染後の小児多臓器炎症症候群の発生率
Erin Chung, Eric J Chow, Naomi C Wilcox et al.

Comparison of Symptoms and RNA Levels in Children and Adults With SARS-CoV-2 Infection in the Community Setting

JAMA Pediatr. 2021 Jun 11. doi: 10.1001/jamapediatrics.2021.2025.

小児および成人COVID-19患者でのRNA量の比較
Florence T Bourgeois, Alba Gutiérrez-Sacristán, Mark S Keller et al.

International Analysis of Electronic Health Records of Children and Youth Hospitalized With COVID-19 Infection in 6 Countries

JAMA Netw Open. 2021 Jun 1;4(6):e2112596. doi: 10.1001/jamanetworkopen.2021.12596.

6カ国におけるCOVID-19感染小児及び青年期の電子カルテを用いた国際的な分析
Jianliang Xu, Kai Xu, Seolkyoung Jung et al.

Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants

Nature. 2021 Jun 7. doi: 10.1038/s41586-021-03676-z.

マウス及びラマで発現させたナノボディによるSARS-CoV-2変異株の中和
Emma B Hodcroft, Moira Zuber, Sarah Nadeau et al.

Spread of a SARS-CoV-2 variant through Europe in the summer of 2020

Nature. 2021 Jun 7. doi: 10.1038/s41586-021-03677-y.

2020年夏の欧州における感染・伝播性が増加していないと考えられるSARS-CoV-2の変異株（20E (EU1)）の流行
Jianying Liu, Yang Liu, Hongjie Xia et al.

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

Nature. 2021 Jun 10. doi: 10.1038/s41586-021-03693-y.

SARS-CoV-2新規変異株（B.1.617系統）や他のSARS-CoV-2変異株で認めるスパイクタンパクの変異を導入したリコンビナントウイルスのPfizer社製の新型コロナワクチン（BNT162b2）による中和
Galit Alter, Jingyou Yu, Jinyan Liu et al.

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

Nature. 2021 Jun 9. doi: 10.1038/s41586-021-03681-2.

ヒトにおけるSARS-CoV-2変異株に対するJanssen/Johnson and Johnson社製のワクチン（Ad26.COV2.S）の免疫原性
Oren Milman, Idan Yelin, Noga Aharony et al.

Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals

Nat Med. 2021 Jun 10. doi: 10.1038/s41591-021-01407-5.

イスラエルにおける新型コロナワクチンを接種していない個人への防御を検討した縦断的研究
C R Simpson, T Shi, E Vasileiou et al.

First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland

Nat Med. 2021 Jun 9. doi: 10.1038/s41591-021-01408-4.

スコットランドにおけるAstraZeneca社製の新型コロナワクチン（ChAdOx1-S）とPfizer社製の新型コロナワクチン（BNT162b2）初回接種と血小板減少症・血栓塞栓症・出血イベントとの関連性
Emma Pritchard, Philippa C Matthews, Nicole Stoesser et al.

Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom

Nat Med. 2021 Jun 9. doi: 10.1038/s41591-021-01410-w.

英国における新規SARS-CoV-2感染におけるワクチン摂取のインパクト
Bin Yang, Junpeng Fan, Jia Huang et al.

Clinical and molecular characteristics of COVID-19 patients with persistent SARS-CoV-2 infection

Nat Commun. 2021 Jun 9;12(1):3501. doi: 10.1038/s41467-021-23621-y.

持続性SARS-CoV-2感染のCOVID-19患者の臨床及び分子生物学的特徴
Silvia Stringhini, María-Eugenia Zaballa, Nick Pullen et al.

Large variation in anti-SARS-CoV-2 antibody prevalence among essential workers in Geneva, Switzerland

Nat Commun. 2021 Jun 8;12(1):3455. doi: 10.1038/s41467-021-23796-4.

スイス、ジュネーブにおけるエッセンシャルワーカーの職種ごとの抗体保有割合の違い
Matthew M Hernandez, Ana S Gonzalez-Reiche, Hala Alshammary et al.

Molecular evidence of SARS-CoV-2 in New York before the first pandemic wave

Nat Commun. 2021 Jun 8;12(1):3463. doi: 10.1038/s41467-021-23688-7.

米国ニューヨーク市で第1波開始前に採取された呼吸器検体におけるSARS-CoV-2 RNAのスクリーニング
Christina D Camell, Matthew J Yousefzadeh, Yi Zhu et al.

Senolytics reduce coronavirus-related mortality in old mice

Science. 2021 Jun 8;eabe4832. doi: 10.1126/science.abe4832.

老齢マウスモデルにおけるSARS-CoV-2感染とFisetin（老化細胞除去採用があるとされる）の効果の検討
Hong Zhou, Jingkai Ji, Xing Chen et al.

Identification of novel bat coronaviruses sheds light on the evolutionary origins of SARS-CoV-2 and related viruses

Cell. 2021 Jun 9;S0092-8674(21)00709-1. doi: 10.1016/j.cell.2021.06.008.

新種のコウモリのコロナウイルスの同定とSARS-CoV-2との進化的関連
Fatima Amanat, Mahima Thapa, Tinting Lei et al.

SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD and S2

Cell. 2021 Jun 8;S0092-8674(21)00706-6. doi: 10.1016/j.cell.2021.06.005.

mRNAワクチンがN末端領域、レセプター結合部位、S2への機能的に多様な抗体を誘導する
Bo Meng, Steven A Kemp, Guido Papa et al.

Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the variant of concern lineage B.1.1.7

Cell Rep. 2021 Jun 8;109292. doi: 10.1016/j.celrep.2021.109292.

SARS-CoV-2におけるΔH69/V70の繰り返す出現と変異株（B.1.1.7系統）におけるこの機能的意義の解析
Erfan Rezvani Ghomi, Fatemeh Khosravi, Ali Mohseni-M et al.

A collection of the novel coronavirus (COVID-19) detection assays, issues, and challenges

Heliyon. 2021 Jun;7(6):e07247. doi: 10.1016/j.heliyon.2021.e07247.

新型コロナウイルス迅速診断キットのまとめと問題点についてのナラティブレビュー
Bhavini Patel Murthy, Elizabeth Zell, Karen Kirtland et al.

Impact of the COVID-19 Pandemic on Administration of Selected Routine Childhood and Adolescent Vaccinations - 10 U.S. Jurisdictions, March-September 2020

MMWR Morb Mortal Wkly Rep. 2021 Jun 11;70(23):840-845. doi: 10.15585/mmwr.mm7023a2.

米国における小児の定期接種ワクチンへのパンデミックのインパクト（2020年3月から9月）
Prabasaj Paul, Anne Marie France, Yutaka Aoki et al.

Genomic Surveillance for SARS-CoV-2 Variants Circulating in the United States, December 2020-May 2021

MMWR Morb Mortal Wkly Rep. 2021 Jun 11;70(23):846-850. doi: 10.15585/mmwr.mm7023a3.

米国における2020年12月から2021年5月までのSARS-CoV-2のゲノムサーベイランスと変異株の検出
Athalia Christie, S Jane Henley, Linda Mattocks et al.

Decreases in COVID-19 Cases, Emergency Department Visits, Hospital Admissions, and Deaths Among Older Adults Following the Introduction of COVID-19 Vaccine - United States, September 6, 2020-May 1, 2021

MMWR Morb Mortal Wkly Rep. 2021 Jun 11;70(23):858-864. doi: 10.15585/mmwr.mm7023e2.

米国における新型コロナワクチン導入後の高齢者10万人あたりのCOVID-19患者、救急外来受診者数、入院者数、死亡者数の減少
Pinkus Tober-Lau, Tatjana Schwarz, David Hillus et al.

Outbreak of SARS-CoV-2 B.1.1.7 Lineage after Vaccination in Long-Term Care Facility, Germany, February-March 2021

Emerg Infect Dis. 2021 Jun 8;27(8). doi: 10.3201/eid2708.210887.

ドイツにおける新型コロナワクチン接種後の高齢者施設で発生したSARS-CoV-2 B.1.1.7系統によるアウトブレイク事例
Tatjana Schwarz, Pinkus Tober-Lau, David Hillus et al.

Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany

Emerg Infect Dis. 2021 Jun 8;27(8). doi: 10.3201/eid2708.211145.

高齢者におけるPfizer社製の新型コロナワクチン（BNT162b2）接種後の抗体・T細胞応答の遅延
Christian Gortázar, Sandra Barroso-Arévalo, Elisa Ferreras-Colino et al.

Natural SARS-CoV-2 Infection in Kept Ferrets, Spain

Emerg Infect Dis. 2021 Jun 12;27(7). doi: 10.3201/eid2707.210096.

飼育されたフェレットにおけるSARS-CoV-2感染
Chunmao Zhang, Zhendong Guo, Zongzheng Zhao et al.

SARS-CoV-2 Aerosol Exhaled by Experimentally Infected Cynomolgus Monkeys

Emerg Infect Dis. 2021 Jun 11;27(7). doi: 10.3201/eid2707.203948.

カニクイザルの感染モデルにおける呼気エアロゾル中のSARS-CoV-2
Sunitha V Kaiser, Annalisa Watson, Basak Dogan et al.

Preventing COVID-19 Transmission in Education Settings

Pediatrics. 2021 Jun 10;e2021051438. doi: 10.1542/peds.2021-051438.

教育施設におけるCOVID-19感染伝播予防方法とその遵守
Rabia Agha, Jeffrey R Avner

Delayed Seasonal RSV Surge Observed During the COVID-19 Pandemic

Pediatrics. 2021 Jun 9;e2021052089. doi: 10.1542/peds.2021-052089.

COVID-19パンデミック下での季節性RSV流行の遅れ
Emilio Cendejas-Bueno, María P Romero-Gómez, Luis Escosa et al.

Lower nasopharyngeal viral loads in pediatric population. The missing piece to understand SARS-CoV-2 infection in children?

J Infect. 2021 Jun 13;S0163-4453(21)00289-9. doi: 10.1016/j.jinf.2021.06.009.

17歳以下の小児は、成人と比較して鼻咽頭のウイルスRNA量が少ない
Kin On Kwok, Edward B McNeil, Margaret Ting Fong Tsoi et al.

Will achieving herd immunity be a road to success to end the COVID-19 pandemic?

J Infect. 2021 Jun 9;S0163-4453(21)00287-5. doi: 10.1016/j.jinf.2021.06.007.

日本を含む32か国における、集団免疫獲得に必要な接種率の推計
Tekin Akpolat, Oğuz Uzun

REDUCED MORTALITY RATE AFTER CORONAVAC VACCINE AMONG HEALTHCARE WORKERS

J Infect. 2021 Jun 8;S0163-4453(21)00285-1. doi: 10.1016/j.jinf.2021.06.005.

中国Sinovac Biotech社製不活化ワクチン接種後の医療従事者で死亡率が低下したとする報告
Ji Yun Noh, Joon Young Song, Hak Jun Hyun et al.

Risk factors for SARS-CoV-2 transmission in non-household clusters

J Infect. 2021 Jun 8;S0163-4453(21)00284-X. doi: 10.1016/j.jinf.2021.06.003.

家庭以外の場所におけるSARS-CoV-2感染のリスク因子
Allison H Bartlett, Karen A Ravin, Lorry G Rubin et al.

SHEA Pediatric Leadership Council Commentary: Inpatient Visitor Considerations for Pediatric Patients during the COVID-19 Pandemic

Infect Control Hosp Epidemiol. 2021 Jun 11;1-9. doi: 10.1017/ice.2021.243.

小児入院患者の保護者の面会は感染予防策に工夫をしたうえで、制限すべきでないとする米国Society for Healthcare Epidemiologyによる論説
Hualei Xin, Jessica Y Wong, Caitriona Murphy et al.

The incubation period distribution of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

Clin Infect Dis. 2021 Jun 12;ciab501. doi: 10.1093/cid/ciab501.

潜伏期間の分布（平均値、中央値、95パーセンタイル）に関するシステマティックレビュー・メタアナリシス
Simon D Pollett, Stephanie A Richard, Anthony C Fries et al.

The SARS-CoV-2 mRNA vaccine breakthrough infection phenotype includes significant symptoms, live virus shedding, and viral genetic diversity

Clin Infect Dis. 2021 Jun 12;ciab543. doi: 10.1093/cid/ciab543.

mRNAワクチン接種後の感染者の症状、ウイルス排泄、変異ウイルスに関する記述
Michael Klompas, Chanu Rhee, Meghan Baker

Universal Use of N95s in Healthcare Settings when Community Covid-19 Rates are High

Clin Infect Dis. 2021 Jun 11;ciab539. doi: 10.1093/cid/ciab539.

SARS-CoV-2のまん延期にはCOVID-19と診断されていない患者に対してN95マスクを標準装備として適応すべきとする論説
Mars Stone, Clara Di Germanio, David J Wright et al.

Use of U.S. Blood Donors for National Serosurveillance of SARS-CoV-2 Antibodies: Basis for an Expanded National Donor Serosurveillance Program

Clin Infect Dis. 2021 Jun 10;ciab537. doi: 10.1093/cid/ciab537.

米国における献血を用いた血清有病率のサーベイランス
Sarah A Buchan, Semra Tibebu, Nick Daneman et al.

Increased household secondary attacks rates with Variant of Concern SARS-CoV-2 index cases

Clin Infect Dis. 2021 Jun 9;ciab496. doi: 10.1093/cid/ciab496.

N501Yは従来株に比較して家庭内における2次感染の割合が高いとする後ろ向きコホート研究（傾向スコアマッチング）
Matthew A Crane, Aleksandra Popovic, Rohan Panaparambil et al.

Reporting of Infectious Diseases in the United States During the COVID-19 Pandemic

Clin Infect Dis. 2021 Jun 7;ciab529. doi: 10.1093/cid/ciab529.

米国におけるパンデミック下での感染症の届出の分析
Laura Pérez Lago, Helena Martínez Lozano, Jose Antonio Pajares Díaz et al.

Proper assignation of reactivation in a COVID-19 recurrence initially interpreted as a reinfection

J Infect Dis. 2021 Jun 9;jiab302. doi: 10.1093/infdis/jiab302.

COVID-19を再燃し、2次感染も引き起こした症例の報告
Ilaria Vicenti, Francesca Gatti, Renzo Scaggiante et al.

Time course of neutralizing antibody in healthcare workers with mild or asymptomatic COVID-19 infection

Open Forum Infect Dis. 2021 Jun 12;ofab312. doi: 10.1093/ofid/ofab312.

医療従事者の軽症例・無症候病原体保有者における中和抗体の7ヶ月目までの持続性を検討した報告
Galia Zacay, David Shasha, Ronen Bareket et al.

BNT162b2 vaccine effectiveness in preventing asymptomatic infection with SARS-CoV-2 virus: a nationwide historical cohort study

Open Forum Infect Dis. 2021 Jun 9;ofab262. doi: 10.1093/ofid/ofab262.

イスラエルにおける、定期的なPCRスクリーニング検査を行っている医療保険会社の職員を対象にPfizer-BioNTech製ワクチンの無症候感染への効果を調べた後ろ向きコホート研究
Di Tian, Zhen Lin, Ellie M Kriner et al.

Ct Values do not Predict SARS-CoV-2 Transmissibility in College Students

J Mol Diagn. 2021 Jun 5;S1525-1578(21)00163-X. doi: 10.1016/j.jmoldx.2021.05.012.

SARS-CoV-2のRT-PCRによるCt値と二次感染を起こすかどうかの相関についての関係を調べた研究
Allison J Greaney, Andrea N Loes, Lauren E Gentles et al.

Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection

Sci Transl Med. 2021 Jun 8;eabi9915. doi: 10.1126/scitranslmed.abi9915.

Moderna社製の新型コロナワクチン（mRNA-1273）で誘導される抗体はSARS-CoV-2感染で誘導される抗体よりもより広範囲にレセプター結合部位に結合する
Rebecca R Taylor, Bhavi Trivedi, Neena Patel et al.

Post-COVID symptoms reported at asynchronous virtual review and stratified follow-up after COVID-19 pneumonia

Clin Med (Lond). 2021 Jun 8;clinmed.2021-0037. doi: 10.7861/clinmed.2021-0037.

オンライン・電話調査を用いたCOVID-19の重症度別のCOVID-19後遺症に関する調査の報告
Simbarashe Takuva, Azwidhwi Takalani, Nigel Garrett et al.

Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study

N Engl J Med. 2021 Jun 2. doi: 10.1056/NEJMc2107920.

Johnson and Johnson/Janssen社製の新型コロナウイルスワクチン(Ad26.COV2.S) の臨床試験における血栓塞栓イベント
Antonella d'Arminio Monforte, Alessandro Tavelli, Pier Mario Perrone et al.

Association between previous infection with SARS CoV-2 and the risk of self-reported symptoms after mRNA BNT162b2 vaccination: Data from 3,078 health care workers

EClinicalMedicine. 2021 Jun;36:100914. doi: 10.1016/j.eclinm.2021.100914.

イタリアにおける、新型コロナウイルス感染歴と医療従事者を対象としたPfizer社製の新型コロナワクチン（BNT162b2）接種後の副反応に頻度との相関についての報告
Maria Krutikov, Tom Palmer, Gokhan Tut et al.

Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study

Lancet Healthy Longev. 2021 Jun;2(6):e362-e370. doi: 10.1016/S2666-7568(21)00093-3.

高齢者施設における抗体保有の有無と感染の相関を調べた前向きコホート研究
Clark D Russell, Cameron J Fairfield, Thomas M Drake et al.

Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study

Lancet Microbe. 2021 Jun 2. doi: 10.1016/S2666-5247(21)00090-2.

英国において最初の新型コロナウイルスのパンデミック中に入院した患者の混合感染、二次感染および抗菌薬の使用に関する多施設共同前向きコホート研究（ISARIC WHO CCP-UK)
Ingibjorg Eva Thorisdottir, Bryndis Bjork Asgeirsdottir, Alfgeir Logi Kristjansson et al.

Depressive symptoms, mental wellbeing, and substance use among adolescents before and during the COVID-19 pandemic in Iceland: a longitudinal, population-based study

Lancet Psychiatry. 2021 Jun 3;S2215-0366(21)00156-5. doi: 10.1016/S2215-0366(21)00156-5.

アイスランドにおける新型コロナウイルスパンデミック前後の思春期の子どもの抑うつ症状、精神的健康、薬物使用に関する縦断的研究
Bakary Sanyang, Abdoulie Kanteh, Effua Usuf et al.

COVID-19 reinfections in The Gambia by phylogenetically distinct SARS-CoV-2 variants-first two confirmed events in west Africa

Lancet Glob Health. 2021 Jun 3;S2214-109X(21)00213-8. doi: 10.1016/S2214-109X(21)00213-8.

西アフリカガンビアにおける系統学的に異なるSARS-CoV-2による再感染症例2例
Emma C Wall, Mary Wu, Ruth Harvey et al.

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

Lancet. 2021 Jun 3;S0140-6736(21)01290-3. doi: 10.1016/S0140-6736(21)01290-3.

Pfizer社製の新型コロナワクチン（BNT162b2）接種によるSARS-CoV-2の変異株（B.1.617.2系統およびB.1.351系統）に対する中和抗体活性
Renato D Lopes, Pedro Gabriel Melo de Barros e Silva, Remo H M Furtado et al.

Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial

Lancet. 2021 Jun 4;S0140-6736(21)01203-4. doi: 10.1016/S0140-6736(21)01203-4.

D-dimer高値のCOVID-19入院患者に対する治療用量または予防用量の抗凝固療法を比較した多施設非盲検ランダム化比較試験（ブラジル）
Myron S Cohen, Ajay Nirula, Mark J Mulligan et al.

Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial

JAMA. 2021 Jun 3. doi: 10.1001/jama.2021.8828.

介護施設および生活支援施設の居住者および職員の新型コロナウイルス感染症の発症率に対するバムラニビマブの有効性を評価したランダム化比較試験
Allison H Oakes, Jonathan A Epstein, Arupa Ganguly et al.

Effect of Opt-In vs Opt-Out Framing on Enrollment in a COVID-19 Surveillance Testing Program: The COVID SAFE Randomized Clinical Trial

JAMA Netw Open. 2021 Jun 1;4(6):e2112434. doi: 10.1001/jamanetworkopen.2021.12434.

米国ペンシルバニア大学におけるSARS-CoV-2スクリーニング検査プログラムのオプトインもしくはオプトアウトでの組み入れを比較したランダム化比較試験
R Ryan Lash, Patrick K Moonan, Brittany L Byers et al.

COVID-19 Case Investigation and Contact Tracing in the US, 2020

JAMA Netw Open. 2021 Jun 1;4(6):e2115850. doi: 10.1001/jamanetworkopen.2021.15850.

米国における積極的疫学調査のまとめ
Zhiqiang Ku, Xuping Xie, Paul R Hinton et al.

Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants

Nature. 2021 Jun 3. doi: 10.1038/s41586-021-03673-2.

マウスにおけるIgM経鼻投与によるSARS-CoV-2の予防効果と治療効果の検討
William T Harvey, Alessandro M Carabelli, Ben Jackson et al.

SARS-CoV-2 variants, spike mutations and immune escape

Nat Rev Microbiol. 2021 Jun 1;1-16. doi: 10.1038/s41579-021-00573-0.

SARS-CoV-2の変異株と免疫逃避に関するナラティブレビュー
Nunziata Maio, Bernard A P Lafont, Debangsu Sil et al.

Fe-S cofactors in the SARS-CoV-2 RNA-dependent RNA polymerase are potential antiviral targets

Science. 2021 Jun 3;eabi5224. doi: 10.1126/science.abi5224.

SARS-CoV-2 RNA依存性RNAポリメラーゼ鉄-硫黄金属補因子が抗ウイルス薬の標的となり得る可能性
Will Fischer, Elena E Giorgi, Srirupa Chakraborty et al.

HIV-1 and SARS-CoV-2: Patterns in the Evolution of Two Pandemic Pathogens

Cell Host Microbe. 2021 Jun 2;S1931-3128(21)00240-7. doi: 10.1016/j.chom.2021.05.012.

HIV-1とSARS-CoV-2の進化に関するナラティブレビュー
Shira Weingarten-Gabbay, Susan Klaeger, Siranush Sarkizova et al.

Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs

Cell. 2021 Jun 1;S0092-8674(21)00701-7. doi: 10.1016/j.cell.2021.05.046.

SARS-CoV-2のpeptidomeのプロファイリングとout-of-frame ORFsからのT細胞エピトープ
Chao Wu, Abraham J Qavi, Asmaa Hachim et al.

Characterization of SARS-CoV-2 N protein reveals multiple functional consequences of the C-terminal domain

iScience. 2021 Jun 1;102681. doi: 10.1016/j.isci.2021.102681.

SARS-CoV-2 N タンパク質の特徴とC末端ドメインの機能
Ron Sender, Yinon M Bar-On, Shmuel Gleizer et al.

The total number and mass of SARS-CoV-2 virions

Proc Natl Acad Sci U S A. 2021 Jun 22;118(25):e2024815118. doi: 10.1073/pnas.2024815118.

感染者1人および全体のSARS-CoV-2粒子量の推定
Fiona P Havers, Michael Whitaker, Julie L Self et al.

Hospitalization of Adolescents Aged 12–17 Years with Laboratory-Confirmed COVID-19 ― COVID-NET, 14 States, March 1, 2020–April 24, 2021

MMWR Morb Mortal Wkly Rep. 2021 Jun 4. doi: 10.15585/mmwr.mm7023e1.

米国における12-17歳の小児の入院率の推移
Marcelo Rodrigues Gonçalves, Rodrigo Citton Padilha Dos Reis, Rodrigo Pedroso Tólio et al.

Social Distancing, Mask Use, and Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, Brazil, April-June 2020

Emerg Infect Dis. 2021 Jun 4;27(8). doi: 10.3201/eid2708.204757.

ソーシャルディスタンスやマスク着用などの感染対策の使用とSARS-CoV-2の相関を検討した症例対照研究
Martin Hoch, Sebastian Vogel, Laura Kolberg et al.

Weekly SARS-CoV-2 Sentinel Surveillance in Primary Schools, Kindergartens, and Nurseries, Germany, June‒November 2020

Emerg Infect Dis. 2021 Jun 4;27(8). doi: 10.3201/eid2708.204859.

2020年6～8月のドイツにおける小学校、幼稚園、保育園での週間SARS-CoV-2定点把握
Hanne-Dorthe Emborg, AnnaSara Carnahan, Karoline Bragstad et al.

Abrupt termination of the 2019/20 influenza season following preventive measures against COVID-19 in Denmark, Norway and Sweden

Euro Surveill. 2021 Jun;26(22):2001160. doi: 10.2807/1560-7917.ES.2021.26.22.2001160.

デンマーク、ノルウェー、スウェーデンにおけるCOVID-19に対する感染対策によると考えられる2019-2020のインフルエンザシーズンの突然の終了
Mayme Marshall, Ian D Ferguson, Paul Lewis et al.

Symptomatic Acute Myocarditis in Seven Adolescents Following Pfizer-BioNTech COVID-19 Vaccination

Pediatrics. 2021 Jun 4;e2021052478. doi: 10.1542/peds.2021-052478.

Pfizer社製の新型コロナワクチン（BNT162b2）接種後の思春期の7名における急性心筋炎
Muh-Yong Yen, Yung-Feng Yen, Shey-Ying Chen et al.

Learning from the past: Taiwan's responses to COVID-19 versus SARS

Int J Infect Dis. 2021 Jun 4;S1201-9712(21)00490-2. doi: 10.1016/j.ijid.2021.06.002.

台湾におけるSARS-CoV-2に対する感染対策の2003年のSARSおよび2009年の2009pdmH1N1流行時との比較
Mohamed Abbas, Nina Jiayue Zhu, Siddharth Mookerjee et al.

Hospital-onset COVID-19 infection surveillance systems: A systematic review

J Hosp Infect. 2021 Jun 4;S0195-6701(21)00220-6. doi: 10.1016/j.jhin.2021.05.016.

医療機関で発生するCOVID-19のサーベイランスシステムに関するシステマティックレビュー
Thomas Pottage, Isobel Garratt, Okechukwu Onianwa et al.

A Comparison of Persistence of SARS-CoV-2 Variants on Stainless Steel

J Hosp Infect. 2021 Jun 4;S0195-6701(21)00219-X. doi: 10.1016/j.jhin.2021.05.015.

SARS-CoV-2変異株（B.1.1.7系統およびB.1.351系統）のステンレス上の生存時間の検討
Ahmed Vanker, Allison McGeer, Gray O'Byrne et al.

Adverse Outcomes Associated with SARS-CoV-2 variant B.1.351 Infection in Vaccinated Residents of a Long Term Care Home, Ontario, Canada

Clin Infect Dis. 2021 Jun 6;ciab523. doi: 10.1093/cid/ciab523.

カナダ・オンタリオ州の長期療養型施設におけるワクチン接種後入居者の新規変異株（B.1.351系統）によるアウトブレイク
Emil Lesho, Brendan Corey, Francois Lebreton et al.

Emergence of the E484K Mutation in SARS-CoV-2 Lineage B.1.1.345 in Upstate New York

Clin Infect Dis. 2021 Jun 4;ciab507. doi: 10.1093/cid/ciab507.

ニューヨークにおけるB.1.1.345系統へのE484K変異の出現
Mark A Jacobson, Adam Zakaria, Zaw Maung et al.

Incidence and Characteristics of Delayed Injection Site Reaction to the mRNA-1273 SARS-CoV2 Vaccine (Moderna) in a Cohort of Hospital Employees

Clin Infect Dis. 2021 Jun 4;ciab518. doi: 10.1093/cid/ciab518.

医療従事者コホートで報告されたModerna社製の新型コロナワクチン（mRNA-1273）接種後の遅延型反応の発生と特徴
Valeria De Giorgi, Kamille A West, Amanda N Henning et al.

Naturally acquired SARS-CoV-2 immunity persists for up to 11 months following infection

J Infect Dis. 2021 Jun 5;jiab295. doi: 10.1093/infdis/jiab295.

SARS-CoV-2感染後の抗体持続期間の11ヶ月目までの検討
Jannae C Parrott, Ariana N Maleki, Valerie E Vassor et al.

Prevalence of SARS-CoV-2 antibodies in New York City adults, June-October, 2020: a population-based survey

J Infect Dis. 2021 Jun 4;jiab296. doi: 10.1093/infdis/jiab296.

米国ニューヨーク市における2020年6-10月時点でのSARS-CoV-2抗体保有割合
Nooshin Razani, Mohsen Malekinejad, George W Rutherford

Clarification regarding Outdoor Transmission of SARS-CoV-2 and Other Respiratory Viruses, a Systematic Review

J Infect Dis. 2021 Jun 4;jiab298. doi: 10.1093/infdis/jiab298.

屋外でのSARS-CoV-2感染リスクに関するシステマティックレビュー
Lutfiye Karcioglu Batur, Nezih Hekim

Correlation between interleukin gene polymorphisms and current prevalence and mortality rates due to novel coronavirus disease 2019 (COVID-2019) in 23 countries

J Med Virol. 2021 Jun 3. doi: 10.1002/jmv.27127.

インターロイキンの遺伝子多型とCOVID-19の有病率、死亡割合の関連（日本ほか23か国を対象にした調査報告）
Selcan Sinaci, Doga Fatma Ocal, Banu Seven et al.

Vertical Transmission of SARS-CoV-2: a prospective cross-sectional study from a tertiary center

J Med Virol. 2021 Jun 3. doi: 10.1002/jmv.27128.

母子感染のリスクについて経腟分娩と帝王切開では差がなかったとする前向き横断研究の報告
Helen Onyeaka, Christian K Anumudu, Zainab T Al-Sharify, Esther Egele-Godswill, Paul Mbaegbu

COVID-19 pandemic: A review of the global lockdown and its far-reaching effects

Sci Prog. Apr-Jun 2021;104(2):368504211019854. doi: 10.1177/00368504211019854.

ロックダウンが社会にもたらした感染症以外への影響
Ori Snapiri, Chen Rosenberg Danziger, Nina Shirman et al.

Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine

Pediatr Infect Dis J. 2021 Jun 2. doi: 10.1097/INF.0000000000003235.

若年層（16-18歳）でみられたPfizer社製の新型コロナワクチン（BNT162b2）後の一過性心筋障害の症例集積
Neha Bansal, Estela Azeka, Cindy Neunert et al.

Multisystem Inflammatory Syndrome Associated with COVID-19 Anti-thrombosis Guideline of Care for Children by Action

Pediatr Cardiol. 2021 Jun 2;1-5. doi: 10.1007/s00246-021-02651-9.

COVID-19 関連小児多系統炎症性症候群の抗血栓治療に関するガイドライン（北米における小児心疾患の高度治療に関するグループによる）
Jack Chun-Chieh Hsu, Maudry Laurent-Rolle, Joanna B Pawlak, Craig B Wilen, Peter Cresswell

Translational shutdown and evasion of the innate immune response by SARS-CoV-2 NSP14 protein

Proc Natl Acad Sci U S A. 2021 Jun 15;118(24):e2101161118. doi: 10.1073/pnas.2101161118.

SARS-CoV-2のNSP14は宿主の翻訳停止や自然免疫からの逃避に寄与する
Vaughn Barry, Sharoda Dasgupta, Daniel L Weller et al.

Patterns in COVID-19 Vaccination Coverage, by Social Vulnerability and Urbanicity ― United States, December 14, 2020–May 1, 2021

MMWR Morb Mortal Wkly Rep. 2021 Jun 4;70(22):818-824. doi: 10.15585/mmwr.mm7022e1.

アメリカにおける社会的脆弱性及び地域別による新型コロナワクチンの接種率
Peter Willeit, Robert Krause, Bernd Lamprecht et al.

Prevalence of RT-qPCR-detected SARS-CoV-2 infection at schools: First results from the Austrian School-SARS-CoV-2 prospective cohort study

Lancet Reg Health Eur. 2021 Jun;5:100086. doi: 10.1016/j.lanepe.2021.100086.

オーストリアの学校におけるSARS-Cov-2陽性者の割合（prevalence):前向き研究
May 2021
Nader Shaikh, Eric J Friedlander, Patrick J Tate et al.

Performance of a Rapid SARS-CoV-2 Antigen Detection Assay in Symptomatic Children

Pediatrics. 2021 May 26;e2021050832. doi: 10.1542/peds.2021-050832.

有症状の小児に対するSARS-CoV-2迅速抗原検査キットの精度
Tim Peto, On behalf of the UK COVID-19 Lateral Flow Oversight Team

COVID-19: Rapid antigen detection for SARS-CoV-2 by lateral flow assay: A national systematic evaluation of sensitivity and specificity for mass-testing

EClinicalMedicine. 2021 May 29. doi: 10.1016/j.eclinm.2021.100924.

英国におけるスクリーニング検査のための抗原検査キットの性能評価
Xuan He, Abishek Chandrashekar, Roland Zahn et al.

Low-Dose Ad26.COV2.S Protection Against SARS-CoV-2 Challenge in Rhesus Macaques

Cell. 2021 May 31;S0092-8674(21)00693-0. doi: 10.1016/j.cell.2021.05.040.

アカゲザルにおける低用量のJohnson and Johnson/Janssen社製の新型コロナウイルスワクチン(Ad26.COV2.S) 一回接種での重症化予防効果
Yosuke Hirotsu, Hiroki Sugiura, Makoto Maejima et al.

Comparison of Roche and Lumipulse quantitative SARS-CoV-2 antigen test performance using automated systems for the diagnosis of COVID-19

Int J Infect Dis. 2021 May 31;S1201-9712(21)00470-7. doi: 10.1016/j.ijid.2021.05.067.

ロシュ及びルミパルスのSARS-CoV-2抗原定量検査の評価
Oriol Roca, Andrés Pacheco, Jordi Rodon et al.

Nasal high flow oxygen therapy in COVID-19 patients does not cause environmental surface contamination

J Hosp Infect. 2021 May 31;S0195-6701(21)00216-4. doi: 10.1016/j.jhin.2021.04.034.

COVID-19患者のネーザルハイフロー治療がもたらす環境中への汚染
Robert W Frenck Jr, Nicola P Klein, Nicholas Kitchin et al.

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

N Engl J Med. 2021 May 27. doi: 10.1056/NEJMoa2107456.

Pfizer社製の新型コロナワクチン（BNT162b2）の若年層(12－15歳）への安全性と有効性を評価したランダム化比較試験の中間報告
Annie K Sparrow, Lisa M Brosseau, Robert J Harrison, Michael T Osterholm

Protecting Olympic Participants from Covid-19 - The Urgent Need for a Risk-Management Approach

N Engl J Med. 2021 May 25. doi: 10.1056/NEJMp2108567.

東京大会開催にむけてリスクマネジメントアプローチが喫緊に必要とする声明
Boris Revollo, Ignacio Blanco, Pablo Soler et al.

Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial

Lancet Infect Dis. 2021 May 27;S1473-3099(21)00268-1. doi: 10.1016/S1473-3099(21)00268-1.

迅速抗原検査によるイベント当日の検査、マスク、換気により屋内のマスギャザリングイベントは安全に実施可能としたランダム化比較試験
Yuxin Chen, Han Shen, Rui Huang, Xin Tong, Chao Wu

Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac

Lancet Infect Dis. 2021 May 27;S1473-3099(21)00287-5. doi: 10.1016/S1473-3099(21)00287-5.

中国Sinovac社製の新型コロナワクチン（不活化ワクチン）で誘導される抗体の、数種類の変異株で認めるスパイクタンパクの変異を含むシュードタイプウイルスに対する中和能
Jean-Claude Tardif, Nadia Bouabdallaoui, Philippe L L'Allier et al.

Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial

Lancet Respir Med. 2021 May 27;S2213-2600(21)00222-8. doi: 10.1016/S2213-2600(21)00222-8.

自宅療養可能な患者を対象に実施したコルヒチンのフェーズ3臨床試験（二重盲検プラセボ対照無作為化多施設試験）
Justin Penner, Omar Abdel-Mannan, Karlie Grant et al.

6-month multidisciplinary follow-up and outcomes of patients with paediatric inflammatory multisystem syndrome (PIMS-TS) at a UK tertiary paediatric hospital: a retrospective cohort study

Lancet Child Adolesc Health. 2021 May 24;S2352-4642(21)00138-3. doi: 10.1016/S2352-4642(21)00138-3.

SARS-CoV-2関連小児炎症性多系統症候群(PIMS-TS)の6週後、6か月後における予後：英国医療機関における後ろ向きコホート研究
Fahad M Iqbal, Kyle Lam, Viknesh Sounderajah et al.

Characteristics and predictors of acute and chronic post-COVID syndrome: A systematic review and meta-analysis

EClinicalMedicine. 2021 May 24;36:100899. doi: 10.1016/j.eclinm.2021.100899.

慢性ポストCOVID症候群に関するシステマティックレビューとメタアナリシス
Alessandro Amaddeo, Carolina Cason, Giorgio Cozzi, Luca Ronfani, Manola Comar

Social distancing measures for COVID-19 are changing winter season

Arch Dis Child. 2021 May 24;archdischild-2021-322004. doi: 10.1136/archdischild-2021-322004.

17歳未満の年齢層における冬季の病原体のトレンドがソーシャルディスタンスにより変化した（イタリア）
Josè Vitale, Nicola Mumoli, Pierangelo Clerici et al.

Assessment of SARS-CoV-2 Reinfection 1 Year After Primary Infection in a Population in Lombardy, Italy

JAMA Intern Med. 2021 May 28. doi: 10.1001/jamainternmed.2021.2959.

イタリア・ロンバルディアの検査施設における1年後までの再感染率
Amir Massarweh, Noa Eliakim-Raz, Amos Stemmer et al.

Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer

JAMA Oncol. 2021 May 28. doi: 10.1001/jamaoncol.2021.2155.

ファイザー社製の新型コロナワクチン（BNT162b2）2回接種後の化学療法使用中の担癌患者における抗体応答
Nawal Al Kaabi, Yuntao Zhang, Shengli Xia et al.

Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial

JAMA. 2021 May 26. doi: 10.1001/jama.2021.8565.

Wuhan Institute of Biological Products／Beijing Institute of Biological Products社製の2種類の新型コロナワクチン（不活化ワクチン）ランダム化比較試験の中間解析
Julia Kristin Stroehlein, Julia Wallqvist, Claire Iannizzi et al.

Vitamin D supplementation for the treatment of COVID-19: a living systematic review

Cochrane Database Syst Rev. 2021 May 24;5:CD015043. doi: 10.1002/14651858.CD015043.

COVID-19治療のためのビタミンD補充のリビング・システマティックレビュー
Caoilfhionn M Connolly, Brian J Boyarsky, Jake A Ruddy et al.

Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series

Ann Intern Med. 2021 May 25. doi: 10.7326/M21-1451.

mRNAベースの新型コロナワクチン2回接種後の膠原病患者における抗体応答
David T Arnold, Alice Milne, Emma Samms et al.

Symptoms After COVID-19 Vaccination in Patients With Persistent Symptoms After Acute Infection: A Case Series

Ann Intern Med. 2021 May 25. doi: 10.7326/M21-1976.

COVID-19後遺症のある方の新型コロナワクチン接種後の後遺症の推移
Felipe Gomes Naveca, Valdinete Nascimento, Victor Costa de Souza et al.

COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence

Nat Med. 2021 May 25. doi: 10.1038/s41591-021-01378-7.

ブラジル・アマゾナス州におけるSARS-CoV-2のゲノム解析と疫学解析の結果報告
Laura Montefusco, Moufida Ben Nasr, Francesca D'Addio et al.

Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection

Nat Metab. 2021 May 25. doi: 10.1038/s42255-021-00407-6.

糖尿病の既往のない方のSARS-CoV-2感染後の短期的・長期的耐糖能異常
Jackson S Turner, Wooseob Kim, Elizaveta Kalaidina et al.

SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans

Nature. 2021 May 24. doi: 10.1038/s41586-021-03647-4.

SARS-CoV-2感染後長期にわたる液性免疫、骨髄における形質細胞、メモリーB細胞の検出
Lewis Au, Annika Fendler, Scott T C Shepherd et al.

Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2

Nat Med. 2021 May 26. doi: 10.1038/s41591-021-01387-6.

PD-1阻害剤使用患者におけるファイザー社製の新型コロナワクチン（BNT162b2）接種後にサイトカイン放出症候群を発症した症例
Jasdeep Singh, Syed Asad Rahman, Nasreen Z Ehtesham, Subhash Hira, Seyed E Hasnain

SARS-CoV-2 variants of concern are emerging in India

Nat Med. 2021 May 27. doi: 10.1038/s41591-021-01397-4.

インドにおける懸念される変異株の台頭
Gregory A Wellenius, Swapnil Vispute, Valeria Espinosa et al.

Impacts of social distancing policies on mobility and COVID-19 case growth in the US

Nat Commun. 2021 May 25;12(1):3118. doi: 10.1038/s41467-021-23404-5.

米国におけるソーシャルディスタンス政策と新型コロナウイルス症例数との相関
Terry C Jones, Guido Biele, Barbara Mühlemann et al.

Estimating infectiousness throughout SARS-CoV-2 infection course

Science. 2021 May 25;eabi5273. doi: 10.1126/science.abi5273.

属性や重症度別等で分けたSARS-CoV-2のRNA量の推移やRNA量を元にした感染性のあるウイルス排出の持続期間の推定
Marion Moreews, Kenz Le Gouge, Samira Khaldi-Plassart et al.

Polyclonal expansion of TCR Vbeta 21.3+ CD4+ and CD8+ T cells is a hallmark of Multisystem Inflammatory Syndrome in Children

Sci Immunol. 2021 May 25;6(59):eabh1516. doi: 10.1126/sciimmunol.abh1516.

川崎病、TSS及び急性期のCOVID-19感染と比較して、MIS-Cにおいては、TCR Vbeta21.3+、CD4+、CD8+のポリクローナルな拡張を認める
Daryl Geers, Marc C Shamier, Susanne Bogers et al.

SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees

Sci Immunol. 2021 May 25;6(59):eabj1750. doi: 10.1126/sciimmunol.abj1750.

SARS-CoV-2の懸念される変異株（B.1.1.7系統とB.1.351系統）はin vitroでCOVID-19回復者のドナーおよびワクチン接種者の体液性応答の部分的に逃避するが、T細胞性免疫からは逃避しない
Yafei Liu, Wai Tuck Soh, Jun-ichi Kishikawa et al.

An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies

Cell. 2021 May 24;S0092-8674(21)00662-0. doi: 10.1016/j.cell.2021.05.032.

SARS-CoV-2のスパイクタンパクに対するin vitroで感染力を増強させる抗体
Kefang Liu, Xiaoqian Pan, Linjie Li et al.

Binding and molecular basis of the bat coronavirus RaTG13 virus to ACE-2 in humans and other species

Cell. 2021 May 24;S0092-8674(21)00661-9. doi: 10.1016/j.cell.2021.05.031.

コウモリのコロナウイルスであるRaTG13ウイルスのヒトや他の種のACE2に対する結合能
CDC COVID-19 Vaccine Breakthrough Case Investigations Team

COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April 30, 2021

MMWR Morb Mortal Wkly Rep. 2021 May 28;70(21):792-793. doi: 10.15585/mmwr.mm7021e3.

2021年1月1日から4月30日までに米国CDCに報告されたワクチン接種後のブレイクスルー感染
Mitra Gultom, Matthias Licheri, Laura Laloli et al.

Susceptibility of Well-Differentiated Airway Epithelial Cell Cultures from Domestic and Wild Animals to Severe Acute Respiratory Syndrome Coronavirus 2

Emerg Infect Dis. 2021 May 26;27(7). doi: 10.3201/eid2707.204660.

種々の家畜や野生動物から採取された気道上皮細胞のSARS-CoV-2へのin vitroでの感受性
Qiuyan Liao, Meihong Dong, Jiehu Yuan et al.

Assessing Community Vulnerability over 3 Waves of COVID-19 Pandemic, Hong Kong, China

Emerg Infect Dis. 2021 May 25;27(7). doi: 10.3201/eid2707.204076.

香港での3つの流行の波における感染への脆弱性の評価
Mark B Salzman, Cheng-Wei Huang, Christopher M O'Brien, Rhina D Castillo

Multisystem Inflammatory Syndrome after SARS-CoV-2 Infection and COVID-19 Vaccination

Emerg Infect Dis. 2021 May 25;27(7). doi: 10.3201/eid2707.210594.

SARS-CoV-2感染者および新型コロナワクチン接種後の成人における多系統炎症性症候群（MIS）の症例報告
Kin On Kwok, Kin Kit Li, Arthur Tang et al.

Psychobehavioral Responses and Likelihood of Receiving COVID-19 Vaccines during the Pandemic, Hong Kong

Emerg Infect Dis. 2021 May 26;27(7). doi: 10.3201/eid2707.210054.

香港における時期別、属性別にみた新型コロナウイルスに対する心理的及び行動学的な反応及び新型コロナワクチン接種傾向
Bo Shu, Marie K Kirby, William G Davis et al.

Multiplex Real-Time Reverse Transcription PCR for Influenza A Virus, Influenza B Virus, and Severe Acute Respiratory Syndrome Coronavirus 2

Emerg Infect Dis. 2021 May 26;27(7). doi: 10.3201/eid2707.210462.

米国CDCによるインフルエンザウイルスA/BおよびSARS-CoV-2に対するマルチプレックスPCR
Anna Loenenbach, Inessa Markus, Ann-Sophie Lehfeld et al.

SARS-CoV-2 variant B.1.1.7 susceptibility and infectiousness of children and adults deduced from investigations of childcare centre outbreaks, Germany, 2021

Euro Surveill. 2021 May;26(21). doi: 10.2807/1560-7917.ES.2021.26.21.2100433.

ドイツの保育園で集団発生調査から推定された子どもと大人の新規変異株（B.1.1.7系統）の感受性と感染性
Duarte-Salles Talita, David Vizcaya, Andrea Pistillo et al.

30-Day Outcomes of Children and Adolescents With COVID-19: An International Experience

Pediatrics. 2021 May 28;e2020042929. doi: 10.1542/peds.2020-042929.

各国データを用いた小児 COVID-19 患者の30日後までのアウトカムとこのインフルエンザとの比較
Hocheol Lee, Eunbi Noh, Huiwon Jeon, Eun Woo Nam

Association between the traffic level from other areas and the COVID-19 prevalence at the provincial levels in South Korea

Int J Infect Dis. 2021 May 24;S1201-9712(21)00457-4. doi: 10.1016/j.ijid.2021.05.054.

韓国における地域外からの交通量とCOVID-19発生率との相関
Jacqui Venturas, Jarrod Zamparini, Erica Shaddock et al.

Comparison of Outcomes in HIV-Positive and HIV-Negative Patients with COVID-19

J Infect. 2021 May 26;S0163-4453(21)00262-0. doi: 10.1016/j.jinf.2021.05.020.

HIV陽性者と陰性者でのCOVID-19アウトカムの比較
Shohei Yamamoto, Akihito Tanaka, Yusuke Oshiro et al.

Seroprevalence of SARS-CoV-2 antibodies in a national hospital and affiliated facility after the second epidemic wave of Japan

J Infect. 2021 May 24;S0163-4453(21)00259-0. doi: 10.1016/j.jinf.2021.05.017.

関東の医療従事者における第2波後の血清有病率
Rodrigo Pires Dos Santos, Stephani Amanda Lukasewicz Ferreira, Otávio Luis da Fontoura Carvalho et al.

COVID-19 transmission events in school staff in a Brazilian prospective-cohort

Infect Control Hosp Epidemiol. 2021 May 27;1-6. doi: 10.1017/ice.2021.255.

ブラジル学校職員におけるSARS-CoV-2感染イベントを評価した前向きコホート研究
Hitomi Kurosu, Kana Watanabe, Katsuki Kurosawa et al.

Possible contact transmission of SARS-CoV-2 in healthcare settings in Japan, 2020-2021

Infect Control Hosp Epidemiol. 2021 May 27;1-12. doi: 10.1017/ice.2021.254.

日本の医療機関におけるSARS-CoV-2の接触感染が疑われた症例集積
Sarah N Redmond, Lucas D Jones, Navid Sadri et al.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in vaccinated and unvaccinated healthcare personnel in a Veterans Affairs healthcare system

Infect Control Hosp Epidemiol. 2021 May 27;1-6. doi: 10.1017/ice.2021.256.

アメリカ合衆国退役軍人省ヘルスケアシステムにおけるPfizer社製の新型コロナワクチン（BNT162b2）接種医療従事者と非接種医療従事者でのSARS-CoV-2感染の比較
Stéphane Marot, Isabelle Malet, Valentin Leducq et al.

Neutralization heterogeneity of United Kingdom and South-African SARS-CoV-2 variants in BNT162b2-vaccinated or convalescent COVID-19 healthcare workers

Clin Infect Dis. 2021 May 29;ciab492. doi: 10.1093/cid/ciab492.

Pfizer社製の新型コロナワクチン（BNT162b2）を接種された医療従事者とCOVID－19回復6ヶ月後の医療従事者の血清の変異株（B.1.1.7、B.1.351）に対する中和活性
H Keipp Talbot, Emily T Martin, Manjusha Gaglani et al.

Coronavirus disease 2019 (COVID-19) Versus Influenza in Hospitalized Adult Patients in the United States: Differences in Demographic and Severity Indicators

Clin Infect Dis. 2021 May 29;ciab123. doi: 10.1093/cid/ciab123.

米国の入院成人患者におけるCOVID-19とインフルエンザの人口統計、重篤尺度の違い
Antonio Leidi, Flora Koegler, Roxane Dumont et al.

Risk of reinfection after seroconversion to SARS-CoV-2: A population-based propensity-score matched cohort study

Clin Infect Dis. 2021 May 27;ciab495. doi: 10.1093/cid/ciab495.

SARS-CoV-2へのセロコンバージョン後の再感染のリスクを検討した人口ベースの傾向スコアを用いたマッチドコホート研究
Yanping Zhang, Wei Luo, Qun Li et al.

Risk Factors for Death Among the First 80 543 COVID-19 Cases in China: Relationships Between Age, Underlying Disease, Case Severity, and Region

Clin Infect Dis. 2021 May 27;ciab493. doi: 10.1093/cid/ciab493.

中国のSARS-CoV-2感染例80,543例における、年齢、基礎疾患、重症度、地域等の死亡リスク因子の解析
Sheikh Taslim Ali, Amy Yeung, Songwei Shan et al.

Serial intervals and case isolation delays for COVID-19: a systematic review and meta-analysis

Clin Infect Dis. 2021 May 26;ciab491. doi: 10.1093/cid/ciab491.

COVID-19の発症間隔と隔離遅延に関するシステマティックレビューとメタアナリシス
Pragya D Yadav, Gajanan N Sapkal, Priya Abraham et al.

Neutralization potential of Covishield vaccinated individuals sera against B.1.617.1

Clin Infect Dis. 2021 May 24;ciab483. doi: 10.1093/cid/ciab483.

インドで最初に検出された変異株（B.1.617.1）に対するAstraZeneca社製のワクチン（Covishield）接種後血清の中和能
Jason H Malenfant, Michelle Eslami, Bonnie L Dao et al.

Seroprevalence of SARS-CoV-2 Among Skilled Nursing Facility Residents and Staff Members - Los Angeles County, August-September 2020

J Infect Dis. 2021 May 24;jiab281. doi: 10.1093/infdis/jiab281.

2020年8～9月米国ロサンゼルス郡における高度看護施設居住者と職員におけるSARS-CoV-2の血清有病率
Jeremy Ratcliff, Dung Nguyen, Matthew Fish et al.

Virological and serological characterization of critically ill patients with COVID-19 in the UK: Interactions of viral load, antibody status and B.1.1.7 variant infection

J Infect Dis. 2021 May 24;jiab283. doi: 10.1093/infdis/jiab283.

英国におけるCOVID-19重症患者のウイルス学的、血清学的特徴：ウイルス負荷、抗体価、新規変異株（B.1.1.7)感染の相互作用
Issei Oi, Isao Ito, Masataka Hirabayashi et al.

Pneumonia Caused by Severe Acute Respiratory Syndrome Coronavirus 2 and Influenza Virus: A Multicenter Comparative Study

Open Forum Infect Dis. 2021 May 29:ofab282. doi: 10.1093/ofid/ofab282.

重症急性呼吸器症候群肺炎のSARS-CoV-2とインフルエンザによる違いを評価した多施設前向きコホート研究
Zachary A Yetmar, Supavit Chesdachai, Tarek Kashour et al.

Prior Statins Use and Risk of Mortality and Severe Disease from COVID-19: A Systematic Review and Meta-Analysis

Open Forum Infect Dis. 2021 May 28:ofab284. doi: 10.1093/ofid/ofab284.

スタチンの使用とCOVID-19による重症化／死亡リスクとの相関に関するシステマティックレビュー・メタアナリシス
Laurent Blairon, Roberto Cupaiolo, Isabelle Thomas et al.

Efficacy comparison of three rapid antigen tests for SARS-CoV-2 and how viral load impact their performance

J Med Virol. 2021 May 29. doi: 10.1002/jmv.27108.

3種類のSARS-CoV-2抗原検査のウイルス量を考慮した精度比較
Shin Jie Yong

Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments

Infect Dis (Lond). 2021 May 22;1-18. doi: 10.1080/23744235.2021.1924397.

COVID-19後遺症、またはポストCOVID症候群の病理、リスク因子、治療に関するレビュー
Sofie Acke, Simon Couvreur, Wichor M Bramer et al.

Global infectious disease risks associated with occupational exposure among non-healthcare workers: a systematic review of the literature

Occup Environ Med. 2021 May 25;oemed-2020-107164. doi: 10.1136/oemed-2020-107164.

種々の病原体の医療従事者以外の職業的暴露による感染リスクについてのシステマティックレビュー
Panayotes Demakakos

Importance of population-based longitudinal studies to understanding the impact of COVID-19

J Epidemiol Community Health. 2021 May 24;jech-2021-217114. doi: 10.1136/jech-2021-217114.

COVID-19の影響を理解するため集団ベースで行われる縦断研究の重要性
Kevin M Biese, Timothy A McGuine, Kristin Haraldsdottir, Leslie Goodavish, Andrew M Watson

COVID-19 Risk in Youth Club Sports: A nationwide sample representing over 200,000 Athletes

J Athl Train. 2021 May 26. doi: 10.4085/1062-6050-0187.21.

青少年を対象としたサッカーとバレーボールのスポーツクラブにおける感染対策とSARS-CoV-2感染リスク: 米国における20万人の競技者を含む437クラブを対象としたアンケート調査
Caroline Vayne, Jérôme Rollin, Yves Gruel et al.

PF4 Immunoassays in Vaccine-Induced Thrombotic Thrombocytopenia

N Engl J Med. 2021 May 19. doi: 10.1056/NEJMc2106383.

（一部の新型コロナワクチン接種後に起こりうる）ワクチン誘発性免疫性血栓性血小板減少症の診断のための抗血小板第4因子抗体検出目的の迅速キットの有用性の検討
Elizabeth M White, Xiaofei Yang, Carolyn Blackman et al.

Incident SARS-CoV-2 Infection among mRNA-Vaccinated and Unvaccinated Nursing Home Residents

N Engl J Med. 2021 May 19. doi: 10.1056/NEJMc2104849.

高齢者介護施設におけるmRNAワクチン接種者と非接種者のSARS-CoV-2感染の発症率の比較
African COVID-19 Critical Care Outcomes Study (ACCCOS) Investigators

Patient care and clinical outcomes for patients with COVID-19 infection admitted to African high-care or intensive care units (ACCCOS): a multicentre, prospective, observational cohort study

Lancet. 2021 May 22;397(10288):1885-1894. doi: 10.1016/S0140-6736(21)00441-4.

アフリカの集中治療室におけるCOVID-19患者の治療と臨床転帰：多施設前向きコホート研究
Muthukumar Ramanathan, Ian D Ferguson, Weili Miao, Paul A Khavari

SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity

Lancet Infect Dis. 2021 May 19;S1473-3099(21)00262-0. doi: 10.1016/S1473-3099(21)00262-0.

英国で最初に探知された新規変異株（B.1.1.7系統）および南アフリカで最初に探知された新規変異株（B.1.351系統）のACE2への親和性
Isao Yokota, Peter Y Shane, Kazufumi Okada et al.

A novel strategy for SARS-CoV-2 mass screening with quantitative antigen testing of saliva: a diagnostic accuracy study

Lancet Microbe. 2021 May 19;S2666-5247(21)00092-6. doi: 10.1016/S2666-5247(21)00092-6.

唾液を用いた抗原定量検査による大規模スクリーニングの新たな戦略：日本における診断精度研究
Rafael Dal-Ré, Linda-Gail Bekker, Christian Gluud et al.

Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities

Lancet Infect Dis. 2021 May 18;S1473-3099(21)00263-2. doi: 10.1016/S1473-3099(21)00263-2.

現在開発中の新型コロナワクチンの臨床試験の進め方についての論説
Mohammad S Razai, Umar A R Chaudhry, Katja Doerholt, Linda Bauld, Azeem Majeed

Covid-19 vaccination hesitancy

BMJ. 2021 May 20;373:n1138. doi: 10.1136/bmj.n1138.

新型コロナワクチン忌避に関するナラティブレビュー
Nazrul Islam, Vladimir M Shkolnikov, Rolando J Acosta et al.

Excess deaths associated with covid-19 pandemic in 2020: age and sex disaggregated time series analysis in 29 high income countries

BMJ. 2021 May 19;373:n1137. doi: 10.1136/bmj.n1137.

2020年のCOVID-19パンデミックに伴う超過死亡：高所得国29カ国における年齢と性別で層別化した時系列分析
Sarah E Daugherty, Yinglong Guo, Kevin Heath et al.

Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study

BMJ. 2021 May 19;373:n1098. doi: 10.1136/bmj.n1098.

SARS-CoV-2感染症における急性期後の後遺症リスク：後ろ向きコホート研究
Leigh J Sowerby, Anthony C Nichols, Richard Gibson et al.

Assessing the Risk of SARS-CoV-2 Transmission via Surgical Electrocautery Plume

JAMA Surg. 2021 May 21. doi: 10.1001/jamasurg.2021.2591.

外科用電気メスの使用で発生するサージカルスモークによるSARS-CoV-2感染リスクの評価
Jonathan H Watanabe, Jimmy Kwon, Bin Nan et al.

Medication Use Patterns in Hospitalized Patients With COVID-19 in California During the Pandemic

JAMA Netw Open. 2021 May 3;4(5):e2110775. doi: 10.1001/jamanetworkopen.2021.10775.

米国カリフォルニア州におけるCOVID-19入院患者に対する薬剤使用の経時的変化
Eric J Formeister, Wade Chien, Yuri Agrawal et al.

Preliminary Analysis of Association Between COVID-19 Vaccination and Sudden Hearing Loss Using US Centers for Disease Control and Prevention Vaccine Adverse Events Reporting System Data

JAMA Otolaryngol Head Neck Surg. 2021 May 20. doi: 10.1001/jamaoto.2021.0869.

米国疾病予防管理センターのワクチン有害事象報告システムのデータを用いた新型コロナワクチン接種と突発性難聴との関連性に関する予備的分析
Yonghong Li, Carmen H Tong, Lance A Bare, James J Devlin

Assessment of the Association of Vitamin D Level With SARS-CoV-2 Seropositivity Among Working-Age Adults

JAMA Netw Open. 2021 May 3;4(5):e2111634. doi: 10.1001/jamanetworkopen.2021.11634.

生産年齢層におけるSARS-CoV-2に対する抗体保有とビタミンDレベルの関連性の評価
David Grande, Nandita Mitra, Xochitl Luna Marti et al.

Consumer Views on Using Digital Data for COVID-19 Control in the United States

JAMA Netw Open. 2021 May 3;4(5):e2110918. doi: 10.1001/jamanetworkopen.2021.10918.

米国におけるCOVID-19対策のためのデジタルデータ利用に関する一般市民を対象としたアンケート
Giovanni E Davogustto, Daniel E Clark, Edward Hardison et al.

Characteristics Associated With Multisystem Inflammatory Syndrome Among Adults With SARS-CoV-2 Infection

JAMA Netw Open. 2021 May 3;4(5):e2110323. doi: 10.1001/jamanetworkopen.2021.10323.

SARS-CoV-2感染による成人COVID-19 関連多系統炎症性症候群（MIS-A）の特徴
Benjamin Aaronson, Sara Nelson Glick, Christa Jefferis Kirk et al.

Assessment of Feasibility of Face Covering in School-Aged Children With Autism Spectrum Disorders and Attention-Deficit/Hyperactivity Disorder

JAMA Netw Open. 2021 May 3;4(5):e2110281. doi: 10.1001/jamanetworkopen.2021.10281.

自閉症スペクトラムおよび注意欠如・多動症の児童におけるマスクの実効性の評価
Vanessa Piechotta, Claire Iannizzi, Khai Li Chai et al.

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review

Cochrane Database Syst Rev. 2021 May 20;5(5):CD013600. doi: 10.1002/14651858.CD013600.pub4.

COVID-19患者に対する回復者血漿または免疫グロブリン両方の有効性を評価したリビングシステマティックレビュー
Shuchi Anand, Maria E Montez-Rath, Jialin Han et al.

Serial SARS-CoV-2 Receptor-Binding Domain Antibody Responses in Patients Receiving Dialysis

Ann Intern Med. 2021 May 18. doi: 10.7326/M21-0256.

米国における透析中のSARS-CoV-2抗体陽性者の経時的な抗体の推移
Eric Y Wang, Tianyang Mao, Jon Klein et al.

Diverse Functional Autoantibodies in Patients with COVID-19

Nature. 2021 May 19. doi: 10.1038/s41586-021-03631-y.

COVID-19患者における多様な機能的な自己抗体の検出
Victoria Haldane, Chuan De Foo, Salma M Abdalla et al.

Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries

Nat Med. 2021 May 17. doi: 10.1038/s41591-021-01381-y.

28カ国におけるCOVID-19パンデミック対策に関する医療システムの適応の評価
Erin M Bange, Nicholas A Han, Paul Wileyto et al.

CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer

Nat Med. 2021 May 20. doi: 10.1038/s41591-021-01386-7.

CD8+T細胞がCOVID-19感染血液がん患者の生存に寄与する
Harald Schmidt, Rebecca Weintraub, Michelle A Williams et al.

Equitable allocation of COVID-19 vaccines in the United States

Nat Med. 2021 May 18. doi: 10.1038/s41591-021-01379-6.

米国における公平なワクチンの分配に関する解析
Brian J Ward, Philipe Gobeil, Annie Séguin et al.

Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19

Nat Med. 2021 May 18. doi: 10.1038/s41591-021-01370-1.

Medicago社製のウイルス様粒子（VLP）ベースの新型コロナワクチン候補の第一相臨床試験結果
David S Khoury, Deborah Cromer, Arnold Reynaldi et al.

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Nat Med. 2021 May 17. doi: 10.1038/s41591-021-01377-8.

COVID-19回復者の中和抗体価をもとに7種類の新型コロナワクチンの中和抗体価と発症予防の相関（いわゆるcorrelates of protection）を検討したモデリング
Stéphane Le Vu, Gabrielle Jones, François Anna et al.

Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance

Nat Commun. 2021 May 21;12(1):3025. doi: 10.1038/s41467-021-23233-6.

フランスにおける残余血清を用いた血清疫学調査の報告（2020年3月、4月、5月の縦断的解析）
Meng Yuan, Deli Huang, Chang-Chun D Lee et al.

Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants

Science. 2021 May 20;eabh1139. doi: 10.1126/science.abh1139.

新規変異株における抗原ドリフトの構造的・機能的影響
Jun Siong Low, Daniela Vaqueirinho, Federico Mele et al.

Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2

Science. 2021 May 18;eabg8985. doi: 10.1126/science.abg8985.

CD4+T細胞応答におけるimmunodominantなスパイクタンパクの領域やHLA、季節性コロナウイルスへの交叉性の検討
Laura Bergamaschi, Federica Mescia, Lorinda Turner et al.

Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease

Immunity. 2021 May 16;S1074-7613(21)00216-8. doi: 10.1016/j.immuni.2021.05.010.

COVID-19の重症度別の免疫応答とウイルスRNA量の推移
Jenna Gettings, Michaila Czarnik, Elana Morris et al.

Mask Use and Ventilation Improvements to Reduce COVID-19 Incidence in Elementary Schools ― Georgia, November 16–December 11, 2020

MMWR Morb Mortal Wkly Rep. 2021 May 28;70(21):779-784. doi: 10.15585/mmwr.mm7021e1.

米国ジョージア州の小学校におけるマスク着用と室内換気の効果の報告
William A Lanier, Kendra D Babitz et al.

COVID-19 Testing to Sustain In-Person Instruction and Extracurricular Activities in High Schools ― Utah, November 2020–March 2021

MMWR Morb Mortal Wkly Rep. 2021 May 28;70(21):785-791. doi: 10.15585/mmwr.mm7021e2.

米国ユタ州の高校における学校単位での定期的なスクリーニング検査によって、対面授業と課外活動を継続したという報告
Christine Kim, Sasha McGee, Shreya Khuntia et al.

Characteristics of COVID-19 Cases and Outbreaks at Child Care Facilities - District of Columbia, July-December 2020

MMWR Morb Mortal Wkly Rep. 2021 May 21;70(20):744-748. doi: 10.15585/mmwr.mm7020a3.

米国ワシントンD.C.の保育施設におけるCOVID-19症例やアウトブレイクの記述疫学（2020年7-8月）
Bhavini Patel Murthy, Natalie Sterrett, Daniel Weller et al.

Disparities in COVID-19 Vaccination Coverage Between Urban and Rural Counties - United States, December 14, 2020-April 10, 2021

MMWR Morb Mortal Wkly Rep. 2021 May 21;70(20):759-764. doi: 10.15585/mmwr.mm7020e3.

米国における都心と地方の新型コロナワクチン普及率の違い（2020年12月14日-2021年4月10日）
Zheng Quan Toh, Rachel A Higgins, Lien Anh Ha Do et al.

Persistence of SARS-CoV-2-Specific IgG in Children 6 Months After Infection, Australia

Emerg Infect Dis. 2021 May 20;27(8). doi: 10.3201/eid2708.210965.

軽症または無症候のSARS-CoV-2感染後の小児における6ヶ月後のIgG応答
Manoj V Murhekar, Tarun Bhatnagar, Jeromie Wesley Vivian Thangaraj et al.

SARS-CoV-2 sero-prevalence among general population and healthcare workers in India, December 2020 - January 2021

Int J Infect Dis. 2021 May 19;S1201-9712(21)00442-2. doi: 10.1016/j.ijid.2021.05.040.

インドの一般市民および医療従事者における血清有病率（2020年12月～2021年1月）
Scott A McDonald, Cees C van den Wijngaard, Cornelia Ch Wielders et al.

Risk factors associated with the incidence of self-reported COVID-19-like illness: Data from a web-based syndromic surveillance system in the Netherlands

Epidemiol Infect. 2021 May 19;1-20. doi: 10.1017/S0950268821001187.

オランダにおけるCOVID-19様疾患の発生率と自己申告制のオンライン症候群サーベイランスシステムを用いた感染リスク因子解析
Romeo R Galang, Suzanne M Newton, Kate R Woodworth et al.

Risk factors for illness severity among pregnant women with confirmed SARS-CoV-2 infection - Surveillance for Emerging Threats to Mothers and Babies Network, 22 state, local, and territorial health departments, March 29, 2020 -March 5, 2021

Clin Infect Dis. 2021 May 22;ciab432. doi: 10.1093/cid/ciab432.

妊婦におけるCOVID-19重症化のリスク因子
Andrew H Karaba, Weiqiang Zhou, Leon L Hsieh et al.

Differential Cytokine Signatures of SARS-CoV-2 and Influenza Infection Highlight Key Differences in Pathobiology

Clin Infect Dis. 2021 May 20;ciab376. doi: 10.1093/cid/ciab376.

COVID-19とインフルエンザでのサイトカインの違い
Anastasia N Vlasova, Annika Diaz, Debasu Damtie et al.

Novel Canine Coronavirus Isolated from a Hospitalized Pneumonia Patient, East Malaysia

Clin Infect Dis. 2021 May 20;ciab456. doi: 10.1093/cid/ciab456.

2017-2018年にマレーシア東部において肺炎で入院した患者で見つかった新型のイヌ科コロナウイルス
Elizabeth C Verna, Charles Landis, Robert S Brown Jr et al.

Factors Associated with Readmission in the US Following Hospitalization with COVID-19

Clin Infect Dis. 2021 May 20;ciab464. doi: 10.1093/cid/ciab464.

COVID-19入院患者の再入院のリスク因子解析
Gabriel Chodick, Lilac Tene, Ran S Rotem et al.

The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real-world data

Clin Infect Dis. 2021 May 17;ciab438. doi: 10.1093/cid/ciab438.

イスラエルの医療従事者におけるPfizer社製の新型コロナワクチン（BNT162b2）の有効性を評価した後ろ向きコホート研究
Francesco Paolo Bianchi, Cinzia Annatea Germinario, Giovanni Migliore et al.

BNT162b2 mRNA Covid-19 vaccine effectiveness in the prevention of SARS-CoV-2 infection: a preliminary report

J Infect Dis. 2021 May 19;jiab262. doi: 10.1093/infdis/jiab262.

イタリアの医療従事者におけるPfizer社製の新型コロナワクチン（BNT162b2）の有効性を評価した後ろ向きコホート研究
Jennifer A Hall, Ross J Harris, Hannah E Emmett et al.

On the sensitivity and specificity of post-mortem upper respiratory tract testing for SARS-CoV-2

J Infect Dis. 2021 May 17;jiab270. doi: 10.1093/infdis/jiab270.

上気道スワブを用いた死後のSARS-CoV-2 PCR検査の感度と特異度
Rachel L Epstein, Heather Sperring, Melissa Hofman et al.

Time to SARS-CoV-2 PCR clearance in immunocompromising conditions: is test-based removal from isolation necessary in severely immunocompromised individuals?

Open Forum Infect Dis. 2021 May 20:ofab164. doi: 10.1093/ofid/ofab164.

免疫抑制患者におけるSARS-CoV-2 PCR陰性までに要する時間に関連する因子
Kenechukwu Egbuonu, Emily P Hyle, Rocio M Hurtado et al.

Yield of SARS-CoV-2 lower respiratory tract testing after a negative nasopharyngeal test among hospitalized persons under investigation for COVID-19

Open Forum Infect Dis. 2021 May 19:ofab257. doi: 10.1093/ofid/ofab257.

鼻咽頭ぬぐい検体でのPCR検査陰性者における下気道検体でのPCR検査陽性
Ivana Lapić, Dragana Šegulja, Dunja Rogić

Assessment of salivary antibody response to BNT162b2 mRNA COVID-19 vaccination

J Med Virol. 2021 May 19. doi: 10.1002/jmv.27096.

Pfizer社製の新型コロナワクチン（BNT162b2）接種後の唾液における抗体応答
Ofer Beharier, Romina Plitman Mayo, Tal Raz et al.

Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine

J Clin Invest. 2021 May 20;150319. doi: 10.1172/JCI150319.

Pfizer社製の新型コロナワクチン（BNT162b2）接種後妊婦における胎児への抗体移行
Ji Hoon Ahn, JungMo Kim, Seon Pyo Hong et al.

Nasal ciliated cells are primary targets for SARS-CoV-2 replication in early stage of COVID-19

J Clin Invest. 2021 May 18;148517. doi: 10.1172/JCI148517.

SARS-CoV-2感染早期における鼻腔線毛細胞でのウイルス増殖
Esteban Ortiz-Prado, Raul Fernandez-Naranjo, Yeferson Torres-Berru, Rachel Lowe, Irene Torres

Exceptional Prices of Medical and Other Supplies during the COVID-19 Pandemic in Ecuador

Am J Trop Med Hyg. 2021 May 20;tpmd210221. doi: 10.4269/ajtmh.21-0221.

COVID-19パンデミック下でのエクアドルにおける医薬品やその他の物資の高騰
Tomer Avni, Leonard Leibovici, Ido Cohen et al.

Tocilizumab in the treatment of COVID-19 - a meta-analysis

QJM. 2021 May 19;hcab142. doi: 10.1093/qjmed/hcab142.

COVID-19に対する治療としてのトシリズマブの有効性を評価したランダム化比較試験のシステマティックレビュー・メタアナリシス
Jerald Sadoff, Mathieu Le Gars, Georgi Shukarev et al.

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

N Engl J Med. 2021 May 13;384(19):1824-1835. doi: 10.1056/NEJMoa2034201.

Janssen/Johnson and Johnson社製ワクチン（Ad26.COV2.S）第1–2a相臨床試験の中間結果
RECOVERY Collaborative Group

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Lancet. 2021 May 14;S0140-6736(21)00897-7. doi: 10.1016/S0140-6736(21)00897-7.

COVID-19入院患者に対する回復者血漿療法有効性を検討したランダム化比較試験（RECOVERY trialの部分解析）
Krutika Kuppalli, Pooja Gala, Kartikeya Cherabuddi et al.

India's COVID-19 crisis: a call for international action

Lancet. 2021 May 14;S0140-6736(21)01121-1. doi: 10.1016/S0140-6736(21)01121-1.

インドにおけるSARS-CoV-2の大規模流行に対する各国の対応への呼びかけ
Alexander Supady, Enya Weber, Marina Rieder et al.

Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial

Lancet Respir Med. 2021 May 14;/S2213-2600(21)00177-6. doi: 10.1016//S2213-2600(21)00177-6.

ECMOを使用するCOVID-19患者でのサイトカイン吸着療法の有効性を評価したランダム化比較試験
Dennis McGonagle, Charlie Bridgewood, James F M Meaney

A tricompartmental model of lung oxygenation disruption to explain pulmonary and systemic pathology in severe COVID-19

Lancet Respir Med. 2021 May 14;/S2213-2600(21)00213-7. doi: 10.1016//S2213-2600(21)00213-7.

COVID-19重症例における肺及び全身病理像を説明する肺酸素化遮断の3コンパートメント（肺胞、肺動脈、気管支動脈循環からの二重酸素供給）モデル
Robert H Shaw, Arabella Stuart, Melanie Greenland et al.

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

Lancet. 2021 May 12;S0140-6736(21)01115-6. doi: 10.1016/S0140-6736(21)01115-6.

ファイザー社製の新型コロナワクチン（BNT162b2）とアストラゼネカ社製の新型コロナワクチン（ChAdOx1 nCoV-19）の混合接種の副反応評価
Daniel Freeman, Bao Sheng Loe, Ly-Mee Yu et al.

Effects of different types of written vaccination information on COVID-19 vaccine hesitancy in the UK (OCEANS-III): a single-blind, parallel-group, randomised controlled trial

Lancet Public Health. 2021 May 12;S2468-2667(21)00096-7. doi: 10.1016/S2468-2667(21)00096-7.

英国における新型コロナワクチンの接種忌避に対する介入としての10通りの情報提供を評価したランダム化比較試験
Lars Christian Lund, Jesper Hallas, Henrik Nielsen et al.

Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study

Lancet Infect Dis. 2021 May 10;S1473-3099(21)00211-5. doi: 10.1016/S1473-3099(21)00211-5.

デンマークにおける入院を要しなかったCOVID-19患者における後遺症を検討した人口ベースのコホート研究
Jamie Lopez Bernal, Nick Andrews, Charlotte Gower et al.

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

BMJ. 2021 May 13;373:n1088. doi: 10.1136/bmj.n1088.

英国におけるAstraZenecaおよびPfizer社製の新型コロナワクチン（それぞれChAdOx1-S、BNT162b2）の高齢者における有効性を評価した症例対照研究（test negative design）
Santiago Romero-Brufau, Ayush Chopra, Alex J Ryu et al.

Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study

BMJ. 2021 May 12;373:n1087. doi: 10.1136/bmj.n1087.

Pfizer社製およびModerna社製の新型コロナワクチン（それぞれBNT162b2、mRNA-1273）の2回目接種延期による公衆衛生的インパクトを推定したモデリング
Inga Holmdahl, Rebecca Kahn, James A Hay, Caroline O Buckee, Michael J Mina

Estimation of Transmission of COVID-19 in Simulated Nursing Homes With Frequent Testing and Immunity-Based Staffing

JAMA Netw Open. 2021 May 3;4(5):e2110071. doi: 10.1001/jamanetworkopen.2021.10071.

高齢者施設における頻回の検査と既感染者ごとの配置によるCOVID-19感染の評価
Ai-Ris Y Collier, Katherine McMahan, Jingyou Yu et al.

Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women

JAMA. 2021 May 13. doi: 10.1001/jama.2021.7563.

妊婦や授乳中の女性へのmRNAベースの新型コロナワクチン接種後の免疫原性
Sherry H-Y Chou, Ettore Beghi, Raimund Helbok et al.

Global Incidence of Neurological Manifestations Among Patients Hospitalized With COVID-19-A Report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium

JAMA Netw Open. 2021 May 3;4(5):e2112131. doi: 10.1001/jamanetworkopen.2021.12131.

グローバルコンソーシアムによるCOVID-19入院症例の神経症状に関する報告
Yaara Finkel, Avi Gluck, Aharon Nachshon et al.

SARS-CoV-2 uses a multipronged strategy to impede host protein synthesis

Nature. 2021 May 12. doi: 10.1038/s41586-021-03610-3.

SARS-CoV-2は複数の機序で宿主のタンパク質合成を阻害する
Chris Wymant, Luca Ferretti, Daphne Tsallis et al.

The epidemiological impact of the NHS COVID-19 App

Nature. 2021 May 12. doi: 10.1038/s41586-021-03606-z.

英国National Health ServiceのCOVID-19接触者追跡アプリが与えた疫学的インパクト
Kevin O Saunders, Esther Lee, Robert Parks et al.

Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses

Nature. 2021 May 10. doi: 10.1038/s41586-021-03594-0.

SARS-CoV-2やこの新規変異株、他の複数のコロナウイルスに対する中和抗体を誘導するナノ粒子型ワクチン候補の前臨床試験
Susan Michie, Robert West

Sustained behavior change is key to preventing and tackling future pandemics

Nat Med. 2021 May 10;27(5):749-752. doi: 10.1038/s41591-021-01345-2.

将来のパンデミックを防ぎ、立ち向かうための鍵となる継続的な行動変容についての論説
Pramod R Bhatt, Alain Scaiola, Gary Loughran et al.

Structural basis of ribosomal frameshifting during translation of the SARS-CoV-2 RNA genome

Science. 2021 May 13;eabf3546. doi: 10.1126/science.abf3546.

SARS-CoV-2 RNAの翻訳時のリボゾームフレームシフトの構造学的根拠
Lina Ma, Sanjaya K Sahu, Marlene Cano et al.

Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection

Sci Immunol. 2021 May 13;eabh2259. doi: 10.1126/science.abh2259.

重症COVID-19とインフルエンザや急性呼吸不全における補体活性化の比較
Stefanie Kreutmair, Susanne Unger, Nicolás Gonzalo Núñez et al.

Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia

Immunity. 2021 May 9;S1074-7613(21)00208-9. doi: 10.1016/j.immuni.2021.05.002.

循環ナチュラルキラーT細胞は予後予測に有用な可能性があるとする報告
Qing Yang, Tassa K Saldi, Patrick K Gonzales et al.

Just 2% of SARS-CoV-2-positive individuals carry 90% of the virus circulating in communities

Proc Natl Acad Sci U S A. 2021 May 25;118(21):e2104547118. doi: 10.1073/pnas.2104547118.

無症候病原体保有者の2%が感染可能な感染可能なウイルス粒子を持つ者の90%を閉めると推定したモデリング
Megan Wallace, Kate R Woodworth, Julia W Gargano et al.

The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years ― United States, May 2021

MMWR Morb Mortal Wkly Rep. 2021 May 14. doi: 10.15585/mmwr.mm7020e1.

米国の予防接種の実施に関する諮問委員会（ACIP）の若年層（12-15歳）に対するPfizer社製の新型コロナワクチン（BNT162b2）接種に関する勧告
Tamara Pilishvili, Katherine E Fleming-Dutra, Jennifer L Farrar et al.

Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel ― 33 U.S. Sites, January–March 2021

MMWR Morb Mortal Wkly Rep. 2021 May 14. doi: 10.15585/mmwr.mm7020e2.

米国33施設の医療従事者における新型コロナワクチン（Moderna社製mRNA-1273およびPfizer社製BNT162b2）の効果を検討した症例対照研究（test negative design）
Auguste Brihn, Jamie Chang, Kelsey OYong et al.

Diagnostic Performance of an Antigen Test with RT-PCR for the Detection of SARS-CoV-2 in a Hospital Setting - Los Angeles County, California, June-August 2020

MMWR Morb Mortal Wkly Rep. 2021 May 14;70(19):702-706. doi: 10.15585/mmwr.mm7019a3.

RT-PCR検査をゴールドスタンダードとして評価した、医療機関における迅速抗原検査の精度
Kayla English, Uei Lei, Frankie Shipman-Amuwo et al.

Community-Based Testing for SARS-CoV-2 - Chicago, Illinois, May-November 2020

MMWR Morb Mortal Wkly Rep. 2021 May 14;70(19):707-711. doi: 10.15585/mmwr.mm7019a4.

米国シカゴで実施されたコニュニティーベースの無料SARS-CoV-2検査に関する報告
Zuelma Contreras, Van Ngo, Marifi Pulido et al.

Industry Sectors Highly Affected by Worksite Outbreaks of Coronavirus Disease, Los Angeles County, California, USA, March 19-September 30, 2020

Emerg Infect Dis. 2021 May 12;27(7). doi: 10.3201/eid2707.210425.

米国カリフォルニア州における産業別の職場アウトブレイクの記述
Barbara Colitti, Luigi Bertolotti, Alessandro Mannelli et al.

Cross-Sectional Serosurvey of Companion Animals Housed with SARS-CoV-2-Infected Owners, Italy

Emerg Infect Dis. 2021 May 11;27(7). doi: 10.3201/eid2707.203314.

イタリアにおけるSARS-CoV-2感染者の家で飼われていたイヌやネコの抗体保有割合
Sophia Hatzianastasiou, Varvara A Mouchtouri, Androula Pavli et al.

COVID-19 Outbreak on a Passenger Ship and Assessment of Response Measures, Greece, 2020

Emerg Infect Dis. 2021 May 12;27(7). doi: 10.3201/eid2707.210398.

ギリシャにおける客船で発生したアウトブレイク対応とその評価
Thérèse Staub, Vic Arendt, Esther Calvo Lasso de la Vega et al.

Case series of four re-infections with a SARS-CoV-2 B.1.351 variant, Luxembourg, February 2021

Euro Surveill. 2021 May 6;26(18):2100423. doi: 10.2807/1560-7917.ES.2021.26.18.2100423.

IgG 抗体価によりSARS-CoV-2の既感染が証明されていた医療従事者に南アフリカで最初に検出された新規変異株（B.1.351系統）による再感染を認めたの症例報告
Stanley A Plotkin, Ofer Levy

Considering Mandatory Vaccination of Children for COVID-19

Pediatrics. 2021 Mar 11;e2021050531. doi: 10.1542/peds.2021-050531.

小児へのCOVID-19 ワクチン義務化についての論説
Ahmed Zaqout, Joanne Daghfal, Israa Alaqad et al.

The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout

Int J Infect Dis. 2021 May 13;S1201-9712(21)00422-7. doi: 10.1016/j.ijid.2021.05.021.

カタールにおいて医療機関データベースを利用してPfizer社製の新型コロナワクチン（BNT162b2）の有効性を評価したコホート研究
Cucunawangsih Cucunawangsih, Ratna Sari Wijaya, Nata Pratama Hardjo Lugito, Ivet Suriapranata

Post-vaccination COVID-19 cases among healthcare workers at Siloam Teaching Hospital, Indonesia

Int J Infect Dis. 2021 May 13;S1201-9712(21)00421-5. doi: 10.1016/j.ijid.2021.05.020.

インドネシアにおけるワクチン2回接種後の医療従事者におけるSARS-CoV-2感染
Dhammika Leshan Wannigama, Mohan Amarasiri, Cameron Hurst et al.

Tracking COVID-19 with wastewater to understand asymptomatic transmission

Int J Infect Dis. 2021 May 11;S1201-9712(21)00406-9. doi: 10.1016/j.ijid.2021.05.005.

タイのバンコクにおけるSARS-CoV-2 RNAの下水サーベイランス
Jiabing Wu, Xiuzhi Chen, Lei Gong et al.

Epidemiological and clinical features of SARS-CoV-2 cluster infection in Anhui Province, Eastern China

Int J Infect Dis. 2021 May 10;S1201-9712(21)00376-3. doi: 10.1016/j.ijid.2021.04.064.

中国安徽省において発生したCOVID-19クラスターの感染世代毎の二次感染率、重症度を調べた報告
Azmaeen Zarif, Mark Joy, Julian Sherlock et al.

The impact of primary care supported shielding on the risk of mortality in people vulnerable to COVID-19: English sentinel network matched cohort study

J Infect. 2021 May 15;S0163-4453(21)00220-6. doi: 10.1016/j.jinf.2021.04.033.

英国のプライマリケアデータベースを用いた、重症化リスクの高い人のシールディングの効果を検討した後ろ向きマッチドコホート研究
Vishal P Shah, Laura E Breeher, Caitlin M Hainy, Melanie D Swift

Evaluation of Healthcare Personnel Exposures to Patients with SARS-CoV-2 Associated with Personal Protective Equipment Use

Infect Control Hosp Epidemiol. 2021 May 12;1-14. doi: 10.1017/ice.2021.219.

COVID-19患者処置時の医療従事者のPPEの着用状況から感染リスクを調査した後ろ向きコホート研究
Lior Rennert, Christopher McMahan

Risk of SARS-CoV-2 reinfection in a university student population

Clin Infect Dis. 2021 May 16;ciab454. doi: 10.1093/cid/ciab454.

米国における大学生を対象にSARS-CoV-2の再感染率を調べた後ろ向きコホート研究
Benoit Bailly, Luc Guilpain, Kevin Bouiller et al.

BNT162b2 mRNA vaccination did not prevent an outbreak of SARS COV-2 variant 501Y.V2 in an elderly nursing home but reduced transmission and disease severity

Clin Infect Dis. 2021 May 16;ciab446. doi: 10.1093/cid/ciab446.

高齢者施設におけるアウトブレイクにおけるPfizer社製の新型コロナワクチン（BNT162b2）接種の効果
David H Canaday, Lenore Carias, Oladayo A Oyebanji et al.

Reduced BNT162b2 mRNA vaccine response in SARS-CoV-2-naive nursing home residents

Clin Infect Dis. 2021 May 16;ciab447. doi: 10.1093/cid/ciab447.

Pfizer社製の新型コロナワクチン（BNT162b2）接種後の医療従事者と高齢者のシュードタイプウイルスに対する中和抗体応答の比較
Joseph D Lutgring, Farrell A Tobolowsky, Kelly M Hatfield et al.

Evaluating the Presence of Replication-Competent SARS-CoV-2 from Nursing Home Residents with Persistently Positive RT-PCR Results

Clin Infect Dis. 2021 May 14;ciab436. doi: 10.1093/cid/ciab436.

継続してPCR陽性となる施設の高齢者におけるウイルス分離の有無
Gage K Moreno, Katarina M Braun, Ian W Pray et al.

SARS-CoV-2 transmission in intercollegiate athletics not fully mitigated with daily antigen testing

Clin Infect Dis. 2021 May 12;ciab343. doi: 10.1093/cid/ciab343.

連日の抗原定量検査スクリーニングを施行していた米国の大学生アスリートと関係スタッフにおいて起きた2つのCOVID-19アウトブレイクの報告
George N Ioannou, Ann M O'Hare, Kristin Berry et al.

Trends over time in the risk of adverse outcomes among patients with SARS-CoV-2 infection

Clin Infect Dis. 2021 May 11;ciab419. doi: 10.1093/cid/ciab419.

米国の2020年2月から9月の間でのCOVID-19の転帰の変化について電子化カルテ情報を用いて調べた後ろ向きコホート研究
Toni Luise Meister, Jill Fortmann, Daniel Todt et al.

Comparable environmental stability and disinfection profiles of the currently circulating SARS-CoV-2 variants of concern B.1.1.7 and B.1.351

J Infect Dis. 2021 May 16;jiab260. doi: 10.1093/infdis/jiab260.

SARS-CoV-2の新規変異株（B.1.1.7系統とB.1.351系統）の環境表面中での安定性に関する報告
Lin Yao, Guo-Lin Wang, Yuan Shen et al.

Persistence of Antibody and Cellular Immune Responses in COVID-19 patients over Nine Months after Infection

J Infect Dis. 2021 May 12;jiab255. doi: 10.1093/infdis/jiab255.

SARS-CoV-2感染9ヶ月後までの液性免疫、細胞性免疫の評価
Brandon Michael Henry, Ivan Szergyuk, Maria Helena Santos de Oliveira et al.

Complement levels at admission as a reflection of Coronavirus Disease 19 (COVID-19) severity state

J Med Virol. 2021 May 11. doi: 10.1002/jmv.27077.

COVID-19の重症度と補体の活性に関する前向き観察研究
Max R O'Donnell, Beatriz Grinsztejn, Matthew J Cummings et al.

A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19

J Clin Invest. 2021 May 11;150646. doi: 10.1172/JCI150646.

重症COVID-19患者に対する回復者血漿の有効性を評価したランダム化比較試験
Alessio Mazzoni, Nicoletta Di Lauria, Laura Maggi et al.

First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in recovered COVID-19 subjects

J Clin Invest. 2021 May 3;149150. doi: 10.1172/JCI149150.

SARS-CoV-2既感染者と未感染者におけるのPfizer社製の新型コロナワクチン（BNT162b2）1回目および2回目接種後の液性免疫および細胞性免疫
Bezawit A Woldemeskel, Caroline C Garliss, Joel N Blankson

SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63

J Clin Invest. 2021 May 17;131(10):e149335. doi: 10.1172/JCI149335.

Pfizer社製の新型コロナワクチン（BNT162b2）およびModerna社製の新型コロナワクチン（mRNA-1273）の接種によるSARS-CoV-2の新規変異株（B.1.1.7系統、B.1.3.5系統）およびHCoV-NL63に対する広域CD4陽性T細胞の免疫応答の誘導
Mark D Fox, Matthew S Leiszler, Michael D Seamon, Benjamin L Garmin

Results of a Shortened Quarantine Protocol on a Midwestern College Campus

Clin Infect Dis. 2021 May 12;ciab342. doi: 10.1093/cid/ciab342.

米国ミッドウェスタン大学における検査陰性確認による濃厚接触者の健康観察期間短縮の試行結果
Edouard Mathieu, Hannah Ritchie, Esteban Ortiz-Ospina et al.

A global database of COVID-19 vaccinations

Nat Hum Behav. 2021 May 10. doi: 10.1038/s41562-021-01122-8.

世界の新型コロナワクチンの接種状況をまとめたデータベースの紹介と接種状況の暫定報告
Vivek Shinde, Sutika Bhikha, Zaheer Hoosain et al.

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

N Engl J Med. 2021 May 5;384(20):1899-1909. doi: 10.1056/NEJMoa2103055.

Novavax社製の新型コロナワクチン（NVX-CoV2373）の南アフリカで最初に検出された新規変異株（B.1.351系統）に対する第2相臨床試験の結果解析による有効性評価
Laith J Abu-Raddad, Hiam Chemaitelly, Adeel A Butt, National Study Group for COVID-19 Vaccination

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

N Engl J Med. 2021 May 5. doi: 10.1056/NEJMc2104974.

カタールにおけるPfizer社製の新型コロナワクチン（BNT162b2）の英国で最初に検出された新規変異株（B.1.1.7系統）と南アフリカで最初に検出された新規変異株（B.1.351系統）に対する有効性を評価した症例対照研究
Thomas M Drake, Cameron J Fairfield, Riinu Pius et al.

Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study

Lancet Rheumatol. 2021 May 7;S2665-9913(21)00104-1. doi: 10.1016/S2665-9913(21)00104-1.

NSAIDs使用とCOVID-19転帰の相関を検討したマッチドコホート研究
GloPID-R, UKCDR, and COVID-19 Clinical Research Coalition Cross-Working Group on COVID-19 Research in LMICs

Priorities for COVID-19 research response and preparedness in low-resource settings

Lancet. 2021 May 6;S0140-6736(21)00980-6. doi: 10.1016/S0140-6736(21)00980-6.

低中所得国における優先すべきCOVID-19研究テーマに関する論説
Eric J Haas, Frederick J Angulo, John M McLaughlin et al.

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Lancet. 2021 May 5;S0140-6736(21)00947-8. doi: 10.1016/S0140-6736(21)00947-8.

イスラエルにおける国のサーベイランスデータをもとにPfizer社製の新型コロナワクチン（BNT162b2）の有効性とインパクトを評価した観察研究
Xiaojun Wu, Xiaofan Liu, Yilu Zhou et al.

3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study

Lancet Respir Med. 2021 May 5;S2213-2600(21)00174-0. doi: 10.1016/S2213-2600(21)00174-0.

COVID-19で人工呼吸器管理にならなかった中等症患者の長期的な呼吸器系の転帰を検討した前向きコホート研究
Anton Pottegård, Lars Christian Lund, Øystein Karlstad et al.

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study

BMJ. 2021 May 5;373:n1114. doi: 10.1136/bmj.n1114.

デンマークとノルウェーにおけるAstraZeneca社製の新型コロナワクチン（ChAdOx1-S）接種と血栓イベントや出血イベントとの相関を検討した人口レベルのコホート研究
Chris Baraniuk

Where are we with drug treatments for covid-19?

BMJ. 2021 May 7;373:n1109. doi: 10.1136/bmj.n1109.

COVID-19の薬物療法についてのナラティブレビュー
Philippa Anna Stilwell, Alasdair P S Munro, Emre Basatemur et al.

Bibliography of published COVID-19 in children literature

Arch Dis Child. 2021 May 6;archdischild-2021-321751. doi: 10.1136/archdischild-2021-321751.

小児のCOVID-19に関する論文の前向きスクリーニングの取り組み
Yoel Angel, Avishay Spitzer, Oryan Henig et al.

Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers

JAMA. 2021 May 6. doi: 10.1001/jama.2021.7152.

医療従事者を対象としたファイザー社製の新型コロナワクチン（BNT162b2）接種とSARS-CoV-2無症状/有症状感染者の発生率との関係
Li Tang, Diego R Hijano, Aditya H Gaur et al.

Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce

JAMA. 2021 May 6. doi: 10.1001/jama.2021.6564.

イスラエルにおけるPfizer-BioNTech BNT162b2ワクチンの無症状病原体保有者および有症状者に対する有効性を評価した定期スクリーニングが実施される医療従事者を対象とした後ろ向きコホート研究
Anita D Misra-Hebert, Xinge Ji, Lara Jehi et al.

COVID-19 Home Monitoring After Diagnosis and Health Care Utilization in an Integrated Health System

JAMA Health Forum. 2021 May 6; 2(5):e210333. doi: 10.1001/jamahealthforum.2021.0333.

COVID-19診断後のホームモニタリングシステムと医療受診行動の関連について
Brian J Boyarsky, William A Werbel, Robin K Avery et al.

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

JAMA. 2021 May 5. doi: 10.1001/jama.2021.7489.

臓器移植患者におけるmRNAベースの新型コロナワクチン1回および2回接種後の抗体応答
Gregory A Roth, Sophia Emmons-Bell, Heather M Alger et al.

Trends in Patient Characteristics and COVID-19 In-Hospital Mortality in the United States During the COVID-19 Pandemic

JAMA Netw Open. 2021 May 3;4(5):e218828. doi: 10.1001/jamanetworkopen.2021.8828.

米国におけるCOVID-19入院患者の死亡率の推移と基本特性
Gilbert T Chua, Joshua Sung Chih Wong, Ivan Lam et al.

Clinical Characteristics and Transmission of COVID-19 in Children and Youths During 3 Waves of Outbreaks in Hong Kong

JAMA Netw Open. 2021 May 3;4(5):e218824. doi: 10.1001/jamanetworkopen.2021.8824.

香港における小児や若年者のCOVID-19感染や臨床的特徴
Carolina Lucas, Jon Klein, Maria E Sundaram et al.

Delayed production of neutralizing antibodies correlates with fatal COVID-19

Nat Med. 2021 May 5. doi: 10.1038/s41591-021-01355-0.

中和抗体応答の遅延とCOVID-19による死亡との相関
Min Zheng, Rajendra Karki, Evan Peter Williams et al.

TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines

Nat Immunol. 2021 May 7. doi: 10.1038/s41590-021-00937-x.

TLR2がSARS-CoV-2のエンベロープタンパク質を認識し炎症性サイトカインを産生する
William N Voss, Yixuan J Hou, Nicole V Johnson et al.

Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes

Science. 2021 May 4;eabg5268. doi: 10.1126/science.abg5268.

受容体結合部位以外のスパイクタンパクの部位を認識するIgGの解析
Guilherme Dias de Melo, Françoise Lazarini, Sylvain Levallois et al.

COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters

Sci Transl Med. 2021 May 3;eabf8396. doi: 10.1126/scitranslmed.abf8396.

ハムスターモデルにおけるCOVID-19の嗅覚障害と嗅上皮細胞における感染・炎症との相関
Meghan E Garrett, Jared Galloway, Helen Y Chu et al.

High resolution profiling of pathways of escape for SARS-CoV-2 spike-binding antibodies

Cell. 2021 May 4;S0092-8674(21)00580-8. doi: 10.1016/j.cell.2021.04.045.

COVID-19回復者血漿を用いた抗スパイクタンパク抗体からの逃避のプロファイリング
Liguo Zhang, Alexsia Richards, M Inmaculada Barrasa et al.

Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues

Proc Natl Acad Sci U S A. 2021 May 25;118(21):e2105968118. doi: 10.1073/pnas.2105968118.

SARS-CoV-2逆転写RNAの培養ヒト細胞のゲノムへの取り込みと患者由来組織での発現
Corinne N Thompson, Scott Hughes, Stephanie Ngai et al.

Rapid Emergence and Epidemiologic Characteristics of the SARS-CoV-2 B.1.526 Variant ― New York City, New York, January 1–April 5, 2021

MMWR Morb Mortal Wkly Rep. 2021 May 14;70(19):712–716. doi: 10.15585/mmwr.mm7019e1.

米国ニューヨーク市における新規変異株（B.1.526系統）の疫学的特徴
Rebecca K Borchering, Cécile Viboud, Emily Howerton et al.

Modeling of Future COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Rates and Nonpharmaceutical Intervention Scenarios ― United States, April–September 2021

MMWR Morb Mortal Wkly Rep. 2021 May 14;70(19):719–724. doi: 10.15585/mmwr.mm7019e3.

米国におけるワクチン接種率と非医薬品介入の程度による感染者数、入院者数、死亡者数のモデリング
François Maclot, Sébastien Bontems, Cécile Meex et al.

Development of a multiplex RT-qPCR using the drop out strategy to screen the SARS-CoV-2 South African 501Y.V2 variant

J Infect. 2021 May 3;S0163-4453(21)00221-8. doi: 10.1016/j.jinf.2021.04.035.

南アフリカで最初に検出された新規変異株（501Y.V2）スクリーニングのためのマルチプレックスRT-qPCR法の開発
Laura Anderson, Emily Schmitz, Philip M Polgreen, Susan E Beekmann, Nasia Safdar

Discontinuation of Isolation Precautions for COVID-19 Patients

Infect Control Hosp Epidemiol. 2021 May 3;1-9. doi: 10.1017/ice.2021.188.

医療機関でのCOVID-19患者に対する隔離予防策の調査
Elizabeth Temkin, Mitchell J Schwaber, Azza Vaturi et al.

Effect of a national policy of universal masking and uniform criteria for SARS-CoV-2 exposure on hospital staff infection and quarantine

Infect Control Hosp Epidemiol. 2021 May 3;1-23. doi: 10.1017/ice.2021.207.

イスラエルにおける院内でのマスク着用義務化や統一された濃厚接触の基準の導入
Ghady Haidar, John W Mellors

Improving the Outcomes of Immunocompromised Patients with COVID-19

Clin Infect Dis. 2021 May 5;ciab397. doi: 10.1093/cid/ciab397.

免疫不全のあるCOVID-19患者の転帰の改善についての論説
Mathilde Bellon, Stephanie Baggio, Frederique Jacquerioz Bausch et al.

SARS-CoV-2 viral load kinetics in symptomatic children, adolescents and adults

Clin Infect Dis. 2021 May 5;ciab396. doi: 10.1093/cid/ciab396.

SARS-CoV-2の従来株によるCOVID-19感染有症状例における発症後7日間のウイルス量の成人と小児の比較
Evann E Hilt, James Boocock, Marisol Trejo et al.

Retrospective Detection of SARS-CoV-2 in Symptomatic Patients prior to Widespread Diagnostic Testing in Southern California

Clin Infect Dis. 2021 May 3;ciab360. doi: 10.1093/cid/ciab360.

米国南カリフォルニアにおけるパンデミック初期の有症状者の検体からのSARS-CoV-2 RNAの検出
Ithan D Peltan, Sarah J Beesley, Brandon J Webb et al.

Evaluation of potential COVID-19 recurrence in patients with late repeat positive SARS-CoV-2 testing

PLoS One. 2021 May 4;16(5):e0251214. doi: 10.1371/journal.pone.0251214.

SARS-CoV-2感染の再燃が疑われる例の頻度を検討したコホート研究
David McEvoy, Conor McAloon, Aine Collins et al.

Relative infectiousness of asymptomatic SARS-CoV-2 infected persons compared with symptomatic individuals: a rapid scoping review

BMJ Open. 2021 May 4;11(5):e042354. doi: 10.1136/bmjopen-2020-042354.

無症状病原体保有者と発症者の感染性の比較についてのスコーピングレビュー
Rohini Mathur, Christopher T Rentsch, Caroline E Morton et al.

Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform

Lancet. 2021 May 8;397(10286):1711-1724. doi: 10.1016/S0140-6736(21)00634-6.

英国National Health ServiceのOpenSAFELY platformを利用した人種関連の重症化リスク因子解析
Juan Ambrosioni, José Luis Blanco, Juliana M Reyes-Urueña et al.

Overview of SARS-CoV-2 infection in adults living with HIV

Lancet HIV. 2021 May;8(5):e294-e305. doi: 10.1016/S2352-3018(21)00070-9.

HIV陽性者におけるSARS-CoV-2感染についてのナラティブレビュー
RECOVERY Collaborative Group

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0.

COVID-19入院例に対するトシリズマブの有効性を評価したランダム化比較試験（RECOVERY trial）
Mark W Tenforde, Samantha M Olson, Wesley H Self et al.

Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years - United States, January-March 2021

MMWR Morb Mortal Wkly Rep. 2021 May 7;70(18):674-679. doi: 10.15585/mmwr.mm7018e1.

米国における65歳以上のCOVID-19入院症例に対するPfizer社製およびModerna社製の新型コロナワクチンの有効性（2021年1月～3月）
Anne M Hause, Julianne Gee, Tara Johnson et al.

Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination - Five U.S. Mass Vaccination Sites, April 2021

MMWR Morb Mortal Wkly Rep. 2021 May 7;70(18):685-688. doi: 10.15585/mmwr.mm7018e3.

米国おけるJanssen社製の新型コロナワクチン接種後の不安障害の症例集積（2021年4月）
David K Shay, Julianne Gee, John R Su et al.

Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021

MMWR Morb Mortal Wkly Rep. 2021 May 7;70(18):680-684. doi: 10.15585/mmwr.mm7018e2.

米国おけるJanssen社製の新型コロナワクチン接種の安全性モニタリング報告（2021年3月-4月）
Paul Wilmes, Jacques Zimmer, Jasmin Schulz et al.

SARS-CoV-2 transmission risk from asymptomatic carriers: Results from a mass screening programme in Luxembourg

Lancet Reg Health Eur. 2021 May;4:100056. doi: 10.1016/j.lanepe.2021.100056.

ルクセンブルクにおける全居住者と外国人労働者を対象とした新型コロナウイルスのマススクリーニングの結果
April 2021
Bradley K Ackerson, Lina S Sy, Sungching C Glenn et al.

Pediatric Vaccination During the COVID-19 Pandemic

Pediatrics. 2021 Apr 15;e2020047092. doi: 10.1542/peds.2020-047092.

小児におけるルーチンの（麻疹など）ワクチン接種率が減少したままであり、今後追加的な対策が必要とする米国からの報告
Jenneke Leentjens, Thijs F van Haaps, Pieter F Wessels, Roger E G Schutgens, Saskia Middeldorp

COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year

Lancet Haematol. 2021 Apr 27;S2352-3026(21)00105-8. doi: 10.1016/S2352-3026(21)00105-8.

COVID-19関連の凝固障害と抗血栓薬に関するナラティブレビュー
Cristina Menni, Kerstin Klaser, Anna May et al.

Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study

Lancet Infect Dis. 2021 Apr 27;S1473-3099(21)00224-3. doi: 10.1016/S1473-3099(21)00224-3.

英国におけるアプリを利用した新型コロナワクチンの副反応および接種後感染を検討した前向き観察研究
Leticia Monin, Adam G Laing, Miguel Muñoz-Ruiz et al.

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

Lancet Oncol. 2021 Apr 27;S1470-2045(21)00213-8. doi: 10.1016/S1470-2045(21)00213-8.

担癌患者におけるファイザー社製の新型コロナワクチン（BNT162b2）の安全性と免疫原性を評価した前向きコホート研究の中間解析
Jessica J Bartoszko, Reed A C Siemieniuk, Elena Kum et al.

Prophylaxis against covid-19: living systematic review and network meta-analysis

BMJ. 2021 Apr 26;373:n949. doi: 10.1136/bmj.n949.

COVID-19の予防薬に関するシステマティックレビュー・ネットワークメタアナリシス
David Aguilera-Alonso, Sara Murias, Amelia Martínez-de-Azagra Garde et al.

Prevalence of thrombotic complications in children with SARS-CoV-2

Arch Dis Child. 2021 Apr 30;archdischild-2020-321351. doi: 10.1136/archdischild-2020-321351.

小児のSARS-CoV-2感染における血栓性の合併症の疫学と臨床像
Ido Somekh, Lital Keinan Boker, Tamy Shohat et al.

Comparison of COVID-19 Incidence Rates Before and After School Reopening in Israel

JAMA Netw Open. 2021 Apr 1;4(4):e217105. doi: 10.1001/jamanetworkopen.2021.7105.

イスラエルでの学校再開前後のCOVID-19発生率の比較による、学生の年齢層ごとの地域流行に与える影響の検討
Lucie Renoud, Charles Khouri, Bruno Revol et al.

Association of Facial Paralysis With mRNA COVID-19 Vaccines: A Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database

JAMA Intern Med. 2021 Apr 27;e212219. doi: 10.1001/jamainternmed.2021.2219.

顔面神経麻痺とmRNAベースの新型コロナワクチン接種の関連
Mikael Norman, Lars Navér, Jonas Söderling et al.

Association of Maternal SARS-CoV-2 Infection in Pregnancy With Neonatal Outcomes

JAMA. 2021 Apr 29;e215775. doi: 10.1001/jama.2021.5775.

妊娠中の母親のSARS-CoV-2感染と新生児の転帰との相関
Isaac See, John R Su, Allison Lale et al.

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021

JAMA. 2021 Apr 30;e217517. doi: 10.1001/jama.2021.7517.

Janssen社製の新型コロナワクチン（Ad26.COV2.S）接種後の脳静脈洞血栓症の症例集積
Susannah L McKay, Farrell A Tobolowsky, Erin D Moritz et al.

Performance Evaluation of Serial SARS-CoV-2 Rapid Antigen Testing During a Nursing Home Outbreak

Ann Intern Med. 2021 Apr 27. doi: 10.7326/M21-0422.

介護施設でのクラスターにおける抗原検査の有用性
Toni M Delorey, Carly G K Ziegler, Graham Heimberg et al.

COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets

Nature. 2021 Apr 29. doi: 10.1038/s41586-021-03570-8.

COVID-19患者の組織の単一細胞解析
Johannes C Melms, Jana Biermann, Huachao Huang et al.

A molecular single-cell lung atlas of lethal COVID-19

Nature. 2021 Apr 29. doi: 10.1038/s41586-021-03569-1.

COVID-19患者の組織の単一細胞解析
Rafael Dal-Ré, Walter Orenstein, Arthur L Caplan

Being fair to participants in placebo-controlled COVID-19 vaccine trials

Nat Med. 2021 Apr 26. doi: 10.1038/s41591-021-01338-1.

新型コロナワクチンのプラセボを使用したランダム化比較試験におけるプラセボ群への倫理的配慮についての論説
Ravindra K Gupta

Will SARS-CoV-2 variants of concern affect the promise of vaccines?

Nat Rev Immunol. 2021 Apr 29;1-2. doi: 10.1038/s41577-021-00556-5.

新規変異株の出現と新型コロナワクチン接種による今後の展望に関する論説
Deborah Cromer, Jennifer A Juno, David Khoury et al.

Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection

Nat Rev Immunol. 2021 Apr 29;1-10. doi: 10.1038/s41577-021-00550-x.

SARS-CoV-2に対する免疫の持続と再感染の予防についてのナラティブレビュー・論説
Justin Lessler, M Kate Grabowski, Kyra H Grantz et al.

Household COVID-19 risk and in-person schooling

Science. 2021 Apr 29;eabh2939. doi: 10.1126/science.abh2939.

対面授業実施による家庭内でのSARS-CoV-2感染リスクと学校における種々の感染対策の実施程度による感染リスクを解析した大規模アンケート調査
Catherine J Reynolds, Corinna Pade, Joseph M Gibbons et al.

Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose

Science. 2021 Apr 30;eabh1282. doi: 10.1126/science.abh1282.

SARS-CoV-2従来株への既感染者における新型コロナワクチン一回接種後の変異株に対する免疫応答
Jessica R MacNeil, John R Su, Karen R Broder et al.

Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021

MMWR Morb Mortal Wkly Rep. 2021 Apr 30;70(17):651-656. doi: 10.15585/mmwr.mm7017e4.

米国におけるJanssen社製の新型コロナワクチン接種後の血小板減少症を伴う血栓症の副反応に関連した当該ワクチンの使用についての予防接種の実施に関する諮問委員会（ACIP）による勧告
Kenneth A Feder, Marcia Pearlowitz, Alexandra Goode et al.

Linked Clusters of SARS-CoV-2 Variant B.1.351 - Maryland, January-February 2021

MMWR Morb Mortal Wkly Rep. 2021 Apr 30;70(17):627-631. doi: 10.15585/mmwr.mm7017a5.

米国で最初に発生した南アフリカで最初に探知された新規変異株（B.1.351系統）によるクラスター
Sujin Yum, Kwan Hong, Sangho Sohn, Jeehyun Kim, Byung Chul Chun

Trends in Viral Respiratory Infections During COVID-19 Pandemic, South Korea

Emerg Infect Dis. 2021 Apr 29;27(6). doi: 10.3201/eid2706.210135.

韓国におけるCOVID-19パンデミック下での呼吸器感染ウイルスの陽性率の推移
Elisa Teyssou, Cathia Soulie, Benoit Visseaux et al.

The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients

J Infect. 2021 Apr 28;S0163-4453(21)00211-5. doi: 10.1016/j.jinf.2021.04.023.

従来株、英国で最初に検出された新規変異株（501Y.V1）、南アフリカで最初に検出された新規変異株（501Y.V2）における鼻咽頭におけるウイルスRNA量の比較
Dimple Y Chudasama, Joe Flannagan, Simon M Collin et al.

Household clustering of SARS-CoV-2 variant of concern B.1.1.7 (VOC-202012-01) in England

J Infect. 2021 Apr 29;S0163-4453(21)00216-4. doi: 10.1016/j.jinf.2021.04.029.

イギリスにおける従来株と英国で最初に検出された新規変異株（B.1.1.7）の家庭内感染の比較
Melanie D Swift, Laura E Breeher, Aaron J Tande et al.

Effectiveness of mRNA COVID-19 vaccines against SARS-CoV-2 infection in a cohort of healthcare personnel

Clin Infect Dis. 2021 Apr 26;ciab361. doi: 10.1093/cid/ciab361.

米国メイヨークリニックの医療従事者のおけるmRNAワクチン2回接種の有効性評価
Manish C Choudhary, Charles R Crain, Xueting Qiu, William Hanage, Jonathan Z Li

SARS-CoV-2 Sequence Characteristics of COVID-19 Persistence and Reinfection

Clin Infect Dis. 2021 Apr 27;ciab380. doi: 10.1093/cid/ciab380.

SARS-CoV-2持続陽性または再感染者におけるSARS-CoV-2のウイルスゲノム解析のシステマティックレビュー
Lisa Müller, Marcel Andrée, Wiebke Moskorz et al.

Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination

Clin Infect Dis. 2021 Apr 27;ciab381. doi: 10.1093/cid/ciab381.

60歳以下と80歳以上の年齢群で比較したPfizer社製の新型コロナワクチン（BNT162b2）接種後の抗体応答
Jennifer R Chevinsky, Guoyu Tao, Amy M Lavery et al.

Late conditions diagnosed 1-4 months following an initial COVID-19 encounter: a matched cohort study using inpatient and outpatient administrative data - United States, March 1-June 30, 2020

Clin Infect Dis. 2021 Apr 28;ciab338. doi: 10.1093/cid/ciab338.

COVID-19患者と非COVID-19患者において発症1～4ヶ月後の後遺症を比較したマッチドコホート研究
Tom T Shimabukuro, Shin Y Kim, Tanya R Myers et al.

Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons

N Engl J Med. 2021 Apr 21. doi: 10.1056/NEJMoa2104983.

米国の妊婦における新型コロナワクチンの安全性に関するサーベイランス報告
Jerald Sadoff, Glenda Gray, An Vandebosch et al.

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

N Engl J Med. 2021 Apr 21. doi: 10.1056/NEJMoa2101544.

Janssen/Johnson and Johnson社製の新型コロナワクチン（Ad26.COV2）の安全性と有効性を評価した第3相臨床試験
Ezgi Hacisuleyman, Caryn Hale, Yuhki Saito et al.

Vaccine Breakthrough Infections with SARS-CoV-2 Variants

N Engl J Med. 2021 Apr 21. doi: 10.1056/NEJMoa2105000.

新型コロナワクチン接種後の変異ウイルス感染者の症例報告
Eleftheria Vasileiou, Colin R Simpson, Ting Shi et al.

Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study

Lancet. 2021 May 1;397(10285):1646-1657. doi: 10.1016/S0140-6736(21)00677-2.

スコットランドにおける新型コロナワクチン導入とCOVID-19による入院率の相関を検討した国レベルの前向きコホート研究
Victoria Jane Hall, Sarah Foulkes, Ayoub Saei et al.

COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study

Lancet. 2021 Apr 23;S0140-6736(21)00790-X. doi: 10.1016/S0140-6736(21)00790-X.

英国の医療従事者におけるファイザー社製の新型コロナワクチン（BNT162b2）の有効性を評価した多施設前向きコホート研究（SIREN studyの部分解析）
Alexandra L Kondratiuk, Timesh D Pillay, Onn Min Kon, Ajit Lalvani

A conceptual framework to accelerate the clinical impact of evolving research into long COVID

Lancet Infect Dis. 2021 Apr 22;S1473-3099(21)00136-5. doi: 10.1016/S1473-3099(21)00136-5.

COVID-19後遺症（long COVID）の研究の推進のための概念的な枠組み
Paul A Goepfert, Bo Fu, Anne-Laure Chabanon et al.

Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study

Lancet Infect Dis. 2021 Apr 19;S1473-3099(21)00147-X. doi: 10.1016/S1473-3099(21)00147-X.

サノフィパスツール社製の新型コロナワクチン（CoV2 preS dTM）の第1-2相臨床試験
Keith J Chappell, Francesca L Mordant, Zheyi Li et al.

Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial

Lancet Infect Dis. 2021 Apr 19;S1473-3099(21)00200-0. doi: 10.1016/S1473-3099(21)00200-0.

豪州クイーンズランド大学の作製した新型コロナワクチンの第1相臨床試験
Asimenia Angelidou, Katherine Sullivan, Patrice R Melvin et al.

Association of Maternal Perinatal SARS-CoV-2 Infection With Neonatal Outcomes During the COVID-19 Pandemic in Massachusetts

JAMA Netw Open. 2021 Apr 1;4(4):e217523. doi: 10.1001/jamanetworkopen.2021.7523.

周産期における母親のSARS-CoV-2感染しと新生児のアウトカムとの相関
José Villar, Shabina Ariff, Robert B Gunier et al.

Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study

JAMA Pediatr. 2021 Apr 22. doi: 10.1001/jamapediatrics.2021.1050.

妊娠時のSARS-CoV-2感染の有無による妊婦および新生児への影響を検討した前向きコホート研究
Christina D Mack, John DiFiori, Caroline G Tai et al.

SARS-CoV-2 Transmission Risk Among National Basketball Association Players, Staff, and Vendors Exposed to Individuals With Positive Test Results After COVID-19 Recovery During the 2020 Regular and Postseason

JAMA Intern Med. 2021 Apr 22. doi: 10.1001/jamainternmed.2021.2114.

米国プロバスケットボール協会（NBA）関係者の陽性例で隔離解除されたがPCRが持続して陽性であった者からの2次感染リスクを検討した後ろ向きコホート研究
Ziyad Al-Aly, Yan Xie, Benjamin Bowe

High-dimensional characterization of post-acute sequalae of COVID-19

Nature. 2021 Apr 22. doi: 10.1038/s41586-021-03553-9.

米国の退役軍人の電子カルテデータを使用したCOVID-19の急性期後の臓器別アウトカムの非COVID-19患者との比較
Prabhu S Arunachalam, Alexandra C Walls, Nadia Golden et al.

Adjuvanting a subunit COVID-19 vaccine to induce protective immunity

Nature. 2021 Apr 19. doi: 10.1038/s41586-021-03530-2.

アカゲザルモデルにおけるアジュバント数種類を付加したサブユニットワクチンの免疫原性を評価した前臨床試験
Hagai Rossman, Smadar Shilo, Tomer Meir et al.

COVID-19 dynamics after a national immunization program in Israel

Nat Med. 2021 Apr 19. doi: 10.1038/s41591-021-01337-2.

イスラエルにおける新型コロナワクチン導入後のSARS-CoV-2感染者の推移
Ani Nalbandian, Kartik Sehgal, Aakriti Gupta et al.

Post-acute COVID-19 syndrome

Nat Med. 2021 Apr;27(4):601-615. doi: 10.1038/s41591-021-01283-z.

COVID-19後遺症（post-acute COVID-19 syndrome）のナラティブレビュー
Peter C Taylor, Andrew C Adams, Matthew M Hufford et al.

Neutralizing monoclonal antibodies for treatment of COVID-19

Nat Rev Immunol. 2021 Apr 19;1-12. doi: 10.1038/s41577-021-00542-x.

COVID-19の治療用のモノクローナル抗体のナラティブレビュー
Steven Riley, Kylie E C Ainslie, Oliver Eales et al.

Resurgence of SARS-CoV-2: detection by community viral surveillance

Science. 2021 Apr 23;eabf0874. doi: 10.1126/science.abf0874.

英国における自己拭いを利用したSARS-CoV-2の市中サーベイランス（REACT-1）
Stefania Capone, Angelo Raggioli, Michela Gentile et al.

Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19

Mol Ther. 2021 Apr 22;S1525-0016(21)00210-0. doi: 10.1016/j.ymthe.2021.04.022.

マウスやサルを用いたゴリラアデノウイルスベクターベースの新型コロナワクチンの免疫原性を評価した前臨床試験
Jérémy Dufloo, Ludivine Grzelak, Isabelle Staropoli et al.

Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies

Cell Rep Med. 2021 Apr 20;S2666-3791(21)00103-8. doi: 10.1016/j.xcrm.2021.100275.

COVID-19症候性患者と無症候性患者の免疫反応の比較
Xianding Deng, Miguel A Garcia-Knight, Mir M Khalid et al.

Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant

Cell. 2021 Apr 20;S0092-8674(21)00505-5. doi: 10.1016/j.cell.2021.04.025.

米国カリフォルニア州で最初に検出されたL452R変異を含むB.1.427/B.1.429系統の新規変異株の感染性や従来株で誘導された抗体のこれらの変異株に対する中和能
Watts L Dietrich, James S Bennett, Byron W Jones, Mohammad H Hosni

Laboratory Modeling of SARS-CoV-2 Exposure Reduction Through Physically Distanced Seating in Aircraft Cabins Using Bacteriophage Aerosol - November 2020

MMWR Morb Mortal Wkly Rep. 2021 Apr 23;70(16):595-599. doi: 10.15585/mmwr.mm7016e1.

SARS-CoV-2のサロゲートとしてのバクテリオファージのエアロゾルによる飛行機内での座席配置ごとの曝露
Richard A Teran, Kelly A Walblay, Elizabeth L Shane et al.

Postvaccination SARS-CoV-2 Infections Among Skilled Nursing Facility Residents and Staff Members - Chicago, Illinois, December 2020-March 2021

MMWR Morb Mortal Wkly Rep. 2021 Apr 30;70(17):632-638. doi: 10.15585/mmwr.mm7017e1.

米国シカゴにおける介護福祉施設での新型コロナワクチン接種後感染の症例集積
Alyson M Cavanaugh, Sarah Fortier, Patricia Lewis et al.

COVID-19 Outbreak Associated with a SARS-CoV-2 R.1 Lineage Variant in a Skilled Nursing Facility After Vaccination Program - Kentucky, March 2021

MMWR Morb Mortal Wkly Rep. 2021 Apr 30;70(17):639-643. doi: 10.15585/mmwr.mm7017e2.

米国の高齢者福祉施設におけるR.1系統のSARS-CoV-2に関連したアウトブレイク
Arnaud Fontanet, Laura Tondeur, Rebecca Grant et al.

SARS-CoV-2 infection in schools in a northern French city: a retrospective serological cohort study in an area of high transmission, France, January to April 2020

Euro Surveill. 2021 Apr;26(15). doi: 10.2807/1560-7917.ES.2021.26.15.2001695.

フランスにおける感染者が報告された高校と同じ市の小学校での血清疫学調査
Cintia Cruz, Nicholas J. White

COVID-19 chemoprevention

Int J Infect Dis. 2021 Apr 23;S1201-9712(21)00356-8. doi: 10.1016/j.ijid.2021.04.045.

SARS-CoV-2感染の予防内服薬候補に関するナラティブレビュー
Mario Martín-Sánchez, Wey Wen Lim, Amy Yeung et al.

COVID-19 transmission in Hong Kong despite universal masking

J Infect. 2021 Apr 22;S0163-4453(21)00205-X. doi: 10.1016/j.jinf.2021.04.019.

香港におけるマスクを使用していないと考えられる状況で起きた感染の疫学的特徴
Ziad A Memish, Abdulrahman Alharthy, Saleh A Alqahtani, Dimitrios Karakitsos

COVID-19 air travel restrictions and vaccine passports: An ongoing debate

Travel Med Infect Dis. 2021 Apr 20;42:102049. doi: 10.1016/j.tmaid.2021.102049.

空路による移動制限とワクチンパスポートに関する議論についての論説
Aparna Dressler, Iris Finci, Christiane Wagner-Wiening, Martin Eichner, Stefan O Brockmann

Epidemiological analysis of 3,219 COVID-19 outbreaks in the state of Baden-Wuerttemberg, Germany

Epidemiol Infect. 2021 Apr 23;1-18. doi: 10.1017/S0950268821000911.

ドイツにおけるCOVID-19アウトブレイク3219事例の疫学的解析
Adnan I Qureshi, William I Baskett, Wei Huang et al.

Re-infection with SARS-CoV-2 in Patients Undergoing Serial Laboratory Testing

Clin Infect Dis. 2021 Apr 25;ciab345. doi: 10.1093/cid/ciab345.

SARS-CoV-2感染からの回復後90日以上経過してから検査を受け再度陽性となった、再感染疑いの割合と再感染疑い例の疫学的特徴
Nandan Gautam, Shyam Madathil, Natascia Tahani et al.

Medium-term outcome of severe to critically ill patients with SARS-CoV-2 infection

Clin Infect Dis. 2021 Apr 24;ciab341. doi: 10.1093/cid/ciab341.

重症COVID-19患者の中期的予後
Nirbachita Biswas, Toheeb Mustapha, Jagdish Khubchandani, James H Price

The Nature and Extent of COVID-19 Vaccination Hesitancy in Healthcare Workers

J Community Health. 2021 Apr 20;1-8. doi: 10.1007/s10900-021-00984-3.

医療従事者におけるワクチン忌避に関するスコーピングレビュー
Sara J Abdallah, Nha Voduc, Vicente F Corrales-Medina et al.

Symptoms, Pulmonary Function and Functional Capacity Four Months after COVID-19

Ann Am Thorac Soc. 2021 Apr 19. doi: 10.1513/AnnalsATS.202012-1489RL.

入院歴別のCOVID-19罹患後3－4ヵ月後の心肺機能についての比較
Ayelet Grupper, Liane Rabinowich, Doron Schwartz et al.

Reduced humoral response to mRNA SARS-Cov-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus

Am J Transplant. 2021 Apr 18. doi: 10.1111/ajt.16615.

SARS‐Cov‐2感染既往のない腎移植レシピエントにおけるファイザー社製の新型コロナワクチン（BNT162b2）接種後の低程度の液性免疫反応
Marie Scully, Deepak Singh, Robert Lown et al.

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

N Engl J Med. 2021 Apr 16. doi: 10.1056/NEJMoa2105385.

アストラゼネカ社製ワクチン（ChAdOx1 nCoV-19）接種後の血小板第4因子に対する病的抗体について
Kate-Lynn Muir, Avyakta Kallam, Scott A Koepsell, Krishna Gundabolu

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination

N Engl J Med. 2021 Apr 14. doi: 10.1056/NEJMc2105869.

Jansen/J&Jのワクチン（Ad26.COV2.S）接種後に血栓性血小板減少を呈した症例の報告
Jerald Sadoff, Kourtney Davis, Macaya Douoguih

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination - Response from the Manufacturer

N Engl J Med. 2021 Apr 16. doi: 10.1056/NEJMc2106075.

Jansen/J&Jのワクチン（Ad26.COV2.S）接種後の血栓性血小板減少についてー製造会社の見解
Gabriele Anichini, Chiara Terrosi, Claudia Gandolfo et al.

SARS-CoV-2 Antibody Response in Persons with Past Natural Infection

N Engl J Med. 2021 Apr 14. doi: 10.1056/NEJMc2103825.

SARS-CoV-2既感染者と未感染者におけるファイザー社製の新型コロナワクチン（BNT162b2）接種後の抗体応答
Trisha Greenhalgh, Jose L Jimenez, Kimberly A Prather et al.

Ten scientific reasons in support of airborne transmission of SARS-CoV-2

Lancet. 2021 Apr 15;S0140-6736(21)00869-2. doi: 10.1016/S0140-6736(21)00869-2.

SARS-CoV-2のエアロゾル感染を示唆する科学的根拠についての論説
Andrew G Letizia, Yongchao Ge, Sindhu Vangeti et al.

SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study

Lancet Respir Med. 2021 Apr 15;S2213-2600(21)00158-2. doi: 10.1016/S2213-2600(21)00158-2.

若年成人層における血清抗体の有無と再感染のリスク（前向きコホート研究）
Baoying Huang, Lianpan Dai, Hui Wang et al.

Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2

Lancet Microbe. 2021 Apr 13. doi: 10.1016/S2666-5247(21)00082-3.

中国の新型コロナワクチン（BBIBP-CorV、ZF2001）接種者の血清の南アフリカで最初に検出された新規変異株（501Y.V2）に対する中和価
Nicole Ngai Yung Tsang, Hau Chi So, Ka Yan Ng et al.

Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis

Lancet Infect Dis. 2021 Apr 12;S1473-3099(21)00146-8. doi: 10.1016/S1473-3099(21)00146-8.

検体の種類とRT-PCR検査の精度に関するシステマティックレビュー・メタアナリシス
Dan Frampton, Tommy Rampling, Aidan Cross et al.

Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study

Lancet Infect Dis. 2021 Apr 12;S1473-3099(21)00170-5. doi: 10.1016/S1473-3099(21)00170-5.

英国で最初に検出された新規変異株（B.1.1.7）の臨床的特徴、ウイルス量と重症度への影響を調査した英国における病院ベースのコホート研究
Woo-Jung Song, Christopher K M Hui, James H Hull et al.

Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses

Lancet Respir Med. 2021 Apr 12;S2213-2600(21)00125-9. doi: 10.1016/S2213-2600(21)00125-9.

COVIDによる急性期/遷延性の咳やポストCOVID症候群におよぼすウイルスの向神経性、神経炎症および神経免疫反応
Mark S Graham, Carole H Sudre, Anna May et al.

Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study

Lancet Public Health. 2021 Apr 12;S2468-2667(21)00055-4. doi: 10.1016/S2468-2667(21)00055-4.

英国で最初に検出された新規変異株（B.1.1.7）に関連する臨床上の変化、再感染、感染性の変化を調査したエコロジカル研究
Joseph G Allen, Andrew M Ibrahim

Indoor Air Changes and Potential Implications for SARS-CoV-2 Transmission

JAMA. 2021 Apr 16. doi: 10.1001/jama.2021.5053.

換気とSARS-CoV-2の伝播に関する論説
Emily E Sickbert-Bennett, James M Samet, Steven E Prince et al.

Fitted Filtration Efficiency of Double Masking During the COVID-19 Pandemic

JAMA Intern Med. 2021 Apr 16. doi: 10.1001/jamainternmed.2021.2033.

二重マスクによるろ過効率の向上
Sivan Haia Perl, Atara Uzan-Yulzari, Hodaya Klainer et al.

SARS-CoV-2-Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women

JAMA. 2021 Apr 12. doi: 10.1001/jama.2021.5782.

ファイザー社製の新型コロナワクチン（BNT162b2）接種後の母乳中の抗体価（IgG、IgA）
Alexey Stukalov, Virginie Girault, Vincent Grass et al.

Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV

Nature. 2021 Apr 12. doi: 10.1038/s41586-021-03493-4.

培養細胞におけるSARS-CoV-2とSARS-CoV感染のプロテオーム解析
Manon Ragonnet-Cronin, Olivia Boyd, Lily Geidelberg et al.

Genetic evidence for the association between COVID-19 epidemic severity and timing of non-pharmaceutical interventions

Nat Commun. 2021 Apr 12;12(1):2188. doi: 10.1038/s41467-021-22366-y.

57か国における流行状況と各種感染対策のタイミングの相関のモデリング
Jean-Louis Excler, Melanie Saville, Seth Berkley, Jerome H Kim

Vaccine development for emerging infectious diseases

Nat Med. 2021 Apr 12;27(4):591-600. doi: 10.1038/s41591-021-01301-0.

新興感染症に対するワクチン開発についてのナラティブレビュー
Nuno R Faria, Thomas A Mellan, Charles Whittaker et al.

Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil

Science. 2021 Apr 14;eabh2644. doi: 10.1126/science.abh2644.

ブラジルからの帰国者において日本で最初に検出された新規変異株（P.1）のブラジル・マナウスにおける疫学とモデリング
Sedighe Karimzadeh, Raj Bhopal, Nguyen Tien Huy

Review of infective dose, routes of transmission, and outcome of COVID-19 caused by the SARS-COV-2: comparison with other respiratory viruses

Epidemiol Infect. 2021 Apr 14;1-22. doi: 10.1017/S0950268821000790.

動物モデルにおけるSARS-CoV-2やその他のウイルスの感染量などのナラティブレビュー
Sara Carazo, Denis Laliberté, Jasmin Villeneuve et al.

Characterization and evolution of infection control practices among SARS-CoV-2 infected healthcare workers of acute care hospitals and long-term care facilities in Quebec, Canada, Spring 2020

Infect Control Hosp Epidemiol. 2021 Apr 15;1-37. doi: 10.1017/ice.2021.160.

カナダ・ケベック州におけるSARS-CoV-2に感染した医療従事者・社会福祉施設従事者の感染対策等に関するアンケート調査
Leigh Smith, Sara M Karaba, Joe Amoah et al.

Hospital-Acquired Infections among Adult Patients Admitted for COVID-19

Infect Control Hosp Epidemiol. 2021 Apr 13;1-15. doi: 10.1017/ice.2021.148.

米国の医療機関におけるCOVID-19による入院患者における医療関連感染
Jenna R Gettings, Jeremy A W Gold, Anne Kimball et al.

SARS-CoV-2 transmission in a Georgia school district - United States, December 2020-January 2021

Clin Infect Dis. 2021 Apr 17;ciab332. doi: 10.1093/cid/ciab332.

米国ジョージア州における学校区におけるSARS-CoV-2感染事例
Katarina M Braun, Gage K Moreno, Ashley Buys et al.

Viral sequencing reveals US healthcare personnel rarely become infected with SARS-CoV-2 through patient contact

Clin Infect Dis. 2021 Apr 15;ciab281. doi: 10.1093/cid/ciab281.

医療従事者の感染例におけるウイルスゲノム解析による感染源の推定
Maureen Betton, Marine Livrozet, Delphine Planas et al.

Sera neutralizing activities against SARS-CoV-2 and multiple variants six month after hospitalization for COVID-19

Clin Infect Dis. 2021 Apr 14;ciab308. doi: 10.1093/cid/ciab308.

COVID-19入院患者の6ヶ月後の血清による各種変異株（D614G、B.1.1.7、P.1、B.1.351）に対する中和価
Laura Ford, Christine Lee, Ian W Pray et al.

Epidemiologic characteristics associated with SARS-CoV-2 antigen-based test results, rRT-PCR cycle threshold values, subgenomic RNA, and viral culture results from university testing

Clin Infect Dis. 2021 Apr 13;ciab303. doi: 10.1093/cid/ciab303.

鼻腔検体を用いた抗原検査、PCR検査、subgenomic RNA、ウイルス分離の結果と疫学的・臨床的特徴との相関
Christine M Thomas, Amy K Liebman, Alma Galván, Jonathan D Kirsch, William M Stauffer

Ensuring COVID-19 Vaccines for Migrant and Immigrant Farmworkers

Am J Trop Med Hyg. 2021 Apr 13;tpmd210199. doi: 10.4269/ajtmh.21-0199.

移民や移住労働者への新型コロナワクチン導入についての論説
Rishi R Goel, Sokratis A Apostolidis, Mark M Painter et al.

Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination

Sci Immunol. 2021 Apr 15;6(58):eabi6950. doi: 10.1126/sciimmunol.abi6950.

既感染者と未感染者におけるmRNAベースの新型コロナワクチン接種後の抗体・メモリーB細胞応答
Sanaz Sohrabizadeh, Shiva Yousefian, Amirhosein Bahramzadeh, Mohammad Hossein Vaziri

A systematic review of health sector responses to the coincidence of disasters and COVID-19

BMC Public Health. 2021 Apr 13;21(1):709. doi: 10.1186/s12889-021-10806-9.

災害とCOVID-19が同時発生した場合の医療保健機関の対応に関するシステマティックレビュー
Andreas Greinacher, Thomas Thiele, Theodore E Warkentin et al.

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

N Engl J Med. 2021 Apr 9. doi: 10.1056/NEJMoa2104840.

アストラゼネカ社製のワクチン（ChAdOx1 nCoV-19）接種後の血栓性血小板減少について
Xiaoying Shen, Haili Tang, Rolando Pajon et al.

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351

N Engl J Med. 2021 Apr 7. doi: 10.1056/NEJMc2103740.

SARS-CoV-2新規変異ウイルス（B.1.429とB.1.351系統）で認めるスパイクタンパク変異を導入したシュードタイプウイルスを用いた、回復者血清やワクチン接種者（Moderna, Novavax社製）の中和試験
Nicole Doria-Rose, Mehul S Suthar, Mat Makowski et al.

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

N Engl J Med. 2021 Apr 6. doi: 10.1056/NEJMc2103916.

モデルナ社製の新型コロナワクチン（mRNA-1273）二回接種後6ヶ月の抗体持続について（第1相臨床試験の追跡結果）
Guo-Lin Wang, Zhuang-Ye Wang, Li-Jun Duan et al.

Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization

N Engl J Med. 2021 Apr 6. doi: 10.1056/NEJMc2103022.

SARS-CoV-2新規変異ウイルスで認めるスパイクタンパク変異を導入したシュードタイプウイルスを用いた、回復者血清やワクチン接種者（Sinopharm, Sinovac社製）の中和試験
Thandeka Moyo-Gwete, Mashudu Madzivhandila, Zanele Makhado et al.

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)

N Engl J Med. 2021 Apr 7. doi: 10.1056/NEJMc2104192.

SARS-CoV-2 501Y.V2(B.1.351)感染によって誘導された従来株や501Y.V3(P.1)に対する中和抗体の交差反応について
Yaniv Lustig, Ital Nemet, Limor Kliker et al.

Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2

N Engl J Med. 2021 Apr 7. doi: 10.1056/NEJMc2104036.

既感染者におけるBNT162b2ワクチン1回接種後の複数のウイルス系統への中和反応
Nina H Schultz, Ingvild H Sørvoll, Annika E Michelsen et al.

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

N Engl J Med. 2021 Apr 9. doi: 10.1056/NEJMoa2104882.

アストラゼネカ社製のワクチン（ChAdOx1 nCoV-19）接種後の血栓性血小板減少について2
Victoria Jane Hall, Sarah Foulkes, Andre Charlett et al.

SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)

Lancet. 2021 Apr 9;S0140-6736(21)00675-9. doi: 10.1016/S0140-6736(21)00675-9.

イギリスの医療従事者を対象とした、抗体陰性者と抗体陽性者のSARS-CoV2感染率の比較（大規模多施設前向きコホート研究SIREN)
Sanjay Ramakrishnan, Dan V Nicolau Jr, Beverly Langford et al.

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial

Lancet Respir Med. 2021 Apr 9;S2213-2600(21)00160-0. doi: 10.1016/S2213-2600(21)00160-0.

COVID-19感染初期の治療法としての吸入ブデソニドの効果を検討した第2相非盲検化ランダム比較試験
Victor M Corman, Verena Claudia Haage, Tobias Bleicker et al.

Comparison of seven commercial SARS-CoV-2 rapid point-of-care antigen tests: a single-centre laboratory evaluation study

Lancet Microbe. 2021 Apr 7. doi: 10.1016/S2666-5247(21)00056-2.

抗原検査キット7種類の性能評価
Maxime Taquet, John R Geddes, Masud Husain, Sierra Luciano, Paul J Harrison

6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records

Lancet Psychiatry. 2021 Apr 1;S2215-0366(21)00084-5. doi: 10.1016/S2215-0366(21)00084-5.

COVID-19感染6ヶ月後の精神神経症状について
Baha Abdalhamid, Peter C Iwen, Michael R Wiley, Catherine B Pratt, Steven H Hinrichs

Genome Analysis for Sequence Variants in SARS-CoV-2 Among Asymptomatic Individuals in a Long-term Care Facility

JAMA Netw Open. 2021 Apr 1;4(4):e217939. doi: 10.1001/jamanetworkopen.2021.7939.

高齢者施設における無症状者のSARS-CoV-2ゲノム解析結果
Leigh Ellyn Preston, Jennifer R Chevinsky, Lyudmyla Kompaniyets et al.

Characteristics and Disease Severity of US Children and Adolescents Diagnosed With COVID-19

JAMA Netw Open. 2021 Apr 1;4(4):e215298. doi: 10.1001/jamanetworkopen.2021.5298.

アメリカにおけるCOVID-19に感染した18歳未満の患者の特徴と重症度
Kevin A Brown, Jonathan Gubbay, Jessica Hopkins et al.

S-Gene Target Failure as a Marker of Variant B.1.1.7 Among SARS-CoV-2 Isolates in the Greater Toronto Area, December 2020 to March 2021

JAMA. 2021 Apr 8. doi: 10.1001/jama.2021.5607.

カナダ・トロントにおけるS-gene target failureを利用したB.1.1.7系統の経時的推移
Lyn Finelli, Vikas Gupta, Tanaz Petigara et al.

Mortality Among US Patients Hospitalized With SARS-CoV-2 Infection in 2020

JAMA Netw Open. 2021 Apr 1;4(4):e216556. doi: 10.1001/jamanetworkopen.2021.6556.

アメリカにおける2020年のSARS-CoV-2感染による死亡率の推移
Sebastian Havervall, Axel Rosell, Mia Phillipson et al.

Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers

JAMA. 2021 Apr 7. doi: 10.1001/jama.2021.5612.

医療従事者の中等症COVID-19罹患の8ヵ月における症状と機能障害
Lawrence O Gostin, I Glenn Cohen, Jana Shaw

Digital Health Passes in the Age of COVID-19: Are "Vaccine Passports" Lawful and Ethical?

JAMA. 2021 Apr 7. doi: 10.1001/jama.2021.5283.

「ワクチンパスポート」の法的・倫理的観点からの論説
Ta-Chou Ng, Hao-Yuan Cheng, Hsiao-Han Chang et al.

Comparison of Estimated Effectiveness of Case-Based and Population-Based Interventions on COVID-19 Containment in Taiwan

JAMA Intern Med. 2021 Apr 6. doi: 10.1001/jamainternmed.2021.1644.

台湾における患者への措置と一般集団への措置の効果を比較したモデリング
Ermias D Belay, Joseph Abrams, Matthew E Oster et al.

Trends in Geographic and Temporal Distribution of US Children With Multisystem Inflammatory Syndrome During the COVID-19 Pandemic

JAMA Pediatr. 2021 Apr 6. doi: 10.1001/jamapediatrics.2021.0630.

米国における小児多臓器炎症症候群の地理的、時間的分布
Johanna Chapin-Bardales, Julianne Gee, Tanya Myers

Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines

JAMA. 2021 Apr 5. doi: 10.1001/jama.2021.5374.

mRNAベースの新型コロナワクチン被接種者における副反応
Óscar Moreno-Pérez, Mariano Andrés, José Manuel León-Ramirez et al.

The COVID-GRAM Tool for Patients Hospitalized With COVID-19 in Europe

JAMA Intern Med. 2021 Apr 5. doi: 10.1001/jamainternmed.2021.0491.

中国で作られたCOVID-19入院患者の重症化予測ツール（COVID-GRAM ）のスペインの第1波の症例での後ろ向き評価
Nareg H Roubinian, Jennifer R Dusendang, Dustin G Mark et al.

Incidence of 30-Day Venous Thromboembolism in Adults Tested for SARS-CoV-2 Infection in an Integrated Health Care System in Northern California

JAMA Intern Med. 2021 Apr 5. doi: 10.1001/jamainternmed.2021.0488.

SARS-CoV-2の検査を受けた成人における30日感の静脈血栓塞栓症の発症率
S Shahzad Mustafa, Allison Ramsey, Mary L Staicu

Administration of a Second Dose of the Moderna COVID-19 Vaccine After an Immediate Hypersensitivity Reaction With the First Dose: Two Case Reports

Ann Intern Med. 2021 Apr 6. doi: 10.7326/L21-0104.

モデルナ社製新型コロナワクチンの初回接種後に即時型アレルギーを呈した症例への2回目接種の方法（段階的接種）に関する2症例の報告
N Ahmad Aziz, Victor M Corman, Antje K C Echterhoff et al.

Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany

Nat Commun. 2021 Apr 9;12(1):2117. doi: 10.1038/s41467-021-22351-5.

SARS-CoV-2の中和抗体価と関連する因子や症状についての血清疫学調査（ドイツ・ボン）
Michal A Stanczak, David E Sanin, Petya Apostolova et al.

IL-33 expression in response to SARS-CoV-2 correlates with seropositivity in COVID-19 convalescent individuals

Nat Commun. 2021 Apr 9;12(1):2133. doi: 10.1038/s41467-021-22449-w.

SARS-CoV-2に反応したIL-33発現は、COVID-19回復期患者の抗体と関連している
Ane Ogbe, Barbara Kronsteiner, Donal T Skelly et al.

T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses

Nat Commun. 2021 Apr 6;12(1):2055. doi: 10.1038/s41467-021-21856-3.

有症状、無症状のSARS-CoV-2感染者および未感染者におけるT細胞応答の違い
Aldo Bonaventura, Alessandra Vecchié, Lorenzo Dagna et al.

Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19

Nat Rev Immunol. 2021 Apr 6;1-11. doi: 10.1038/s41577-021-00536-9.

COVID-19の主要な発症機序としての、内皮細胞機能不全と免疫学的血栓形成
Tim Flerlage, David F Boyd, Victoria Meliopoulos, Paul G Thomas, Stacey Schultz-Cherry

Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract

Nat Rev Microbiol. 2021 Apr 6;1-17. doi: 10.1038/s41579-021-00542-7.

インフルエンザウイルスとSARS-CoV-2の気道における病態と宿主の応答についてのナラティブレビュー
Fan Yang, Sandra C A Nielsen, Ramona A Hoh et al.

Shared B cell memory to coronaviruses and other pathogens varies in human age groups and tissues

Science. 2021 Apr 12;eabf6648. doi: 10.1126/science.abf6648.

コロナウイルスや他のウイルスに対する共通のメモリーB細胞
Laura K Stein, Naomi A Mayman, Mandip S Dhamoon, Johanna T Fifi

The emerging association between COVID-19 and acute stroke

Trends Neurosci. 2021 Apr 8;S0166-2236(21)00071-0. doi: 10.1016/j.tins.2021.03.005.

COVID-19と脳卒中との関連に関するナラティブレビュー
Matthew K Siggins, Ryan S Thwaites, Peter J M Openshaw

Durability of immunity to SARS-CoV-2 and other respiratory viruses

Trends Microbiol. 2021 Apr 8;S0966-842X(21)00092-5. doi: 10.1016/j.tim.2021.03.016.

SARS-CoV-2とその他の呼吸器ウイルスにおける獲得免疫とこの持続性についてのナラティブレビュー
Peter A C Wing, Thomas P Keeley, Xiaodong Zhuang et al.

Hypoxic and pharmacological activation of HIF inhibits SARS-CoV-2 infection of lung epithelial cells

Cell Rep. 2021 Apr 5. doi: 10.1016/j.celrep.2021.109020.

肺上皮細胞におけるSARS-CoV-2感染における低酸素誘導因子（HIF）の関与とHIF阻害薬による治療
Samira Sami, Caitlin R Turbyfill, Shelby Daniel-Wayman et al.

Community Transmission of SARS-CoV-2 Associated with a Local Bar Opening Event - Illinois, February 2021

MMWR Morb Mortal Wkly Rep. 2021 Apr 9;70(14):528-532. doi: 10.15585/mmwr.mm7014e3.

バーのオープニングイベントにおけるクラスターと地域への二次感染事例（米国イリノイ州）
Anthea L Katelaris, Jessica Wells, Penelope Clark et al.

Epidemiologic Evidence for Airborne Transmission of SARS-CoV-2 during Church Singing, Australia, 2020

Emerg Infect Dis. 2021 Apr 5;27(6). doi: 10.3201/eid2706.210465.

教会での合唱によるエアロゾル感染が疑われたクラスター
Mina Park, Colleen Pawliuk, Tribesty Nguyen et al.

Determining the communicable period of SARS-CoV-2: A rapid review of the literature, March to September 2020

Euro Surveill. 2021 Apr;26(14):2001506. doi: 10.2807/1560-7917.ES.2021.26.14.2001506.

SARS-CoV-2の感染性のある期間についてのラピッドレビュー
Isabelle Sermet-Gaudelus, Sarah Temmam, Christèle Huon et al.

Prior infection by seasonal coronaviruses, as assessed by serology, does not prevent SARS-CoV-2 infection and disease in children, France, April to June 2020

Euro Surveill. 2021 Apr;26(13):2001782. doi: 10.2807/1560-7917.ES.2021.26.13.2001782.

小児における季節性コロナウイルス感染で誘導された抗体のSARS-CoV-2感染に対する防御の欠如
Cristiano Donadio, Antonio Rainone, Adéline Gouronnec, JoëlBelmin, Carmelo Lafuente –Lafuente

Asymptomatic COVID-19 cases among older patients despite BNT162b2 vaccination: a case series in a geriatric rehabilitation ward during an outbreak.

J Infect. 2021 Apr 11. doi: 10.1016/j.jinf.2021.04.004.

高齢者リハビリテーション施設でのクラスターにおけるファイザー社製のワクチン（BNT161b2）接種後感染患者
Danielle L Silva, Caroline M Lima, Vanessa C R Magalhães et al.

Fungal and bacterial coinfections increase mortality of severely ill COVID-19 patients

J Hosp Infect. 2021 Apr 11. doi: 10.1016/j.jhin.2021.04.001.

COVID-19重症例における細菌または真菌による共感染における死亡オッズの増加
Jan C Semenza, Cornelia Adlhoch, Agoritsa Baka et al.

COVID-19 research priorities for non-pharmaceutical public health and social measures

Epidemiol Infect. 2021 Apr 5;149:e87. doi: 10.1017/S0950268821000716.

ECDCによる公衆衛生的社会的対策に関する研究における研究のプライオリティの評価
Elizabeth Wenqian Wang, Jacqueline G Parchem, Robert L Atmar, Eva Clark

SARS-CoV-2 Vaccination During Pregnancy: A Complex Decision

Open Forum Infect Dis. 2021 Apr 10:ofab180. doi: 10.1093/ofid/ofab180.

妊婦への新型コロナワクチン接種についてのナラティブレビュー・論説
Nick K Jones, Lucy Rivett, Shaun Seaman et al.

Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection

Elife. 2021 Apr 8;10:e68808. doi: 10.7554/eLife.68808.

ファイザー社製の新型コロナワクチン（BNT162b2）の一回接種での無症候性感染への有効性の検討
Kevin A Brown, Jean-Paul R Soucy, Sarah A Buchan et al.

The mobility gap: estimating mobility thresholds required to control SARS-CoV-2 in Canada

CMAJ. 2021 Apr 7;cmaj.210132. doi: 10.1503/cmaj.210132.

カナダにおける人流と感染者数との相関
Kevin E McVaney, Paul E Pepe, Lauren M Maloney et al.

The relationship of large city out-of-hospital cardiac arrests and the prevalence of COVID-19

EClinicalMedicine. 2021 Apr 7. doi: 10.1016/j.eclinm.2020.100815.

院外心停止症例の増加と地域でのCOVID-19の流行の相関
Paul Aveyard, Min Gao, Nicola Lindson et al.

Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study

Lancet Respir Med. 2021 Apr 1;S2213-2600(21)00095-3. doi: 10.1016/S2213-2600(21)00095-3.

基礎疾患の呼吸器疾患への治療薬使用状況とCOVID-19重症化との関連（一般集団におけるコホート研究）
Steven H Woolf, Derek A Chapman, Roy T Sabo, Emily B Zimmerman

Excess Deaths From COVID-19 and Other Causes in the US, March 1, 2020, to January 2, 2021

JAMA. 2021 Apr 2. doi: 10.1001/jama.2021.5199.

2020年3月1日から2021年1月2日までのアメリカにおけるCOVID-19とその他の原因による超過死亡の解析結果
William F. Parker, Govind Persad, Monica E. Peek

Fair Allocation at COVID-19 Mass Vaccination Sites

JAMA Health Forum. 2021 Apr 2; 2(4):e210464. doi: 10.1001/jamahealthforum.2021.0464.

アメリカのCOVID-19ワクチン集団接種会場で公正にワクチンを分配し、接種する方法について
Gery P Guy Jr, Greta M Massetti, Erin Sauber-Schatz

Mask Mandates, On-Premises Dining, and COVID-19

JAMA. 2021 Apr 1. doi: 10.1001/jama.2021.5455.

マスクの義務化と屋内飲食がCOVID-19感染に与える影響
Josh Banerjee, Catherine P Canamar, Christian Voyageur et al.

Mortality and Readmission Rates Among Patients With COVID-19 After Discharge From Acute Care Setting With Supplemental Oxygen

JAMA Netw Open. 2021 Apr 1;4(4):e213990. doi: 10.1001/jamanetworkopen.2021.3990.

在宅酸素で退院したCOVID-19患者の死亡率と再入院率について
Joseph E Ebinger, Justyna Fert-Bober, Ignat Printsev et al.

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2

Nat Med. 2021 Apr 1. doi: 10.1038/s41591-021-01325-6.

SARS-COV-2既感染者におけるファイザーワクチン（BNT162b2）接種後の抗体応答
Sebastian Günther, Patrick Y A Reinke, Yaiza Fernández-García et al.

X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease

Science. 2021 Apr 2;eabf7945. doi: 10.1126/science.abf7945.

X線結晶構造解析を用いたSARS-CoV-2のメインプロテアーゼの活性部位とアロステリック部位の阻害剤の同定
Carl Graham, Jeffrey Seow, Isabella Huettner et al.

Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant

Immunity. 2021 Apr 1. doi: 10.1016/j.immuni.2021.03.023.

SARS-CoV-2のスパイクのドミナントおよびサブドミナントエピトープを認識するモノクローナル抗体の中和能はイギリスで最初に検出された新規変異株（B.1.1.7）により影響をうける
Whitney E. Harrington, Olesya Trakhimets, Daniela V. Andrade et al.

Rapid decline of neutralizing antibodies is associated with decay of IgM in adults recovered from mild COVID-19 disease

Cell Rep Med. 2021 Apr 1. doi: 10.1016/j.xcrm.2021.100253.

軽症COVID-19回復例における中和抗体価の急速な減衰はIgM抗体価の減衰と関連する
Marco Mandolesi, Daniel J. Sheward, Leo Hanke et al.

SARS-CoV-2 protein subunit vaccination of mice and rhesus macaques elicits potent and durable neutralizing antibody responses

Cell Rep Med. 2021 Apr 1. doi: 10.1016/j.xcrm.2021.100252.

マウスおよびアカゲザルモデルを利用したサブユニットワクチン候補の前臨床試験
Tyler N Starr, Allison J Greaney, Adam S Dingens, Jesse D Bloom

Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016

Cell Rep Med. 2021 Apr 1. doi: 10.1016/j.xcrm.2021.100255.

モノクローナル抗体LY-CoV555およびLY-CoV016とのカクテルを回避するSARS-CoV-2変異に関する報告
Dan Davidi, Susan Fitzgerald, Hannah L. Glaspell et al.

Amplicon residues in research laboratories masquerade as COVID-19 in surveillance tests

Cell Rep Methods. 2021 Apr 2. doi: 10.1016/j.crmeth.2021.100005.

PCRの増幅産物であるアンプリコンの残存物によるPCRの偽陽性
Mark G Thompson, Jefferey L Burgess, Allison L Naleway et al.

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021

MMWR Morb Mortal Wkly Rep. 2021 Apr 2;70(13):495-500. doi: 10.15585/mmwr.mm7013e3.

米国の医療従事者におけるmRNAベースの新型コロナワクチンの有効性評価（中間報告）
Jemma L. Geoghegan, Jordan Douglas, Xiaoyun Ren et al.

Use of Genomics to Track Coronavirus Disease Outbreaks, New Zealand

Emerg Infect Dis. 2021 Apr 1;27(5). doi: 10.3201/eid2705.204579.

ニュージーランドにおけるSARS-CoV-2ゲノム解析
Hanna Y. Ehrlich, Adora Harizaj, Lauren Campbell et al.

SARS-CoV-2 in Nursing Homes after 3 Months of Serial, Facilitywide Point Prevalence Testing, Connecticut, USA

Emerg Infect Dis. 2021 Apr 1;27(5). doi: 10.3201/eid2705.204936.

米国コネチカット州の高齢者福祉施設における施設全体の経時的なスクリーニング
Natalia Fintelman-Rodrigues, Aline P D da Silva, Monique Cristina Dos Santos et al.

Genetic Evidence and Host Immune Response in Persons Reinfected with SARS-CoV-2, Brazil

Emerg Infect Dis. 2021 Apr 2;27(5). doi: 10.3201/eid2705.204912.

ブラジルにおける再感染例のウイルスゲノム解析と抗体応答
Sindhu B Naidu, Amar J Shah, Anita Saigal et al.

The high mental health burden of "Long COVID" and its association with on-going physical and respiratory symptoms in all adults discharged from hospital

Eur Respir J. 2021 Apr 1;2004364. doi: 10.1183/13993003.04364-2020.

COVID-19後遺症における精神症状の頻度とこの身体症状との相関
Amihai Rottenstreich, Gila Zarbiv, Esther Oiknine-Djian et al.

Efficient maternofetal transplacental transfer of anti- SARS-CoV-2 spike antibodies after antenatal SARS-CoV-2 BNT162b2 mRNA vaccination

Clin Infect Dis. 2021 Apr 3;ciab266. doi: 10.1093/cid/ciab266.

ワクチン接種を受けた母親から生まれた新生児はIgG陽性となり、周産期でのワクチン接種によって母子の感染防御が期待できる
Michael Schuit, Jennifer Biryukov, Katie Beck et al.

The stability of an isolate of the SARS-CoV-2 B.1.1.7 lineage in aerosols is similar to three earlier isolates

J Infect Dis. 2021 Apr 2;jiab171. doi: 10.1093/infdis/jiab171.

英国で最初に検出された新規変異株（B.1.1.7）と従来株のエアロゾル中での安定性の比較
Ignacio Mazzitelli, Lucia Bleichmar, María Guillermina Ludueña et al.

IgG immune complexes may contribute to neutrophil activation in the course of severe COVID-19

J Infect Dis. 2021 Apr 2;jiab174. doi: 10.1093/infdis/jiab174.

COVID-19重症例においてIgG免疫複合体が好中球活性化と相関
M J A Reid, P Prado, H Brosnan et al.

Assessing testing strategies and duration of quarantine in contact tracing for SARS-CoV-2: a retrospective study of San Francisco’s COVID-19 contact tracing program, June- August, 2020

Open Forum Infect Dis. 2021 Apr 2:ofab171. doi: 10.1093/ofid/ofab171.

米国サンフランシスコにおける接触者追跡の後ろ向き解析（2020年6-8月）
Sean Wei Xiang Ong, Siew-Wai Fong, Barnaby Edward Young et al.

Persistent symptoms and association with inflammatory cytokine signatures in recovered COVID-19 patients

Open Forum Infect Dis. 2021 Apr 2:ofab156. doi: 10.1093/ofid/ofab156.

COVID-19回復者における遷延する症状と相関する炎症性サイトカインの特徴
Li Guo, Yeming Wang, Liang Kang et al.

Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study

Emerg Microbes Infect. 2021 Apr 2;10(1):664-676. doi: 10.1080/22221751.2021.1905488.

季節性コロナウイルス（OC43）とSARS-CoV-2の交差免疫とCOVID-19重症度の相関を検討した後ろ向き研究
The Lancet Neurology

Long COVID: understanding the neurological effects

Lancet Neurol. 2021 Apr;20(4):247. doi: 10.1016/S1474-4422(21)00059-4.

COVID-19の神経学的後遺症についての論説
Anna Jeffery-Smith, Kate Dun-Campbell, Roshni Janarthanan et al.

Infection and transmission of SARS-CoV-2 in London care homes reporting no cases or outbreaks of COVID-19: Prospective observational cohort study, England 2020

Lancet Reg Health Eur. 2021 Apr;3:100038. doi: 10.1016/j.lanepe.2021.100038.

イギリス・ロンドンにおける第一波の際に新型コロナウイルス感染やクラスターの報告のなかった高齢者福祉施設での潜在的な感染や伝播についてのコホート研究
March 2021
Kai Wu, Anne P Werner, Matthew Koch et al.

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine

N Engl J Med. 2021 Mar 17. doi: 10.1056/NEJMc2102179.

モデルナ社製の新型コロナワクチン（mRNA-1273）で誘導される抗体のシュードタイプウイルスに対する中和活性
Andreza Francisco Martins, Alexandre Prehn Zavascki, Priscila Lamb Wink et al.

Detection of SARS-CoV-2 lineage P.1 in patients from a region with exponentially increasing hospitalisation rate, February 2021, Rio Grande do Sul, Southern Brazil

Euro Surveill. 2021 Mar;26(12):2100276. doi: 10.2807/1560-7917.ES.2021.26.12.2100276.

ブラジルで最初に検出された変異株（P.1系統）の流行と感染者数の急増について
Jamie Lopez Bernal, Mary A Sinnathamby, Suzanne Elgohari et al.

The impact of social and physical distancing measures on COVID-19 activity in England: findings from a multi-tiered surveillance system

Euro Surveill. 2021 Mar;26(11):2001062. doi: 10.2807/1560-7917.ES.2021.26.11.2001062.

英国における複数のサーベイランスシステムを用いたphysical distancingの有効性の検討
Inessa Markus, Gyde Steffen, Raskit Lachmann et al.

COVID-19: cross-border contact tracing in Germany, February to April 2020

Euro Surveill. 2021 Mar;26(10):2001236. doi: 10.2807/1560-7917.ES.2021.26.10.2001236.

ドイツにおける国境をまたいだ接触者追跡調査
Kamelia R Stanoeva, Annemiek A van der Eijk, Adam Meijer et al.

Towards a sensitive and accurate interpretation of molecular testing for SARS-CoV-2: a rapid review of 264 studies

Euro Surveill. 2021 Mar;26(10):2001134. doi: 10.2807/1560-7917.ES.2021.26.10.2001134.

核酸検査についてのラピッドレビュー
Mark A Hall, David M Studdert

"Vaccine Passport" Certification - Policy and Ethical Considerations

N Engl J Med. 2021 Mar 31. doi: 10.1056/NEJMp2104289.

「ワクチンパスポート」の政策や倫理的検討事項に関する論説
Sandra C Quinn, Michele P Andrasik

Addressing Vaccine Hesitancy in BIPOC Communities - Toward Trustworthiness, Partnership, and Reciprocity

N Engl J Med. 2021 Mar 31. doi: 10.1056/NEJMp2103104.

BIPOC(黒人・先住民・有色人種)コミュニティのワクチン忌避への対応ー信頼、パートナーシップ、互恵関係の構築に関する論説
Harriet Forbes, Caroline E Morton, Seb Bacon et al.

Association between living with children and outcomes from covid-19: OpenSAFELY cohort study of 12 million adults in England

BMJ. 2021 Mar 18;372:n628. doi: 10.1136/bmj.n628.

OpenSAFELYプラットフォームを用いた小児との同居とSARS-CoV-2感染、COVID-19重症化、死亡のアウトカムとの相関
Peter C Jentsch, Madhur Anand, Chris T Bauch

Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study

Lancet Infect Dis. 2021 Mar 31;S1473-3099(21)00057-8. doi: 10.1016/S1473-3099(21)00057-8.

社会的疫学的背景による新型コロナワクチンの優先順位付け：数理モデル研究
Katherine R W Emary, Tanya Golubchik, Parvinder K Aley et al.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Lancet. 2021 Mar 30;S0140-6736(21)00628-0. doi: 10.1016/S0140-6736(21)00628-0.

VOC202012/01(B.1.1.7)に対するアストラゼネカ社製のChAdOx1 nCoV-19ワクチンの効果
Søren Dinesen Østergaard, Morten Schmidt, Erzsébet Horváth-Puhó, Reimar Wernich Thomsen, Henrik Toft Sørensen

Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence?

Lancet. 2021 Mar 30;S0140-6736(21)00762-5. doi: 10.1016/S0140-6736(21)00762-5.

デンマークにおける血栓塞栓症の罹患率から推定したアストラゼネカ社製新型コロナワクチン接種者における期待される血栓塞栓症患者数
Daniel Ayoubkhani, Kamlesh Khunti, Vahé Nafilyan et al.

Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study

BMJ. 2021 Mar 31;372:n693. doi: 10.1136/bmj.n693.

COVID-19で入院した患者のポストCOVID症候群について（後ろ向きコホート研究)
Louise E Smith, Henry W W Potts, Richard Amlôt et al.

Adherence to the test, trace, and isolate system in the UK: results from 37 nationally representative surveys

BMJ. 2021 Mar 31;372:n608. doi: 10.1136/bmj.n608.

イギリスにおけるCOVID-19検査や接触者調査、自主隔離システムの遵守に関するオンライン調査結果
Update to living systematic review on drug treatments for covid-19

BMJ. 2021 Mar 31;372:n858. doi: 10.1136/bmj.n858.

COVID-19治療薬のliving systematic reviewのアップデート（複数の治療薬についてのエビデンスを追加）
Update to living WHO guideline on drugs for covid-19

BMJ. 2021 Mar 31;372:n860. doi: 10.1136/bmj.n860.

WHOによるCOVID-19治療薬のliving guidanceのアップデート（イベルメクチンを推奨しないことを追加）
Jenny A Doust, Katy J L Bell, Mariska M G Leeflang et al.

Guidance for the design and reporting of studies evaluating the clinical performance of tests for present or past SARS-CoV-2 infection

BMJ. 2021 Mar 29;372:n568. doi: 10.1136/bmj.n568.

SARS-CoV-2の現在または過去の感染を検出するための検査の精度評価のデザインと報告についてのガイダンス
Hemalkumar B Mehta, Shuang Li, James S Goodwin

Risk Factors Associated With SARS-CoV-2 Infections, Hospitalization, and Mortality Among US Nursing Home Residents

JAMA Netw Open. 2021 Mar 1;4(3):e216315. doi: 10.1001/jamanetworkopen.2021.6315.

米国の老人ホーム入居者における、 SARS-CoV-2感染、入院、死亡に関連するリスク因子
Andrea M Lerner, Daphne A Robinson, Linda Yang et al.

Toward Understanding COVID-19 Recovery: National Institutes of Health Workshop on Postacute COVID-19

Ann Intern Med. 2021 Mar 30. doi: 10.7326/M21-1043.

COVID-19治癒経過の理解にむけて：米国国立衛生研究所によるPostacute COVID-19に関するワークショップの報告
Sandile Cele, Inbal Gazy, Laurelle Jackson et al.

Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma

Nature. 2021 Mar 29. doi: 10.1038/s41586-021-03471-w.

南アフリカ株で最初に検出された新規変異株（501Y.V2）の従来株感染後に誘導された抗体からの免疫逃避
André F Rendeiro, Hiranmayi Ravichandran, Yaron Bram et al.

The spatial landscape of lung pathology during COVID-19 progression

Nature. 2021 Mar 29. doi: 10.1038/s41586-021-03475-6.

COVID-19における肺の病理学的・免疫学的・分子生物学的解析
Matan Levine-Tiefenbrun, Idan Yelin, Rachel Katz et al.

Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine

Nat Med. 2021 Mar 29. doi: 10.1038/s41591-021-01316-7.

イスラエルにおける1回目のmRNAワクチン接種12日目以降のウイルスRNA量の減少について
Alain Townsend, Pramila Rijal, Julie Xiao et al.

A haemagglutination test for rapid detection of antibodies to SARS-CoV-2

Nat Commun. 2021 Mar 29;12(1):1951. doi: 10.1038/s41467-021-22045-y.

SARS-CoV-2感染後の血球凝集試験（HAT）を用いた抗体検査について
James D Munday, Katharine Sherratt, Sophie Meakin et al.

Implications of the school-household network structure on SARS-CoV-2 transmission under school reopening strategies in England

Nat Commun. 2021 Mar 29;12(1):1942. doi: 10.1038/s41467-021-22213-0.

英国における学年（初等教育・中等教育）に注目した学校再開の戦略
Chongwei Bi, Gerardo Ramos-Mandujano, Yeteng Tian et al.

Simultaneous Detection and Mutation Surveillance of SARS-CoV-2 and co-infections of multiple respiratory viruses by Rapid field-deployable sequencing

Med (N Y). 2021 Mar 31. doi: 10.1016/j.medj.2021.03.015.

SARS-CoV-2（変異株含む）や他の呼吸器ウイルスのフィールドで運用可能な病原体ゲノム解析
Halima A Shuwa, Tovah N Shaw, Sean B Knight et al.

Alterations in T and B cell function persist in convalescent COVID-19 patients

Med (N Y). 2021 Mar 31. doi: 10.1016/j.medj.2021.03.013.

COVID-19回復患者におけるT細胞及びB細胞の変化
Nicole L. Washington, Karthik Gangavarapu, Mark Zeller et al.

Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States

Cell. 2021 Mar 30. doi: 10.1016/j.cell.2021.03.052.

英国で最初に検出された新規変異株（B.1.1.7）変異株のアメリカでの疫学
Wanwisa Dejnirattisai, Daming Zhou, Piyada Supasa et al.

Antibody evasion by the P.1 strain of SARS-CoV-2

Cell. 2021 Mar 30. doi: 10.1016/j.cell.2021.03.055.

ブラジルからの渡航者において日本で最初に検出された新規変異株（P.1）における免疫逃避
Nancy Matic, Christopher F Lowe, Gordon Ritchie et al.

Rapid Detection of SARS-CoV-2 Variants of Concern, Including B.1.1.28/P.1, in British Columbia, Canada

Emerg Infect Dis. 2021 Mar 30;27(6). doi: 10.3201/eid2706.210532.

カナダのブリティッシュコロンビアにおけるPCRを用いた新規変異株スクリーニング
Ray Izquierdo-Lara, Goffe Elsinga, Leo Heijnen et al.

Monitoring SARS-CoV-2 Circulation and Diversity through Community Wastewater Sequencing, the Netherlands and Belgium

Emerg Infect Dis. 2021 Mar 31;27(5). doi: 10.3201/eid2705.204410.

オランダとベルギーにおける下水中のSARS-CoV-2 RNAゲノム解析
Andrew Jeremijenko, Hiam Chemaitelly, Houssein H. Ayoub et al.

Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar

Emerg Infect Dis. 2021 Mar 31;27(5). doi: 10.3201/eid2705.204365.

カタールにおける10の外国人労働者コミュニティにおける血清有病率
Patricia Nicole Wiegele, Iyad Kabar, Laura Kerschke et al.

Symptom Diary–Based Analysis of Disease Course among Patients with Mild Coronavirus Disease, Germany, 2020

Emerg Infect Dis. 2021 Mar 31;27(5). doi: 10.3201/eid2705.204507.

ドイツの軽症例313例における日誌を用いた症状経過のまとめ
Li Wang, Xiaoyu Fan, Gaston Bonenfant et al.

Susceptibility to SARS-CoV-2 of Cell Lines and Substrates Commonly Used to Diagnose and Isolate Influenza and Other Viruses

Emerg Infect Dis. 2021 Mar 31;27(5). doi: 10.3201/eid2705.210023.

インフルエンザや他の呼吸器ウイルスの分離に用いられる培養細胞のSARS-CoV-2への感受性
James Peng, Jamin Liu, Sabrina A Mann et al.

Estimation of secondary household attack rates for emergent spike L452R SARS-CoV-2 variants detected by genomic surveillance at a community-based testing site in San Francisco

Clin Infect Dis. 2021 Mar 31;ciab283. doi: 10.1093/cid/ciab283.

米国カリフォルニア州で最初に検出された変異株（B.1.427およびB.1.429）の家庭内二次感染率の従来株との比較
Ayten Gunduz, Murat Fırat, Gamze Turkoglu

Comparison of the Simultaneous Conjunctiva and Oropharynx-Nasopharynx Swab Results in Patients Applying to the SARS-CoV-2 Outpatient Clinic for the First Time

J Med Virol. 2021 Mar 30. doi: 10.1002/jmv.26981.

結膜スワブと鼻咽頭スワブによるSARS-COV2のPCR検出率、ウイルス量の比較
Qian He, Qunying Mao, Chaoqiang An et al.

Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates

Emerg Microbes Infect. 2021 Mar 29;10(1):629-637. doi: 10.1080/22221751.2021.1902245.

マウスモデルにおける中国の4種類のCOVID-19ワクチンの組み合わせによる中和抗体価
Lucie White, Philippe van Basshuysen

Privacy versus Public Health? A Reassessment of Centralised and Decentralised Digital Contact Tracing

Sci Eng Ethics. 2021 Mar 29;27(2):23. doi: 10.1007/s11948-021-00301-0.

接触者調査アプリのプライバシーへの配慮とその効果について
John M Kelso

Misdiagnosis of systemic allergic reactions to mRNA COVID-19 vaccines

Ann Allergy Asthma Immunol. 2021 Mar 26;S1081-1206(21)00257-X. doi: 10.1016/j.anai.2021.03.024.

mRNAベースの新型コロナワクチン接種後のアナフィラキシーと誤って診断された4症例
E Marchant, D Ready, G Wimbury et al.

Determining the acceptability of testing contacts of confirmed COVID-19 cases to improve secondary case ascertainment

J Public Health (Oxf). 2021 Mar 30;fdab079. doi: 10.1093/pubmed/fdab079.

濃厚接触者に対する検査の受容性について
Christelle Vauloup-Fellous, Sarah Maylin, Claire Périllaud-Dubois et al.

Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients

Eur J Clin Microbiol Infect Dis. 2021 Mar 29;1-7. doi: 10.1007/s10096-021-04232-3.

市販の抗体検査30種類の性能（感度・特異度）評価
Salim S Abdool Karim, Tulio de Oliveira

New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications

N Engl J Med. 2021 Mar 24. doi: 10.1056/NEJMc2100362.

新規変異株の臨床上、公衆衛生上、ワクチンへの影響に関する論説
Shmuel Benenson, Yonatan Oster, Matan J Cohen, Ran Nir-Paz

BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers

N Engl J Med. 2021 Mar 23. doi: 10.1056/NEJMc2101951.

イスラエルエルサレムの医療従事者におけるBNT162b2 mRNAワクチンの効果
William Daniel, Marc Nivet, John Warner, Daniel K Podolsky

Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center

N Engl J Med. 2021 Mar 23. doi: 10.1056/NEJMc2102153.

米国テキサス州の医療機関の従業員におけるmRNAワクチンの効果（速報）
Jocelyn Keehner, Lucy E Horton, Michael A Pfeffer et al.

SARS-CoV-2 Infection after Vaccination in Health Care Workers in California

N Engl J Med. 2021 Mar 23. doi: 10.1056/NEJMc2101927.

米国カリフォルニア州の医療従事者におけるるmRNAワクチン接種後のSARS-CoV-2 感染
Todd Bradley, Elin Grundberg, Rangaraj Selvarangan et al.

Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine

N Engl J Med. 2021 Mar 23. doi: 10.1056/NEJMc2102051.

SARS-CoV-2mRNAワクチン1回接種後の抗体反応
Yap Boum, Karl Njuwa Fai, Birgit Nicolay et al.

Performance and operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy study

Lancet Infect Dis. 2021 Mar 25;S1473-3099(21)00132-8. doi: 10.1016/S1473-3099(21)00132-8.

有症状・無症状のSARS-CoV-2感染者に対する、迅速抗原検査・迅速抗体検査の有用性や実用性に関する前向き研究（カメルーン）
Arjuna S Maharaj, Jennifer Parker, Jessica P Hopkins et al.

The effect of seasonal respiratory virus transmission on syndromic surveillance for COVID-19 in Ontario, Canada

Lancet Infect Dis. 2021 Mar 25;S1473-3099(21)00151-1. doi: 10.1016/S1473-3099(21)00151-1.

COVID-19の症候群サーベイランスへの、季節性呼吸器ウイルス感染症伝播の影響
Stephanie J Salyer, Justin Maeda, Senga Sembuche et al.

The first and second waves of the COVID-19 pandemic in Africa: a cross-sectional study

Lancet. 2021 Mar 24;S0140-6736(21)00632-2. doi: 10.1016/S0140-6736(21)00632-2.

アフリカにおけるCOVID-19第一波、第二波の発生状況（横断研究）
Colin Pawlowski, A J Venkatakrishnan, Eshwan Ramudu et al.

Pre-existing conditions are associated with COVID-19 patients' hospitalization, despite confirmed clearance of SARS-CoV-2 virus

EClinicalMedicine. 2021 Mar 23;100793. doi: 10.1016/j.eclinm.2021.100793.

SARS-CoV-2ウイルス排除が確認されたCOVID-19患者における、遷延する症状による再入院は、感染前の状態が関連しているとした研究報告
Wan-Mui Chan, Jonathan Daniel Ip, Allen Wing-Ho Chu et al.

Phylogenomic analysis of COVID-19 summer and winter outbreaks in Hong Kong: An observational study

Lancet Reg Health West Pac. 2021 May;10:100130. doi: 10.1016/j.lanwpc.2021.100130.

香港における2020年夏季および2020-2021年冬季のSARS-CoV-2ゲノム解析
Paul A Kristiansen, Mark Page, Valentina Bernasconi et al.

WHO International Standard for anti-SARS-CoV-2 immunoglobulin

Lancet. 2021 Mar 23;S0140-6736(21)00527-4. doi: 10.1016/S0140-6736(21)00527-4.

WHOによるSARS-CoV-2抗体の国際標準品について
Wan Ni Chia, Feng Zhu, Sean Wei Xiang Ong et al.

Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study

Lancet Microbe. 2021 Mar 23. doi: 10.1016/S2666-5247(21)00025-2.

SARS-CoV-2中和抗体の経時的動態と免疫能の持続期間：縦断的研究
Maura Boldrini, Peter D Canoll, Robyn S Klein

How COVID-19 Affects the Brain

JAMA Psychiatry. 2021 Mar 26. doi: 10.1001/jamapsychiatry.2021.0500.

COVID-19の脳への影響に関するナラティブレビュー
Domenico Luca Grieco, Luca S Menga, Melania Cesarano et al.

Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure: The HENIVOT Randomized Clinical Trial

JAMA. 2021 Mar 25. doi: 10.1001/jama.2021.4682.

COVID-19による中等度・重度の呼吸不全例におけるヘルメット式非侵襲的陽圧換気量法とナーザルハイフローの有効性を比較したランダム化比較試験
Jacqueline Dinnes, Jonathan J Deeks, Ada Adriano et al.

Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection

Cochrane Database Syst Rev. 2021 Mar 24;3:CD013705. doi: 10.1002/14651858.CD013705.pub2.

SARS-CoV-2診断のための迅速抗原検査や迅速核酸検査のシステマティックレビュー
Erik Volz, Swapnil Mishra, Meera Chand et al.

Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England

Nature. 2021 Mar 25. doi: 10.1038/s41586-021-03470-x.

英国公衆衛生庁による英国における SARS-CoV-2 B.1.1.7変異株の感染・伝播性性評価
Raoul De Gasparo, Mattia Pedotti, Luca Simonelli et al.

Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice

Nature. 2021 Mar 25. doi: 10.1038/s41586-021-03461-y.

二重特異性IgG様分子は新規変異株のシュードタイプウイルスを中和し、マウスにおいて発病予防し免疫逃避を抑制する
Delphine Planas, Timothée Bruel, Ludivine Grzelak et al.

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Nat Med. 2021 Mar 26. doi: 10.1038/s41591-021-01318-5.

感染者とワクチン接種者のSARS-CoV-2の新規変異株（B.1.1.7、B.1.351）に対する中和抗体反応
Ni Huang, Paola Pérez, Takafumi Kato et al.

SARS-CoV-2 infection of the oral cavity and saliva

Nat Med. 2021 Mar 25. doi: 10.1038/s41591-021-01296-8.

SARS-CoV-2感染者の口腔内組織の感染と免疫応答
Leonidas Stamatatos, Julie Czartoski, Yu-Hsin Wan et al.

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Science. 2021 Mar 25;eabg9175. doi: 10.1126/science.abg9175.

SARS-CoV-2既感染者に接種されたmRNAワクチンによる変異株のシュードタイプウイルスへの交差反応性を示す中和抗体の上昇
Shan Zhao, Nancy Schuurman, Wentao Li et al.

Serologic Screening of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Cats and Dogs during First Coronavirus Disease Wave, the Netherlands

Emerg Infect Dis. 2021 Mar 24;27(5). doi: 10.3201/eid2705.204055.

オランダで第1波に実施された猫と犬に対するSARS-CoV-2血清抗体価スクリーニングの結果
Tudor A. Codreanu, Sera Ngeh, Abigail Trewin, Paul K. Armstrong

Successful Control of an Onboard COVID-19 Outbreak Using the Cruise Ship as a Quarantine Facility, Western Australia

Emerg Infect Dis. 2021 Mar 24;27(5). doi: 10.3201/eid2705.204142.

クルーズ船で発生したCOVID-19アウトブレイクのコントロールに成功したオーストラリア西部の事例
Ricardo Rabagliati, Nicolás Rodríguez, Carolina Núñez et al.

COVID-19-Associated Mold Infection in Critically Ill Patients, Chile

Emerg Infect Dis. 2021 Mar 24;27(5). doi: 10.3201/eid2705.204412.

COVID-19関連真菌感染症に関する報告
Stéphanie Haim-Boukobza, Bénédicte Roquebert, Sabine Trombert-Paolantoni et al.

Detecting Rapid Spread of SARS-CoV-2 Variants, France, January 26-February 16, 2021

Emerg Infect Dis. 2021 Mar 26;27(5). doi: 10.3201/eid2705.210397.

フランスにおけるSARS-CoV-2変異株の感染拡大について（2021年1月26日~2月16日）
Caroline M Williams, Daniel Pan, Jonathan Decker et al.

Exhaled SARS-CoV-2 quantified by face-mask sampling in hospitalised patients with covid-19

J Infect. 2021 Mar 24;S0163-4453(21)00135-3. doi: 10.1016/j.jinf.2021.03.018.

呼気中のSARS-CoV-2定量的検出法と呼気中のRNA量と重症化リスクとの関連について
Peng Wu, Fengfeng Liu, Zhaorui Chang et al.

Assessing asymptomatic, pre-symptomatic and symptomatic transmission risk of SARS-CoV-2

Clin Infect Dis. 2021 Mar 27;ciab271. doi: 10.1093/cid/ciab271.

無症状、発症前、有症状での感染リスクの比較
Eric R A Vos, Michiel van Boven, Gerco den Hartog et al.

Associations between measures of social distancing and SARS-CoV-2 seropositivity: a nationwide population-based study in the Netherlands

Clin Infect Dis. 2021 Mar 27;ciab264. doi: 10.1093/cid/ciab264.

ソーシャルディスタンスなどの感染リスク因子を解析した血清疫学調査
Frederic Lamoth, Russell E Lewis, Thomas J Walsh, Dimitrios P Kontoyiannis

Navigating the uncertainties of COVID-19 associated aspergillosis (CAPA): A comparison with influenza associated aspergillosis (IAPA)

J Infect Dis. 2021 Mar 26;jiab163. doi: 10.1093/infdis/jiab163.

インフルエンザ関連肺アスペルギルス症とCOVID-19関連肺アスペルギルス症の臨床所見の違いについてのまとめ
Chang Kyung Kang, Minji Kim, Soojin Lee et al.

Longitudinal Analysis of Human Memory T-Cell Response according to the Severity of Illness up to 8 Months after SARS-CoV-2 Infection

J Infect Dis. 2021 Mar 23;jiab159. doi: 10.1093/infdis/jiab159.

SARS-CoV-2に対するメモリーT細胞の8ヶ月目までの持続性評価
Kieran Dee, Daniel M Goldfarb, Joanne Haney et al.

Human rhinovirus infection blocks SARS-CoV-2 replication within the respiratory epithelium: implications for COVID-19 epidemiology

J Infect Dis. 2021 Mar 23;jiab147. doi: 10.1093/infdis/jiab147.

培養細胞でのライノウイルスによるSARS-CoV-2感染の干渉
Julien Dupraz, Audrey Butty, Olivier Duperrex et al.

Prevalence of SARS-CoV-2 in household members and other close contacts of COVID-19 cases: a serologic study in canton of Vaud, Switzerland

Open Forum Infect Dis. 2021 Mar 26:ofab149. doi: 10.1093/ofid/ofab149.

COVID-19の家族内感染に対する血清疫学調査
Judith Malmgren, Boya Guo, Henry G Kaplan

Continued proportional age shift of confirmed positive COVID-19 incidence over time to children and young adults: Washington State March-August 2020

PLoS One. 2021 Mar 24;16(3):e0243042. doi: 10.1371/journal.pone.0243042.

米国ワシントン州におけるCOVID-19感染者の年代分布の推移について
Pasquale Stefanizzi, Andrea Martinelli, Davide Ferorelli et al.

Rapid decrease of SARS-COV-2 circulation in a big Italian Hospital 6 weeks after the start of the immunization program

J Hosp Infect. 2021 Mar 24;S0195-6701(21)00113-4. doi: 10.1016/j.jhin.2021.03.016.

イタリアの大病院における医療従事者の新型コロナワクチン接種後の流行減少
M Catherine McEllistrem, Cornelius J Clancy, Deanna J Buehrle, Aaron Lucas, Brooke K Decker

Single dose of a mRNA SARS-CoV-2 vaccine is associated with lower nasopharyngeal viral load among nursing home residents with asymptomatic COVID-19

Clin Infect Dis. 2021 Mar 26;ciab263. doi: 10.1093/cid/ciab263.

mRNAベースのワクチン1回接種と高齢者福祉施設の入居者の鼻咽頭ウイルスRNA量の相関
Markus Hoffmann, Prerna Arora, Rüdiger Groß et al.

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

Cell. 2021 Mar 20;S0092-8674(21)00367-6. doi: 10.1016/j.cell.2021.03.036.

新型コロナウイルスの新規変異株（B.1.351、P.1）で認める変異を導入したシュードタイプウイルスによる中和抗体の回避
Venkata Viswanadh Edara, Carson Norwood, Katharine Floyd et al.

Infection and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant

Cell Host Microbe. 2021 Mar 20;S1931-3128(21)00137-2. doi: 10.1016/j.chom.2021.03.009.

従来株感染後の回復者血清やModernaの新型コロナワクチン（mRNA-1273）で誘導される抗体による新規変異株（B.1.351）に対する中和価
Venkata Viswanadh Edara, William H Hudson, Xuping Xie, Rafi Ahmed, Mehul S Suthar

Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination

JAMA. 2021 Mar 19. doi: 10.1001/jama.2021.4388.

従来株感染後の回復者血清やModernaの新型コロナワクチン（mRNA-1273）で誘導される抗体による新規変異株（B.1.1.7）に対する中和価
Timothy Doyle, Katherine Kendrick, Thomas Troelstrup et al.

COVID-19 in Primary and Secondary School Settings During the First Semester of School Reopening - Florida, August-December 2020

MMWR Morb Mortal Wkly Rep. 2021 Mar 26;70(12):437-441. doi: 10.15585/mmwr.mm7012e2.

米国フロリダ州の小中高における生徒の新型コロナウイルス感染（2020年8月～12月）
Rebecca B Hershow, Karen Wu, Nathaniel M Lewis et al.

Low SARS-CoV-2 Transmission in Elementary Schools - Salt Lake County, Utah, December 3, 2020-January 31, 2021

MMWR Morb Mortal Wkly Rep. 2021 Mar 26;70(12):442-448. doi: 10.15585/mmwr.mm7012e3.

米国ユタ州の小学校で接触者となった生徒におけるの新型コロナウイルスの二次感染率（2020年12月3日～2021年1月31日）
Patrick Dawson, Mary Claire Worrell, Sara Malone et al.

Pilot Investigation of SARS-CoV-2 Secondary Transmission in Kindergarten Through Grade 12 Schools Implementing Mitigation Strategies - St. Louis County and City of Springfield, Missouri, December 2020

MMWR Morb Mortal Wkly Rep. 2021 Mar 26;70(12):449-455. doi: 10.15585/mmwr.mm7012e4.

米国ミズーリ州の幼稚園から高校における新型コロナウイルスの二次感染（2020年12月）
Kevin G Volpp, Bruce H Kraut, Smita Ghosh, John Neatherlin

Minimal SARS-CoV-2 Transmission After Implementation of a Comprehensive Mitigation Strategy at a School - New Jersey, August 20-November 27, 2020

MMWR Morb Mortal Wkly Rep. 2021 Mar 19;70(11):377-381. doi: 10.15585/mmwr.mm7011a2.

米国・ニュージャージー州の高校における定期スクリーニング検査等の施行と新型コロナウイルス感染（2020年8月20日～11月27日）
Xiaozhou Fan, Barbara H Johnson, Stephen S Johnston et al.

Monthly Trend in Mortality and Length of Stay among COVID-19 Patients: Analysis of a Nationwide Multi-Hospital United States Database

Infect Control Hosp Epidemiol. 2021 Mar 19;1-8. doi: 10.1017/ice.2021.110.

米国の複数病院のデータベースにおけるCOVID-19患者の死亡率と入院期間の推移
Romain Martischang, Anne Iten, Isabelle Arm et al.

SARS-CoV-2 seroconversion and occupational exposure of employees at a Swiss university hospital: a large longitudinal cohort study

Infect Control Hosp Epidemiol. 2021 Mar 19;1-53. doi: 10.1017/ice.2021.117.

スイスの大学病院職員における血清疫学調査（2020年3月～6月）
Cherie Faith Lopez Monsalud, Mary Frazier Greene Lind, Carolyn Hines et al.

Mitigating Staff Shortages: Risk of Permitting Healthcare Workers to Return to Work after COVID-19 Exposure

Infect Control Hosp Epidemiol. 2021 Mar 19;1-9. doi: 10.1017/ice.2021.121.

米国における新型コロナウイルス患者への低リスクの曝露のあった医療従事者における後の感染判明率
April N McDougal, Dana Elhassani, Mary Ann DeMaet et al.

Outbreak of SARS-CoV-2 Among Operating Room Staff of a Tertiary Referral Center: An Epidemiologic and Environmental Investigation

Infect Control Hosp Epidemiol. 2021 Mar 19;1-27. doi: 10.1017/ice.2021.116.

米国医療機関の手術室職員間で起きたアウトブレイクの接触者追跡・環境サンプリングなどを利用した調査
Belinda Ostrowsky, Lauren M Weil, Rho Olaisen et al.

Real-Time Virtual Infection Prevention and Control Assessments in Skilled Nursing Homes, New York, March 2020 - A Pilot Project

Infect Control Hosp Epidemiol. 2021 Mar 19;1-27. doi: 10.1017/ice.2021.100.

米国ニューヨーク州の介護施設における新型コロナウイルスに対するビデオ会議を使用した院内感染対策アセスメント
Vincent Chi-Chung Cheng, Shuk-Ching Wong, Danny Wah-Kun Tong et al.

Multi-pronged infection control strategy to achieve zero nosocomial COVID-19 infection among Hong Kong healthcare workers in the first 300 days of combat

Infect Control Hosp Epidemiol. 2021 Mar 19;1-39. doi: 10.1017/ice.2021.119.

香港における院内感染対策戦略
Javier Guzman, Tamara Hafner, Lalla Arkia Maiga, Ursula Giedion

COVID-19 vaccines pricing policy options for low-income and middle- income countries

BMJ Glob Health. 2021 Mar;6(3):e005347. doi: 10.1136/bmjgh-2021-005347.

低・中所得国における新型コロナワクチンの価格設定に関する政策
Rita M Meganck, Ralph S Baric

Developing Therapeutic Approaches for Twenty-First-Century Emerging Infectious Viral Diseases

Nat Med. 2021 Mar;27(3):401-410. doi: 10.1038/s41591-021-01282-0.

COVID-19を含む21世紀の新興感染症の治療アプローチの開発に関するナラティブレビュー
Shabir A Madhi, Vicky Baillie, Clare L Cutland et al.

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

N Engl J Med. 2021 Mar 16. doi: 10.1056/NEJMoa2102214.

新規変異株（B.1.351）に対するAstraZenecaの新型コロナワクチン（ChAdOx1 nCoV-19）の有効性
Maria Krutikov, Andrew Hayward, Laura Shallcross

Spread of a Variant SARS-CoV-2 in Long-Term Care Facilities in England

N Engl J Med. 2021 Mar 16. doi: 10.1056/NEJMc2035906.

英国の高齢者福祉施設における新規変異株（B.1.1.7）の流行状況
Zhenyu He, Lili Ren, Juntao Yang et al.

Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study

Lancet. 2021 Mar 20;397(10279):1075-1084. doi: 10.1016/S0140-6736(21)00238-5.

中国の武漢における血清有病率と液性免疫の持続性についての縦断研究
Christian Holm Hansen, Daniela Michlmayr, Sophie Madeleine Gubbels, Kåre Mølbak, Steen Ethelberg

Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study

Lancet. 2021 Mar 27;397(10280):1204-1212. doi: 10.1016/S0140-6736(21)00575-4.

デンマークにおける再感染への防御を評価した人口レベルの観察研究
Paul C Cremer, Antonio Abbate, Kristin Hudock et al.

Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial

Lancet Rheumatol. 2021 Mar 17. doi: 10.1016/S2665-9913(21)00070-9.

COVID-19中等症・重症例に対するマブリリムマブの有効性を評価したランダム化比較試験（MASH-COVID）
INSPIRATION Investigators

Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial

JAMA. 2021 Mar 18. doi: 10.1001/jama.2021.4152.

集中治療室に入室したCOVID-19患者における中用量と標準用量の予防的抗凝固療法の有効性を評価したランダム化比較試験
The Writing Committee for the COMEBAC Study Group

Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19

JAMA. 2021 Mar 17. doi: 10.1001/jama.2021.3331.

COVID-19入院例における4ヶ月後の臨床的転帰
Robert L Stout, Steven J Rigatti

Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020

JAMA Netw Open. 2021 Mar 1;4(3):e211552.

米国において過去に症状を認めなかった人口における血清有病率（2020年9月30日現在）
Ahmed O Hassan, Friederike Feldmann, Haiyan Zhao et al.

A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques

Cell Rep Med. 2021 Mar 18;100230. doi: 10.1016/j.xcrm.2021.100230.

アカゲザルにおけるチンパンジーアデノウイルスベクターベースの1回経鼻接種のみの新型コロナワクチン候補の有効性
Melissa K Siebach, Giovanni Piedimonte, Sylvia H Ley

COVID-19 in childhood: Transmission, clinical presentation, complications and risk factors

Pediatr Pulmonol. 2021 Mar 15. doi: 10.1002/ppul.25344.

小児におけるCOVID-19についてのナラティブレビュー：感染伝播、臨床像、合併症およびリスク因子
Megan M Sheehan, Anita J Reddy, Michael B Rothberg

Reinfection Rates among Patients who Previously Tested Positive for COVID-19: a Retrospective Cohort Study

Clin Infect Dis. 2021 Mar 15;ciab234. doi: 10.1093/cid/ciab234.

クリーブランドクリニックの電子カルテデータを用いて解析した新型コロナウイルスへの再感染率
Arunasingam Abayasingam, Harikrishnan Balachandran, David Agapiou et al.

Long-term persistence of RBD-positive memory B cells encoding neutralising antibodies in SARS-CoV-2 infection

Cell Rep Med. 2021 Mar 14;100228. doi: 10.1016/j.xcrm.2021.100228.

中和抗体をコードするメモリーB細胞の6ヶ月までの持続性評価
Nicola Cotugno, Alessandra Ruggiero, Francesco Bonfante et al.

Virological and immunological features of SARS-CoV-2-infected children who develop neutralizing antibodies

Cell Rep. 2021 Mar 16;34(11):108852. doi: 10.1016/j.celrep.2021.108852.

新型コロナウイルス感染小児における中和抗体を含めた免疫応答
Naveenchandra Suryadevara, Swathi Shrihari, Pavlo Gilchuk et al.

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

Cell. 2021 Mar 16;S0092-8674(21)00357-3. doi: 10.1016/j.cell.2021.03.029.

新型コロナウイルスのスパイクタンパクのN末端ドメインに対する中和活性のあるモノクローナル抗体
Matthew McCallum, Anna De Marco, Florian A Lempp et al.

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

Cell. 2021 Mar 16;S0092-8674(21)00356-1. doi: 10.1016/j.cell.2021.03.028.

新型コロナウイルスのスパイクタンパクのN末端ドメインのエピトープマッピング
Sarah A. Clark, Lars E. Clark, Junhua Pan et al.

SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms

Cell. 2021 Mar 16;S0092-8674(21)00355-X. doi: 10.1016/j.cell.2021.03.027.

免疫不全患者における新型コロナウイルスの免疫逃避
Polly van den Berg, Elissa M Schechter-Perkins, Rebecca S Jack et al.

Effectiveness of three versus six feet of physical distancing for controlling spread of COVID-19 among primary and secondary students and staff: A retrospective, state-wide cohort study

Clin Infect Dis. 2021 Mar 10;ciab230. doi: 10.1093/cid/ciab230.

小中高生や教職員における身体的距離（physical distancing）のポリシーを3フィート以上とした学校区と6フィート以上とした学校区での新型コロナウイルスの感染率の違い（米国マサチューセッツ州）
Aaron J Tande, Benjamin D Pollock, Nilay D Shah et al.

Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening

Clin Infect Dis. 2021 Mar 10;ciab229. doi: 10.1093/cid/ciab229.

米国の医療機関で処置前に行われるPCRスクリーニングにおける新型コロナワクチンの新型コロナウイルスの無症候感染の相対リスクへの影響を検討した後ろ向きコホート研究
Joseph A Lewnard, Katia J Bruxvoort, Heidi Fischer et al.

Prevention of COVID-19 among older adults receiving pneumococcal conjugate vaccine suggests interactions between Streptococcus pneumoniae and SARS-CoV-2 in the respiratory tract

J Infect Dis. 2021 Mar 9;jiab128. doi: 10.1093/infdis/jiab128.

高齢者における肺炎球菌ワクチン接種とCOVID-19罹患率の相関
Muluneh Alene, Leltework Yismaw, Moges Agazhe Assemie et al.

Serial interval and incubation period of COVID-19: a systematic review and meta-analysis

BMC Infect Dis. 2021 Mar 11;21(1):257. doi: 10.1186/s12879-021-05950-x.

COVID-19の発症間隔と潜伏期間に関するシステマティックレビュー・メタアナリシス
Jad A Elharake, Mehr Shafiq, SarahAnn M McFadden, Amyn A Malik, Saad B Omer

The Association of COVID-19 Risk Perception, County Death Rates, and Voluntary Health Behaviors among U.S. Adult Population

J Infect Dis. 2021 Mar 10;jiab131. doi: 10.1093/infdis/jiab131.

米国におけるCOVID-19による死亡率とリスク認識および（身体的距離等)自発的な感染対策との相関
Jay K Varma, Jeff Thamkittikasem, Katherine Whittemore et al.

COVID-19 Infections among Students and Staff in New York City Public Schools

Pediatrics. 2021 Mar 9;e2021050605. doi: 10.1542/peds.2021-050605.

米国ニューヨーク市の公立学校における生徒と教職員における新型コロナウイルス感染
Nicholas G Davies, Christopher I Jarvis, CMMID COVID-19 Working Group et al.

Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7

Nature. 2021 Mar 15. doi: 10.1038/s41586-021-03426-1.

Spike gene target failureのデータを用いた英国におけるB.1.1.7系統の新規変異株への感染による死亡率の上昇
Jasmin S Kutter, Dennis de Meulder, Theo M Bestebroer et al.

SARS-CoV and SARS-CoV-2 are transmitted through the air between ferrets over more than one meter distance

Nat Commun. 2021 Mar 12;12(1):1653. doi: 10.1038/s41467-021-21918-6.

フェレットを用いた1m以上離れたケージ間（1方向性の空気の流れあり）でSARSコロナウイルスと新型コロナウイルスの感染
Dami A Collier, Anna De Marco, Isabella A T M Ferreira et al.

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Nature. 2021 Mar 11. doi: 10.1038/s41586-021-03412-7.

Pfizerの新型コロナワクチン（BNT162b2）で誘導された抗体によるB.1.1.7系統の新規変異株で認めるスパイクタンパク変異±E484K変異を導入したシュードタイプウイルスの中和能評価。
Shuyuan Zhang, Shuyuan Qiao, Jinfang Yu et al.

Bat and pangolin coronavirus spike glycoprotein structures provide insights into SARS-CoV-2 evolution

Nat Commun. 2021 Mar 11;12(1):1607. doi: 10.1038/s41467-021-21767-3.

コウモリやセンザンコウ由来のコロナウイルスのスパイクタンパク構造から示唆される新型コロナウイルスの出現過程の検討
Houriiyah Tegally, Eduan Wilkinson, Marta Giovanetti et al.

Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein

Nature. 2021 Mar 9. doi: 10.1038/s41586-021-03402-9.

新規変異株501Y.V2の南アフリカにおける疫学的変遷
Rachel Wilf-Miron, Vicki Myers, Mor Saban

Incentivizing Vaccination Uptake: The "Green Pass" Proposal in Israel

JAMA. 2021 Mar 15. doi: 10.1001/jama.2021.4300.

イスラエルにおける新型コロナワクチンの接種のインセンティブとしての（社会活動時に提示する）「グリーンパス」導入の論説
Brian J Boyarsky, William A Werbel, Robin K Avery et al.

Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients

JAMA. 2021 Mar 15. doi: 10.1001/jama.2021.4385.

臓器移植レシピエントにおけるmRNAベースの新型コロナワクチンによる抗体誘導の検討
Wilfredo F Garcia-Beltran, Evan C Lam, Kerri St Denis et al.

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Cell. 2021 Mar 12;S0092-8674(21)00298-1. doi: 10.1016/j.cell.2021.03.013.

mRNAベースの新型コロナワクチンで誘導された抗体による新規変異株で認めるスパイクタンパク変異を導入した10種類のシュードタイプウイルスの中和能評価。
Jennifer L Kriss, Laura E Reynolds, Alice Wang et al.

COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons - United States, December 14, 2020-February 14, 2021

MMWR Morb Mortal Wkly Rep. 2021 Mar 19;70(11):389-395. doi: 10.15585/mmwr.mm7011e2.

米国の新型コロナワクチン接種者における2回接種完了者の割合と接種間隔（2020年12月14日～2021年2月14日）
Amadea Britton, Kara M Jacobs Slifka, Chris Edens et al.

Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks - Connecticut, December 2020-February 2021

MMWR Morb Mortal Wkly Rep. 2021 Mar 19;70(11):396-401. doi: 10.15585/mmwr.mm7011e3.

新型コロナウイルスのアウトブレイクが発生した2カ所の米国の高齢者福祉施設におけるPfizerの新型コロナワクチン（BNT162b2）の有効性
Maged Gomaa Hemida

The next-generation Coronaviruses diagnostic techniques with particular emphasis on the SARS-CoV-2

J Med Virol. 2021 Mar 10. doi: 10.1002/jmv.26926.

新型コロナウイルスに重点を置いたコロナウイルス診断技術についてのナラティブレビュー
The Lancet

Access to COVID-19 vaccines: looking beyond COVAX

Lancet. 2021 Mar 13;397(10278):941. doi: 10.1016/S0140-6736(21)00617-6.

COVAX以外のメカニズムによる新型コロナワクチンのアクセス向上の必要に関するランセットによるeditorial
Deepti Gurdasani, Nisreen A Alwan, Trisha Greenhalgh et al.

School reopening without robust COVID-19 mitigation risks accelerating the pandemic

Lancet. 2021 Mar 10;S0140-6736(21)00622-X. doi: 10.1016/S0140-6736(21)00622-X.

学校再開によるCOVID-19パンデミックの加速を抑制するための強力な対応策の必要性についての論説
Kathryn E Stephenson, Mathieu Le Gars, Jerald Sadoff et al.

Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19

JAMA. 2021 Mar 11. doi: 10.1001/jama.2021.3645.

Jansen/J&Jのワクチン（Ad26.COV2.S）の第1相臨床試験結果
Hee Kyoung Choi, Chunguang Cui, Hyeri Seok et al.

Feasibility of ultraviolet light-emitting diode irradiation robot for terminal decontamination of COVID-19 patient rooms

Infect Control Hosp Epidemiol. 2021 Mar 9;1-25. doi: 10.1017/ice.2021.95.

COVID-19患者の病室の消毒のためのUV照射ロボットの試験運用
Florian Krammer, Komal Srivastava, Hala Alshammary et al.

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

N Engl J Med. 2021 Mar 10. doi: 10.1056/NEJMc2101667.

新型コロナウイルス抗体保有者におけるmRNAワクチン(BNT162b2、 mRNA-1273)の単回接種後の抗体量饒変化
Siri R Kadire, Valeria Fabre, Richard P Wenzel

Doctor, How Long Should I Isolate?

N Engl J Med. 2021 Mar 25;384(12):e47. doi: 10.1056/NEJMclde2100910.

COVID-19患者の隔離期間に関する臨床医の2通りの考え方
Eric Goralnick, Christoph Kaufmann, Atul A Gawande

Mass-Vaccination Sites - An Essential Innovation to Curb the Covid-19 Pandemic

N Engl J Med. 2021 Mar 10. doi: 10.1056/NEJMp2102535.

効率的な新型コロナワクチン接種のための（スタジアム、アリーナ、コンベンションセンターなどにおける）大規模接種施設の重要性についての論説
Jean B Nachega, Nadia A Sam-Agudu, Refiloe Masekela et al.

Addressing challenges to rolling out COVID-19 vaccines in African countries

Lancet Glob Health. 2021 Mar 10;S2214-109X(21)00097-8. doi: 10.1016/S2214-109X(21)00097-8.

アフリカ諸国での新型コロナワクチンを展開する際の課題
Sunil S Bhopal, Jayshree Bagaria, Bayanne Olabi, Raj Bhopal

Children and young people remain at low risk of COVID-19 mortality

Lancet Child Adolesc Health. 2021 Mar 10;S2352-4642(21)00066-3. doi: 10.1016/S2352-4642(21)00066-3.

7か国における子供や若者のCOVID-19による死亡率の分析
Tapfumanei Mashe, Faustinos Tatenda Takawira, Hlanai Gumbo et al.

Surveillance of SARS-CoV-2 in Zimbabwe shows dominance of variants of concern

Lancet Microbe. 2021 Mar 10. doi: 10.1016/S2666-5247(21)00061-6.

ジンバブエにおける新型コロナウイルスのゲノムサーベイランスで判明したB.1.351 (501Y.V2) の流行
Nicole Lurie, Gerald T Keusch, Victor J Dzau

Urgent lessons from COVID 19: why the world needs a standing, coordinated system and sustainable financing for global research and development

Lancet. 2021 Mar 9;S0140-6736(21)00503-1. doi: 10.1016/S0140-6736(21)00503-1.

COVID-19等に対応する研究開発のためのグローバルな資金調達システムの必要性についての論説
David Nicolás, Emmanuel Coloma, Juan M Pericàs

Alternatives to conventional hospitalisation that enhance health systems' capacity to treat COVID-19

Lancet Infect Dis. 2021 Mar 9;S1473-3099(21)00093-1. doi: 10.1016/S1473-3099(21)00093-1.

COVID-19の医療体制強化のための医療機関の代替手段の検討についての論説
Lloyd B Mulenga, Jonas Z Hines, Sombo Fwoloshi et al.

Prevalence of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-sectional cluster sample survey

Lancet Glob Health. 2021 Mar 9;S2214-109X(21)00053-X. doi: 10.1016/S2214-109X(21)00053-X.

ザンビアの6地区における抗体保有割合（2020年7月時点）
Jingrong Weng, Yichen Li, Jie Li et al.

Gastrointestinal sequelae 90 days after discharge for COVID-19

Lancet Gastroenterol Hepatol. 2021 Mar 9;S2468-1253(21)00076-5. doi: 10.1016/S2468-1253(21)00076-5.

COVID-19による入院から3ヶ月後の消化器系の後遺症
Robert Challen, Ellen Brooks-Pollock, Jonathan M Read et al.

Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study

BMJ. 2021 Mar 9;372:n579. doi: 10.1136/bmj.n579.

英国におけるB.1.1.7系統の新規変異株感染による死亡リスクを検討したマッチドコホート研究
Athalia Christie, Sarah A Mbaeyi, Rochelle P Walensky

CDC Interim Recommendations for Fully Vaccinated People: An Important First Step

JAMA. 2021 Mar 10. doi: 10.1001/jama.2021.4367.

米国CDCによる新型コロナワクチン接種後（2回接種から2週間後）の感染対策等に関する暫定推奨についての論説
Jesse T Jacob, Julia M Baker, Scott K Fridkin et al.

Risk Factors Associated With SARS-CoV-2 Seropositivity Among US Health Care Personnel

JAMA Netw Open. 2021 Mar 1;4(3):e211283. doi: 10.1001/jamanetworkopen.2021.1283.

米国の医療従事者における血清疫学調査による感染リスク因子解析
James Nugent, Abinet Aklilu, Yu Yamamoto et al.

Assessment of Acute Kidney Injury and Longitudinal Kidney Function After Hospital Discharge Among Patients With and Without COVID-19

JAMA Netw Open. 2021 Mar 1;4(3):e211095. doi: 10.1001/jamanetworkopen.2021.1095.

米国の5病院での急性腎障害（AKI）を合併したCOVID-19入院患者とCOVID-19以外での入院患者における腎機能の経時的変化の比較
Shubham Sharma, Roven Pinto, Abhishek Saha, Swetaprovo Chaudhuri, Saptarshi Basu

On secondary atomization and blockage of surrogate cough droplets in single- and multilayer face masks

Sci Adv. 2021 Mar 5;7(10):eabf0452. doi: 10.1126/sciadv.abf0452.

単層、2層、および3層のマスクの様々なサイズや速度の飛沫に対するブロック効果のシミュレーション
Jianmin Zuo, Alexander C Dowell, Hayden Pearce et al.

Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection

Nat Immunol. 2021 Mar 5. doi: 10.1038/s41590-021-00902-8.

新型コロナウイルス感染6ヶ月後の特異的T細胞応答
Xinhua Chen, Zhiyuan Chen, Andrew S Azman et al.

Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis

Lancet Glob Health. 2021 Mar 8;S2214-109X(21)00026-7. doi: 10.1016/S2214-109X(21)00026-7.

新型コロナウイルスの血清疫学調査のシステマティックレビュー・メタアナリシス
Raches Ella, Siddharth Reddy, Harsh Jogdand et al.

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

Lancet Infect Dis. 2021 Mar 8;S1473-3099(21)00070-0. doi: 10.1016/S1473-3099(21)00070-0.

Bharat Biotechの新型コロナワクチン（BBV152）の第1相、第2相臨床試験の中間報告
Christopher R Wilcox, Nazrul Islam, Hajira Dambha-Miller

Association between influenza vaccination and hospitalisation or all-cause mortality in people with COVID-19: a retrospective cohort study

BMJ Open Respir Res. 2021 Mar;8(1):e000857. doi: 10.1136/bmjresp-2020-000857.

COVID-19患者におけるインフルエンザワクチン接種と入院または全死因死亡率の関連
Kimberly G Blumenthal, Lacey B Robinson, Carlos A Camargo Jr et al.

Acute Allergic Reactions to mRNA COVID-19 Vaccines

JAMA. 2021 Mar 8. doi: 10.1001/jama.2021.3976.

米国の医療従事者におけるmRNAベースの新型コロナワクチンに対する急性アレルギー反応
Benjamin J Ryan, Michael P Muehlenbein, Jon Allen et al.

Sustaining University Operations during the COVID-19 Pandemic

Disaster Med Public Health Prep. 2021 Mar 8;1-24. doi: 10.1017/dmp.2021.69.

米国ベイラー大学を例としたパンデミック下の大学運営の維持に関する論説
Rita E Chen, Xianwen Zhang, James Brett Case et al.

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

Nat Med. 2021 Mar 4. doi: 10.1038/s41591-021-01294-w.

モノクローナル抗体、動物モデル免疫後の血清、ヒト回復者血清、BNT162b2 mRNAワクチンで誘導された抗体による変異株の中和試験
Lavanya Vijayasingham, Evelyne Bischof, Jeannette Wolfe, Gender and COVID-19 Research Agenda-setting Initiative

Sex-disaggregated data in COVID-19 vaccine trials

Lancet. 2021 Mar 13;397(10278):966-967. doi: 10.1016/S0140-6736(21)00384-6.

新型コロナワクチンの男女別のデータの必要性についての論説
Christian Karagiannidis, Wolfram Windisch, Daniel F McAuley, Tobias Welte, Reinhard Busse

Major differences in ICU admissions during the first and second COVID-19 wave in Germany

Lancet Respir Med. 2021 Mar 5;S2213-2600(21)00101-6. doi: 10.1016/S2213-2600(21)00101-6.

ドイツの集中治療室（ICU）における第1波と第2波でのCOVID-19患者の経過や転帰の比較
Maya Moshe, Anna Daunt, Barnaby Flower et al.

SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy study

BMJ. 2021 Mar 2;372:n423. doi: 10.1136/bmj.n423.

英国における新型コロナウイルスの血清疫学調査での使用のための抗体検査キット数種類の評価
Malia Skjefte, Michelle Ngirbabul, Oluwasefunmi Akeju et al.

COVID-19 vaccine acceptance among pregnant women and mothers of young children: results of a survey in 16 countries

Eur J Epidemiol. 2021 Mar 1;1-15. doi: 10.1007/s10654-021-00728-6.

16か国の妊婦と母親における新型コロナワクチンの接種意向に関するアンケート調査
Kimberly G Blumenthal, Esther E Freeman, Rebecca R Saff et al.

Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2

N Engl J Med. 2021 Mar 3. doi: 10.1056/NEJMc2102131.

Modernaの新型コロナワクチン（mRNA-1273）による局所の遅延型アレルギー反応
PRINCIPLE Trial Collaborative Group

Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Lancet. 2021 Mar 4;S0140-6736(21)00461-X. doi: 10.1016/S0140-6736(21)00461-X.

入院リスクの高いCOVID-19疑い患者におけるアジスロマイシンの有効性を評価したランダム化比較試験（PRINCIPLE trial）
Chloe I Bloom, Thomas M Drake, Annemarie B Docherty et al.

Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK

Lancet Respir Med. 2021 Mar 4;S2213-2600(21)00013-8. doi: 10.1016/S2213-2600(21)00013-8.

英国における呼吸器系の基礎疾患を有するCOVID-19入院患者における転帰と吸入ステロイドの使用の影響を検討した前向きコホート研究
Frederik A Copper, Cindy Chiu de Vázquez, Allan Bell et al.

Preparing for COVID-19 vaccine roll-out through simulation exercises

Lancet Glob Health. 2021 Mar 3;S2214-109X(21)00051-6. doi: 10.1016/S2214-109X(21)00051-6.

WHOの作成した各国における新型コロナワクチン導入のシミュレーションエクササイズ
Peter R Chai, Farah Z Dadabhoy, Hen-Wei Huang et al.

Assessment of the Acceptability and Feasibility of Using Mobile Robotic Systems for Patient Evaluation

JAMA Netw Open. 2021 Mar 1;4(3):e210667. doi: 10.1001/jamanetworkopen.2021.0667.

米国における診療ロボットへの受容性に関する全国アンケート調査とボストンの医療機関における医療面接での試験的な使用
John P Moore

Approaches for Optimal Use of Different COVID-19 Vaccines: Issues of Viral Variants and Vaccine Efficacy

JAMA. 2021 Mar 4. doi: 10.1001/jama.2021.3465.

変異株への有効性等に応じた数種類の新型コロナワクチンの使い分けへのアプローチに関する論説
Carlos Del Rio, Preeti Malani

COVID-19 in 2021-Continuing Uncertainty

JAMA. 2021 Mar 4. doi: 10.1001/jama.2021.3760.

新型コロナワクチンについて考えられるいくつかの疑問点についての現時点でのエビデンス
Eduardo López-Medina, Pío López, Isabel C Hurtado et al.

Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial

JAMA. 2021 Mar 4. doi: 10.1001/jama.2021.3071.

COVID-19軽症患者におけるイベルメクチンの症状軽快までの期間に対する有効性を評価したランダム化臨床試験
Christopher J L Murray, Peter Piot

The Potential Future of the COVID-19 Pandemic: Will SARS-CoV-2 Become a Recurrent Seasonal Infection?

JAMA. 2021 Mar 3. doi: 10.1001/jama.2021.2828.

COVID-19パンデミックの今後について考えられるシナリオと季節性を伴う感染症となった際の対策についての論説
Max A Schumm, Joseph E Hadaya, Nisha Mody, Bethany A Myers, Melinda Maggard-Gibbons

Filtering Facepiece Respirator (N95 Respirator) Reprocessing: A Systematic Review

JAMA. 2021 Mar 3. doi: 10.1001/jama.2021.2531.

N95マスクの再利用のための消毒方法に関するシステマティックレビュー
Riccardo Lubrano, Silvia Bloise, Alessia Testa et al.

Assessment of Respiratory Function in Infants and Young Children Wearing Face Masks During the COVID-19 Pandemic

JAMA Netw Open. 2021 Mar 1;4(3):e210414. doi: 10.1001/jamanetworkopen.2021.0414.

小児におけるサージカルマスクの着用による呼吸困難の有無や酸素飽和度などの呼吸器系の指標への影響
Man Lung Yeung, Jade Lee Lee Teng, Lilong Jia et al.

Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system

Cell. 2021 Mar 2;S0092-8674(21)00283-X. doi: 10.1016/j.cell.2021.02.053.

可溶性ACE2を介した新型コロナウイルスの細胞侵入
Yinghui Liu, Gaowei Hu, Yuyan Wang et al.

Functional and genetic analysis of viral receptor ACE2 orthologs reveals a broad potential host range of SARS-CoV-2

Proc Natl Acad Sci U S A. 2021 Mar 23;118(12):e2025373118. doi: 10.1073/pnas.2025373118.

新型コロナウイルスの宿主となりうる哺乳動物の幅の検討のためのACE2の機能的、遺伝的解析
Guy T Clifton, Rituparna Pati, Florian Krammer et al.

SARS-CoV-2 Infection Risk Among Active Duty Military Members Deployed to a Field Hospital - New York City, April 2020

MMWR Morb Mortal Wkly Rep. 2021 Mar 5;70(9):308-311. doi: 10.15585/mmwr.mm7009a3.

2020年4月に米国ニューヨーク市における第1波で設置されたCOVID-19患者専用の臨時診療施設に派遣された軍人における感染リスク
Alexandre Gaymard, Paolo Bosetti, Adeline Feri et al.

Early assessment of diffusion and possible expansion of SARS-CoV-2 Lineage 20I/501Y.V1 (B.1.1.7, variant of concern 202012/01) in France, January to March 2021

Euro Surveill. 2021 Mar;26(9):2100133. doi: 10.2807/1560-7917.ES.2021.26.9.2100133.

フランスにおける新型コロナウイルスの変異株（501Y.V1）の感染拡大の初期評価（2021年1月～3月）
Ludger Klimek, Natalija Novak, Beatriz Cabanillas et al.

Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation

Allergy. 2021 Mar 3. doi: 10.1111/all.14794.

Modernaの新型コロナワクチン（mRNA-1273）のアレルギー成分についての論説
Sara E Oliver, Julia W Gargano, Heather Scobie et al.

The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Janssen COVID-19 Vaccine - United States, February 2021

MMWR Morb Mortal Wkly Rep. 2021 Mar 5;70(9):329-332. doi: 10.15585/mmwr.mm7009e4.

米国の予防接種の実施に関する諮問委員会（ACIP）によるJanssenの新型コロナワクチン（Ad.26.COV2.S）についての暫定勧告
Paula Bianca Blomquist, Hikaru Bolt, Simon Packer et al.

Risk of symptomatic COVID-19 due to aircraft transmission: a retrospective cohort study of contact-traced flights during England's containment phase

Influenza Other Respir Viruses. 2021 Mar 1. doi: 10.1111/irv.12846.

接触者追跡データを利用して航空機における新型コロナウイルス感染リスクを検討した後ろ向きコホート研究
Gery P Guy Jr, Florence C Lee, Gregory Sunshine et al.

Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates - United States, March 1-December 31, 2020

MMWR Morb Mortal Wkly Rep. 2021 Mar 12;70(10):350-354. doi: 10.15585/mmwr.mm7010e3.

米国におけるマスクの着用やレストランでの食事のとCOVID-19の発症者や死亡者の伸び率の相関（2020年3月～12月）
François Lamontagne, Thomas Agoritsas, Reed Siemieniuk et al.

A living WHO guideline on drugs to prevent covid-19

BMJ. 2021 Mar 1;372:n526. doi: 10.1136/bmj.n526.

COVID-19予防薬に関するWHOのリビング・ガイドライン
Michael Drozd, Mar Pujades-Rodriguez, Patrick J Lillie et al.

Non-communicable disease, sociodemographic factors, and risk of death from infection: a UK Biobank observational cohort study

Lancet Infect Dis. 2021 Mar 1;S1473-3099(20)30978-6. doi: 10.1016/S1473-3099(20)30978-6.

UK Biobankのデータを使用したCOVID-19死亡リスクに関連する因子の探索
Saman Saadat, Zahra Rikhtegaran Tehrani, James Logue et al.

Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2

JAMA. 2021 Mar 1. doi: 10.1001/jama.2021.3341.

mRNAワクチンの単回接種で誘導された抗体価の既感染者と未感染者での比較
Perrine Janiaud, Cathrine Axfors, John P A Ioannidis, Lars G Hemkens

Recruitment and Results Reporting of COVID-19 Randomized Clinical Trials Registered in the First 100 Days of the Pandemic

JAMA Netw Open. 2021 Mar 1;4(3):e210330. doi: 10.1001/jamanetworkopen.2021.0330.

COVID-19が世界で初めて報告された日（2020年1月1日）から100日間で登録されたランダム化比較試験の研究対象者募集状況と試験結果の報告状況
Shannon Wongvibulsin, Brian T Garibaldi, Annukka A R Antar et al.

Development of Severe COVID-19 Adaptive Risk Predictor (SCARP), a Calculator to Predict Severe Disease or Death in Hospitalized Patients With COVID-19

Ann Intern Med. 2021 Mar 2;M20-6754. doi: 10.7326/M20-6754.

COVID-19の重症化や死亡の予測ツール（SCARP）の開発と検討
Katja van den Hurk, Eva-Maria Merz, Femmeke J Prinsze et al.

Low awareness of past SARS-CoV-2 infection in healthy plasma donors

Cell Rep Med. 2021 Mar 1;100222. doi: 10.1016/j.xcrm.2021.100222.

オランダの健常な血漿献血者を対照とした血清疫学調査
Jessica A. Plante, Brooke M. Mitchell, Kenneth S. Plante et al.

The Variant Gambit: COVID's Next Move

Cell Host Microbe. 2021 Mar 1. doi: 10.1016/j.chom.2021.02.020.

新型コロナウイルス変異株の進化的背景や今後の研究の展望に関する論説
Ehud Rinott, Ilan Youngster, Yair E Lewis

Reduction in COVID-19 Patients Requiring Mechanical Ventilation Following Implementation of a National COVID-19 Vaccination Program - Israel, December 2020-February 2021

MMWR Morb Mortal Wkly Rep. 2021 Mar 5;70(9):326-328. doi: 10.15585/mmwr.mm7009e3.

イスラエルにおけるCOVID-19ワクチンの接種率と相関する人工呼吸器を必要とするCOVID-19患者数の推移
Laura M Groves, Lauren Usagawa, Joe Elm et al.

Community Transmission of SARS-CoV-2 at Three Fitness Facilities - Hawaii, June-July 2020

MMWR Morb Mortal Wkly Rep. 2021 Mar 5;70(9):316-320. doi: 10.15585/mmwr.mm7009e1.

米国ハワイ州の3カ所のフィットネスジムで発生したインストラクターを初発患者とした新型コロナウイルスのアウトブレイク（2020年6月～7月）
Frances R Lendacki, Richard A Teran, Stephanie Gretsch, Marielle J Fricchione, Janna L Kerins

COVID-19 Outbreak Among Attendees of an Exercise Facility - Chicago, Illinois, August-September 2020

MMWR Morb Mortal Wkly Rep. 2021 Mar 5;70(9):321-325. doi: 10.15585/mmwr.mm7009e2.

米国イリノイ州シカゴのフィットネスジムで発生した新型コロナウイルスのアウトブレイク（2020年8月～9月）
Merryn Voysey, Sue Ann Costa Clemens, Shabir A Madhi et al.

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Lancet. 2021 Mar 6;397(10277):881-891. doi: 10.1016/S0140-6736(21)00432-3.

AstraZenecaのワクチン（AZD1222）の接種間隔延長の免疫原性と有効性への影響を評価したランダム化比較試験
Siri R Kadire, Robert M Wachter, Nicole Lurie

Delayed Second Dose versus Standard Regimen for Covid-19 Vaccination

N Engl J Med. 2021 Mar 4;384(9):e28. doi: 10.1056/NEJMclde2101987.

新型コロナワクチンの2回目の接種時期の延期に関する論説
Jonas Vlachos, Edvin Hertegård, Helena B Svaleryd

The effects of school closures on SARS-CoV-2 among parents and teachers

Proc Natl Acad Sci U S A. 2021 Mar 2;118(9):e2020834118. doi: 10.1073/pnas.2020834118.

スウェーデンにおける学校閉鎖の保護者・教師の新型コロナウイルス感染に対する影響
Rahul Subramanian, Qixin He, Mercedes Pascual

Quantifying asymptomatic infection and transmission of COVID-19 in New York City using observed cases, serology, and testing capacity

Proc Natl Acad Sci U S A. 2021 Mar 2;118(9):e2019716118. doi: 10.1073/pnas.2019716118.

米国・ニューヨーク市における報告例、血清疫学調査、および検査のキャパシティを用いて推定したSARS-CoV-2の無症状病原体保有者の割合と無症状病原体保有者からの感染
February 2021
Anne E. Watkins, Eli P. Fenichel, Daniel M. Weinberger et al.

Increasing SARS-CoV-2 Testing Capacity with Pooled Saliva Samples

Emerg Infect Dis. 2021 Feb 25;27(4). doi: 10.3201/eid2704.204200

唾液検体のプーリング検査の評価
Ann Kristin Skrindo Knudsen, Kim Stene-Larsen, Kristin Gustavson et al.

Prevalence of mental disorders, suicidal ideation and suicides in the general population before and during the COVID-19 pandemic in Norway: A population-based repeated cross-sectional analysis

Lancet Reg Health Eur. 2021 May;4:100071. doi: 10.1016/j.lanepe.2021.100071.

ノルウェーにおけるCOVID-19パンデミック発生以前と発生後の精神疾患、希死念慮、自殺の有病率の比較
Azman Rashid, Karla Therese L Sy, Jacob M Cabrejas et al.

A clinician's primer on epidemiology for COVID-19

Med (N Y). 2021 Feb 27. doi: 10.1016/j.medj.2021.02.007.

臨床医を対象としたCOVID-19の疫学に関する主要な概念と用語についての解説
Dongyan Zhou, Jasper Fuk-Woo Chan, Biao Zhou et al.

Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies

Cell Host Microbe. 2021 Feb 25;S1931-3128(21)00098-6. doi: 10.1016/j.chom.2021.02.019.

ハムスターモデルを用いたヒトモノクローナル抗体使用後の鼻甲介からのSARS-CoV-2感染リスクの検討
Michael S Piepenbrink, Jun-Gyu Park, Fatai S Oladunni et al.

Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters

Cell Rep Med. 2021 Feb 25;100218. doi: 10.1016/j.xcrm.2021.100218.

ハムスターにおけるヒトモノクローナル抗体の吸入の新型コロナウイルス感染に対する治療効果の検討
Mik Wetterslev, Peter Karl Jacobsen, Christian Hassager et al.

Cardiac arrhythmias in critically ill patients with coronavirus disease 2019: a retrospective population-based cohort study

Acta Anaesthesiol Scand. 2021 Feb 27. doi: 10.1111/aas.13806.

デンマークにおけるCOVID-19のICU患者における不整脈
Zoë Hyde

Difference in SARS-CoV-2 attack rate between children and adults may reflect bias

Clin Infect Dis. 2021 Feb 26;ciab183. doi: 10.1093/cid/ciab183.

小児と成人における2次感染率の差をもたらすバイアスの可能性についての論説
Maria Prendecki, Candice Clarke, Jonathan Brown et al.

Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine

Lancet. 2021 Feb 25;S0140-6736(21)00502-X. doi: 10.1016/S0140-6736(21)00502-X.

mRNAワクチンの単回接種で誘導された液性免疫と細胞性免疫応答の既感染者と未感染者での比較
Charlotte Manisty, Ashley D Otter, Thomas A Treibel et al.

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals

Lancet. 2021 Feb 25;S0140-6736(21)00501-8. doi: 10.1016/S0140-6736(21)00501-8.

mRNAワクチンの単回接種で誘導された抗体応答の既感染者と未感染者での比較
Jiangmei Liu, Lan Zhang, Yaqiong Yan et al.

Excess mortality in Wuhan city and other parts of China during the three months of the covid-19 outbreak: findings from nationwide mortality registries

BMJ. 2021 Feb 24;372:n415. doi: 10.1136/bmj.n415.

中国における新型コロナウイルス流行開始から3ヶ月間の武漢や他の都市における超過死亡
Perrine Janiaud, Cathrine Axfors, Andreas M Schmitt et al.

Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis

JAMA. 2021 Feb 26. doi: 10.1001/jama.2021.2747.

回復者血漿によるCOVID-19臨床転帰の改善を検討したシステマティックレビュー
C. Buddy Creech, Shannon C. Walker, Robert J. Samuels

SARS-CoV-2 Vaccines

JAMA. 2021 Feb 26. doi: 10.1001/jama.2021.3199.

新型コロナワクチンについてのナラティブレビュー
Joshua P Metlay, Jennifer S Haas, Alexander E Soltoff, Katrina A Armstrong

Household Transmission of SARS-CoV-2

JAMA Netw Open. 2021 Feb 1;4(2):e210304. doi: 10.1001/jamanetworkopen.2021.0304.

電子カルテを利用した新型コロナウイルスの家庭内感染のリスクを検討した後ろ向きコホート研究
Joseph E Marcus, Dianne N Frankel, Mary T Pawlak et al.

Risk Factors Associated With COVID-19 Transmission Among US Air Force Trainees in a Congregant Setting

JAMA Netw Open. 2021 Feb 1;4(2):e210202. doi: 10.1001/jamanetworkopen.2021.0202.

集団生活をする米空軍の訓練生における新型コロナウイルス感染リスクを検討した前向きコホート研究
Alyson M Cavanaugh, Douglas Thoroughman, Holly Miranda, Kevin Spicer

Suspected Recurrent SARS-CoV-2 Infections Among Residents of a Skilled Nursing Facility During a Second COVID-19 Outbreak - Kentucky, July-November 2020

MMWR Morb Mortal Wkly Rep. 2021 Feb 26;70(8):273-277. doi: 10.15585/mmwr.mm7008a3.

米国ケンタッキー州の高齢者福祉施設における新型コロナウイルスへの再感染疑いの検討
M Capelli, P Gatti

Anosmia in the first coronavirus disease 2019 outbreak in Europe: functional recovery after eight months

J Laryngol Otol. 2021 Feb 26;1-5. doi: 10.1017/S0022215121000670.

新型コロナウイルス感染8か月後の嗅覚味覚障害の回復度
Sandra Rajme-López, María F González-Lara, Edgar Ortiz-Brizuela et al.

Large scale screening for SARS-CoV-2 among healthcare workers: prevalence and risk factors for asymptomatic/pauci-symptomatic carriers, with emphasis on PPE use

Infect Control Hosp Epidemiol. 2021 Feb 24;1-17. doi: 10.1017/ice.2021.68.

メキシコの医療機関で2020年4月と7月に行われた医療従事者の大規模スクリーニング
Asmaa M Altamimi, Dalia A Obeid, Taghreed A Alaifan et al.

Assessment of 12 Qualitative RT-PCR commercial kits for the detection of SARS-CoV-2

J Med Virol. 2021 Feb 25. doi: 10.1002/jmv.26900.

12種類のPCRキットの比較
Gerco den Hartog, Eric R A Vos, Lotus L van den Hoogen et al.

Persistence of antibodies to SARS-CoV-2 in relation to symptoms in a nationwide prospective study

Clin Infect Dis. 2021 Feb 24;ciab172. doi: 10.1093/cid/ciab172.

オランダにおける新型コロナウイルス感染7ヶ月後までの抗体の持続性に関する研究
REMAP-CAP Investigators

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

N Engl J Med. 2021 Feb 25. doi: 10.1056/NEJMoa2100433.

COVID-19の重症患者におけるインターロイキン6受容体拮抗薬（トシリズマブとサリルマブ）の有効性を検討したランダム化比較試験
Ivan O Rosas, Norbert Bräu, Michael Waters et al.

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

N Engl J Med. 2021 Feb 25. doi: 10.1056/NEJMoa2028700.

COVID-19の入院患者におけるインターロイキン6受容体拮抗薬（トシリズマブとサリルマブ）の有効性を検討したランダム化比較試験2
RECOVERY Collaborative Group

Dexamethasone in Hospitalized Patients with Covid-19

N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436.

COVID-19の入院患者におけるデキサメタゾンの有効性を検討したランダム化比較試験（最終報告）
Michael Karbiener, Maria R Farcet, Reinhard Ilk et al.

Longitudinal analysis of SARS-CoV-2 antibodies in 8000 U.S. first-time convalescent plasma donations

Transfusion. 2021 Feb 22. doi: 10.1111/trf.16291.

回復者血漿ドナーから収集された血漿における抗体価の解析
Noa Dagan, Noam Barda, Eldad Kepten et al.

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

N Engl J Med. 2021 Feb 24. doi: 10.1056/NEJMoa2101765.

イスラエルにおけるPfizer/BioNTechワクチン（BNT162b2）のリアルワールドでの有効性評価
Al Ozonoff, Etsuro Nanishi, Ofer Levy

Bell's palsy and SARS-CoV-2 vaccines

Lancet Infect Dis. 2021 Feb 24;S1473-3099(21)00076-1. doi: 10.1016/S1473-3099(21)00076-1.

ワクチン接種とベル麻痺との関連に関する論説
Rosanna W Peeling, Piero L Olliaro, Debrah I Boeras, Noah Fongwen

Scaling up COVID-19 rapid antigen tests: promises and challenges

Lancet Infect Dis. 2021 Feb 23;S1473-3099(21)00048-7. doi: 10.1016/S1473-3099(21)00048-7.

新型コロナウイルスの抗原検査についてのナラティブレビュー・論説
Leora R Feldstein, Mark W Tenforde, Kevin G Friedman et al.

Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19

JAMA. 2021 Feb 24;e212091. doi: 10.1001/jama.2021.2091.

小児における多臓器炎症性症候群（MIS-C）とCOVID-19重症例の臨床的特徴・転帰の比較
Raymond A Harvey, Jeremy A Rassen, Carly A Kabelac et al.

Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection

JAMA Intern Med. 2021 Feb 24;e210366. doi: 10.1001/jamainternmed.2021.0366.

新型コロナウイルスに対する抗体の有無と将来の感染リスクとの相関
Daming Zhou, Wanwisa Dejnirattisai, Piyada Supasa et al.

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera

Cell. 2021 Feb 23. doi: 10.1016/j.cell.2021.02.037.

南アフリカで最初に探知された変異株（B.1.351系統）の既感染者やワクチン接種者の血清からの免疫逃避
Emanuele Andreano, Emanuele Nicastri, Ida Paciello et al.

Extremely potent human monoclonal antibodies from COVID-19 convalescent patients

Cell. 2021 Feb 23;S0092-8674(21)00224-5. doi: 10.1016/j.cell.2021.02.035.

COVID-19回復患者から同定された非常に強力なヒトモノクローナル抗体の解析
Qianqian Li, Jianhui Nie, Jiajing Wu et al.

No higher infectivity but immune escape of SARS-CoV-2 501Y.V2 variants

Cell. 2021 Feb 23. doi: 10.1016/j.cell.2021.02.042.

南アフリカで最初に探知された変異株（B.1.351系統）はin vitroにおいて感染性に変化ないが免疫逃避を認める
Xianwen Zhang, Yang Liu, Jianying Liu et al.

A trans-complementation system for SARS-CoV-2 recapitulates authentic viral replication without virulence

Cell. 2021 Feb 23;S0092-8674(21)00233-6. doi: 10.1016/j.cell.2021.02.044.

トランス相補性システムで作成されたBSL-2で使用可能な一回感染性新型コロナウイルス
Jeremy A W Gold, Jenna R Gettings, Anne Kimball et al.

Clusters of SARS-CoV-2 Infection Among Elementary School Educators and Students in One School District - Georgia, December 2020-January 2021

MMWR Morb Mortal Wkly Rep. 2021 Feb 26;70(8):289-292. doi: 10.15585/mmwr.mm7008e4.

米国ジョージア州における1つの学校区の小学校の教員と生徒において発生した新型コロナウイルスのアウトブレイク（2020年12月～2021年1月の）
Sharoda Dasgupta, Ahmed M Kassem, Gregory Sunshine et al.

Differences in rapid increases in county-level COVID-19 incidence by implementation of statewide closures and mask mandates - United States, June 1-September 30, 2020

Ann Epidemiol. 2021 Feb 14;S1047-2797(21)00021-1. doi: 10.1016/j.annepidem.2021.02.006.

米国における州の封鎖及びマスク着用義務と群レベルでのCOVID-19患者の急増との相関
Vasanthi Avadhanula, Erin G Nicholson, Laura Ferlic-Stark et al.

Viral load of SARS-CoV-2 in adults during the first and second wave of COVID-19 pandemic in Houston, TX: the potential of the super-spreader

J Infect Dis. 2021 Feb 15;jiab097. doi: 10.1093/infdis/jiab097.

新型コロナウイルスRNA量高値と疫学的・臨床的特徴
Joakim Dillner, K Miriam Elfström, Jonas Blomqvist et al.

High amounts of SARS-CoV-2 precede sickness among asymptomatic healthcare workers

J Infect Dis. 2021 Feb 13;jiab099. doi: 10.1093/infdis/jiab099.

無症状病原体保有者における新型コロナウイルスRNA量と後日の発症との関係
Andrea M Pallotta, ChungYun Kim, Steven M Gordon, Alice Kim

Monoclonal antibodies for treating COVID-19

Cleve Clin J Med. 2021 Feb 17. doi: 10.3949/ccjm.88a.ccc074.

新型コロナウイルスに対するモノクローナル抗体療法に関するナラティブレビュー
Peter A Ubel

Vaccinating Health Care Employees - Do They All Deserve Early Access?

N Engl J Med. 2021 Feb 19. doi: 10.1056/NEJMpv2101203.

医療従事者に対する新型コロナワクチン優先接種の妥当性についての論説
Ivan Sisa, Estefania Noblecilla, Fadya Orozco

Rationale to continue approving placebo-controlled COVID-19 vaccine trials in LMICs

Lancet. 2021 Feb 19;S0140-6736(21)00357-3. doi: 10.1016/S0140-6736(21)00357-3.

低中所得国（LMICs）におけるCOVID-19ワクチンのプラセボを用いた臨床試験の継続の是非についての論説
John F R Robertson, Herb F Sewell, Marcia Stewart

Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?

Lancet. 2021 Feb 19;S0140-6736(21)00455-4. doi: 10.1016/S0140-6736(21)00455-4.

Pfizer/BioNTechの新型コロナワクチン（BNT162b2）の2回目接種時期についての論説
Retesh Bajaj, Hannah C Sinclair, Kush Patel et al.

Delayed-onset myocarditis following COVID-19

Lancet Respir Med. 2021 Feb 19;S2213-2600(21)00085-0. doi: 10.1016/S2213-2600(21)00085-0.

成人における心不全を合併した新型コロナウイルス感染数週間後の多臓器炎症症候群（MIS-A）の症例集積
Jennifer K Logue, Nicholas M Franko, Denise J McCulloch et al.

Sequelae in Adults at 6 Months After COVID-19 Infection

JAMA Netw Open. 2021 Feb 1;4(2):e210830. doi: 10.1001/jamanetworkopen.2021.0830.

COVID-19発症6ヶ月後までの後遺症を検討したコホート研究
Eric J Nelson, Sarah L McKune, Kathleen A Ryan et al.

SARS-CoV-2 Positivity on or After 9 Days Among Quarantined Student Contacts of Confirmed Cases

JAMA. 2021 Feb 19. doi: 10.1001/jama.2021.2392.

小児の濃厚接触者の健康観察期間の短縮の是非の評価
James T Lee, Elisabeth M Hesse, Heather N Paulin et al.

Clinical and Laboratory Findings in Patients with Potential SARS-CoV-2 Reinfection, May-July 2020

Clin Infect Dis. 2021 Feb 18;ciab148. doi: 10.1093/cid/ciab148.

新型コロナウイルス再感染疑い例の臨床的評価（2020年5月～7月）
Stephen Hills, Yolanda Eraso

Factors associated with non-adherence to social distancing rules during the COVID-19 pandemic: a logistic regression analysis

BMC Public Health. 2021 Feb 13;21(1):352. doi: 10.1186/s12889-021-10379-7.

パンデミックにおける英国での身体的距離に関するルールの不遵守に関連する因子の検討
Julianne Gee, Paige Marquez, John Su et al.

First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021

MMWR Morb Mortal Wkly Rep. 2021 Feb 26;70(8):283-288. doi: 10.15585/mmwr.mm7008e3.

米国における新型コロナワクチン導入1ヶ月目の安全性モニタリング（2020年12月14日～2021年1月13日）
Carolina K V Nonaka, Marília Miranda Franco, Tiago Gräf et al.

Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation, Brazil

Emerg Infect Dis. 2021 Feb 19;27(5). doi: 10.3201/eid2705.210191.

ブラジルにおけるE484K変異を有する新型コロナウイルスへの再感染例
Winston McCormick, Michael Koster, Geetika Sood, Leonard A Mermel

Level of respiratory protection for healthcare workers caring for COVID-19 patients: A survey of hospital epidemiologists

Infect Control Hosp Epidemiol. 2021 Feb 19;1-8. doi: 10.1017/ice.2021.74.

COVID-19患者の診療にあたる医療従事者のPPEに関するアンケート
Mathew R P Sapiano, Margaret A Dudeck, Minn Soe et al.

Impact of coronavirus disease 2019 (COVID-19) on US Hospitals and Patients, April-July 2020

Infect Control Hosp Epidemiol. 2021 Feb 19;1-8. doi: 10.1017/ice.2021.69.

米国の病院におけるCOVID-19患者・全患者の病床占有率の推移（2020年4月から7月）
Farah Hameed, Eugene Palatulan, Abhishek Jaywant et al.

Outcomes of a COVID-19 Recovery Program for Patients Hospitalized with SARS-CoV-2 Infection in New York City: A Prospective Cohort Study

PM R. 2021 Feb 18. doi: 10.1002/pmrj.12578.

COVID-19入院患者のための筋力・心肺機能回復プログラムの結果
Patrick Schwab, Arash Mehrjou, Sonali Parbhoo et al.

Real-time prediction of COVID-19 related mortality using electronic health records

Nat Commun. 2021 Feb 16;12(1):1058. doi: 10.1038/s41467-020-20816-7.

電子カルテデータを使用したCOVID-19関連の死亡率のリアルタイム予測システム（CovEWS）の検討
Hye Min Kim, Adam J Saffer, Wenlin Liu et al.

How Public Health Agencies Break through COVID-19 Conversations: A Strategic Network Approach to Public Engagement

Health Commun. 2021 Feb 16;1-9. doi: 10.1080/10410236.2021.1886393.

米国の公衆衛生関連の公的機関による新型コロナウイルス関連のTwitterを通したリスクコミュニケーションの評価
Carl A Latkin, Lauren Dayton, Grace Yi, Brian Colon, Xiangrong Kong

Mask usage, social distancing, racial, and gender correlates of COVID-19 vaccine intentions among adults in the US

PLoS One. 2021 Feb 16;16(2):e0246970. doi: 10.1371/journal.pone.0246970.

米国の成人における新型コロナワクチンの接種の意向とマスクの着用、社会的距離、人種、および性別との相関について
Sharon Amit, Gili Regev-Yochay, Arnon Afek, Yitshak Kreiss, Eyal Leshem

Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients

Lancet. 2021 Feb 18;S0140-6736(21)00448-7. doi: 10.1016/S0140-6736(21)00448-7.

イスラエルの医療従事者コホートにおけるPfizer/BioNTechの新型コロナワクチン（BNT162b2）の有効性の検討
Alessandro Sette, Shane Crotty

Adaptive immunity to SARS-CoV-2 and COVID-19

Cell. 2021 Feb 18;184(4):861-880. doi: 10.1016/j.cell.2021.01.007.

新型コロナウイルスに対する適応免疫応答に関するナラティブレビュー
Wanwisa Dejnirattisai, Daming Zhou, Helen M. Ginn et al.

The antigenic anatomy of SARS-CoV-2 receptor binding domain

Cell. 2021 Feb 18. doi: 10.1016/j.cell.2021.02.032.

新型コロナウイルススパイクを認識するヒトモノクローナル抗体の解析
Piyada Supasa, Daming Zhou, Wanwisa Dejnirattisai et al.

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

Cell. 2021 Feb 18. doi: 10.1016/j.cell.2021.02.033.

英国で最初に検出された新型コロナウイルスの変異株（B.1.1.7系統）の感染回復者およびワクチン接種者の血清による中和試験
Brecht Ingelbeen, Laurène Peckeu, Marie Laga et al.

Reducing contacts to stop SARS-CoV-2 transmission during the second pandemic wave in Brussels, Belgium, August to November 2020

Euro Surveill. 2021 Feb;26(7):2100065. doi: 10.2807/1560-7917.ES.2021.26.7.2100065.

ベルギーのブリュッセルにおける第2波での接触機会を減らす取り組み（2020年8月～11月）
Anne Carroll, Eleanor McNamara

Comparison and correlation of commercial SARS-CoV-2 real-time-PCR assays, Ireland, June 2020

Euro Surveill. 2021 Feb;26(6):2002079. doi: 10.2807/1560-7917.ES.2021.26.6.2002079.

新型コロナウイルスPCRのCt値やコピー数の比較
Anna Jeffery-Smith, Nalini Iyanger, Sarah V Williams et al.

Antibodies to SARS-CoV-2 protect against re-infection during outbreaks in care homes, September and October 2020

Euro Surveill. 2021 Feb;26(5):2100092. doi: 10.2807/1560-7917.ES.2021.26.5.2100092.

英国の高齢者福祉施設のアウトブレイクにおける新型コロナウイルス抗体陽性者の感染の有無の検討
Helle Daugaard Larsen, Jannik Fonager, Frederikke Kristensen Lomholt et al.

Preliminary report of an outbreak of SARS-CoV-2 in mink and mink farmers associated with community spread, Denmark, June to November 2020

Euro Surveill. 2021 Feb;26(5):2100009. doi: 10.2807/1560-7917.ES.2021.26.5.210009.

デンマークで発生したミンクおよびミンク養殖業者における新型コロナウイルスのアウトブレイクの暫定報告（2020年6月から11月）
Michael Kidd, Alex Richter, Angus Best et al.

S-variant SARS-CoV-2 lineage B1.1.7 is associated with significantly higher viral loads in samples tested by ThermoFisher TaqPath RT-qPCR

J Infect Dis. 2021 Feb 13;jiab082. doi: 10.1093/infdis/jiab082.

英国で最初に検出された新型コロナウイルスの変異株（B.1.1.7系統）で認めるS-gene target failureの有無とウイルスRNA量の相関
Yannic C Bartsch, Stephanie Fischinger, Sameed M Siddiqui et al.

Discrete SARS-CoV-2 antibody titers track with functional humoral stability

Nat Commun. 2021 Feb 15;12(1):1018. doi: 10.1038/s41467-021-21336-8.

新型コロナウイルスのレセプター結合部位（RBD）に対する抗体の閾値と中和価やT細胞性免疫、エフェクター機能との相関
Amy G Feldman, Sean T O'Leary, Lara Danziger Isakov

The Risk of Resurgence in Vaccine Preventable Infections Due to COVID-Related Gaps in Immunization

Clin Infect Dis. 2021 Feb 13;ciab127. doi: 10.1093/cid/ciab127.

パンデミックにおけるワクチン接種率低下によるワクチンで予防可能な疾病の流行リスク
Yannic C Bartsch, Chuangqi Wang, Tomer Zohar et al.

Humoral signatures of protective and pathological SARS-CoV-2 infection in children

Nat Med. 2021 Feb 12. doi: 10.1038/s41591-021-01263-3.

小児における新型コロナウイルス感染の重症度や小児多臓器炎症症候群（MIS-C）と抗体価や抗体の種類との関係
Q Sue Huang, Tim Wood, Lauren Jelley et al.

Impact of the COVID-19 nonpharmaceutical interventions on influenza and other respiratory viral infections in New Zealand

Nat Commun. 2021 Feb 12;12(1):1001. doi: 10.1038/s41467-021-21157-9.

ニュージーランドにおける非薬物的介入のインフルエンザやその他の呼吸器感染症への効果の検討
Richard G Jung, Pietro Di Santo, Cole Clifford et al.

Methodological quality of COVID-19 clinical research

Nat Commun. 2021 Feb 11;12(1):943. doi: 10.1038/s41467-021-21220-5.

COVID-19関連研究の質の検討
Zijun Wang, Fabian Schmidt, Yiska Weisblum et al.

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Nature. 2021 Feb 10. doi: 10.1038/s41586-021-03324-6.

新型コロナウイルスに対するmRNAワクチンで誘導される血清や複数のモノクローナル抗体の新規変異株への中和価
Ricardo Águas, Adam Mahdi, Rima Shretta et al.

Potential health and economic impacts of dexamethasone treatment for patients with COVID-19

Nat Commun. 2021 Feb 10;12(1):915. doi: 10.1038/s41467-021-21134-2.

COVID-19患者に対するデキサメタゾンの健康および経済への影響
Supaporn Wacharapluesadee, Chee Wah Tan, Patarapol Maneeorn et al.

Evidence for SARS-CoV-2 related coronaviruses circulating in bats and pangolins in Southeast Asia

Nat Commun. 2021 Feb 9;12(1):972. doi: 10.1038/s41467-021-21240-1.

東南アジアのコウモリとセンザンコウから検出されたSARS-CoV-2関連コロナウイルスのRNAやこれらに対する抗体の検出
Antoni G Wrobel, Donald J Benton, Pengqi Xu et al.

Structure and binding properties of Pangolin-CoV spike glycoprotein inform the evolution of SARS-CoV-2

Nat Commun. 2021 Feb 5;12(1):837. doi: 10.1038/s41467-021-21006-9.

センザンコウから検出されたコロナウイルスのスパイクタンパクの構造解析とACE2への結合能
Yang Liu, Jianying Liu, Hongjie Xia et al.

Neutralizing Activity of BNT162b2-Elicited Serum - Preliminary Report

N Engl J Med. 2021 Feb 17. doi: 10.1056/NEJMc2102017.

Pfizer/BioNTechの新型コロナワクチン（BNT162b2）接種後に誘発される抗体の中和活性
Jeffrey Shuren, Timothy Stenzel

The FDA's Experience with Covid-19 Antibody Tests

N Engl J Med. 2021 Feb 18;384(7):592-594. doi: 10.1056/NEJMp2033687.

新型コロナウイルスの抗体検査に関するFDAの経験について
Michael J Mina, Tim E Peto, Marta García-Fiñana, Malcolm G Semple, Iain E Buchan

Clarifying the evidence on SARS-CoV-2 antigen rapid tests in public health responses to COVID-19

Lancet. 2021 Feb 17;S0140-6736(21)00425-6. doi: 10.1016/S0140-6736(21)00425-6.

英国における新型コロナウイルスの抗原検査キットの公衆衛生対応上の意義についての論説
Robert A Raschke, Sumit Agarwal, Pooja Rangan, C William Heise, Steven C Curry

Discriminant Accuracy of the SOFA Score for Determining the Probable Mortality of Patients With COVID-19 Pneumonia Requiring Mechanical Ventilation

JAMA. 2021 Feb 17;e211545. doi: 10.1001/jama.2021.1545.

人工呼吸器を要するCOVID-19患者におけるSequential Organ Failure Assessment（SOFA）スコアの予後予測のための有用性の検討
Igor H Murai, Alan L Fernandes, Lucas P Sales et al.

Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial

JAMA. 2021 Feb 17;e2026848. doi: 10.1001/jama.2020.26848.

酸素使用が必要または基礎疾患のあるCOVID-19におけるビタミンDの単回高用量投与の入院日数の減少に対する有効性を評価したランダム化比較試験
Mulenga Mwenda, Ngonda Saasa, Nyambe Sinyange et al.

Detection of B.1.351 SARS-CoV-2 Variant Strain ― Zambia, December 2020

MMWR Morb Mortal Wkly Rep. 2021 Feb 26;70(8):280-282. doi: 10.15585/mmwr.mm7008e2.

ザンビアにおける南アフリカで最初に検出された新型コロナウイルスの変異株（B.1.351系統）の検出（2020年12月）
Jocelyn J Herstein, Abraham Degarege, Derry Stover et al.

Characteristics of SARS-CoV-2 Transmission among Meat Processing Workers in Nebraska, USA, and Effectiveness of Risk Mitigation Measures

Emerg Infect Dis. 2021 Feb 16;27(4). doi: 10.3201/eid2704.204800.

米国ネブラスカ州の食肉加工労働者における新型コロナウイルス流行の特徴と感染対策の有効性の検討
David Skegg, Peter Gluckman, Geoffrey Boulton et al.

Future scenarios for the COVID-19 pandemic

Lancet. 2021 Feb 27;397(10276):777-778. doi: 10.1016/S0140-6736(21)00424-4.

COVID-19パンデミックの今後のシナリオについての論説
Emma S Winkler, Pavlo Gilchuk, Jinsheng Yu et al.

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection

Cell. 2021 Feb 12. doi: 10.1016/j.cell.2021.02.026.

新型コロナウイルスに対する中和抗体におけるFc領域のエフェクター機能の必要性の検討
Joachim L. Schultze, Anna C. Aschenbrenner

COVID-19 and the human innate immune system

Cell. 2021 Feb 16. doi: 10.1016/j.cell.2021.02.029.

新型コロナウイルスに対する自然免疫応答に関するナラティブレビュー
Delfina Janiri, Angelo Carfì, Georgios D Kotzalidis et al.

Posttraumatic Stress Disorder in Patients After Severe COVID-19 Infection

JAMA Psychiatry. 2021 Feb 18;e210109. doi: 10.1001/jamapsychiatry.2021.0109.

重症COVID-19からの回復者における心的外傷後ストレス障害（PTSD）の発症についての黄疸研究
Purnema Madahar, Hannah Wunsch, Prabhat Jha, Arthur S Slutsky, Daniel Brodie

Trends in COVID-19-related in-hospital mortality: lessons learned from nationwide samples

Lancet Respir Med. 2021 Feb 15;S2213-2600(21)00080-1. doi: 10.1016/S2213-2600(21)00080-1.

COVID-19による院内死亡率の傾向についての論説
Annakan V Navaratnam, William K Gray, Jamie Day, Julia Wendon, Tim W R Briggs

Patient factors and temporal trends associated with COVID-19 in-hospital mortality in England: an observational study using administrative data

Lancet Respir Med. 2021 Feb 15;S2213-2600(20)30579-8. doi: 10.1016/S2213-2600(20)30579-8.

英国における経時的なCOVID-19による院内死亡率と死亡リスク因子解析
Commissioners of the Lancet COVID-19 Commission, Task Force Chairs and members of the Lancet COVID-19 Commission, Commission Secretariat and Staff of the Lancet COVID-19 Commission

Priorities for the COVID-19 pandemic at the start of 2021: statement of the Lancet COVID-19 Commission

Lancet. 2021 Feb 12;S0140-6736(21)00388-3. doi: 10.1016/S0140-6736(21)00388-3.

ランセットCOVID-19委員会による声明文：2021年のCOVID-19パンデミック対応における優先課題
Olivier J Wouters, Kenneth C Shadlen, Maximilian Salcher-Konrad et al.

Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment

Lancet. 2021 Feb 12;S0140-6736(21)00306-8. doi: 10.1016/S0140-6736(21)00306-8.

COVID-19ワクチンの世界的な普及への課題（生産、価格、配分、導入に重点をおいて）
Seth C Inzaule, Sofonias K Tessema, Yenew Kebede, Ahmed E Ogwell Ouma, John N Nkengasong

Genomic-informed pathogen surveillance in Africa: opportunities and challenges

Lancet Infect Dis. 2021 Feb 12;S1473-3099(20)30939-7. doi: 10.1016/S1473-3099(20)30939-7.

アフリカにおける病原体ゲノム情報に基づくサーベイランスの利点と課題について
The Lancet Infectious Diseases

The COVID-19 exit strategy-why we need to aim low

Lancet Infect Dis. 2021 Feb 11;S1473-3099(21)00080-3. doi: 10.1016/S1473-3099(21)00080-3

COVID-19パンデミックの出口戦略についてのエディトリアル
Arnaud Fontanet, Brigitte Autran, Bruno Lina et al.

SARS-CoV-2 variants and ending the COVID-19 pandemic

Lancet. 2021 Feb 11;S0140-6736(21)00370-6. doi: 10.1016/S0140-6736(21)00370-6.

新型コロナウイルスの変異株の出現とパンデミックの終結のための対策・対応についての論説
Laura Shallcross, Danielle Burke, Owen Abbott et al.

Factors associated with SARS-CoV-2 infection and outbreaks in long-term care facilities in England: a national cross-sectional survey

Lancet Healthy Longev. 2021 Feb 11. doi: 10.1016/S2666-7568(20)30065-9.

英国の高齢者福祉施設におけるSARS-CoV-2感染と関連するリスク因子解析のための全国横断調査
Munyaradzi Makoni

Tanzania refuses COVID-19 vaccines

Lancet. 2021 Feb 13;397(10274):566. doi: 10.1016/S0140-6736(21)00362-7.

タンザニア政府のワクチン導入拒否に関する概況
Joshua M Sharfstein, Jesse L Goodman, Luciana Borio

The US Regulatory System and COVID-19 Vaccines: The Importance of a Strong and Capable FDA

JAMA. 2021 Feb 15. doi: 10.1001/jama.2021.1961.

米国のCOVID-19ワクチンのレギュラトリーシステムにおけるFDAの役割と重要性
Jocelin Hall, Katherine Myall, Jodie L Lam et al.

Identifying patients at risk of post-discharge complications related to COVID-19 infection

Thorax. 2021 Feb 4;thoraxjnl-2020-215861. doi: 10.1136/thoraxjnl-2020-215861.

英国におけるCOVID-19後遺症の発症リスクを検討したコホート研究
Tom T Shimabukuro, Matthew Cole, John R Su

Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021

JAMA. 2021 Feb 12. doi: 10.1001/jama.2021.1967.

米国でCDCに報告されたPfizer-BioNTechおよびModernaのCOVID-19ワクチン接種後のアナフィラキシーの症例集積（2020年12月14日～2021年1月18日）
Suma Thomas, Divyang Patel, Barbara Bittel et al.

Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial

JAMA Netw Open. 2021 Feb 1;4(2):e210369. doi: 10.1001/jamanetworkopen.2021.0369.

COVID-19の外来患者における高用量の亜鉛とアスコルビン酸の症状持続期間・軽減に対する効果を評価したランダム化臨床試験
Rohit Vashisht, Ayan Patel, Bridgit O Crews et al.

Age- and Sex-Associated Variations in the Sensitivity of Serological Tests Among Individuals Infected With SARS-CoV-2

JAMA Netw Open. 2021 Feb 1;4(2):e210337. doi: 10.1001/jamanetworkopen.2021.0337.

新型コロナウイルスに対する抗体検査の感度の年齢や性別による変動の評価
David W Nauen, Jody E Hooper, C Matthew Stewart, Isaac H Solomon

Assessing Brain Capillaries in Coronavirus Disease 2019

JAMA Neurol. 2021 Feb 12. doi: 10.1001/jamaneurol.2021.0225.

COVID-19の剖検例における脳血管の病理学的解析
David A Edwards, Dennis Ausiello, Jonathan Salzman et al.

Exhaled aerosol increases with COVID-19 infection, age, and obesity

Proc Natl Acad Sci U S A. 2021 Feb 23;118(8):e2021830118. doi: 10.1073/pnas.2021830118.

健常者と霊長類感染モデルで評価した呼気中のエアロゾル排出量と新型コロナウイルス感染・年齢・肥満との相関
Erin Dunbar, Emily Godbout, Rachel Pryor, Henry J Rozycki, Gonzalo Bearman

Impact of COVID-19 Vaccination Program on Healthcare Worker Infections in an Academic Hospital

Infect Control Hosp Epidemiol. 2021 Feb 10;1-5. doi: 10.1017/ice.2021.62.

米国の大学病院におけるCOVID-19ワクチン接種プログラムやマスク、社会的距離の確保が医療従事者のSARS-CoV-2感染に与える影響について
M Khalid Ijaz, Raymond W Nims, Julie McKinney

Indirect transmission of SARS-CoV-2 infection: What do we know and what don't we know?

Infect Control Hosp Epidemiol. 2021 Feb 9;1-7. doi: 10.1017/ice.2021.57.

新型コロナウイルスの接触感染についての論説
Hayley A Thompson, Andria Mousa, Amy Dighe et al.

SARS-CoV-2 setting-specific transmission rates: a systematic review and meta-analysis

Clin Infect Dis. 2021 Feb 9;ciab100. doi: 10.1093/cid/ciab100.

新型コロナウイルスの2次感染率や再生産数に関するシステマティックレビュー・メタアナリシス
Xuping Xie, Yang Liu, Jianying Liu et al.

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

Nat Med. 2021 Feb 8. doi: 10.1038/s41591-021-01270-4.

ファイザーのワクチン（BTN162b2）2回接種後の血清の英国および南アフリカで最初に探知された変異株の変異を有するウイルスに対する中和能の評価
Jennifer N Rauch, Eric Valois, Jose Carlos Ponce-Rojas et al.

Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Screening Using Reverse Transcriptase-Quantitative Polymerase Chain Reaction or CRISPR-Based Assays in Asymptomatic College Students

JAMA Netw Open. 2021 Feb 1;4(2):e2037129. doi: 10.1001/jamanetworkopen.2020.37129.

無症候性の大学生を対象としたRT-qPCRおよびCRISPRを用いた検出系による新型コロナウイルススクリーニングの比較
Wenjuan Zhang, Brian D Davis, Stephanie S Chen et al.

Emergence of a Novel SARS-CoV-2 Variant in Southern California

JAMA. 2021 Feb 11. doi: 10.1001/jama.2021.1612.

南カリフォルニアで検出された新規変異株について
John T Brooks, Jay C Butler

Effectiveness of Mask Wearing to Control Community Spread of SARS-CoV-2

JAMA. 2021 Feb 10. doi: 10.1001/jama.2021.1505.

市中感染拡大抑制のためのマスクの有効性についての論説
Jennifer Abbasi

Researchers Investigate What COVID-19 Does to the Heart

JAMA. 2021 Feb 10. doi: 10.1001/jama.2021.0107.

COVID-19の心臓病変に関する論説
Can Liu, Andrew J. Martins, William W. Lau et al.

Time-resolved Systems Immunology Reveals a Late Juncture Linked to Fatal COVID-19

Cell. 2021 Feb 10; doi: 10.1016/j.cell.2021.02.018.

COVID-19患者の免疫応答の変遷と疾患の重症度および転帰との関連について
Romain Gasser, Marc Cloutier, Jérémie Prévost et al.

Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2

Cell Rep. 2021 Feb 10;108790. doi: 10.1016/j.celrep.2021.108790.

回復期のCOVID-19患者の血漿のSARS-CoV-2に対する中和活性におけるIgMの主な役割について
Agnes Bonifacius, Sabine Tischer-Zimmermann, Anna C Dragon et al.

COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses

Immunity. 2021 Feb 9;54(2):340-354.e6. doi: 10.1016/j.immuni.2021.01.008.

新型コロナウイルスに対する経時的な液性免疫と細胞性免疫の推移とこれらの免疫の季節性コロナウイルスへの交叉性
Elizabeth M. Anderson, Eileen C. Goodwin, Anurag Verma et al.

Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection

Cell. 2021 Feb 9; doi: 10.1016/j.cell.2021.02.010.

季節性コロナウイルスに対する抗体は新型コロナウイルス感染時に増加するが、新型コロナウイルスの感染防御とは相関しない
John T Brooks, Donald H Beezhold, John D Noti et al.

Maximizing Fit for Cloth and Medical Procedure Masks to Improve Performance and Reduce SARS-CoV-2 Transmission and Exposure, 2021

MMWR Morb Mortal Wkly Rep. 2021 Feb 19;70(7):254-257. doi: 10.15585/mmwr.mm7007e1.

布マスクと医療用マスクのフィッティングを最適化するための着用法についてのシミュレーション
Kimberly H Nguyen, Anup Srivastav, Hilda Razzaghi et al.

COVID-19 Vaccination Intent, Perceptions, and Reasons for Not Vaccinating Among Groups Prioritized for Early Vaccination ― United States, September and December 2020

MMWR Morb Mortal Wkly Rep. 2021 Feb 12;70(6):217-222. doi: 10.15585/mmwr.mm7006e3.

米国における接種の希望、理解、および接種を行わない理由に関するアンケート調査（2020年9月、12月）
COVID-19 Stats: Percentage of Middle and High School Students Aged 13-21 Years Attending In-Person Classes Who Reported Observing Fellow Students Wearing a Mask All the Time,* by School Setting and Activity - United States, October 2020

MMWR Morb Mortal Wkly Rep. 2021 Feb 12;70(6):223. doi: 10.15585/mmwr.mm7006a5.

通学している13～21歳の中学生および高校生における、様々な活動においてマスクを常時着用している生徒の割合（2020年10月）
Michael Klompas, Meghan A Baker, Chanu Rhee et al.

A SARS-CoV-2 Cluster in an Acute Care Hospital

Ann Intern Med. 2021 Feb 9. doi: 10.7326/M20-7567.

米国ボストンの病院（Brigham and Women's Hospital）におけるクラスター対応と症例対照研究
Francesca Crovetto, Fàtima Crispi, Elisa Llurba et al.

Impact of SARS-CoV-2 Infection on Pregnancy Outcomes: A Population-Based Study

Clin Infect Dis. 2021 Feb 8;ciab104. doi: 10.1093/cid/ciab104.

スペインにおける新型コロナウイルス感染が妊娠の転帰に及ぼす影響についての人口ベースのコホート研究
Angela Wahl, Lisa E Gralinski, Claire E Johnson et al.

SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801

Nature. 2021 Feb 9. doi: 10.1038/s41586-021-03312-w.

ヒトの肺組織を移植したマウスにおける抗ウイルス薬EIDD-2801の新型コロナウイルス感染に対する治療および予防効果
Lawrence O Gostin, Daniel A Salmon, Heidi J Larson

Mandating COVID-19 Vaccines

JAMA. 2021 Feb 9;325(6):532-533. doi: 10.1001/jama.2020.26553.

COVID-19ワクチンの義務化の合法性および倫理的妥当性についての論説
Emily A Largent, Franklin G Miller

Problems With Paying People to Be Vaccinated Against COVID-19

JAMA. 2021 Feb 9;325(6):534-535. doi: 10.1001/jama.2020.27121.

COVID-19ワクチン接種に対するインセンティブ供与の是非についての論説
Iain Beehuat Tan, Clive Tan, Li Yang Hsu et al.

Prevalence and Outcomes of SARS-CoV-2 Infection Among Migrant Workers in Singapore

JAMA. 2021 Feb 9;325(6):584-585. doi: 10.1001/jama.2020.24071.

シンガポールの外国人労働者における新型コロナウイルス感染の有病率と転帰
Peter F Rebeiro, David M Aronoff, M Kevin Smith

The Impact of State Mask-Wearing Requirements on the Growth of COVID-19 Cases in the United States

Clin Infect Dis. 2021 Feb 7;ciab101. doi: 10.1093/cid/ciab101.

米国の各州におけるマスク着用義務化のタイミングとCOVID-19発生率の変遷の相関
Christelle Elias, Abel Sekri, Pierre Leblanc, Michel Cucherat, Philippe Vanhems

Incubation period of COVID-19: a meta-analysis

Int J Infect Dis. 2021 Feb 3;S1201-9712(21)00081-3. doi: 10.1016/j.ijid.2021.01.069.

新型コロナウイルスの潜伏期間のメタアナリシス
Ross Martin, Jiani Li, Aiyappa Parvangada et al.

Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir

Antiviral Res. 2021 Feb 5;188:105033. doi: 10.1016/j.antiviral.2021.105033.

ヒトやミンクで確認された新型コロナウイルス変異株のレムデシビル耐性についての評価
Oliver T R Toovey, Kirsty N Harvey, Paul W Bird, Julian Wei-Tze Wei-Tze Tang

Introduction of Brazilian SARS-CoV-2 484K.V2 related variants into the UK

J Infect. 2021 Feb 3;S0163-4453(21)00047-5. doi: 10.1016/j.jinf.2021.01.025.

新型コロナウイルスの新規変異株484K.V2のブラジルから英国への輸入
Kevin R McCarthy, Linda J Rennick, Sham Nambulli et al.

Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape

Science. 2021 Feb 3;eabf6950. doi: 10.1126/science.abf6950.

新型コロナウイルスの抗体からの逃避を引き起こす複数の系統で認められる塩基欠失の解析
Emily H Adhikari, Catherine Y Spong

COVID-19 Vaccination in Pregnant and Lactating Women

JAMA. 2021 Feb 8. doi: 10.1001/jama.2021.1658.

妊娠中および授乳中の女性へのCOVID-19ワクチン接種に関する論説
Sonja A Rasmussen, Denise J Jamieson

Pregnancy, Postpartum Care, and COVID-19 Vaccination in 2021

JAMA. 2021 Feb 8. doi: 10.1001/jama.2021.1683.

妊娠中および授乳中の女性へのCOVID-19ワクチン接種に関する論説2
Dennis Egger, Edward Miguel, Shana S Warren et al.

Falling living standards during the COVID-19 crisis: Quantitative evidence from nine developing countries

Sci Adv. 2021 Feb 5;7(6):eabe0997. doi: 10.1126/sciadv.abe0997.

アフリカ、アジア、ラテンアメリカの発展途上国9ヶ国におけるCOVID-19パンデミック下の生活水準の低下
Sahil Loomba, Alexandre de Figueiredo, Simon J Piatek, Kristen de Graaf, Heidi J Larson

Measuring the impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA

Nat Hum Behav. 2021 Feb 5. doi: 10.1038/s41562-021-01056-1.

英国および米国における誤った情報によるCOVID-19ワクチン接種是非への影響を検討したランダム化比較試験
Adva Gadoth, Megan Halbrook, Rachel Martin-Blais et al.

Cross-sectional Assessment of COVID-19 Vaccine Acceptance Among Health Care Workers in Los Angeles

Ann Intern Med. 2021 Feb 9. doi: 10.7326/M20-7580.

米国ロサンゼルスの医療従事者におけるCOVID-19ワクチン接種是非に関するアンケート調査
Allison J Greaney, Andrea N Loes, Katharine H D Crawford et al.

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies

Cell Host Microbe. 2021 Feb 8;S1931-3128(21)00082-2. doi: 10.1016/j.chom.2021.02.003.

ヒトのポリクローナル抗体から逃避する新型コロナウイルスの受容体結合ドメイン（RBD）の変異の網羅的マッピング
Otávio M Espíndola, Yago C P Gomes, Carlos Otávio Brandão et al.

Inflammatory cytokine patterns associated with neurological diseases in COVID-19

Ann Neurol. 2021 Feb 6. doi: 10.1002/ana.26041.

COVID-19の神経症状に関連する血中および脳脊髄液中の炎症性サイトカイン
Heesoo Joo, Gabrielle F Miller, Gregory Sunshine et al.

Decline in COVID-19 Hospitalization Growth Rates Associated with Statewide Mask Mandates - 10 States, March-October 2020

MMWR Morb Mortal Wkly Rep. 2021 Feb 12;70(6):212-216. doi: 10.15585/mmwr.mm7006e2.

米国の10州におけるマスク着用義務化と時系列的相関を認めたCOVID-19による入院増加率の低減（2020年3月～10月）
Lisa C Barrios, Margaret A Riggs, Ridgely Fisk Green et al.

Observed Face Mask Use at Six Universities - United States, September-November 2020

MMWR Morb Mortal Wkly Rep. 2021 Feb 12;70(6):208-211. doi: 10.15585/mmwr.mm7006e1.

米国のマスク着用が義務づけられている6大学におけるマスク着用率とマスク着用者における正しく着用している者の割合（2020年9月～11月）
Alvin Kuo Jing Teo, Yukti Choudhury, Iain Beehuat Tan et al.

Saliva is more sensitive than nasopharyngeal or nasal swabs for diagnosis of asymptomatic and mild COVID-19 infection

Sci Rep. 2021 Feb 4;11(1):3134. doi: 10.1038/s41598-021-82787-z.

シンガポールにおける唾液、鼻咽頭ぬぐい液、鼻腔拭い液を利用した検査感度の比較
Steven A Kemp, Dami A Collier, Rawlings P Datir et al.

SARS-CoV-2 evolution during treatment of chronic infection

Nature. 2021 Feb 5. doi: 10.1038/s41586-021-03291-y.

新型コロナウイルス慢性感染患者における回復後血漿による治療前後で認めたウイルスゲノムの変異
Jordan J Feld, Christopher Kandel, Mia J Biondi et al.

Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial

Lancet Respir Med. 2021 Feb 5;S2213-2600(20)30566-X. doi: 10.1016/S2213-2600(20)30566-X.

軽症COVID-19患者に対してペグインターフェロンラムダまたはプラセボを使用した第2相ランダム化比較試験
Sangeeta Mehta, Flavia Machado, Arthur Kwizera et al.

COVID-19: a heavy toll on health-care workers

Lancet Respir Med. 2021 Feb 5;S2213-2600(21)00068-0. doi: 10.1016/S2213-2600(21)00068-0.

COVID-19パンデミックが医療従事者に及ぼす影響についての論説
Thomas Roederer, Bastien Mollo, Charline Vincent et al.

Seroprevalence and risk factors of exposure to COVID-19 in homeless people in Paris, France: a cross-sectional study

Lancet Public Health. 2021 Feb 5;S2468-2667(21)00001-3. doi: 10.1016/S2468-2667(21)00001-3.

フランス・パリのホームレスにおけるCOVID-19の血清疫学調査
Michaël Schwarzinger, Verity Watson, Pierre Arwidson, François Alla, Stéphane Luchini

COVID-19 vaccine hesitancy in a representative working-age population in France: a survey experiment based on vaccine characteristics

Lancet Public Health. 2021 Feb 5;S2468-2667(21)00012-8. doi: 10.1016/S2468-2667(21)00012-8.

フランス生産年齢人口におけるCOVID-19ワクチン接種の是非に関するアンケート調査
Daniela Lucidi, Giulia Molinari, Martina Silvestri et al.

Patient-reported olfactory recovery after SARS-CoV-2 infection: A 6-month follow-up study

Int Forum Allergy Rhinol. 2021 Feb 4. doi: 10.1002/alr.22775.

SARS-CoV-2感染6ヶ月後の嗅覚障害の回復度
Radhika Gharpure, Angela Guo, Courtney Krier Bishnoi et al.

Early COVID-19 First-Dose Vaccination Coverage Among Residents and Staff Members of Skilled Nursing Facilities Participating in the Pharmacy Partnership for Long-Term Care Program - United States, December 2020-January 2021

MMWR Morb Mortal Wkly Rep. 2021 Feb 5;70(5):178-182. doi: 10.15585/mmwr.mm7005e2.

米国の高齢者福祉施設の居住者と職員を対象としたCOVID-19ワクチン接種率（2020年12月～2021年1月）
Sharon Amit, Sharon Alexsandra Beni, Asaf Biber et al.

Post-Vaccination COVID-19 among Healthcare Workers, Israel

Emerg Infect Dis. 2021 Feb 1;27(4). doi: 10.3201/eid2704.210016.

イスラエルの医療従事者におけるワクチン接種後10日目までのCOVID-19の症例集積
Denis Y Logunov, Inna V Dolzhikova, Dmitry V Shcheblyakov et al.

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Lancet. 2021 Feb 2;S0140-6736(21)00234-8. doi: 10.1016/S0140-6736(21)00234-8.

ロシアのアデノウイルスベクターワクチンGam-COVID-Vac（Sputnik V）の第3相臨床試験
Michael Marks, Pere Millat-Martinez, Dan Ouchi et al.

Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study

Lancet Infect Dis. 2021 Feb 2;S1473-3099(20)30985-3. doi: 10.1016/S1473-3099(20)30985-3.

スペイン・カタルーニャの282クラスターにおける感染リスク因子解析
Houriiyah Tegally, Eduan Wilkinson, Richard J Lessells et al.

Sixteen novel lineages of SARS-CoV-2 in South Africa

Nat Med. 2021 Feb 2. doi: 10.1038/s41591-021-01255-3.

南アフリカにおける新型コロナウイルスゲノム解析
RECOVERY Collaborative Group

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Lancet. 2021 Feb 13;397(10274):605-612. doi: 10.1016/S0140-6736(21)00149-5.

RECOVERYプラットフォームを利用したCOVID-19入院患者におけるアジスロマイシンの有効性を検討したランダム化比較試験
Wayne C Koff, Theodore Schenkelberg, Tere Williams et al.

Development and deployment of COVID-19 vaccines for those most vulnerable

Sci Transl Med. 2021 Feb 3;13(579):eabd1525. doi: 10.1126/scitranslmed.abd1525.

高齢者や基礎疾患のある者へのCOVID-19ワクチン開発と導入についての論説
Annette B Vogel, Isis Kanevsky, Ye Che et al.

Immunogenic BNT162b vaccines protect rhesus macaques from SARS-CoV-2

Nature. 2021 Feb 1. doi: 10.1038/s41586-021-03275-y.

Pfizer/BioNTechのCOVID-19ワクチン（BNT162b1/BNT162b2）接種はアカゲザルの新型コロナウイルス神瀬を防御する
The Lancet

Genomic sequencing in pandemics

Lancet. 2021 Feb 6;397(10273):445. doi: 10.1016/S0140-6736(21)00257-9.

新型コロナウイルスゲノム解析・ウイルスゲノムサーベイランスの有用性と留意点についての論説
Jeremy Guenezan, Magali Garcia, Deidre Strasters et al.

Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Nasopharyngeal Viral Load in Patients With COVID-19: A Randomized Clinical Trial

JAMA Otolaryngol Head Neck Surg. 2021 Feb 4;e205490. doi: 10.1001/jamaoto.2020.5490.

COVID-19患者における0.5%ポビドンヨード（マウスウォッシュ、うがい薬、および点鼻薬）による鼻咽頭のウイルス量の減少への効果を検討したランダム化比較試験
Aurélien Sokal, Pascal Chappert, Giovanna Barba-Spaeth et al.

Maturation and persistence of the anti-SARS-CoV-2 memory B cell response

Cell. 2021 Feb 2;S0092-8674(21)00093-3. doi: 10.1016/j.cell.2021.01.050.

軽症および重症のCOVID-19患者におけるメモリーB細胞応答の感染6ヶ月後までの縦断的解析
Anthony Zheng, Laksmi S Govindasamy, Jane Thomas et al.

Lessons from a successful public health response to COVID-19 in a New South Wales residential aged care facility, 2020

Aust N Z J Public Health. 2021 Feb;45(1):13-16. doi: 10.1111/1753-6405.13077.

オーストラリア・ニューサウスウェールズ州の老人介護施設におけるCOVID-19アウトブレイクに対する公衆衛生対応
Silvia Stringhini, María-Eugenia Zaballa, Javier Perez-Saez et al.

Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak

Lancet Infect Dis. 2021 Feb 1;S1473-3099(21)00054-2. doi: 10.1016/S1473-3099(21)00054-2.

スイスのジュネーブにおける第2波ピーク後（11月下旬から12月下旬）に行われた血清疫学調査
Naïm Ouldali, Julie Toubiana, Denise Antona et al.

Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children

JAMA. 2021 Feb 1. doi: 10.1001/jama.2021.0694.

小児多臓器炎症症候群（MIS-C）における発熱持続と静脈内免疫グロブリン（IVIG）単独またはメチルプレドニゾロン併用との相関についてのサーベイランス研究
Russell M Viner, Oliver T Mytton, Chris Bonell et al.

Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults: A Systematic Review and Meta-analysis

JAMA Pediatr. 2021 Feb 1;175(2):143-156. doi: 10.1001/jamapediatrics.2020.4573.

成人と比較した小児および思春期の若年者のSARS-CoV-2感染に対する感受性についてのシステマティックレビュー・メタアナリシス
Dani Dumitriu, Ukachi N Emeruwa, Erin Hanft et al.

Outcomes of Neonates Born to Mothers With Severe Acute Respiratory Syndrome Coronavirus 2 Infection at a Large Medical Center in New York City

JAMA Pediatr. 2021 Feb 1;175(2):157-167. doi: 10.1001/jamapediatrics.2020.4298.

米国ニューヨーク市の大規模医療センターで新型コロナウイルス感染症の母親から生まれた新生児の臨床経過
Kevin A Brown, Aaron Jones, Nick Daneman et al.

Association Between Nursing Home Crowding and COVID-19 Infection and Mortality in Ontario, Canada

JAMA Intern Med. 2021 Feb 1;181(2):229-236. doi: 10.1001/jamainternmed.2020.6466.

カナダのオンタリオ州における老人ホームの過密度合いと新型コロナウイルス感染および死亡率との関連
Sujan K Dhar, Vishnupriyan K, Sharat Damodar, Shashi Gujar, Manjula Das

IL-6 and IL-10 as predictors of disease severity in COVID-19 patients: results from meta-analysis and regression

Heliyon. 2021 Feb;7(2):e06155. doi: 10.1016/j.heliyon.2021.e06155.

COVID-19患者の重症度の予測因子としてのIL-6およびIL-10を評価したメタアナリシスと回帰分析
Shahzad Shaefi, Samantha K Brenner, Shruti Gupta et al.

Extracorporeal membrane oxygenation in patients with severe respiratory failure from COVID-19

Intensive Care Med. 2021 Feb 2;1-14. doi: 10.1007/s00134-020-06331-9.

米国の複数の医療機関における体外式膜型人工肺（ECMO）使用の死亡率への影響の効果を検討したコホート研究
R A Armstrong, A D Kane, E Kursumovic, F C Oglesby, T M Cook

Mortality in patients admitted to intensive care with COVID-19: an updated systematic review and meta-analysis of observational studies

Anaesthesia. 2021 Feb 1. doi: 10.1111/anae.15425.

COVID-19で集中治療室に入室した患者の死亡率についてのシステマティックレビュー・メタアナリシス
Carles Bautista-Rodriguez, Joan Sanchez-de-Toledo, Bradley C Clark et al.

Multisystem Inflammatory Syndrome in Children: An International Survey

Pediatrics. 2021 Feb;147(2):e2020024554. doi: 10.1542/peds.2020-024554.

小児多臓器炎症症候群（MIS-C）の症状、経過、重症化の予測因子に関する複数国での後ろ向き研究
Theresa Andrasfay, Noreen Goldman

Reductions in 2020 US life expectancy due to COVID-19 and the disproportionate impact on the Black and Latino populations

Proc Natl Acad Sci U S A. 2021 Feb 2;118(5):e2014746118. doi: 10.1073/pnas.2014746118.

2020年の米国におけるCOVID-19による平均余命の短縮と、黒人およびヒスパニックにおける平均余命の不均衡な影響
İsmail Salcan, Faruk KarakeÜili, Sara Salcan et al.

Is taste and smell impairment irreversible in COVID-19 patients?

Eur Arch Otorhinolaryngol. 2021 Feb;278(2):411-415. doi:10.1007/s00405-020-06560-0.

COVID-19患者における味覚障害と嗅覚障害の持続性についてのコホート研究
January 2021
Christine M Szablewski, Karen T Chang, Clinton J McDaniel et al.

SARS-CoV-2 Transmission Dynamics in a Sleep-Away Camp

Pediatrics. 2021 Jan 27;e2020046524. doi: 10.1542/peds.2020-046524.

米国ジョージア州のユースキャンプにおける数例の感染源を発端としたアウトブレイク
Peter Richmond, Lara Hatchuel, Min Dong et al.

Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial

Lancet. 2021 Jan 29;S0140-6736(21)00241-5. doi: 10.1016/S0140-6736(21)00241-5.

Clover Biopharmaceuticalsによる組換えタンパクワクチン（SCB-2019）の第1相臨床試験
Dustin D Flannery, Sigrid Gouma, Miren B Dhudasia et al.

Assessment of Maternal and Neonatal Cord Blood SARS-CoV-2 Antibodies and Placental Transfer Ratios

JAMA Pediatr. 2021 Jan 29;e210038. doi: 10.1001/jamapediatrics.2021.0038.

米国フィラデルフィアにおける母体血および新生児の臍帯血中の新型コロナウイルスに対する抗体の相関および胎盤移行率の調査
Edwards Pradenas, Benjamin Trinité, Víctor Urrea et al.

Stable neutralizing antibody levels six months after mild and severe COVID-19 episode

Med (N Y). 2021 Jan 31. doi: 10.1016/j.medj.2021.01.005.

軽症および重症COVID-19からの回復者における発症6か月後までのシュードタイプウイルスを用いたSARS-CoV-2に対する中和抗体価の経時的評価
Rapat Pittayanon, Natee Faknak, Prooksa Ananchuensook et al.

Amount of contamination on the face shield of endoscopists during upper endoscopy between patients in two positions: a randomized study

J Gastroenterol Hepatol. 2021 Jan 28. doi: 10.1111/jgh.15416.

左側臥位または腹臥位の患者に上部消化管内視鏡を施行した際のATP測定によるフェイスシールド汚染量を測定したランダム化比較試験
Takako Miki, Shohei Yamamoto, Yosuke Inoue et al.

Association between living with others and depressive symptoms in Japanese hospital workers during the COVID-19 pandemic

Psychiatry Clin Neurosci. 2021 Jan 28. doi: 10.1111/pcn.13206.

国立国際医療研究センターの医療従事者におけるパンデミック下での抑うつ症状と同居者の有無との相関
Yang Li, Hongjie Hou, Jie Diao, Yadong Wang, Haiyan Yang

Neutrophil-to-lymphocyte ratio is independently associated with COVID-19 severity: An updated meta-analysis based on adjusted effect estimates

Int J Lab Hematol. 2021 Jan 27. doi: 10.1111/ijlh.13475.

好中球/リンパ球比（NLR）とCOVID-19の重症度との関連性についてのメタアナリシス
Jean-Baptiste Lascarrou, Gwenhael Colin, Aurélie Le Thuaut et al.

Predictors of negative first SARS-CoV-2 RT-PCR despite final diagnosis of COVID-19 and association with outcome

Sci Rep. 2021 Jan 27;11(1):2388. doi: 10.1038/s41598-021-82192-6.

最初のRT-PCR検査で偽陰性であったCOVID-19患者における臨床的特徴に関する多施設共同症例対照研究
Mujan Varasteh Kia, Brandyn D Lau, Oluwafemi P Owodunni et al.

Nonadministration of pharmacologic venous thromboembolism prophylaxis is less common in hospitalized patients with COVID-19

J Thromb Thrombolysis. 2021 Jan 28;1-5. doi: 10.1007/s11239-021-02384-9.

COVID-19で入院した患者とその他の患者における静脈血栓塞栓症（VTE）予防のための抗凝固薬の使用状況や使用忘れとVTE発症との比較
Julia M Baker, Kristin N Nelson, Elizabeth Overton et al.

Quantification of Occupational and Community Risk Factors for SARS-CoV-2 Seropositivity Among Health Care Workers in a Large U.S. Health Care System

Ann Intern Med. 2021 Jan 29. doi: 10.7326/M20-7145.

米国・アトランタの大規模医療機関グループにおける医療従事者の職業上および市中関連の曝露による新型コロナウイルス抗体陽性のリスク因子解析
Alexander Muik, Ann-Kathrin Wallisch, Bianca Sänger et al.

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera

Science. 2021 Jan 29;eabg6105. doi: 10.1126/science.abg6105.

Pfizer/BioNTechのワクチン（のBNT162b）接種後の血清によるB.1.1.7（英国変異株）と同様の変異を持つシュードタイプウイルスの中和試験結果
Michael A Martin, David VanInsberghe, Katia Koelle

Insights from SARS-CoV-2 sequences

Science. 2021 Jan 29;371(6528):466-467. doi: 10.1126/science.abf3995.

新型コロナウイルスゲノムの配列決定と関連するメタデータの充実によるヒトへのスピルオーバーのタイミングの推定、ウイルス流行の傾向分析、ウイルスの新しい宿主への適応の分析などについての論説
Tyler N Starr, Allison J Greaney, Amin Addetia et al.

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

Science. 2021 Jan 25;eabf9302. doi: 10.1126/science.abf9302.

RegeneronおよびEli Lilyのモノクローナル抗体医薬から逃避する新型コロナウイルスの受容体結合ドメイン（RBD）変異のマッピング
C Garrett Rappazzo, Longping V Tse, Chengzi I Kaku et al.

Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody

Science. 2021 Jan 25;eabf4830. doi: 10.1126/science.abf4830.

SARSやこれに類似のコロナウイルスにユニバーサルに強い活性をもつヒトモノクローナル抗体の分析
Kris M White, Romel Rosales, Soner Yildiz et al.

Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A

Science. 2021 Jan 25;eabf4058. doi: 10.1126/science.abf4058.

新型コロナウイルスに対し高い抗ウイルス活性を有するプリチデプシン（アプリジン）のマウス感染モデルにおける有効性の評価
Philip J M Brouwer, Mitch Brinkkemper, Pauline Maisonnasse et al.

Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection

Cell. 2021 Jan 25; doi:10.1016/j.cell.2021.01.035.

カニクイザルにおける組換えタンパクワクチンによるSARS-CoV-2感染予防効果
Timothy A Bates, Jules B Weinstein, Scotland Farley et al.

Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2

Cell Rep. 2021 Jan 26;108737. doi: 10.1016/j.celrep.2021.108737.

SARS-CoVに対する抗体のSARS-CoV-2への交叉性
Emma C Thomson, Laura E Rosen, James G Shepherd et al.

Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

Cell, 2021 Jan 28; doi:10.1016/j.cell.2021.01.037

複数の変異株で認められるスパイクタンパク変異の一つであるN439Kの疫学的、臨床的、分子生物学的解析
Maureen J Miller, Lanfang Xu, Jin Qin et al.

Impact of COVID-19 on Cervical Cancer Screening Rates Among Women Aged 21-65 Years in a Large Integrated Health Care System - Southern California, January 1-September 30, 2019, and January 1-September 30, 2020

MMWR Morb Mortal Wkly Rep. 2021 Jan 29;70(4):109-113. doi: 10.15585/mmwr.mm7004a1.

米国・南カリフォルニアの大規模医療機関グループにおける21～65歳の女性の子宮頸がんスクリーニング率に対するパンデミックの影響（2019年1月1日～9月30日、2020年1月1日～9月30日）
Ian W Pray, Anna Kocharian, Jordan Mason, Ryan Westergaard, Jonathan Meiman

Trends in Outbreak-Associated Cases of COVID-19 - Wisconsin, March-November 2020

MMWR Morb Mortal Wkly Rep. 2021 Jan 29;70(4):114-117. doi: 10.15585/mmwr.mm7004a2.

米国ウィスコンシン州における2020年3月～11月のCOVID-19アウトブレイクの傾向
Mark D Fox, David C Bailey, Michael D Seamon, Marie Lynn Miranda

Response to a COVID-19 Outbreak on a University Campus - Indiana, August 2020

MMWR Morb Mortal Wkly Rep. 2021 Jan 29;70(4):118-122. doi: 10.15585/mmwr.mm7004a3.

米国インディアナ州の大学のキャンパスにおけるCOVID-19アウトブレイク対応（2020年8月）
Christine Atherstone, Molly Siegel, Emily Schmitt-Matzen et al.

SARS-CoV-2 Transmission Associated with High School Wrestling Tournaments - Florida, December 2020-January 2021

MMWR Morb Mortal Wkly Rep. 2021 Jan 29;70(4):141-143. doi: 10.15585/mmwr.mm7004e4.

米国フロリダ州における高校のレスリングトーナメントに関連するSARS-CoV-2感染の報告(2020年12月～2021年1月）
Amy Falk, Alison Benda, Peter Falk et al.

COVID-19 Cases and Transmission in 17 K-12 Schools - Wood County, Wisconsin, August 31-November 29, 2020

MMWR Morb Mortal Wkly Rep. 2021 Jan 29;70(4):136-140. doi: 10.15585/mmwr.mm7004e3.

米国ウィスコンシン州ウッド郡の17のK-12（幼稚園から高校まで）におけるCOVID-19のサーベイランス研究（2020年8月31日～11月29日）
Kanecia O Zimmerman, Ibukunoluwa C Akinboyo, M Alan Brookhart et al.

Incidence and Secondary Transmission of SARS-CoV-2 Infections in Schools

Pediatrics. 2021 Jan 8;e2020048090. doi: 10.1542/peds.2020-048090.

米国ノースカロライナ州で学校を再開した11学校区のK-12（幼稚園から高校まで）におけるCOVID-19のサーベイランス研究
Jeffrey M Kubiak, Elisabeth A Murphy, Jim Yee et al.

SARS-CoV-2 serology levels in pregnant women and their neonates

Am J Obstet Gynecol. 2021 Jan 23;S0002-9378(21)00053-3. doi: 10.1016/j.ajog.2021.01.016.

妊婦の抗体価と臨床的特徴や新生児の臍帯血における抗体価との相関
Elizabeth Partridge, Ellen McCleery, Ritu Cheema et al.

Evaluation of Seasonal Respiratory Virus Activity Before and After the Statewide COVID-19 Shelter-in-Place Order in Northern California

JAMA Netw Open. 2021 Jan 4;4(1):e2035281. doi: 10.1001/jamanetworkopen.2020.35281.

米国カリフォルニア北部における外出禁止令発出前後の季節性のある呼吸器ウイルスの流行評価
Katherine E Lowe, Joe Zein, Umur Hatipoglu, Amy Attaway

Association of Smoking and Cumulative Pack-Year Exposure With COVID-19 Outcomes in the Cleveland Clinic COVID-19 Registry

JAMA Intern Med. 2021 Jan 25;e208360. doi: 10.1001/jamainternmed.2020.8360.

米国クリーブランドクリニックにおける喫煙歴とCOVID-19による入院率、死亡率との相関
Kimberly E Hanson, Angela M Caliendo, Cesar A Arias et al.

The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing

Clin Infect Dis. 2021 Jan 22;ciab048. doi: 10.1093/cid/ciab048.

COVID-19の診断に関する米国感染症学会（IDSA）ガイドライン
Sean Wei Xiang Ong , Yian Kim Tan, Kristen Kelli Coleman et al.

Lack of viable severe acute respiratory coronavirus virus 2 (SARS-CoV-2) among PCR-positive air samples from hospital rooms and community isolation facilities

Infect Control Hosp Epidemiol. 2021 Jan 25;1-6. doi: 10.1017/ice.2021.8.

シンガポールにおける新型コロナウイルス感染者の病室や隔離施設で採取され、新型コロナウイルスのRNAを認めた空気サンプルでは感染性のあるウイルス粒子を認めなかった
Jeong Yun Yang, Michael D Parkins, Andrew Canakis et al.

Outcomes of COVID-19 Among Hospitalized Health Care Workers in North America

JAMA Netw Open. 2021 Jan 4;4(1):e2035699. doi: 10.1001/jamanetworkopen.2020.35699.

北米の複数の医療機関の医療従事者（HCW）におけるCOVID-19の重症化率、死亡率の報告
Katlyn Nemani, Chenxiang Li, Mark Olfson et al.

Association of Psychiatric Disorders With Mortality Among Patients With COVID-19

JAMA Psychiatry. 2021 Jan 27;e204442. doi: 10.1001/jamapsychiatry.2020.4442.

COVID-19患者の死亡率と精神疾患の既往との相関
Mattia Bellan, Daniele Soddu, Piero Emilio Balbo et al.

Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge

JAMA Netw Open. 2021 Jan 4;4(1):e2036142. doi: 10.1001/jamanetworkopen.2020.36142.

COVID-19患者の退院3-4か月後の身体的・精神的後遺症の評価
Monita Karmakar, Paula M Lantz, Renuka Tipirneni

Association of Social and Demographic Factors With COVID-19 Incidence and Death Rates in the US

JAMA Netw Open. 2021 Jan 4;4(1):e2036462. doi: 10.1001/jamanetworkopen.2020.36462.

米国における社会経済的背景因子とCOVID-19発生率および死亡率との関連
Hanny Al-Samkari, Shruti Gupta, Rebecca Karp Leaf et al.

Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients With COVID-19

Ann Intern Med. 2021 Jan 26. doi: 10.7326/M20-6739.

COVID-19重症例における早期の抗凝固薬使用の効果を検討した多施設コホート研究
Viviane C Veiga, João A G G Prats, Danielle L C Farias et al.

Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial

BMJ. 2021 Jan 20;372:n84. doi: 10.1136/bmj.n84.

COVID-19中等症・重症例におけるトシリズマブ使用15日後の臨床的アウトカムを評価したランダム化比較試験
Robert L Gottlieb, Ajay Nirula, Peter Chen et al.

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial

JAMA. 2021 Jan 21;e210202. doi: 10.1001/jama.2021.0202.

COVID-19軽症例におけるbamlanivimab・etesevimabの併用療法またはbamlanivimab単独療法のウイルス量への影響を評価したランダム化比較試験
Matthew A Crane, Kenneth M Shermock, Saad B Omer et al.

Change in Reported Adherence to Nonpharmaceutical Interventions During the COVID-19 Pandemic, April-November 2020

JAMA. 2021 Jan 22;e210286. doi: 10.1001/jama.2021.0286.

米国における2020年4月から11月までの一般市民の感染対策の遵守率の変遷についてのアンケート調査
Burkhard Tönshoff, Barbara Müller, Roland Elling et al.

Prevalence of SARS-CoV-2 Infection in Children and Their Parents in Southwest Germany

JAMA Pediatr. 2021 Jan 22;e210001. doi: 10.1001/jamapediatrics.2021.0001.

ドイツ南西部の小児と親におけるPCRと抗体検査を組み合わせた有病率の調査
Eva Leidman, Lindsey M Duca, John D Omura et al.

COVID-19 Trends Among Persons Aged 0-24 Years - United States, March 1-December 12, 2020

MMWR Morb Mortal Wkly Rep. 2021 Jan 22;70(3):88-94. doi: 10.15585/mmwr.mm7003e1.

米国における0-24歳におけるCOVID-19の変遷（2020年3月1日～12月12日）
Benido Impouma, Franck Mboussou, Francis Kasolo, Zabulon Yoti, Matshidiso R Moeti

Preparing for a COVID-19 resurgence in the WHO African region

Lancet. 2021 Jan 30;397(10272):373. doi: 10.1016/S0140-6736(20)32725-2.

アフリカにおけるCOVID-19症例数再増への対策についてのWHOアフリカ地域事務局による論説
Jessica L Prince-Guerra, Olivia Almendares, Leisha D Nolen et al.

Evaluation of Abbott BinaxNOW Rapid Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites - Pima County, Arizona, November 3-17, 2020

MMWR Morb Mortal Wkly Rep. 2021 Jan 22;70(3):100-105. doi: 10.15585/mmwr.mm7003e3.

米国アリゾナ州の2カ所の検査場におけるAbbottの新型コロナウイルス抗原検査の評価（2020年11月3日～11月17日）
Christina D Mack, Erin B Wasserman, Cria G Perrine et al.

Implementation and Evolution of Mitigation Measures, Testing, and Contact Tracing in the National Football League, August 9-November 21, 2020

MMWR Morb Mortal Wkly Rep. 2021 Jan 29;70(4):130-135. doi: 10.15585/mmwr.mm7004e2.

米国ナショナルフットボールリーグにおける感染対策、検査、接触者追跡の実施と変遷（2020年8月9日～11月21日）
CDC COVID-19 Response Team, Food and Drug Administration

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021

MMWR Morb Mortal Wkly Rep. 2021 Jan 29;70(4):125-129. doi: 10.15585/mmwr.mm7004e1.

米国におけるModerna社のCOVID-19ワクチン1回目接種後のアナフィラキシーを含むアレルギー反応の報告（2020年12月21日-2021年1月10日）
Samira Sami, Lara J Akinbami, Lyle R Petersen et al.

Prevalence of SARS-CoV-2 Antibodies in First Responders and Public Safety Personnel, New York City, New York, USA, May-July 2020

Emerg Infect Dis. 2021 Jan 25;27(3). doi: 10.3201/eid2703.204340.

米国ニューヨーク市の警察官、救急隊員、消防隊員、医療従事者、刑務官、検視官等公共サービスを提供する者におけるSARS-CoV-2に対する抗体保有割合（2020年5月～7月）
Ornella Punzo, Stefania Bellino, Luigi Palmieri et al.

Clinical characteristics of individuals under 40 years of age who died with COVID-19 in Italy

J Med Virol. 2021 Jan 22. doi: 10.1002/jmv.26788.

イタリアにおけるCOVID-19関連で死亡した40歳未満の患者の臨床的特徴
Kimberly D Spencer, Christina L Chung, Alison Stargel et al.

COVID-19 Case Investigation and Contact Tracing Efforts from Health Departments - United States, June 25-July 24, 2020

MMWR Morb Mortal Wkly Rep. 2021 Jan 22;70(3):83-87. doi: 10.15585/mmwr.mm7003a3.

米国各州の保健局によるCOVID-19の積極的疫学調査と接触者追跡（2020年6月25日～7月24日）
Raches Ella, Krishna Mohan Vadrevu, Harsh Jogdand et al.

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Lancet Infect Dis. 2021 Jan 21;S1473-3099(20)30942-7. doi: 10.1016/S1473-3099(20)30942-7.

Bharat Biotech社による新型コロナウイルスの全粒子不活化ワクチン（BBV152）の第1相臨床試験の結果
Daniel P Oran, Eric J Topol

The Proportion of SARS-CoV-2 Infections That Are Asymptomatic : A Systematic Review

Ann Intern Med. 2021 Jan 22;M20-6976. doi: 10.7326/M20-6976.

無症候性のSARS-CoV-2感染の割合に関するシステマティックレビュー
Melek Chaouch

Loop-mediated isothermal amplification (LAMP): An effective molecular point-of-care technique for the rapid diagnosis of coronavirus SARS-CoV-2

Rev Med Virol. 2021 Jan 21;e2215. doi: 10.1002/rmv.2215.

新型コロナウイルス感染の迅速診断のためのポイントオブケア（POC）検査としてのLAMP法に関するナラティブレビュー
Claudia Alteri, Valeria Cento, Antonio Piralla et al.

Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy

Nat Commun. 2021 Jan 19;12(1):434. doi: 10.1038/s41467-020-20688-x.

イタリアのロンバルディアにおける流行初期の新型コロナウイルスのウイルスゲノム解析
Jerome H Kim, Florian Marks, John D Clemens

Looking beyond COVID-19 vaccine phase 3 trials

Nat Med. 2021 Jan 19. doi: 10.1038/s41591-021-01230-y.

COVID-19ワクチンの第3相臨床試験後の導入戦略についての論説
Renato D Lopes, Ariane V S Macedo, Pedro G M de Barros E Silva et al.

Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial

JAMA. 2021 Jan 19;325(3):254-264. doi: 10.1001/jama.2020.25864.

COVID-19による入院患者におけるアンジオテンシン変換酵素阻害薬およびアンジオテンシンII受容体拮抗薬の中止または継続の生存日数および退院までの日数への影響を評価したランダム化比較試験
Milena Sokolowska, Thomas Eiwegger, Markus Ollert et al.

EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines

Allergy. 2021 Jan 16. doi: 10.1111/all.14739.

COVID-19ワクチンによる重症アレルギー反応の診断、治療、予防に関する欧州アレルギー臨床免疫学会（EAACI）の声明
James A Fuller, Avi Hakim, Kerton R Victory et al.

Mitigation Policies and COVID-19-Associated Mortality - 37 European Countries, January 23-June 30, 2020

MMWR Morb Mortal Wkly Rep. 2021 Jan 15;70(2):58-62. doi: 10.15585/mmwr.mm7002e4.

ヨーロッパ37か国における流行抑制のための政策とCOVID-19関連の死亡率との関連性（2020年1月23日から6月30日）
Suparna Bagchi, Josephine Mak, Qunna Li et al.

Rates of COVID-19 Among Residents and Staff Members in Nursing Homes - United States, May 25-November 22, 2020

MMWR Morb Mortal Wkly Rep. 2021 Jan 15;70(2):52-55. doi: 10.15585/mmwr.mm7002e2.

米国の老人ホームにおける居住者および職員のCOVID-19発生率の変遷（2020年5月25日～11月22日）
CDC COVID-19 Response Team, Food and Drug Administration

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020

MMWR Morb Mortal Wkly Rep. 2021 Jan 15;70(2):46-51. doi: 10.15585/mmwr.mm7002e1.

米国におけるPfizer-BioNTech社のCOVID-19ワクチン1回目接種後のアナフィラキシーを含むアレルギー反応の報告（2020年12月14-23日）
Guillaume Butler-Laporte, Alexander Lawandi, Ian Schiller et al.

Comparison of Saliva and Nasopharyngeal Swab Nucleic Acid Amplification Testing for Detection of SARS-CoV-2: A Systematic Review and Meta-analysis

JAMA Intern Med. 2021 Jan 15;e208876. doi: 10.1001/jamainternmed.2020.8876.

新型コロナウイルスの核酸検出のための唾液検体または鼻咽頭ぬぐい検体を比較したシステマティックレビュー・メタアナリシス
Karola S Jering, Brian L Claggett, Jonathan W Cunningham et al.

Clinical Characteristics and Outcomes of Hospitalized Women Giving Birth With and Without COVID-19

JAMA Intern Med. 2021 Jan 15;e209241. doi: 10.1001/jamainternmed.2020.9241.

出産のために入院したCOVID-19合併患者と非合併患者の臨床的特徴とアウトカムの比較
Christian Gaebler, Zijun Wang, Julio C C Lorenzi et al.

Evolution of antibody immunity to SARS-CoV-2

Nature. 2021 Jan 18. doi: 10.1038/s41586-021-03207-w.

SARS-CoV-2感染半年後までの液性免疫とスパイクタンパクのレセプター結合部位特異的なB細胞応答
Fang Li, Yuan-Yuan Li, Ming-Jin Liu et al.

Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study

Lancet Infect Dis. 2021 Jan 18;S1473-3099(20)30981-6. doi: 10.1016/S1473-3099(20)30981-6.

武漢におけるSARS-CoV-2の家庭内感染と感染の危険因子ついての後ろ向きコホート研究
Dawn M Bravata, Anthony J Perkins, Laura J Myers et al.

Association of Intensive Care Unit Patient Load and Demand With Mortality Rates in US Department of Veterans Affairs Hospitals During the COVID-19 Pandemic

JAMA Netw Open. 2021 Jan 4;4(1):e2034266. doi: 10.1001/jamanetworkopen.2020.34266.

米国の退役軍人病院の集中治療室におけるCOVID-19患者によるひっ迫度（病床稼働率と病床需要）とCOVID-19患者の死亡率の相関
Alberto García-Ortega, Grace Oscullo, Pilar Calvillo et al.

Incidence, risk factors, and thrombotic load of pulmonary embolism in patients hospitalized for COVID-19 infection

J Infect. 2021 Jan 10;S0163-4453(21)00007-4. doi:10.1016/j.jinf.2021.01.003.

COVID-19で入院した患者の肺塞栓症（PE）の発生率、リスク因子、血栓量に関するコホート研究
Anis Abobaker, Taha Nagib, Ahmed Alsoufi

The impact of certain genetic variants (single nucleotide polymorphisms) on incidence and severity of COVID-19

J Gene Med. 2021 Jan 12;e3310. doi:10.1002/jgm.3310.

一塩基多型の新型コロナウイルス感染やCOVID-19重症化への影響についてのナラティブレビュー
Xiao-Dong Yang, Hong-Li Li, Yue-E Cao

Influence of Meteorological Factors on the COVID-19 Transmission with Season and Geographic Location

Int J Environ Res Public Health. 2021 Jan 9;18(2):484. doi: 10.3390/ijerph18020484.

異なる季節及び地理的位置における気象要因の新型コロナウイルス伝播への影響のモデリング
Edward P Fenlon Iii, Susie Chen, Carrie B Ruzal-Shapiro, Diego Jaramillo, Alexis B R Maddocks

Extracardiac imaging findings in COVID-19-associated multisystem inflammatory syndrome in children

Pediatr Radiol. 2021 Jan 12;1-9. doi: 10.1007/s00247-020-04929-1.

COVID-19に関連した小児多臓器炎症性症候群（MIS-C）の心外画像所見についての論文
Junjie Shen, Congju Wang, Chen Dong, Zaixiang Tang, Hongpeng Sun

Reductions in mortality resulting from COVID-19 quarantine measures in China

J Public Health (Oxf). 2021 Jan 12;fdaa249. doi: 10.1093/pubmed/fdaa249.

中国蘇州市におけるCOVID-19に対する感染対策と全死因における死亡数との相関
Forest W Arnold, Sarah Bishop, Leah Oppy, LaShawn Scott, Gina Stevenson

Surveillance testing reveals a significant proportion of hospitalized patients with SARS-CoV-2 are asymptomatic

Am J Infect Control. 2021 Jan 9;S0196-6553(21)00005-5. doi: 10.1016/j.ajic.2021.01.005.

米国ルイジアナ州の一病院における入院時全例スクリーニングにおけるのSARS-CoV-2感染の無症候例の割合
Chaolin Huang, Lixue Huang, Yeming Wang et al.

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

Lancet. 2021 Jan 16;397(10270):220-232. doi: 10.1016/S0140-6736(20)32656-8.

COVID-19入院患者の退院6ヶ月後における残存症状、検査所見、抗体価
Zachary Levin, Kimberly Choyke, Archelle Georgiou, Soumya Sen, Pinar Karaca-Mandic

Trends in Pediatric Hospitalizations for Coronavirus Disease 2019

JAMA Pediatr. 2021 Jan 11;e205535. doi: 10.1001/jamapediatrics.2020.5535.

米国22州における小児のCOVID-19入院患者の推移
Louis du Plessis, John T McCrone, Alexander E Zarebski et al.

Establishment and lineage dynamics of the SARS-CoV-2 epidemic in the UK

Science. 2021 Jan 8;eabf2946. doi: 10.1126/science.abf2946.

英国で流行している新型コロナウイルスのウイルスゲノム解析とこれらの時間的・空間的ダイナミクス
Chanyan Huang, Jalal Soleimani, Svetlana Herasevich et al.

Clinical Characteristics, Treatment, and Outcomes of Critically Ill Patients With COVID-19: A Scoping Review

Mayo Clin Proc. 2021 Jan;96(1):183-202. doi: 10.1016/j.mayocp.2020.10.022.

COVID-19の重症患者の臨床的特徴、治療、およびアウトカムについてのスコーピングレビュー
Wilfredo F Garcia-Beltran, Evan C Lam, Michael G Astudillo et al.

COVID-19-neutralizing antibodies predict disease severity and survival

Cell. 2021 Jan 21;184(2):476-488.e11. doi: 10.1016/j.cell.2020.12.015.

新型コロナウイルスに対する抗体の中和能と重症度や生存との相関
Jennifer M Dan, Jose Mateus, Yu Kato et al.

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Science. 2021 Jan 6;eabf4063. doi: 10.1126/science.abf4063.

SARS-CoV-2感染8ヶ月後までの液性免疫と細胞性検疫の評価
Christine Atherstone, Meaghan L Peterson, Mackenzie Malone et al.

Time from Start of Quarantine to SARS-CoV-2 Positive Test Among Quarantined College and University Athletes - 17 States, June-October 2020

MMWR Morb Mortal Wkly Rep. 2021 Jan 8;70(1):7-11. doi: 10.15585/mmwr.mm7001a2.

米国17州の大学生アスリートにおける接触者としての健康観察開始から検査陽性となるまでの日数の調査
Amanda Jones, Veronica Fialkowski, Lauren Prinzing et al.

Assessment of Day-7 Postexposure Testing of Asymptomatic Contacts of COVID-19 Patients to Evaluate Early Release from Quarantine - Vermont, May-November 2020

MMWR Morb Mortal Wkly Rep . 2021 Jan 8;70(1):12-13. doi: 10.15585/mmwr.mm7001a3.

無症候で経過した接触者における接触7日後の検査による健康観察終了の妥当性評価
Jordana B Cohen, Thomas C Hanff, Preethi William et al.

Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial

Lancet Respir Med. 2021 Jan 7;S2213-2600(20)30558-0. doi: 10.1016/S2213-2600(20)30558-0.

レニン・アンジオテンシン系阻害薬継続または中止の転帰への影響を評価したランダム化比較試験
Mayara Lisboa Bastos, Sara Perlman-Arrow, Dick Menzies, Jonathon R Campbell

The Sensitivity and Costs of Testing for SARS-CoV-2 Infection With Saliva Versus Nasopharyngeal Swabs : A Systematic Review and Meta-analysis

Ann Intern Med. 2021 Jan 12. doi: 10.7326/M20-6569.

新型コロナウイルス検査のための唾液検体または鼻咽頭ぬぐい検体の感度とコストを比較したシステマティックレビュー・メタアナリシス
Romina Libster, Gonzalo Pérez Marc, Diego Wappner et al.

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

N Engl J Med. 2021 Jan 6. doi: 10.1056/NEJMoa2033700.

高齢者におけるCOVID-19重症化予防のための早期高抗体価回復者血漿療法に関するRCT
Jonas F Ludvigsson, Lars Engerström, Charlotta Nordenhäll, Emma Larsson

Open Schools, Covid-19, and Child and Teacher Morbidity in Sweden

N Engl J Med. 2021 Jan 6. doi: 10.1056/NEJMc2026670.

政策として休校措置をとらなったスウェーデンの小児と教員における重症COVID-19
Adam S Lauring, Emma B Hodcroft

Genetic Variants of SARS-CoV-2-What Do They Mean?

JAMA. 2021 Jan 6. doi: 10.1001/jama.2020.27124.

新型コロナウイルスの変異の意義に関する論説
Maura M Zylla, Uta Merle, Johannes A Vey et al.

Predictors and Prognostic Implications of Cardiac Arrhythmias in Patients Hospitalized for COVID-19

J Clin Med. 2021 Jan 2;10(1):133. doi: 10.3390/jcm10010133.

COVID-19での入院患者における不整脈のリスク因子と予後への影響についてのコホート研究
Rahi Abouk, Babak Heydari

The Immediate Effect of COVID-19 Policies on Social-Distancing Behavior in the United States

Public Health Rep. 2021 Jan 5;33354920976575. doi: 10.1177/0033354920976575.

米国におけるCOVID-19に対する社会的距離戦略の効果を検討した論文
Carleen Klumpp-Thomas, Heather Kalish, Matthew Drew et al.

Standardization of ELISA protocols for serosurveys of the SARS-CoV-2 pandemic using clinical and at-home blood sampling

Nat Commun. 2021 Jan 4;12(1):113. doi: 10.1038/s41467-020-20383-x.

医療機関および在宅で採取された血液検体を用いたSARS-CoV-2の血清疫学調査のためのELISAプロトコルの標準化
Jacek Baj, Marzanna Ciesielka, Grzegorz Buszewicz et al.

COVID-19 in the autopsy room-requirements, safety, recommendations and pathological findings

Forensic Sci Med Pathol. 2021 Jan 4;1-13. doi: 10.1007/s12024-020-00341-1.

COVID-19における剖検や埋葬時の手順と感染対策に関するレビュー
Pavel Hamet, Zdenka Pausova, Redha Attaoua et al.

SARS-COV-2 receptor ACE2 gene is associated with hypertension and severity of COVID-19: interaction with sex, obesity and smoking

Am J Hypertens. 2021 Jan 2;hpaa223. doi: 10.1093/ajh/hpaa223.

COVID-19の重症度と新型コロナウイルスのレセプターであるACE2遺伝子SNP、高血圧、性別、肥満、喫煙との関係
Sama Rezasoltani, Abbas Yadegar, Behzad Hatami, Hamid Asadzadeh Aghdaei, Mohammad Reza Zali

Antimicrobial Resistance as a Hidden Menace Lurking Behind the COVID-19 Outbreak: The Global Impacts of Too Much Hygiene on AMR

Front Microbiol. 2020 Dec 15;11:590683. doi: 10.3389/fmicb.2020.590683.

COVID-19への過度な抗菌薬や消毒剤等の利用によって発生しうる薬剤耐性（AMR）についてのナラティブレビュー
December 2020
Charlotte V Hobbs, Lora M Martin, Sara S Kim et al.

Factors Associated with Positive SARS-CoV-2 Test Results in Outpatient Health Facilities and Emergency Departments Among Children and Adolescents Aged <18 Years - Mississippi, September-November 2020

MMWR Morb Mortal Wkly Rep. 2020 Dec 18;69(50):1925-1929. doi: 10.15585/mmwr.mm6950e3.

米国ミシシッピ州でクリニックや救急外来を受診した18歳未満の小児におけるSARS-CoV-2検査陽性と相関するリスク因子の解析（2020年9月～11月）
October 2020
Young Joon Park, Young June Choe, Ok Park et al.

Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020

Emerg Infect Dis. 2020 Oct;26(10):2465-2468. doi: 10.3201/eid2610.201315.

韓国におけるCOVID-19アウトブレイクの接触者追跡調査
July 2020
Chen Stein-Zamir, Nitza Abramson, Hanna Shoob et al.

A large COVID-19 outbreak in a high school 10 days after schools' reopening, Israel, May 2020

Euro Surveill. 2020 Jul;25(29):2001352. doi: 10.2807/1560-7917.ES.2020.25.29.2001352.

イスラエルで学校再開から10日後に高校で発生した大規模なCOVID-19アウトブレイク（2020年5月）